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Description and aim of the thesis 
Botanicals and botanical preparations have become widely available in the form of food 
supplements and other food preparations. In Europe the safety of botanicals and their derived 
food products has to comply with the general requirements set out in regulation (EC) No 
178/2002. Risk assessment procedures which consist of hazard identification, hazard 
characterization, exposure assessment, and risk characterization, evaluating the consequences of 
exposure to different classes of chemicals in food (e.g. additives, contaminants, pesticide 
residues, veterinary drug residues and natural toxicants) have been harmonized (Barlow et al. 
2006; EFSA 2009a; WHO 2015). So far these regulatory procedures did not focus on botanicals 
and botanical preparations. In 2009 the European Food Safety Authority (EFSA) published a 
toolkit to help assess the safety of botanicals and derived preparations. A compendium of 
botanicals that have been reported to contain substances that may be of health concern when 
used in food or food supplements was part of that tool (EFSA 2012a). Also guidelines for risk 
assessment of botanicals and botanical preparations were provided (EFSA 2009a) indicating that 
a risk assessment should include the definition of the botanical species including the plant and 
preparation(s) of interest, environmental conditions of growing, part(s) of the botanical used, the 
manufacturing processes used for making the botanical preparation, evaluation of the 
compositional, toxicological and exposure data, definition of the biologically active substances 
and their levels, and the history of use. In spite of these guidelines, at the present state-of-the-art 
the safety and risks of botanicals and botanical preparations are generally not assessed before 
they enter the market. 
An important aim of the present thesis was to perform risk assessment of selected botanicals and 
their derived preparations focusing especially on samples likely to contain alkenylbenzenes, 
 
including myristicin, apiol, safrole, methyleugenol, elemicin, and estragole (Figure 1), to give a 
better understanding of when risk management actions would be needed for botanicals and 
derived preparations containing these ingredients. Samples containing alkenylbenzenes may be 
of concern because these compounds may be genotoxic and carcinogenic displaying similar 
characteristics regarding mode of action (MOA) and tumor formation (Phillips et al. 1981; Miller 
et al. 1983; Randerath et al. 1984; Wiseman et al. 1985; NTP 2000; Zhou et al. 2007; Kobets et 
al. 2016). In the present thesis a MOA based risk assessment of especially two of the 
alkenylbenzenes, myristicin and apiol, for which tumor data are not available, was performed. 
This was done using physiologically based kinetic (PBK) modelling and read-across from safrole 
and the margin of exposure (MOE) approach. Botanical preparations included in the risk 
assessments performed in the present thesis were basil-containing pesto and nutmeg-based plant 
food supplements (PFS). Given that several of the preparations analyzed contained several 
alkenylbenzenes a risk assessment of combined exposure to these alkenylbenzenes was included 
as well. 
 
Physicochemical properties of the structurally related alkenylbenzenes 
The alkenylbenzenes of interest are allylbenzenes with alkoxy substitution at the para position. 
The alkenylbenzenes safrole (3,4-methylenedioxyallylbenzene), myristicin (5-methoxy-3,4-
methylenedioxyallylbenzene) and apiole (2,5-dimethoxy-3,4-methylenedioxyallylbenzene) have 
a 3,4-methylenedioxy substituent (Figure 1). The other compounds, estragole (4-
methoxyallylbenzene), methyleugenol (3,4-dimethoxyallylbenzene) and elemicin (3,4,5-
trimethoxyallylbenzene) do not contain a  3,4-methylenedioxy substituent (Figure 1). All 
molecules, except safrole, contain one or more methoxy groups. 
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The aforementioned alkenylbenzenes are colorless or slightly yellow oily liquids, with the 
characteristic odor of the plants from which they can be extracted. They are practically insoluble 
in water with a maximum solubility of 500 mg/l, and have octanol/water partition coefficients 
(log Kow values) ranging from 3.0 to 3.5. They are miscible with most organic solvents, and 
generally denser than water (EPA 1986b). Because these alkenylbenzenes are structurally 
related, they may share similar metabolism, MOA and biological effects (JECFA 2009; van den 
Berg et al. 2012). This similarity provides the basis for the MOA based read-across and risk 
assessments of the present thesis. 
 
 
 
Figure 1. The structural formulas of the alkenylbenzenes estragole, methyleugenol, elemicin, 
safrole, myristicin and apiol. 
 
Natural occurrence and estimated daily intake (EDI) of alkenylbenzenes from different 
sources 
The alkenylbenzenes are naturally occurring in a variety of botanicals including anise, star anise, 
fennel, sweet fennel and parsley that belong to the plant family Umbelliferae, nutmeg and mace 
that belong to the plant family Myristicaceae, sweet and exotic basil that belong to the family 
Labiatae, and tarragon that belongs to the plant family Compositeae. The intake of the 
 
alkenylbenzenes occurs from consumption of spices and herb and spice oils. The levels of 
alkenylbenzenes in spices vary significantly depending on exact growing region, plant maturity 
at harvest, harvesting techniques, storage conditions and processing methods (e.g. extraction, 
drying). Nutmeg is the main source of exposure to myristicin, safrole, and elemicin, with an 
average content of 5292, 2099, and 1395 mg/kg respectively, as based on data from a variety of 
sources, including industry data and published reports (JECFA 2009; van den Berg et al. 2012). 
Exposure to estragole and methyleugenol occurs mainly by consumption of basil, with an 
average content of 1162 mg/kg for estragole and 62.8 mg/kg for methyleugenol, depending on 
harvest and storage time, and plant height (maturity) (Miele et al. 2001). Intake of apiole is 
predominantly from consumption of parsley with an average content of 8.7 mg/kg (JECFA 
2009). 
Plant Food Supplements (PFS) are concentrated sources of dietary ingredients derived from 
various plants and herbal extracts. Exposure to alkenylbenzenes through PFS is dependent on the 
level of the alkenylbenzenes in the PFS and amount and frequency of PFS intake. PFS made of 
essential oils were found to contain highly concentrated levels of alkenylbenzenes, and may 
result in high intakes (Archer 1988; van den Berg et al. 2011). General concerns related to the 
quality and safety of botanicals and botanical preparations such as PFS are often related to the 
presence of naturally occurring toxic compounds (EFSA 2004; JECFA 2009). Especially the use 
of highly concentrated plant material, which is usually marketed in the form of capsules or 
powder and supposed to supplement the normal diet, raises concerns. 
Exposure to myristicin, safrole, estragole, and methyleugenol from food occurs mostly from 
basil, nutmeg, and parsley. The estimated daily intake (EDI) of these four alkenylbenzenes from 
the use of spices and spice oils ranges from 0.9 to 166 μg/kg bw per day, with the EDI of safrole 
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being the lowest and that for estragole the highest (JECFA 2009). The dietary intakes of elemicin 
and apiole from all sources, with EDI values of 0.04 and 0.43 μg/kg bw per day, respectively 
(JECFA 2009), were reported to make a minor contribution to the overall alkenylbenzene intake. 
With respect to alkenylbenzene exposure, pesto paste eaters are considered the highest exposed 
group, with 20 mg methyleugenol on average in each meal, making the daily consumption 
amount to 250 μg/kg bw per day of methyleugenol for a 70 kg person (Miele et al. 2001). In 
2001 The Scientific Committee on Food (SCF) concluded that the structural analogues, 
methyleugenol, estragole, and safrole are genotoxic and carcinogenic and indicated the need for 
a reduction in exposure and restrictions in the levels of use (SCF 2001a; SCF 2001b; SCF 2002). 
However, SCF or EFSA opinions on myristicin, apiole and elemicin are not available. 
Further investigation is needed to assess the potential risk to human health from low-level dietary 
exposure to alkenylbenzenes present in foods and essential oils (JECFA 2009). To this end, the 
EDI values in the present thesis will be calculated based on alkenylbenzene levels in samples 
containing alkenylbenzenes purchased from the market, taking into consideration the possible 
combined exposure to different alkenylbenzenes. Combined exposure can be evaluated by dose 
addition, which is considered appropriate for mixtures with components acting by a similar 
MOA, at a similar target organ, and causing a similar adverse effect i.e. liver carcinogenicity 
(EPA 1986a; EPA 1988; EPA 2000). This implies that the response to the mixture can be 
predicted by summing up the EDIs of the alkenylbenzenes assuming equal potency, or using 
their toxic equivalency factors (TEFs) relative to a reference alkenylbenzene. This requires 
definition of relative potency factors (RPFs) or toxic equivalency factors (TEFs) which were not 
available at the start of these studies. 
 
 
Absorption, Distribution, Metabolism and Excretion (ADME) of alkenylbenzenes 
Many studies on the fate and behavior of alkenylbenzenes were performed in in vitro models and 
in experimental animals, and results thus obtained were important in the interpretation of toxicity 
and extrapolation to humans (IPCS 1986a; Lipscomb and Ohanian 2007).  
Toxicokinetic and metabolic experiments for alkenylbenzenes indicate that they undergo rapid 
and complete absorption following oral intake (Kamienski and Casida 1970; Fritsch et al. 1975; 
Fritsch et al. 1975; Benedetti et al. 1977; Sutton et al. 1985; Anthony et al. 1987; Lee et al. 
1998).  
The metabolites of elemicin, myristicin, and safrole have been identified in rat urine and the 
presence of some of them has been demonstrated in human urine of a nutmeg abuser (Beyer et al. 
2006) (see also below). Figure 2 shows the proposed metabolic pathways of myristicin, which 
are similar to those for the structurally related alkenylbenzenes (Punt et al. 2008; JECFA 2009; 
Al-Subeihi et al. 2011; Martati et al. 2012; van den Berg et al. 2012). The primary 
biotransformation process of alkenylbenzenes is O-demethyl(en)ation that yields a phenolic 
derivative, that is mostly excreted as the sulfate or glucuronic acid conjugate (Benedetti et al. 
1977; Zangouras et al. 1981; Sangster et al. 1983; Anthony et al. 1987; Lee et al. 1998; Beyer et 
al. 2006). Epoxidation of the double bond in the allyl side-chain is the alternative 
biotransformation pathway, yielding the 2’,3’-epoxide. In vivo, the epoxide is rapidly detoxified 
by epoxide hydrolase or via glutathione conjugation and this prevents it from forming detectable 
levels of DNA adducts (Luo et al. 1992; Luo and Guenthner 1995). Hydroxylation of the alkene 
side-chain to yield the 1’-hydroxy metabolite is considered the primary bioactivation pathway 
(Drinkwater et al. 1976; Benedetti et al. 1977; Zangouras et al. 1981; Miller et al. 1983). The 1’-
hydroxymetabolite can be conjugated with either glucuronic acid or sulfate. The sulfate 
C
ha
pt
er
 1
Chapter 1 | General introduction
13
 
being the lowest and that for estragole the highest (JECFA 2009). The dietary intakes of elemicin 
and apiole from all sources, with EDI values of 0.04 and 0.43 μg/kg bw per day, respectively 
(JECFA 2009), were reported to make a minor contribution to the overall alkenylbenzene intake. 
With respect to alkenylbenzene exposure, pesto paste eaters are considered the highest exposed 
group, with 20 mg methyleugenol on average in each meal, making the daily consumption 
amount to 250 μg/kg bw per day of methyleugenol for a 70 kg person (Miele et al. 2001). In 
2001 The Scientific Committee on Food (SCF) concluded that the structural analogues, 
methyleugenol, estragole, and safrole are genotoxic and carcinogenic and indicated the need for 
a reduction in exposure and restrictions in the levels of use (SCF 2001a; SCF 2001b; SCF 2002). 
However, SCF or EFSA opinions on myristicin, apiole and elemicin are not available. 
Further investigation is needed to assess the potential risk to human health from low-level dietary 
exposure to alkenylbenzenes present in foods and essential oils (JECFA 2009). To this end, the 
EDI values in the present thesis will be calculated based on alkenylbenzene levels in samples 
containing alkenylbenzenes purchased from the market, taking into consideration the possible 
combined exposure to different alkenylbenzenes. Combined exposure can be evaluated by dose 
addition, which is considered appropriate for mixtures with components acting by a similar 
MOA, at a similar target organ, and causing a similar adverse effect i.e. liver carcinogenicity 
(EPA 1986a; EPA 1988; EPA 2000). This implies that the response to the mixture can be 
predicted by summing up the EDIs of the alkenylbenzenes assuming equal potency, or using 
their toxic equivalency factors (TEFs) relative to a reference alkenylbenzene. This requires 
definition of relative potency factors (RPFs) or toxic equivalency factors (TEFs) which were not 
available at the start of these studies. 
 
 
Absorption, Distribution, Metabolism and Excretion (ADME) of alkenylbenzenes 
Many studies on the fate and behavior of alkenylbenzenes were performed in in vitro models and 
in experimental animals, and results thus obtained were important in the interpretation of toxicity 
and extrapolation to humans (IPCS 1986a; Lipscomb and Ohanian 2007).  
Toxicokinetic and metabolic experiments for alkenylbenzenes indicate that they undergo rapid 
and complete absorption following oral intake (Kamienski and Casida 1970; Fritsch et al. 1975; 
Fritsch et al. 1975; Benedetti et al. 1977; Sutton et al. 1985; Anthony et al. 1987; Lee et al. 
1998).  
The metabolites of elemicin, myristicin, and safrole have been identified in rat urine and the 
presence of some of them has been demonstrated in human urine of a nutmeg abuser (Beyer et al. 
2006) (see also below). Figure 2 shows the proposed metabolic pathways of myristicin, which 
are similar to those for the structurally related alkenylbenzenes (Punt et al. 2008; JECFA 2009; 
Al-Subeihi et al. 2011; Martati et al. 2012; van den Berg et al. 2012). The primary 
biotransformation process of alkenylbenzenes is O-demethyl(en)ation that yields a phenolic 
derivative, that is mostly excreted as the sulfate or glucuronic acid conjugate (Benedetti et al. 
1977; Zangouras et al. 1981; Sangster et al. 1983; Anthony et al. 1987; Lee et al. 1998; Beyer et 
al. 2006). Epoxidation of the double bond in the allyl side-chain is the alternative 
biotransformation pathway, yielding the 2’,3’-epoxide. In vivo, the epoxide is rapidly detoxified 
by epoxide hydrolase or via glutathione conjugation and this prevents it from forming detectable 
levels of DNA adducts (Luo et al. 1992; Luo and Guenthner 1995). Hydroxylation of the alkene 
side-chain to yield the 1’-hydroxy metabolite is considered the primary bioactivation pathway 
(Drinkwater et al. 1976; Benedetti et al. 1977; Zangouras et al. 1981; Miller et al. 1983). The 1’-
hydroxymetabolite can be conjugated with either glucuronic acid or sulfate. The sulfate 
Chapter 1 | General introduction
14
 
conjugate is an unstable sulfate ester, and is considered to be the proximate hepatocarcinogenic 
agent (Smith et al. 2002) since it hydrolyses to form a reactive electrophilic intermediate, which 
binds to DNA. Rodent studies have shown that the formation of DNA adducts in the liver of 
exposed rodents is dose dependent (Drinkwater et al. 1976; Swanson et al. 1981; Miller et al. 
1982; Boberg et al. 1983; Miller et al. 1983; Caldwell et al. 1992; Chan and Caldwell 1992; 
Hasheminejad and Caldwell 1994; Gardner et al. 1995; Daimon et al. 1998). The relative 
contribution of the different biotransformation routes of the alkenylbenzenes was also shown to 
be dose dependent and to show species and sex differences (Table 1). From all these data it is 
concluded that at low doses in humans, mice and rats, significant amounts of alkenylbenzenes 
are O-dealkylated. When dose levels increase, the relative amount of 1’-hydroxylation increases. 
In all species bioactivation to 1’-hydroxy occurs, but there may be species differences and/or 
differences between the alkenylbenzenes: so quantifying it for each congener is essential to 
obtain insight in relative bioactivation of the different alkenylbenzenes. The overview presented 
in table 1 also reveals that detection of a 1’-hydroxy alkenylbenzene in urine reflects its 
glucurondiation and thus its detoxification rather than its bioactivation by sulfation. This implies 
that relative differences in bioactivation and detoxification for each specific congener in rat and 
human cannot be derived from urinary metabolite patterns, and remain to be established before 
you can do read-across for risk assessment. The  observation that the 1’-hydroxy metabolites of 
myristicin, safrole and elemicin are present in the urine of rats administered pure 
alkenylbenzenes at 100 mg/kg bw via oral intubation but absent from the urine of rodents or 
humans consuming nutmeg (50 times lower amount) may be due to dose or matrix effects. 
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conjugate is an unstable sulfate ester, and is considered to be the proximate hepatocarcinogenic 
agent (Smith et al. 2002) since it hydrolyses to form a reactive electrophilic intermediate, which 
binds to DNA. Rodent studies have shown that the formation of DNA adducts in the liver of 
exposed rodents is dose dependent (Drinkwater et al. 1976; Swanson et al. 1981; Miller et al. 
1982; Boberg et al. 1983; Miller et al. 1983; Caldwell et al. 1992; Chan and Caldwell 1992; 
Hasheminejad and Caldwell 1994; Gardner et al. 1995; Daimon et al. 1998). The relative 
contribution of the different biotransformation routes of the alkenylbenzenes was also shown to 
be dose dependent and to show species and sex differences (Table 1). From all these data it is 
concluded that at low doses in humans, mice and rats, significant amounts of alkenylbenzenes 
are O-dealkylated. When dose levels increase, the relative amount of 1’-hydroxylation increases. 
In all species bioactivation to 1’-hydroxy occurs, but there may be species differences and/or 
differences between the alkenylbenzenes: so quantifying it for each congener is essential to 
obtain insight in relative bioactivation of the different alkenylbenzenes. The overview presented 
in table 1 also reveals that detection of a 1’-hydroxy alkenylbenzene in urine reflects its 
glucurondiation and thus its detoxification rather than its bioactivation by sulfation. This implies 
that relative differences in bioactivation and detoxification for each specific congener in rat and 
human cannot be derived from urinary metabolite patterns, and remain to be established before 
you can do read-across for risk assessment. The  observation that the 1’-hydroxy metabolites of 
myristicin, safrole and elemicin are present in the urine of rats administered pure 
alkenylbenzenes at 100 mg/kg bw via oral intubation but absent from the urine of rodents or 
humans consuming nutmeg (50 times lower amount) may be due to dose or matrix effects. 
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Figure 2. Proposed metabolic pathways of the alkenylbenzene myristicin (Kamienski and Casida 
1970; Sangster et al. 1987; Lee et al. 1998; Beyer et al. 2006). 
 
Carcinogenicity and MOA 
The adverse critical effect of the alkenylbenzenes is the formation of liver tumors, and for some 
of the alkenylbenzenes long term carcinogenicity studies in rodents are actually available (Hagan 
et al. 1967; Borchert et al. 1973; Lipsky et al. 1981a; Lipsky et al. 1981b; Lipsky et al. 1981c; 
Miller et al. 1983; NTP 2000) (Table 2). The purpose of testing chemicals for carcinogenicity in 
a chronic lifetime exposure scenario with experimental animals is to identify potential cancer 
hazards for humans. Positive findings require careful interpretation in relation to MOA, possible 
interspecies differences in background incidence and in response and with respect to high dose to 
low dose extrapolation (WHO 2009b). Virtually all chemicals associated with cancer in humans 
have been found to increase the incidence of neoplasms in experimental animals albeit not 
causing necessarily the same type of tumor (McGregor and Anderson 1999). For alkylating 
compounds, genetic changes arise from the reactivity of the carcinogen with DNA, because the 
reactive proximate carcinogen may operate as an electrophilic reactant covalently binding to 
DNA as a fundamental part of the MOA underlying induction of carcinogenesis. Carcinogens 
that act through such genotoxic mechanisms are usually multi-organ and trans-species 
carcinogens that can be active with a single dose and are effective at low exposures (Vaino et al. 
1992; Williams 1992).  
32P-postlabeling indicated that estragole, safrole, methyleugenol, myristicin, elemicin, and apiol 
have the ability to produce DNA adducts in adult mouse liver upon intraperitoneal injections. 
Estragole, methyleugenol and safrole showed the highest activity of the alkenylbenzenes tested 
(Randerath et al. 1984). Similar results were shown by Phillips et al. 1984, who reported that in 
neonatal mice upon intraperitoneal injections the ability to form DNA adducts was in the 
following order; methyleugenol > estragole > safrole > myristicin > apiol (Phillips et al. 1984). 
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Using human HepG2 cells exposed in vitro, the level of DNA adduct formation by estragole, 
methyleugenol and safrole was the highest at low concentration (50 μmol/l), while at higher 
concentration (450 μmol/l), the level of adduct formation of myristicin was as high as that of 
safrole and methyleugenol (Zhou et al. 2007). 
Long-term carcinogenicity data from studies with rodents given high dose levels showed 
increased incidences of hepatocellular carcinoma especially with safrole, estragole and 
methyleugenol (Table 2). These studies indicate that the structurally related alkenylbenzenes are 
compounds that are genotoxic and carcinogenic, with relative difference in potency. Similar long 
term carcinogenicity studies for myristicin, elemicin and apiole are not available. 
 
Risk assessment approach 
In the present thesis risk assessment of consumption of the alkenylbenzene-containing samples 
was performed using the MOE approach. The MOE approach is the approach recommended for 
risk assessment of compounds that are both genotoxic and carcinogenic (EFSA 2005). The MOE 
is a dimensionless ratio comparing a standardized reference point derived, by mathematical 
modelling, from the animal data within the observed range of experimental data, with the EDI of 
the compound of interest resulting from the use of food containing that compound. The EFSA 
Scientific Committee considered that an MOE of 10000 or more, based on animal cancer 
bioassay data, “would be of low concern from a public health point of view and might reasonably 
be considered as a low priority for risk management actions” (EFSA 2005). The EFSA 
recommends the use of the BMDL10 as a reference point for MOE calculations, which is the 
lower confidence limit of the benchmark dose resulting in a 10% extra cancer incidence above 
background level (EFSA 2009a; EFSA 2009b). In previous studies, the BMDL10 values for 
 
safrole, estragole, and methyleugenol could be derived from in vivo tumor data (van den Berg et 
al. 2011). Table 3 presents an overview of these BMDL10 values. However, not for all 
alkenylbenzenes tumor data enabling definition of a BMDL10 for risk assessment are available. 
Such data are missing for elemicin, myristicin and apiol. Previously, a BMDL10 value for 
elemicin was derived by read-across from methyleugenol and estragole (EFSA 2005; van den 
Berg et al. 2012) (Table 3). In the present thesis a similar approach with read-across form safrole 
was undertaken for myristicin and apiol.  
Van den Berg et al. (2011) investigated the alkenylbenzene content in 28 PFS samples 
containing botanicals including basil, fennel, sassafras, nutmeg, cinnamon, and calamus (van den 
Berg et al. 2011),  and performed a risk assessment using the MOE aproach. The results obtained 
revealed that out of  28 PFS samples, 25 samples contained alkenylbenzenes at levels that would 
result in EDIs that would give rise to MOE values below 10000, indicating a priority for risk 
management. Among these 25 PFS samples, there were 4 nutmeg-based samples shown to 
contain methyleugenol and safrole at levels that would result in EDI values that gave rise to 
MOE values < 10000 (van den Berg et al. 2011). In addition to safrole and methyleugenol, 
nutmeg may also contain myristicin and elemicin (JECFA 2009).  
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Table 3. BMDL10 values of alkenylbenzenes as  derived from in vivo tumor data for safrole, 
estragole, and methyleugenol , or obtained by read-across from methyleugenol and estragole 
for elemicin. NA, Not Available. 
Compound 
BMDL10 
(mg/kg bw) 
Reference 
Methyleugenol 15.3-34.0 
(van den Berg et al. 2011) Safrole 1.9-5.1 
Estragole 3.3-6.5 
Elemicin 30.6-68.0 (van den Berg et al. 2012) 
Myristicin NA NA 
Apiol NA NA 
 
The aim of the present study was to develop a MOA and PBK modeling based approach for 
read-across in risk assessment from safrole, for which in vivo toxicity studies are available to 
myristicin and apiol for which tumor data are not reported, thus contributing to alternatives in 
animal testing, and to use the outcomes for risk assessment for the consumption of PFS and 
other botanical products containing myristicin and structurally related alkenylbenzenes 
considering individual and combined exposure. The next section illustrates in some more 
detail how PBK modeling can be used to estimate BMDL10 values for alkenylbenzenes for 
which no tumor data are available. 
 
PBK modeling 
PBK models are developed in order to study effects related to interspecies, intraspecies, high 
to low dose, route to route, and exposure scenario extrapolations using in vitro and in vivo 
kinetic data. PBK models, in general, are developed to integrate diverse sets of kinetics data, 
and predict tissue dosimetry for situations relevant to human dietary levels. 
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Table 3. BMDL10 values of alkenylbenzenes as  derived from in vivo tumor data for safrole, 
estragole, and methyleugenol , or obtained by read-across from methyleugenol and estragole 
for elemicin. NA, Not Available. 
Compound 
BMDL10 
(mg/kg bw) 
Reference 
Methyleugenol 15.3-34.0 
(van den Berg et al. 2011) Safrole 1.9-5.1 
Estragole 3.3-6.5 
Elemicin 30.6-68.0 (van den Berg et al. 2012) 
Myristicin NA NA 
Apiol NA NA 
 
The aim of the present study was to develop a MOA and PBK modeling based approach for 
read-across in risk assessment from safrole, for which in vivo toxicity studies are available to 
myristicin and apiol for which tumor data are not reported, thus contributing to alternatives in 
animal testing, and to use the outcomes for risk assessment for the consumption of PFS and 
other botanical products containing myristicin and structurally related alkenylbenzenes 
considering individual and combined exposure. The next section illustrates in some more 
detail how PBK modeling can be used to estimate BMDL10 values for alkenylbenzenes for 
which no tumor data are available. 
 
PBK modeling 
PBK models are developed in order to study effects related to interspecies, intraspecies, high 
to low dose, route to route, and exposure scenario extrapolations using in vitro and in vivo 
kinetic data. PBK models, in general, are developed to integrate diverse sets of kinetics data, 
and predict tissue dosimetry for situations relevant to human dietary levels. 
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A PBK model is represented by a set of mathematical equations that together describe the 
process of a substance entering the body (absorption), dispersing throughout the fluids and 
tissues of the body (distribution), the biotransformation to its metabolites (metabolism), and 
the elimination from the body (excretion), having all the compartments mutually connected 
through the systemic circulation. Steps to build a PBK model are as follows (Rietjens et al. 
2011); First define the structure of the model including organs and tissues that are of 
importance for the kinetic processes and the toxicity of the compound of interest. Second, 
mathematically describe the relevant processes, using equations for absorption, distribution, 
excretion and metabolism the latter including separate Michaelis–Menten equations for each 
metabolic conversion, one for each important metabolic route. Third, define the values of the 
model parameters needed to develop the PBK model for a specific compound. Fourth, using 
software, e.g. Berkeley Madonna, solve the mass-balance differential equations and predict 
the levels of the parent compound and its relevant metabolites at certain dose levels in the 
relevant compartments of the body in time. Fifth, evaluate the model against experimental in 
vivo data to support the validity of the model and thus its subsequent predictions. In a final 
step the model can be used to make predictions. The parameters needed for the model are 
physiological parameters (cardiac output, tissue blood flow rate, tissue volumes), 
physicochemical parameters (partition coefficients), kinetic and biochemical parameters 
(describing metabolic processes, rates of absorption, biotransformation). These parameters 
can be obtained from literature, experimentally (in vitro or in vivo), and/or by using in silico 
tools such as for example Quantitative Structure Activity Relationships (QSAR). A 
quantitative evaluation of how input parameters influence the model output of relevance to 
the risk assessment can be provided via a sensitivity analysis (Iman and Helton 1988; Farrar 
et al. 1989; Krewski et al. 1995; Campolongo and Saltelli 1997; Nestorov 2001; Gueorguieva 
et al. 2006; Chiu et al. 2007; Loizou et al. 2008). In a sensitivity analysis one input parameter 
 
 
is changed (for example by 5 %) while the other parameters are kept at their initial value and 
it is estimated how the prediction is affected by that change. Sensitivity analysis results are 
presented as high (absolute value of  the sensitivity coefficient greater than or equal to 0.5), 
medium (absolute value greater than or equal to 0.2 but less than 0.5) or low (absolute value 
of the sensitivity coefficient greater than or equal to 0.1 but less than 0.2); parameters with a 
sensitivity coefficient less than 0.1 are generally not listed (Kohn 1995; IPCS 2010). 
 
Objectives and outline of the thesis 
The aim of the present PhD project was to develop a MOA and PBK modeling based 
approach for read-across in risk assessment from safrole for which in vivo toxicity studies are 
available to myristicin and apiol for which tumor data are not reported, and to use the 
outcomes for risk assessment for the consumption of PFS and other botanical products 
containing myristicin and structurally related alkenylbenzenes considering individual and 
combined exposure. 
The introduction chapter (this chapter) starts with a short background and definition of the 
aim of the thesis, followed by a description of the physicochemical properties, natural 
occurrence and EDI of the alkenylbenzenes, as well as of their ADME characteristics, 
carcinogenicity and MOA, the relevant risk assessment approach, and finally PBK modelling. 
Chapter 2 of the thesis describes the development of a PBK model for myristicin in male rat 
and human, enabling the prediction of dose-dependent effects in bioactivation and 
detoxification of myristicin. This allows comparison of the PBK model-based prediction of 
bioactivation of myristicin to the PBK model-based predictions for bioactivation of the 
structurally related compound safrole, enabling estimation of a BMDL10 for myristicin from 
read-across to the BMDL10 available for safrole, thereby facilitating risk assessment of 
current dietary exposure to myristicin. 
C
ha
pt
er
 1
Chapter 1 | General introduction
25
 
 
A PBK model is represented by a set of mathematical equations that together describe the 
process of a substance entering the body (absorption), dispersing throughout the fluids and 
tissues of the body (distribution), the biotransformation to its metabolites (metabolism), and 
the elimination from the body (excretion), having all the compartments mutually connected 
through the systemic circulation. Steps to build a PBK model are as follows (Rietjens et al. 
2011); First define the structure of the model including organs and tissues that are of 
importance for the kinetic processes and the toxicity of the compound of interest. Second, 
mathematically describe the relevant processes, using equations for absorption, distribution, 
excretion and metabolism the latter including separate Michaelis–Menten equations for each 
metabolic conversion, one for each important metabolic route. Third, define the values of the 
model parameters needed to develop the PBK model for a specific compound. Fourth, using 
software, e.g. Berkeley Madonna, solve the mass-balance differential equations and predict 
the levels of the parent compound and its relevant metabolites at certain dose levels in the 
relevant compartments of the body in time. Fifth, evaluate the model against experimental in 
vivo data to support the validity of the model and thus its subsequent predictions. In a final 
step the model can be used to make predictions. The parameters needed for the model are 
physiological parameters (cardiac output, tissue blood flow rate, tissue volumes), 
physicochemical parameters (partition coefficients), kinetic and biochemical parameters 
(describing metabolic processes, rates of absorption, biotransformation). These parameters 
can be obtained from literature, experimentally (in vitro or in vivo), and/or by using in silico 
tools such as for example Quantitative Structure Activity Relationships (QSAR). A 
quantitative evaluation of how input parameters influence the model output of relevance to 
the risk assessment can be provided via a sensitivity analysis (Iman and Helton 1988; Farrar 
et al. 1989; Krewski et al. 1995; Campolongo and Saltelli 1997; Nestorov 2001; Gueorguieva 
et al. 2006; Chiu et al. 2007; Loizou et al. 2008). In a sensitivity analysis one input parameter 
 
 
is changed (for example by 5 %) while the other parameters are kept at their initial value and 
it is estimated how the prediction is affected by that change. Sensitivity analysis results are 
presented as high (absolute value of  the sensitivity coefficient greater than or equal to 0.5), 
medium (absolute value greater than or equal to 0.2 but less than 0.5) or low (absolute value 
of the sensitivity coefficient greater than or equal to 0.1 but less than 0.2); parameters with a 
sensitivity coefficient less than 0.1 are generally not listed (Kohn 1995; IPCS 2010). 
 
Objectives and outline of the thesis 
The aim of the present PhD project was to develop a MOA and PBK modeling based 
approach for read-across in risk assessment from safrole for which in vivo toxicity studies are 
available to myristicin and apiol for which tumor data are not reported, and to use the 
outcomes for risk assessment for the consumption of PFS and other botanical products 
containing myristicin and structurally related alkenylbenzenes considering individual and 
combined exposure. 
The introduction chapter (this chapter) starts with a short background and definition of the 
aim of the thesis, followed by a description of the physicochemical properties, natural 
occurrence and EDI of the alkenylbenzenes, as well as of their ADME characteristics, 
carcinogenicity and MOA, the relevant risk assessment approach, and finally PBK modelling. 
Chapter 2 of the thesis describes the development of a PBK model for myristicin in male rat 
and human, enabling the prediction of dose-dependent effects in bioactivation and 
detoxification of myristicin. This allows comparison of the PBK model-based prediction of 
bioactivation of myristicin to the PBK model-based predictions for bioactivation of the 
structurally related compound safrole, enabling estimation of a BMDL10 for myristicin from 
read-across to the BMDL10 available for safrole, thereby facilitating risk assessment of 
current dietary exposure to myristicin. 
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Chapter 3 describes PBK models for the alkenylbenzene apiol in rat and human, based on the 
PBK models previously developed for the structurally related alkenylbenzenes safrole. Using 
the newly developed models, the level of metabolic activation of apiol in rat and human was 
predicted to obtain insight in species differences in the bioactivation of apiol and read-across 
to the related alkenylbenzene safrole. The models were also used for read-across from safrole 
to apiol and definition of a BMDL10 for apiol. 
Chapter 4 evaluates the risk of exposure to methyleugenol and related alkenylbenzenes 
through consumption of pesto sauce. To this end the levels of methyleugenol and other 
alkenylbenzenes in basil-containing sauce of pesto were quantified enabling an associated risk 
assessment based on the MOE approach, taking into consideration the possible combined 
exposure to different alkenylbenzenes and the BMDL10 values as defined in literature (Table 
3) and in chapter 2 and 3 of the thesis.  
Chapter 5 evaluates the risk of exposure to myristicin and related alkenylbenzenes through 
human exposure to nutmeg-based PFS based on the MOE approach. Chemical analyses of 
various PFS samples were performed and the amount of alkenylbenzenes that would be 
consumed through consumption of these nutmeg-based PFS where quantified. MOE values 
where calculated for the individual alkenylbenzenes as well as taking into account the 
presence of more than one alkenylbenzenes within selected PFS samples.  
Chapter 6 summarizes the results obtained in the thesis, compiles the overall discussion and 
presents the future perspectives that follow from the results obtained.  
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Chapter 3 describes PBK models for the alkenylbenzene apiol in rat and human, based on the 
PBK models previously developed for the structurally related alkenylbenzenes safrole. Using 
the newly developed models, the level of metabolic activation of apiol in rat and human was 
predicted to obtain insight in species differences in the bioactivation of apiol and read-across 
to the related alkenylbenzene safrole. The models were also used for read-across from safrole 
to apiol and definition of a BMDL10 for apiol. 
Chapter 4 evaluates the risk of exposure to methyleugenol and related alkenylbenzenes 
through consumption of pesto sauce. To this end the levels of methyleugenol and other 
alkenylbenzenes in basil-containing sauce of pesto were quantified enabling an associated risk 
assessment based on the MOE approach, taking into consideration the possible combined 
exposure to different alkenylbenzenes and the BMDL10 values as defined in literature (Table 
3) and in chapter 2 and 3 of the thesis.  
Chapter 5 evaluates the risk of exposure to myristicin and related alkenylbenzenes through 
human exposure to nutmeg-based PFS based on the MOE approach. Chemical analyses of 
various PFS samples were performed and the amount of alkenylbenzenes that would be 
consumed through consumption of these nutmeg-based PFS where quantified. MOE values 
where calculated for the individual alkenylbenzenes as well as taking into account the 
presence of more than one alkenylbenzenes within selected PFS samples.  
Chapter 6 summarizes the results obtained in the thesis, compiles the overall discussion and 
presents the future perspectives that follow from the results obtained.  
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ABSTRACT 
The present study describes physiologically based kinetic (PBK) models for the 
alkenylbenzene myristicin that were developed by extension of the PBK models for the 
structurally related alkenylbenzene safrole in rat and human. The newly developed myristicin 
models revealed that the formation of the proximate carcinogenic metabolite 1’-
hydroxymyristicin in liver is at most 1.8-fold higher in rat than in human and limited for the 
ultimate carcinogenic metabolite 1’-sulfoxymyristicin to (2.8–4.0)-fold higher in human. In 
addition, a comparison was made between the relative importance of bioactivation for 
myristicin and safrole. Model predictions indicate that for these related compounds, the 
formation of the 1’-sulfoxy metabolites in rat and human liver is comparable with a difference 
of < 2.2-fold over a wide dose range. The results from this PBK analysis support that risk 
assessment of myristicin may be based on the BMDL10 derived for safrole of 1.9–5.1 mg/kg 
bw per day. Using an estimated daily intake of myristicin of 0.0019 mg/kg bw per day 
resulting from the use of herbs and spices, this results in MOE values for myristicin that 
amount to 1000–2700, indicating a priority for risk management. The results obtained 
illustrate that PBK modeling provides insight into possible species differences in the 
metabolic activation of myristicin. Moreover, they provide and contributing to alternatives in 
animal testing example of how PBK modeling can facilitate a read-across in risk assessment 
from a compound for which in vivo toxicity studies are available to a related compound for 
which tumor data are not reported, thus contributing to alternatives in animal testing. 
 
 
INTRODUCTION 
Myristicin (1-allyl-5-methoxy-3,4 methylene-dioxybenzene or methoxysafrole) is naturally 
occurring and present in several spices including nutmeg and mace of trees of Myristica species, 
principally Myristica fragrans Hout, and their essential oils (Forrest and Heacock 1972; 
Matthews et al. 1974; Sammy and Nawar 1968). There is a potential for human exposure to 
myristicin through foods, beverages, food supplements, and traditional medicines. Myristicin 
belongs to the group of alkenylbenzenes that contains structural analogues such as 
methyleugenol, estragole, elemicin, safrole, and apiol (Figure 1), compounds that are all 
naturally occurring in herbs and spices such as basil, nutmeg, and their essential oils (Barceloux 
2009). Safrole, estragole, and methyleugenol have been shown to induce hepatic tumors in rats 
or mice upon chronic oral exposure to high doses and upon administration to male CD-1 mice 
during the preweaning period (Borchert et al. 1973; Drinkwater et al. 1976; Ioannides et al. 1981; 
Wislocki et al. 1977; Innes 1969; National Toxicology 2000). Tumors were found especially in 
the liver at frequencies that amounted to, for example, 2/50, 3/50, 14/50, and 25/50 at 0, 37, 75, 
and 150 mg methyleugenol/kg bw per day in male rats (National Toxicology 2000). A summary 
of further incidences of malignant tumor formation in mice and rats after administration of 
estragole, methyleugenol, or safrole can be found in our previous paper (van den Berg et al. 
2011). However, myristicin is less well studied than its structurally related analogues, and only 
limited toxicological data are available. While in vitro genotoxicity studies indicate that 
myristicin is mutagenic and capable of inducing the formation of DNA adducts (EFSA 2012; 
Zhou et al. 2007b), no two-year carcinogenicity studies of myristicin in experimental animals are 
available hampering its risk assessment.  
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ABSTRACT 
The present study describes physiologically based kinetic (PBK) models for the 
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resulting from the use of herbs and spices, this results in MOE values for myristicin that 
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metabolic activation of myristicin. Moreover, they provide and contributing to alternatives in 
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from a compound for which in vivo toxicity studies are available to a related compound for 
which tumor data are not reported, thus contributing to alternatives in animal testing. 
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Matthews et al. 1974; Sammy and Nawar 1968). There is a potential for human exposure to 
myristicin through foods, beverages, food supplements, and traditional medicines. Myristicin 
belongs to the group of alkenylbenzenes that contains structural analogues such as 
methyleugenol, estragole, elemicin, safrole, and apiol (Figure 1), compounds that are all 
naturally occurring in herbs and spices such as basil, nutmeg, and their essential oils (Barceloux 
2009). Safrole, estragole, and methyleugenol have been shown to induce hepatic tumors in rats 
or mice upon chronic oral exposure to high doses and upon administration to male CD-1 mice 
during the preweaning period (Borchert et al. 1973; Drinkwater et al. 1976; Ioannides et al. 1981; 
Wislocki et al. 1977; Innes 1969; National Toxicology 2000). Tumors were found especially in 
the liver at frequencies that amounted to, for example, 2/50, 3/50, 14/50, and 25/50 at 0, 37, 75, 
and 150 mg methyleugenol/kg bw per day in male rats (National Toxicology 2000). A summary 
of further incidences of malignant tumor formation in mice and rats after administration of 
estragole, methyleugenol, or safrole can be found in our previous paper (van den Berg et al. 
2011). However, myristicin is less well studied than its structurally related analogues, and only 
limited toxicological data are available. While in vitro genotoxicity studies indicate that 
myristicin is mutagenic and capable of inducing the formation of DNA adducts (EFSA 2012; 
Zhou et al. 2007b), no two-year carcinogenicity studies of myristicin in experimental animals are 
available hampering its risk assessment.  
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Figure 1. Structural formulas of the alkenylbenzenes, estragole, methyleugenol, elemicin, 
 safrole, myristicin, and apiol. 
 
Some short-term studies were conducted on the induction of hepatic tumors, in which male 
B6C3F1 mice were given myristicin during the preweaning period in two separate experiments. 
In the first experiment, myristicin was injected with a total dose of 3.75 μmol to 33 male 
B6C3F1 mice over a period of 22 days, and the total duration of the experiment was 12 months. 
In a second experiment, 45 male B6C3F1 mice were each injected with a total dose of 4.75 μmol 
myristicin over a period of 22 days, and the total duration of the experiment was 18 months. In 
these short-term exposure experiments, myristicin had no detectable activity for the initiation of 
hepatic tumors (Miller et al. 1983). 
In agreement with hepatocarcinogenicity in mice (Miller et al. 1983), DNA adduct formation 
upon exposure to myristicin was generally lower and less persistent than DNA adduct formation 
upon exposure to methyleugenol and estragole and appeared to be about 2-fold lower than DNA 
adduct formation upon exposure to safrole, both in in vitro study (Zhou et al. 2007a) and in in 
vivo studies (Table 1) (Phillips et al. 1984; Randerath et al. 1984). N2-(trans-isomyristicin-3’-yl)-
2’-deoxyguanosine was found to be the major myristicin DNA adduct formed when mice were 
 
 
given cola drinks instead of water up to 8 weeks. In a parallel experiment, pregnant ICR mice 
were treated by gastric intubation with a single dose of 6 mg of myristicin, and the level of 
myristicin adducts in maternal and fetal liver was 68 and 63 % of the total adducts (Randerath et 
al. 1993). In freshly isolated rat hepatocytes in primary culture, safrole, estragole, and 
methyleugenol induced unscheduled DNA synthesis (UDS) and cytotoxicity at the 
concentrations of 10−6 to 10−3 M, (Howes et al. 1990) while myristicin showed cytotoxicity. In 
these studies, concentrations inducing UDS were generally close to or already at concentrations 
detecting cytotoxicity, hampering interpretation of the data. The data supporting a genotoxic 
mode of action for the tumor induction by the alkenylbenzenes rather come from studies 
reporting DNA adduct formation. In these studies, myristicin, as well as estragole, 
methyleugenol, and safrole, all showed positive results (Zhou et al. 2007a; Kobets et al. 2016; 
Phillips et al. 1984; Randerath et al. 1984). A schematic overview of the detoxification and 
bioactivation of myristicin that is similar to that of its structurally related compound safrole 
(Swanson et al. 1979; Borchert et al. 1973; Drinkwater et al. 1976) is shown in Figure 2. 
Epoxidation of the double bond in the allyl side chain yields the 2,3-epoxide. In in vitro 
experiments, the epoxide readily forms DNA adducts, but rapid detoxification by epoxide 
hydrolase and glutathione S-transferases (GSTs) prevents it from forming detectable levels of 
DNA adducts in vivo (Luo et al. 1992; Luo and Guenthner 1996). The primary bioactivation 
pathway of myristicin is 1’-hydroxylation of the alkene side chain to yield the 1’-hydroxy 
metabolite which can be conjugated with either glucuronic acid representing a detoxification 
reaction or sulfate representing the ultimate bioactivation to 1’-sulfoxymyristicin (Drinkwater et 
al. 1976; Benedetti et al. 1977; Zangouras et al. 1981; Miller et al. 1983). The 1’-sulfoxy 
metabolite represents the ultimate carcinogenic metabolite (Wiseman et al. 1985, 1987; 
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detecting cytotoxicity, hampering interpretation of the data. The data supporting a genotoxic 
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reporting DNA adduct formation. In these studies, myristicin, as well as estragole, 
methyleugenol, and safrole, all showed positive results (Zhou et al. 2007a; Kobets et al. 2016; 
Phillips et al. 1984; Randerath et al. 1984). A schematic overview of the detoxification and 
bioactivation of myristicin that is similar to that of its structurally related compound safrole 
(Swanson et al. 1979; Borchert et al. 1973; Drinkwater et al. 1976) is shown in Figure 2. 
Epoxidation of the double bond in the allyl side chain yields the 2,3-epoxide. In in vitro 
experiments, the epoxide readily forms DNA adducts, but rapid detoxification by epoxide 
hydrolase and glutathione S-transferases (GSTs) prevents it from forming detectable levels of 
DNA adducts in vivo (Luo et al. 1992; Luo and Guenthner 1996). The primary bioactivation 
pathway of myristicin is 1’-hydroxylation of the alkene side chain to yield the 1’-hydroxy 
metabolite which can be conjugated with either glucuronic acid representing a detoxification 
reaction or sulfate representing the ultimate bioactivation to 1’-sulfoxymyristicin (Drinkwater et 
al. 1976; Benedetti et al. 1977; Zangouras et al. 1981; Miller et al. 1983). The 1’-sulfoxy 
metabolite represents the ultimate carcinogenic metabolite (Wiseman et al. 1985, 1987; 
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Randerath et al. 1984; Phillips et al. 1984). 1’-Sulfoxy metabolites of alkenylbenzenes may react 
readily with DNA, RNA, and proteins but can also be detoxified through reaction with H2O or 
conjugation with glutathione (Phillips et al. 1984; Miller et al. 1983; Fennell et al. 1984; Ishii et 
al. 2011). Therefore, only a fraction of the 1’-sulfoxy metabolite is expected to form DNA 
adducts (Rietjens et al. 2014). 
Although myristicin is thus likely to also induce DNA adducts and liver tumors, its risk 
assessment at low realistic dietary intake levels is hampered by the fact that carcinogenicity 
studies are lacking (Hallstrom and Thuvander 1997). Therefore, the aim of the present study was 
to characterize the detoxification and bioactivation of myristicin and to develop a physiologically 
based kinetic (PBK) model to describe the ultimate formation of the 1’-sulfoxy metabolite in the 
liver of both rat and human and subsequently perform a read-across-based risk assessment using 
a similar PBK model previously described for safrole for which tumor data from long-term 
toxicity testing are available. Previously, using a similar approach and read-across from estragole 
and methyleugenol, the risk of exposure to elemicin for which also only limited in vivo rodent 
tumor data were available could be evaluated (van den Berg et al. 2012). Such a PBK modeling-
based read-across illustrates a novel approach for animal-free risk assessment of a genotoxic 
carcinogen without the need for a long-term carcinogenicity study. 
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Randerath et al. 1984; Phillips et al. 1984). 1’-Sulfoxy metabolites of alkenylbenzenes may react 
readily with DNA, RNA, and proteins but can also be detoxified through reaction with H2O or 
conjugation with glutathione (Phillips et al. 1984; Miller et al. 1983; Fennell et al. 1984; Ishii et 
al. 2011). Therefore, only a fraction of the 1’-sulfoxy metabolite is expected to form DNA 
adducts (Rietjens et al. 2014). 
Although myristicin is thus likely to also induce DNA adducts and liver tumors, its risk 
assessment at low realistic dietary intake levels is hampered by the fact that carcinogenicity 
studies are lacking (Hallstrom and Thuvander 1997). Therefore, the aim of the present study was 
to characterize the detoxification and bioactivation of myristicin and to develop a physiologically 
based kinetic (PBK) model to describe the ultimate formation of the 1’-sulfoxy metabolite in the 
liver of both rat and human and subsequently perform a read-across-based risk assessment using 
a similar PBK model previously described for safrole for which tumor data from long-term 
toxicity testing are available. Previously, using a similar approach and read-across from estragole 
and methyleugenol, the risk of exposure to elemicin for which also only limited in vivo rodent 
tumor data were available could be evaluated (van den Berg et al. 2012). Such a PBK modeling-
based read-across illustrates a novel approach for animal-free risk assessment of a genotoxic 
carcinogen without the need for a long-term carcinogenicity study. 
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Figure 2. Proposed metabolic pathways of the alkenylbenzene myristicin. 
 
 
MATERIAL AND METHODS 
Chemicals 
Myristicin, tris(hydroxymethyl)aminomethane, uridine 5’-diphosphoglucuronide acid (UDPGA), 
reduced L-glutathione (GSH), alamethicin (from Trichodermaviride), 3’-phosphoadenosine-5’-
phosphosulfate (PAPS), β-nicotinamide adenine dinucleotide (NAD+), and reduced β-
nicotinamide adenine dinucleotide phosphate (NADPH) were obtained from Roche Diagnostics 
(Mannheim, Germany). Dimethyl sulfoxide (DMSO) was obtained from Acros Organics (Geel, 
Belgium). Potassium dihydrogen phosphate, dipotassium hydrogen phosphate trihydrate, acetic 
acid, and magnesium chloride were supplied by VWR International (Darmstadt, Germany). 
Acetonitrile (ACN) (UPLC/MS grade) was purchased from Biosolve BV (Valkenswaard, The 
Netherlands). Trifluoroacetic acid TFA was obtained from Merck (Darmstadt, Germany). Pooled 
male rat liver microsomes and S9 from Sprague–Dawley and mixed gender pooled human liver 
microsomes and S9 were obtained from BD Gentest (Woburn, USA). Pooled male Sprague–
Dawley rat lung, kidney, and small intestinal microsomes and pooled gender human lung, 
kidney, and intestinal microsomes were purchased from BioPredic International (Rennes, 
France). 
 
Synthesis of 1’-hydroxymyristicin and 1’-oxomyristicin 
The synthesis of 1’-hydroxymyristicin from myristicin was done as described previously by 
Jeurissen et al. (2004), and 1’-oxomyristicin was synthesized from 1’-hydroxymyristicin 
according to the method used for the synthesis of 1’-oxoestragole from 1’-hydroxyestragole 
(Wislocki et al. 1976). 
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Figure 2. Proposed metabolic pathways of the alkenylbenzene myristicin. 
 
 
MATERIAL AND METHODS 
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nicotinamide adenine dinucleotide phosphate (NADPH) were obtained from Roche Diagnostics 
(Mannheim, Germany). Dimethyl sulfoxide (DMSO) was obtained from Acros Organics (Geel, 
Belgium). Potassium dihydrogen phosphate, dipotassium hydrogen phosphate trihydrate, acetic 
acid, and magnesium chloride were supplied by VWR International (Darmstadt, Germany). 
Acetonitrile (ACN) (UPLC/MS grade) was purchased from Biosolve BV (Valkenswaard, The 
Netherlands). Trifluoroacetic acid TFA was obtained from Merck (Darmstadt, Germany). Pooled 
male rat liver microsomes and S9 from Sprague–Dawley and mixed gender pooled human liver 
microsomes and S9 were obtained from BD Gentest (Woburn, USA). Pooled male Sprague–
Dawley rat lung, kidney, and small intestinal microsomes and pooled gender human lung, 
kidney, and intestinal microsomes were purchased from BioPredic International (Rennes, 
France). 
 
Synthesis of 1’-hydroxymyristicin and 1’-oxomyristicin 
The synthesis of 1’-hydroxymyristicin from myristicin was done as described previously by 
Jeurissen et al. (2004), and 1’-oxomyristicin was synthesized from 1’-hydroxymyristicin 
according to the method used for the synthesis of 1’-oxoestragole from 1’-hydroxyestragole 
(Wislocki et al. 1976). 
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Microsomal metabolism of myristicin 
First, it was determined which organs are involved in the biotransformation of myristicin in rat 
and human. For this purpose, liver, kidney, lung, and small intestine microsomes from male 
Sprague–Dawley rat and pooled gender human were used. Incubations were performed by 
adding myristicin to incubation mixtures containing 1 mg/mL of the microsomal protein 
preparations and 3 mM NADPH in 0.2 M Tris–HCl (pH 7.4). After 1 min of pre-incubation at 37 
°C, myristicin (final concentration, 1000 μM) was added from a 100 times concentrated stock 
solution in DMSO so that the final DMSO content was 1 % (v/v). Incubations were carried out 
for 30 min after which the reactions were terminated by adding 25 μl (0.25 times the incubation 
volume) of ice-cold ACN. Samples were centrifuged for 5 min at 13000×g, and the supernatant 
was stored at −20 °C until UPLC analysis. As metabolism of myristicin was observed only in 
incubations with liver microsomes for male rats and pooled gender human, the determination of 
kinetic constants for the formation of microsomal metabolites was performed only for the liver 
fractions. Incubations to determine kinetic constants were performed following the conditions 
described above using final concentrations of myristicin from 25 to 1000 μM for rat and human 
liver. In all incubations, the final concentration of DMSO, in which myristicin was dissolved, 
was kept at 1 % (v/v). The formation of different microsomal metabolites was linear with time 
and microsomal protein concentration under the conditions described. Blank incubations were 
performed in the absence of the cofactor NADPH. All incubations were performed in triplicate. 
 
Glucuronidation of 1’-hydroxymyristicin to 1’-hydroxymyristicin glucuronide 
The kinetic constants for the metabolic conversion of 1’-hydroxymyristicin to 1’-
hydroxymyristicin glucuronide (HMG) by both male rat and human liver fractions were 
 
 
determined as described previously for the related 1’-hydroxyalkenylbenzenes (Punt et al. 2008; 
van den Berg et al. 2012; Punt et al. 2009; Martati et al. 2011, 2012; Al-Subeihi et al. 2011, 
2012). Briefly, incubations contained (final concentrations) 10 mM of UDPGA and 0.5 mg/ml of 
male Sprague–Dawley or pooled gender human S9 protein in 0.2 M Tris–HCl (pH 7.4) 
containing 10 mM of MgCl2. To overcome enzyme latency and to obtain maximal 
glucuronidation activity, incubations containing S9 were pretreated on ice with 0.025 mg/ml 
alamethicin added from a 200 times concentrated stock dissolved in methanol (Fisher et al. 2000; 
Lin and Wong 2002). After 15 min of alamethicin treatment, samples were pre-incubated at 37 
°C for 1 min, and reactions were subsequently started by adding 1’-hydroxymyristicin at final 
concentrations of 10 to 1200 μM. 1’-Hydroxymyristicin was added from 100 times concentrated 
stock solutions in DMSO. The reaction mixtures were incubated for 30 and 180 min for rat and 
human, respectively, and terminated by adding 25 μl (0.25 times the incubation volume) of ice-
cold ACN. Blank incubations were carried out in the absence of the cofactor UDPGA. 
Experiments were performed in triplicate. The longer incubation time in human samples was 
required due to the lower rate of glucuronidation. The formation of 1’-hydroxymyristicin 
glucuronide was linear with time and the S9 protein concentration under the experimental 
conditions described. All samples were centrifuged for 5 min at 16000×g, and the supernatant 
was stored at −20 °C until ultra-performance liquid chromatography (UPLC) analysis. 
 
Oxidation of 1’-hydroxymyristicin to 1’-oxomyristicin 
The kinetic constants for the enzymatic conversion of 1’-hydroxymyristicin to 1’-oxomyristicin 
were determined using incubation mixtures containing (final concentrations) 3 mM NAD+, 2 
mM GSH, and 1 mg/ml rat or human liver microsomes in 0.2 M Tris–HCl (pH 7.4). GSH was 
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Microsomal metabolism of myristicin 
First, it was determined which organs are involved in the biotransformation of myristicin in rat 
and human. For this purpose, liver, kidney, lung, and small intestine microsomes from male 
Sprague–Dawley rat and pooled gender human were used. Incubations were performed by 
adding myristicin to incubation mixtures containing 1 mg/mL of the microsomal protein 
preparations and 3 mM NADPH in 0.2 M Tris–HCl (pH 7.4). After 1 min of pre-incubation at 37 
°C, myristicin (final concentration, 1000 μM) was added from a 100 times concentrated stock 
solution in DMSO so that the final DMSO content was 1 % (v/v). Incubations were carried out 
for 30 min after which the reactions were terminated by adding 25 μl (0.25 times the incubation 
volume) of ice-cold ACN. Samples were centrifuged for 5 min at 13000×g, and the supernatant 
was stored at −20 °C until UPLC analysis. As metabolism of myristicin was observed only in 
incubations with liver microsomes for male rats and pooled gender human, the determination of 
kinetic constants for the formation of microsomal metabolites was performed only for the liver 
fractions. Incubations to determine kinetic constants were performed following the conditions 
described above using final concentrations of myristicin from 25 to 1000 μM for rat and human 
liver. In all incubations, the final concentration of DMSO, in which myristicin was dissolved, 
was kept at 1 % (v/v). The formation of different microsomal metabolites was linear with time 
and microsomal protein concentration under the conditions described. Blank incubations were 
performed in the absence of the cofactor NADPH. All incubations were performed in triplicate. 
 
Glucuronidation of 1’-hydroxymyristicin to 1’-hydroxymyristicin glucuronide 
The kinetic constants for the metabolic conversion of 1’-hydroxymyristicin to 1’-
hydroxymyristicin glucuronide (HMG) by both male rat and human liver fractions were 
 
 
determined as described previously for the related 1’-hydroxyalkenylbenzenes (Punt et al. 2008; 
van den Berg et al. 2012; Punt et al. 2009; Martati et al. 2011, 2012; Al-Subeihi et al. 2011, 
2012). Briefly, incubations contained (final concentrations) 10 mM of UDPGA and 0.5 mg/ml of 
male Sprague–Dawley or pooled gender human S9 protein in 0.2 M Tris–HCl (pH 7.4) 
containing 10 mM of MgCl2. To overcome enzyme latency and to obtain maximal 
glucuronidation activity, incubations containing S9 were pretreated on ice with 0.025 mg/ml 
alamethicin added from a 200 times concentrated stock dissolved in methanol (Fisher et al. 2000; 
Lin and Wong 2002). After 15 min of alamethicin treatment, samples were pre-incubated at 37 
°C for 1 min, and reactions were subsequently started by adding 1’-hydroxymyristicin at final 
concentrations of 10 to 1200 μM. 1’-Hydroxymyristicin was added from 100 times concentrated 
stock solutions in DMSO. The reaction mixtures were incubated for 30 and 180 min for rat and 
human, respectively, and terminated by adding 25 μl (0.25 times the incubation volume) of ice-
cold ACN. Blank incubations were carried out in the absence of the cofactor UDPGA. 
Experiments were performed in triplicate. The longer incubation time in human samples was 
required due to the lower rate of glucuronidation. The formation of 1’-hydroxymyristicin 
glucuronide was linear with time and the S9 protein concentration under the experimental 
conditions described. All samples were centrifuged for 5 min at 16000×g, and the supernatant 
was stored at −20 °C until ultra-performance liquid chromatography (UPLC) analysis. 
 
Oxidation of 1’-hydroxymyristicin to 1’-oxomyristicin 
The kinetic constants for the enzymatic conversion of 1’-hydroxymyristicin to 1’-oxomyristicin 
were determined using incubation mixtures containing (final concentrations) 3 mM NAD+, 2 
mM GSH, and 1 mg/ml rat or human liver microsomes in 0.2 M Tris–HCl (pH 7.4). GSH was 
Chapter 2 | PBK modelling of the bioactivation of myristicin
48
 
 
added to the incubation mixtures to trap the reactive 1’-oxo metabolite formed after oxidation of 
1’-hydroxymyristicin. The level of GSH in the incubations was optimized in a previous study to 
obtain maximum scavenging of 1’-oxoestragole (Punt et al. 2009). To this end, incubations were 
performed in the presence of increasing concentrations of GSH, ranging from 2 to 10 mM. At a 
concentration of 2 mM GSH maximum formation of GS-1’-oxoestragole was reached in the 
incubations, pointing at maximum scavenging of 1’-oxoestragole at this concentration (Punt et 
al. 2009). Kinetic constants for this reaction in rat and human liver were derived by performing 
incubations with NAD+ as a cofactor, given that in rat and human liver, NAD+ is mainly present 
in an oxidized form with levels of NAD+ being much higher than those of NADH. In a previous 
study, it was shown that the highest level of 1’-hydroxy alkenylbenzene oxidation occurs in 
incubations with microsomes in the presence of NAD+ as cofactor. In incubations with pooled 
human liver cytosol in the presence of NAD+ or NADP+, lower levels of oxidation were 
observed, indicating that the reaction is not primarily catalyzed by alcohol dehydrogenases 
(ADH) or other enzymes present in the cytosol (Punt et al. 2010). The enzyme responsible for 
the oxidation may be 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) (Punt et al. 2010). 
Prior to the addition of 1’-hydroxymyristicin at final concentrations ranging between 10 and 
4000 μM to the incubation mixture from 100 times concentrated stock solutions in DMSO, 
samples were pre-incubated for 1 min at 37 °C. Reactions were terminated after 10 min of 
incubation at 37 °C by adding 25 μl (0.25 times the incubation volume) of ice-cold ACN. The 
formation of the GSH conjugate of 1’-oxomyristicin (GS-1’-oxomyristicin) was linear with time 
and microsomal protein concentration under the experimental conditions used. Blank incubations 
were performed without the cofactor NAD+. Incubations were performed in triplicate. All 
 
 
samples were centrifuged for 5 min at 13000×g, and the supernatant was stored at −20 °C until 
UPLC analysis. 
 
Sulfonation of 1’-hydroxymyristicin to 1’-sulfoxymyristicin 
The formation of 1’-sulfoxymyristicin was determined using incubations containing male rat 
liver Sprague–Dawley or pooled gender human liver S9 proteins, PAPS as a cofactor, and GSH, 
which acts as a scavenger of the reactive carbocation formed due to the unstable nature of the 1’-
sulfoxy metabolite in an aqueous environment (van den Berg et al. 2012; Martati et al. 2011; Al-
Subeihi et al. 2011). Incubation mixtures containing (final concentrations) 10 mM of GSH, 0.2 
mM of PAPS, and 3 mg/ml of S9 proteins in 0.1 M potassium phosphate (pH 8.2) were pre-
incubated for 1 min at 37 °C. After the pre-incubation, 1’-hydroxymyristicin dissolved in DMSO 
was added in final concentrations ranging between 10 and 6000 μM while keeping the final 
content of DMSO at 1 % (v/v). The reaction was terminated after 360 min of incubation by 
adding 25 μl (0.25 times the incubation volume) of ice-cold ACN. The formation of the GSH 
conjugate of 1’-sulfoxymyristicin was linear with time and S9 protein concentrations under the 
experimental conditions used. Blank incubations were performed in the absence of PAPS. 
Incubations were performed in triplicate. All samples were centrifuged for 5 min at 16000×g, 
and the supernatant was stored at −20 °C until ultra-performance liquid chromatography (UPLC) 
analysis. 
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added to the incubation mixtures to trap the reactive 1’-oxo metabolite formed after oxidation of 
1’-hydroxymyristicin. The level of GSH in the incubations was optimized in a previous study to 
obtain maximum scavenging of 1’-oxoestragole (Punt et al. 2009). To this end, incubations were 
performed in the presence of increasing concentrations of GSH, ranging from 2 to 10 mM. At a 
concentration of 2 mM GSH maximum formation of GS-1’-oxoestragole was reached in the 
incubations, pointing at maximum scavenging of 1’-oxoestragole at this concentration (Punt et 
al. 2009). Kinetic constants for this reaction in rat and human liver were derived by performing 
incubations with NAD+ as a cofactor, given that in rat and human liver, NAD+ is mainly present 
in an oxidized form with levels of NAD+ being much higher than those of NADH. In a previous 
study, it was shown that the highest level of 1’-hydroxy alkenylbenzene oxidation occurs in 
incubations with microsomes in the presence of NAD+ as cofactor. In incubations with pooled 
human liver cytosol in the presence of NAD+ or NADP+, lower levels of oxidation were 
observed, indicating that the reaction is not primarily catalyzed by alcohol dehydrogenases 
(ADH) or other enzymes present in the cytosol (Punt et al. 2010). The enzyme responsible for 
the oxidation may be 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) (Punt et al. 2010). 
Prior to the addition of 1’-hydroxymyristicin at final concentrations ranging between 10 and 
4000 μM to the incubation mixture from 100 times concentrated stock solutions in DMSO, 
samples were pre-incubated for 1 min at 37 °C. Reactions were terminated after 10 min of 
incubation at 37 °C by adding 25 μl (0.25 times the incubation volume) of ice-cold ACN. The 
formation of the GSH conjugate of 1’-oxomyristicin (GS-1’-oxomyristicin) was linear with time 
and microsomal protein concentration under the experimental conditions used. Blank incubations 
were performed without the cofactor NAD+. Incubations were performed in triplicate. All 
 
 
samples were centrifuged for 5 min at 13000×g, and the supernatant was stored at −20 °C until 
UPLC analysis. 
 
Sulfonation of 1’-hydroxymyristicin to 1’-sulfoxymyristicin 
The formation of 1’-sulfoxymyristicin was determined using incubations containing male rat 
liver Sprague–Dawley or pooled gender human liver S9 proteins, PAPS as a cofactor, and GSH, 
which acts as a scavenger of the reactive carbocation formed due to the unstable nature of the 1’-
sulfoxy metabolite in an aqueous environment (van den Berg et al. 2012; Martati et al. 2011; Al-
Subeihi et al. 2011). Incubation mixtures containing (final concentrations) 10 mM of GSH, 0.2 
mM of PAPS, and 3 mg/ml of S9 proteins in 0.1 M potassium phosphate (pH 8.2) were pre-
incubated for 1 min at 37 °C. After the pre-incubation, 1’-hydroxymyristicin dissolved in DMSO 
was added in final concentrations ranging between 10 and 6000 μM while keeping the final 
content of DMSO at 1 % (v/v). The reaction was terminated after 360 min of incubation by 
adding 25 μl (0.25 times the incubation volume) of ice-cold ACN. The formation of the GSH 
conjugate of 1’-sulfoxymyristicin was linear with time and S9 protein concentrations under the 
experimental conditions used. Blank incubations were performed in the absence of PAPS. 
Incubations were performed in triplicate. All samples were centrifuged for 5 min at 16000×g, 
and the supernatant was stored at −20 °C until ultra-performance liquid chromatography (UPLC) 
analysis. 
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Identification and quantification of metabolism of myristicin and 1’-hydroxymyristicin by 
UPLC 
Microsomal incubations with myristicin only detected primary metabolites, and all incubation 
conditions were chosen such that substrate conversion did not exceed 10 % of the initial 
substrate concentration, a condition that is also essential to ascertain adequate determination of 
the kinetic constants. Secondary metabolism of the relevant 1’-hydroxy metabolite of myristicin 
was taken into account by determining the kinetic constants for its conversion in (a) 
glucuronidation, (b) sulfation, and (c) oxidation, again under conditions that allowed adequate 
definition of kinetic constants and with <10 % substrate conversion. Incubation samples were 
subjected to UPLC analysis that was performed as described previously (Punt et al. 2008). 
Identification was achieved by comparing the UV spectra of the formed metabolites to the 
spectra of the synthesized 1’-hydroxymyristicin and 1’-oxomyristicin reference standards. 
Quantification of all formed metabolites was done by comparing the peak areas to those of 
calibration curves of the corresponding reference compounds, determined using UPLC with 
photodiode array detection (UPLC-PDA). The UPLC system was composed of a Waters 
(Waters, Milford, MA) Acquity solvent manager, sample manager, and photodiode array 
detector, equipped with Water Acquity UPLC BEH C18 column. 
For 2’,3’-dihydroxymyristicin and 5-allyl-2,3-dihydroxyanisole that were found to have the same 
UV spectrum as 1’-hydroxymyristicin, and for 1’-hydroxymyristicin, estimation was based on 
the comparison of the peak area of the formed metabolites to the calibration curve of the 
synthesized 1’-hydroxymyristicin at a wavelength of 210 nm. For 3’-hydroxymyristicin, 
estimation was based on the comparison of the peak area to the calibration curve of the GSH 
adduct of synthetised 1’-oxymyristicin at a wavelength of 212 nm, because 3’-hydroxymyristicin 
 
 
was found to have the same UV spectrum as the GSH adduct of synthetised 1’-oxymyristicin. 
The gradient for analysis of microsomal metabolites was performed with 100 % ACN and 
ultrapure water containing 0.1 % (v/v) TFA. The flow rate was 0.6 ml/min. The gradient started 
at 10 % ACN, increased to 50 % ACN over 4 min, increased to 80 % over 0.5 min, followed by 
decrease to 10 % ACN over 0.5 min, and finally kept at 10 % for 1 min. 
1’-Hydroxymyristicin glucuronide was estimated based on the comparison of the peak area of 
the formed metabolite to the calibration curve of 1’-hydroxymyristicin at a wavelength of 210 
nm. The flow rate was 0.6 ml/min. The gradient was made using a mixture of ACN and ultrapure 
water containing 0.1 % (v/v) TFA. The gradient started at 10 % ACN, increased to 60 % over 3.5 
min, after which ACN was increased to 80 % over 0.5 min, and kept at 80 % for 0.5 min, and 
finally decreased to 10 % over 0.5 min. 
Quantification of GS-1’-oxomyristicin was based on a calibration curve of the GSH adduct of the 
synthesized 1’-oxymyristicin made as previously described (van den Berg et al. 2012; Punt et al. 
2009; Martati et al. 2011; Al-Subeihi et al. 2011). In short, a 60 μM concentration of the 
synthetic standard of 1’-oxomyristicin, dissolved in ACN, was incubated with different 
concentrations of GSH (i.e., 0–20 μM) in 0.2 M Tris–HCl (pH 7.4) for 6-hr at 37 °C, resulting in 
full conversion of the GSH to GS-1’-oxymyristicin. Quantification was done by comparing the 
peak areas of the formed GS-1’-oxo metabolite in the incubation mixtures with peak areas of the 
GS-1’-oxymyristicin calibration curve thus obtained at a wavelength of 212 nm. The gradient for 
analysis of the metabolite consisted of a mixture of ACN and ultrapure water containing 0.1 % 
(v/v) TFA. The flow rate was 0.6 ml/min, The gradient started with 10 % ACN, increased to 30 
% ACN over 2.5 min, after which ACN was increased to 80 % over 0.5 min, kept at 80 % for 0.5 
min, followed by a decrease to 10 % over 0.5 min, and finally kept at 10 % for 0.5 min. 
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Identification and quantification of metabolism of myristicin and 1’-hydroxymyristicin by 
UPLC 
Microsomal incubations with myristicin only detected primary metabolites, and all incubation 
conditions were chosen such that substrate conversion did not exceed 10 % of the initial 
substrate concentration, a condition that is also essential to ascertain adequate determination of 
the kinetic constants. Secondary metabolism of the relevant 1’-hydroxy metabolite of myristicin 
was taken into account by determining the kinetic constants for its conversion in (a) 
glucuronidation, (b) sulfation, and (c) oxidation, again under conditions that allowed adequate 
definition of kinetic constants and with <10 % substrate conversion. Incubation samples were 
subjected to UPLC analysis that was performed as described previously (Punt et al. 2008). 
Identification was achieved by comparing the UV spectra of the formed metabolites to the 
spectra of the synthesized 1’-hydroxymyristicin and 1’-oxomyristicin reference standards. 
Quantification of all formed metabolites was done by comparing the peak areas to those of 
calibration curves of the corresponding reference compounds, determined using UPLC with 
photodiode array detection (UPLC-PDA). The UPLC system was composed of a Waters 
(Waters, Milford, MA) Acquity solvent manager, sample manager, and photodiode array 
detector, equipped with Water Acquity UPLC BEH C18 column. 
For 2’,3’-dihydroxymyristicin and 5-allyl-2,3-dihydroxyanisole that were found to have the same 
UV spectrum as 1’-hydroxymyristicin, and for 1’-hydroxymyristicin, estimation was based on 
the comparison of the peak area of the formed metabolites to the calibration curve of the 
synthesized 1’-hydroxymyristicin at a wavelength of 210 nm. For 3’-hydroxymyristicin, 
estimation was based on the comparison of the peak area to the calibration curve of the GSH 
adduct of synthetised 1’-oxymyristicin at a wavelength of 212 nm, because 3’-hydroxymyristicin 
 
 
was found to have the same UV spectrum as the GSH adduct of synthetised 1’-oxymyristicin. 
The gradient for analysis of microsomal metabolites was performed with 100 % ACN and 
ultrapure water containing 0.1 % (v/v) TFA. The flow rate was 0.6 ml/min. The gradient started 
at 10 % ACN, increased to 50 % ACN over 4 min, increased to 80 % over 0.5 min, followed by 
decrease to 10 % ACN over 0.5 min, and finally kept at 10 % for 1 min. 
1’-Hydroxymyristicin glucuronide was estimated based on the comparison of the peak area of 
the formed metabolite to the calibration curve of 1’-hydroxymyristicin at a wavelength of 210 
nm. The flow rate was 0.6 ml/min. The gradient was made using a mixture of ACN and ultrapure 
water containing 0.1 % (v/v) TFA. The gradient started at 10 % ACN, increased to 60 % over 3.5 
min, after which ACN was increased to 80 % over 0.5 min, and kept at 80 % for 0.5 min, and 
finally decreased to 10 % over 0.5 min. 
Quantification of GS-1’-oxomyristicin was based on a calibration curve of the GSH adduct of the 
synthesized 1’-oxymyristicin made as previously described (van den Berg et al. 2012; Punt et al. 
2009; Martati et al. 2011; Al-Subeihi et al. 2011). In short, a 60 μM concentration of the 
synthetic standard of 1’-oxomyristicin, dissolved in ACN, was incubated with different 
concentrations of GSH (i.e., 0–20 μM) in 0.2 M Tris–HCl (pH 7.4) for 6-hr at 37 °C, resulting in 
full conversion of the GSH to GS-1’-oxymyristicin. Quantification was done by comparing the 
peak areas of the formed GS-1’-oxo metabolite in the incubation mixtures with peak areas of the 
GS-1’-oxymyristicin calibration curve thus obtained at a wavelength of 212 nm. The gradient for 
analysis of the metabolite consisted of a mixture of ACN and ultrapure water containing 0.1 % 
(v/v) TFA. The flow rate was 0.6 ml/min, The gradient started with 10 % ACN, increased to 30 
% ACN over 2.5 min, after which ACN was increased to 80 % over 0.5 min, kept at 80 % for 0.5 
min, followed by a decrease to 10 % over 0.5 min, and finally kept at 10 % for 0.5 min. 
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Quantification of 1’-sulfoxymyristicin was done using UPLC analysis as described for the 
estimation of 1’-sulfoxysafrole (Martati et al. 2011). The UV spectrum of the GSH adduct of 1’-
sulfoxymyristicin was found to be similar to the UV spectrum of the GSH conjugate of 1’-
oxomyristicin, and estimation of the GSH adduct of 1’-sulfoxymyristicin was thus accomplished 
by comparing the peak area of this metabolite to the calibration curve of GS-1’-oxomyristicin at 
a wavelength 305 nm. The gradient for analysis of the metabolite consisted of a mixture of ACN 
and ultrapure water containing 0.1 % (v/v) TFA. The flow rate was 0.6 ml/min, starting at 0 % 
ACN and increasing the percentage of ACN to 20 % over 0.2 min, followed by an increase to 30 
% ACN over 4.3 min, then increasing to 100 % over 0.3 min, and keeping it at 100 % for 0.2 
min, and finally decreasing to 0 % over 0.2 min and keeping it at 0 % for 0.8 min. Separation and 
purification of the GSH adduct of 1’-sulfoxymyristicin was performed by collecting the peak of 
the metabolite from the UPLC column. Then, LC–MS analysis of the metabolite was conducted 
using a micro-TOF MS (Bruker) coupled to an Agilent LC (1200 Series) equipped with Altima 
C18 column (150 × 4.6 mm, 3 μm). The mobile phase used consisted of (A) nanopure water with 
0.1 % formic acid and (B) HPLC-grade ACN with 0.1 % formic acid. Elution was at a flow rate 
of 0.8 ml/min, starting at 22 % B with a linear increase to 100 % B in 30 min. Subsequently, the 
gradient returned linearly to the initial conditions in 2 min and remained 13 min at this condition 
prior to the next injection. Mass spectrometric analysis was in the negative electrospray mode 
using a spray capillary voltage of 4500 V, a capillary temperature of 200 °C, and nitrogen as 
nebulizer gas at 8.0 L/min. 
 
 
 
 
 
Determination of kinetic constants 
Kinetic constants for the metabolic conversions of myristicin and 1’-hydroxymyristicin were 
derived by fitting the data to the standard Michaelis–Menten equation, 
? ? ???? ? ??? ??? ? ??? 
For conversion of 1’-hydroxymyristicin to 1’-sulfoxymyristicin, a first-order rate linear equation 
was used: 
? ? ???? ? ??? 
In which [S] represents the substrate concentration, Vmax the maximum velocity, and Km the 
Michaelis–Menten constant for the formation of the different metabolites of myristicin or 1’-
hydroxymyristicin, kHMS the first-order rate constant for sulfonation of 1’-hydroxymyristicin. 
Data analysis was accomplished using GraphPad Prism, version 5.04 (GraphPad Software, San 
Diego, CA). 
 
Physiologically based kinetic (PBK) models 
Two PBK models were developed describing the relative importance of bioactivation and 
detoxification of myristicin in rat and human at different oral dose levels. The models developed 
in this study were essentially based on the PBK models previously defined for the metabolism of 
estragole (Punt et al. 2008, 2009), methyleugenol (Al-Subeihi et al. 2011, 2012), elemicin (van 
den Berg et al. 2012), and safrole (Martati et al. 2011, 2012) in rat and human. A schematic 
overview of the developed PBK models for myristicin metabolism in rat and human is shown in 
Figure 3. The models consist of several compartments representing different organs and tissues 
(i.e., liver, fat tissue, richly perfused tissues, and slowly perfused tissues) that are mutually 
connected through the systemic circulation. First-order kinetics was used to describe the uptake 
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Quantification of 1’-sulfoxymyristicin was done using UPLC analysis as described for the 
estimation of 1’-sulfoxysafrole (Martati et al. 2011). The UV spectrum of the GSH adduct of 1’-
sulfoxymyristicin was found to be similar to the UV spectrum of the GSH conjugate of 1’-
oxomyristicin, and estimation of the GSH adduct of 1’-sulfoxymyristicin was thus accomplished 
by comparing the peak area of this metabolite to the calibration curve of GS-1’-oxomyristicin at 
a wavelength 305 nm. The gradient for analysis of the metabolite consisted of a mixture of ACN 
and ultrapure water containing 0.1 % (v/v) TFA. The flow rate was 0.6 ml/min, starting at 0 % 
ACN and increasing the percentage of ACN to 20 % over 0.2 min, followed by an increase to 30 
% ACN over 4.3 min, then increasing to 100 % over 0.3 min, and keeping it at 100 % for 0.2 
min, and finally decreasing to 0 % over 0.2 min and keeping it at 0 % for 0.8 min. Separation and 
purification of the GSH adduct of 1’-sulfoxymyristicin was performed by collecting the peak of 
the metabolite from the UPLC column. Then, LC–MS analysis of the metabolite was conducted 
using a micro-TOF MS (Bruker) coupled to an Agilent LC (1200 Series) equipped with Altima 
C18 column (150 × 4.6 mm, 3 μm). The mobile phase used consisted of (A) nanopure water with 
0.1 % formic acid and (B) HPLC-grade ACN with 0.1 % formic acid. Elution was at a flow rate 
of 0.8 ml/min, starting at 22 % B with a linear increase to 100 % B in 30 min. Subsequently, the 
gradient returned linearly to the initial conditions in 2 min and remained 13 min at this condition 
prior to the next injection. Mass spectrometric analysis was in the negative electrospray mode 
using a spray capillary voltage of 4500 V, a capillary temperature of 200 °C, and nitrogen as 
nebulizer gas at 8.0 L/min. 
 
 
 
 
 
Determination of kinetic constants 
Kinetic constants for the metabolic conversions of myristicin and 1’-hydroxymyristicin were 
derived by fitting the data to the standard Michaelis–Menten equation, 
? ? ???? ? ??? ??? ? ??? 
For conversion of 1’-hydroxymyristicin to 1’-sulfoxymyristicin, a first-order rate linear equation 
was used: 
? ? ???? ? ??? 
In which [S] represents the substrate concentration, Vmax the maximum velocity, and Km the 
Michaelis–Menten constant for the formation of the different metabolites of myristicin or 1’-
hydroxymyristicin, kHMS the first-order rate constant for sulfonation of 1’-hydroxymyristicin. 
Data analysis was accomplished using GraphPad Prism, version 5.04 (GraphPad Software, San 
Diego, CA). 
 
Physiologically based kinetic (PBK) models 
Two PBK models were developed describing the relative importance of bioactivation and 
detoxification of myristicin in rat and human at different oral dose levels. The models developed 
in this study were essentially based on the PBK models previously defined for the metabolism of 
estragole (Punt et al. 2008, 2009), methyleugenol (Al-Subeihi et al. 2011, 2012), elemicin (van 
den Berg et al. 2012), and safrole (Martati et al. 2011, 2012) in rat and human. A schematic 
overview of the developed PBK models for myristicin metabolism in rat and human is shown in 
Figure 3. The models consist of several compartments representing different organs and tissues 
(i.e., liver, fat tissue, richly perfused tissues, and slowly perfused tissues) that are mutually 
connected through the systemic circulation. First-order kinetics was used to describe the uptake 
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of myristicin from the gastrointestinal (GI) tract assuming a direct uptake by the liver with an 
absorption rate constant (ka) of 1.0 h−1, which is based on the fast and complete absorption of the 
structurally related alkenylbenzene safrole from the GI tract (Punt et al. 2008). For rat and 
human, the liver was the only organ able to convert myristicin to different microsomal 
metabolites. 2’,3’-Dihydroxymyristicin (DHM), 3’-hydroxymyristicin (3HM), 1’-
hydroxymyristicin (HM), and 5-allyl-2,3-dihydroxyanisole (DHA) were formed in incubations 
with both rat and human liver. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Schematic overview of the PBK model for myristicin in rat and human. 
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Accordingly, mass balance equations for myristicin in rat liver and human were as follows: 
???? ?? ? ???????? ?? ? ?? ? ???? ? ??? ???? ???  
???????? ? ??? ???? ????? ? ??? ???? ??  
????????? ? ??? ???? ??????? ? ??? ???? ??  
????????? ? ??? ???? ??????? ? ??? ???? ??  
????????? ? ??? ???? ??????? ? ??? ???? ??  
??????? ?? ? ?????? ?? ? ?? ? ??????? ??????? ? ????????? 
??? ? ??? ???  
Where UptakeM (μmol) is the amount of myristicin taken up from the GI tract, AGIM (μmol) is 
the amount of myristicin remaining in the GI tract, and ALM (μmol) is the amount of myristicin 
in the liver or CLM is the myristicin concentration in the liver (μmol/L). CAM and CVM are the 
myristicin concentrations in the arterial and venous blood (both in μmol/L), QL is the blood flow 
rate to a tissue (L/h), QC is the cardiac output (L/h), VL is the volume of liver, PLM is the 
tissue/blood partition coefficient of myristicin, and Vmax and Km are the values representing the 
maximum rate of formation and Michaelis–Menten constant, respectively, for the formation of 
2’,3’-dihydroxymyristicin (DHM), 3’-hydroxymyristicin (3HM), 1’-hydroxymyristicin (HM), 
and 5-allyl-2,3-dihydroxyanisole (DHA). 
The mass balance equation for the metabolic conversion of 1’-hydroxymyristicin by 
glucuronidation, oxidation, and sulfonation in the liver in rat and human liver is as follows: 
????? ?? ? ?????? ? ??? ???? ????? ? ??? ???? ???  
?????????? ? ???? ????? ?????? ? ???? ????? ??  
???????? ? ???? ????? ?????? ? ???? ????? ??  
????? ? ???? ?????  
??? ? ??? ???  
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of myristicin from the gastrointestinal (GI) tract assuming a direct uptake by the liver with an 
absorption rate constant (ka) of 1.0 h−1, which is based on the fast and complete absorption of the 
structurally related alkenylbenzene safrole from the GI tract (Punt et al. 2008). For rat and 
human, the liver was the only organ able to convert myristicin to different microsomal 
metabolites. 2’,3’-Dihydroxymyristicin (DHM), 3’-hydroxymyristicin (3HM), 1’-
hydroxymyristicin (HM), and 5-allyl-2,3-dihydroxyanisole (DHA) were formed in incubations 
with both rat and human liver. 
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Accordingly, mass balance equations for myristicin in rat liver and human were as follows: 
???? ?? ? ???????? ?? ? ?? ? ???? ? ??? ???? ???  
???????? ? ??? ???? ????? ? ??? ???? ??  
????????? ? ??? ???? ??????? ? ??? ???? ??  
????????? ? ??? ???? ??????? ? ??? ???? ??  
????????? ? ??? ???? ??????? ? ??? ???? ??  
??????? ?? ? ?????? ?? ? ?? ? ??????? ??????? ? ????????? 
??? ? ??? ???  
Where UptakeM (μmol) is the amount of myristicin taken up from the GI tract, AGIM (μmol) is 
the amount of myristicin remaining in the GI tract, and ALM (μmol) is the amount of myristicin 
in the liver or CLM is the myristicin concentration in the liver (μmol/L). CAM and CVM are the 
myristicin concentrations in the arterial and venous blood (both in μmol/L), QL is the blood flow 
rate to a tissue (L/h), QC is the cardiac output (L/h), VL is the volume of liver, PLM is the 
tissue/blood partition coefficient of myristicin, and Vmax and Km are the values representing the 
maximum rate of formation and Michaelis–Menten constant, respectively, for the formation of 
2’,3’-dihydroxymyristicin (DHM), 3’-hydroxymyristicin (3HM), 1’-hydroxymyristicin (HM), 
and 5-allyl-2,3-dihydroxyanisole (DHA). 
The mass balance equation for the metabolic conversion of 1’-hydroxymyristicin by 
glucuronidation, oxidation, and sulfonation in the liver in rat and human liver is as follows: 
????? ?? ? ?????? ? ??? ???? ????? ? ??? ???? ???  
?????????? ? ???? ????? ?????? ? ???? ????? ??  
???????? ? ???? ????? ?????? ? ???? ????? ??  
????? ? ???? ?????  
??? ? ??? ???  
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where ALHM is the amount of 1’-hydroxymyristicin in the liver (μmol), CLHM is the 1’-
hydroxymyristicin concentration in the liver (μmol/L), PLHM is the liver/blood partition 
coefficient of 1’-hydroxymyristicin, and Vmax and Km are the maximum rate of formation and 
Michaelis–Menten constant, respectively, for the formation of the different 1’-hydroxymyristicin 
metabolites in the liver, including 1’-hydroxymyristicin glucuronide, 1’-oxomyristicin, and kHMS 
is the first-order rate constant for sulfonation of 1’-hydroxymyristicin that was used instead of 
Km and Vmax as sulfonation showed no saturation. Vmax and Km values and first-order rate 
constants k in case of the absence of saturation (for sulfonation of 1’-hydroxymyristicin in rat 
and human) for the different metabolic pathways of myristicin and 1’-hydroxymyristicin were 
derived from results from in vitro experiments in the present study. Vmax values that were derived 
in vitro expressed as nmol min−1 (mg liver microsomal or S9 protein)−1 were scaled to values 
representing the Vmax per μmol h−1 (g liver)−1 using microsomal protein yields of 35 mg/g for rat 
and 32 mg/g for human liver and S9 protein yields of 143 mg/g for liver, as defined previously 
(Punt et al. 2008, 2009), based on Medinsky et al. (1994). First-order rate constant k expressed in 
ml min−1 (mg liver S9 protein)−1 was scaled to values expressed in ml h−1 per g liver using the 
same conversion factor for S9 protein yield. Tables 2 and 3 summarize the physiological 
parameters (i.e., tissue volumes, cardiac output, and tissue blood flows) for rat and human, 
respectively, which were derived from the literature (Brown et al. 1997). Partition coefficients 
were derived in silico based on a method described by DeJongh et al. (1997) using the log Kow. 
Log Kow values for myristicin (Clog P 3.1721) and 1’-hydroxymyristicin (Clog P 1.6151) were 
estimated using Chemdraw professional 15 (ChemOffice® Professional 15.0 by perkin elmer). 
Mass balance equations were coded and numerically integrated in Berkely Madonna 8.3.18 
(Macey and Oster, UC Berkeley, CA) using Rosenbrock’s algorithm for stiff systems. PBK 
 
 
models in rat and human liver were run for 720-hr, because that would be the time for total 
clearance of myristicin in human tissues after one dose. 
 
Table 2. Parameters used in the physiologically based kinetic model for myristicin in male rat. 
Physiological parameters 
(Brown, 1997) Tissue: blood partition coefficients 
body weight (kg) 0.25 myristicin 
percentage of body weight        liver  
        liver 3.4        fat 1.68 
        fat 7.0        rapidly perfused 37.73 
       rapidly perfused 5.1        slowly perfused 1.68 
       slowly perfused 60.2  0.67 
       blood 7.4 1’-hydroxymyristicin  
         liver 0.94 
cardiac output (L/h) 5.4   
percentage of cardiac output   
        liver 25   
        fat 7.0   
        rapidly perfused 51.0   
        slowly perfused 17.0   
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where ALHM is the amount of 1’-hydroxymyristicin in the liver (μmol), CLHM is the 1’-
hydroxymyristicin concentration in the liver (μmol/L), PLHM is the liver/blood partition 
coefficient of 1’-hydroxymyristicin, and Vmax and Km are the maximum rate of formation and 
Michaelis–Menten constant, respectively, for the formation of the different 1’-hydroxymyristicin 
metabolites in the liver, including 1’-hydroxymyristicin glucuronide, 1’-oxomyristicin, and kHMS 
is the first-order rate constant for sulfonation of 1’-hydroxymyristicin that was used instead of 
Km and Vmax as sulfonation showed no saturation. Vmax and Km values and first-order rate 
constants k in case of the absence of saturation (for sulfonation of 1’-hydroxymyristicin in rat 
and human) for the different metabolic pathways of myristicin and 1’-hydroxymyristicin were 
derived from results from in vitro experiments in the present study. Vmax values that were derived 
in vitro expressed as nmol min−1 (mg liver microsomal or S9 protein)−1 were scaled to values 
representing the Vmax per μmol h−1 (g liver)−1 using microsomal protein yields of 35 mg/g for rat 
and 32 mg/g for human liver and S9 protein yields of 143 mg/g for liver, as defined previously 
(Punt et al. 2008, 2009), based on Medinsky et al. (1994). First-order rate constant k expressed in 
ml min−1 (mg liver S9 protein)−1 was scaled to values expressed in ml h−1 per g liver using the 
same conversion factor for S9 protein yield. Tables 2 and 3 summarize the physiological 
parameters (i.e., tissue volumes, cardiac output, and tissue blood flows) for rat and human, 
respectively, which were derived from the literature (Brown et al. 1997). Partition coefficients 
were derived in silico based on a method described by DeJongh et al. (1997) using the log Kow. 
Log Kow values for myristicin (Clog P 3.1721) and 1’-hydroxymyristicin (Clog P 1.6151) were 
estimated using Chemdraw professional 15 (ChemOffice® Professional 15.0 by perkin elmer). 
Mass balance equations were coded and numerically integrated in Berkely Madonna 8.3.18 
(Macey and Oster, UC Berkeley, CA) using Rosenbrock’s algorithm for stiff systems. PBK 
 
 
models in rat and human liver were run for 720-hr, because that would be the time for total 
clearance of myristicin in human tissues after one dose. 
 
Table 2. Parameters used in the physiologically based kinetic model for myristicin in male rat. 
Physiological parameters 
(Brown, 1997) Tissue: blood partition coefficients 
body weight (kg) 0.25 myristicin 
percentage of body weight        liver  
        liver 3.4        fat 1.68 
        fat 7.0        rapidly perfused 37.73 
       rapidly perfused 5.1        slowly perfused 1.68 
       slowly perfused 60.2  0.67 
       blood 7.4 1’-hydroxymyristicin  
         liver 0.94 
cardiac output (L/h) 5.4   
percentage of cardiac output   
        liver 25   
        fat 7.0   
        rapidly perfused 51.0   
        slowly perfused 17.0   
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Table 3. Parameters used in the physiologically based kinetic model for myristicin in human. 
Physiological parameters 
(Brown, 1997) 
Tissue: blood partition coefficients 
 
body weight (Kg) 60 myristicin 
percentage of body weight        liver 4.22 
        liver 2.6        fat 83.45 
       fat 21.4        rapidly perfused 4.22 
     rapidly perfused 5.0        slowly perfused 2.81 
     slowly perfused 51.7   
blood 7.9 1’-hydroxymyristicin  
         liver 0.93 
cardiac output (L/h) 310   
percentage of cardiac output   
        liver 22.7   
        fat 5.2   
        rapidly perfused 47.3   
 
Sensitivity analysis 
To determine which parameters have the greatest influence on model predictions, a sensitivity 
analysis was performed as described previously (Punt et al. 2008, 2009; van den Berg et al. 
2012; Martati et al. 2011, 2012; Al-Subeihi et al. 2011, 2012). For this purpose, normalized 
sensitivity coefficients (SCs) were determined using the following equation: 
?? ? ??? ? ?? ??? ? ?? ? ?? ?? ??  
where C is the initial value of the model output, C′ is the modified value of the model output 
resulting from an increase in parameter value, P is the initial parameter value, and P′ represents 
the modified parameter value. An increase of 5 % in parameter values was used to analyze the 
effect of a change in parameter on the formation of 1’-hydroxymyristicin and 1’-
 
 
sulfoxymyristicin (expressed as a percentage of the dose). Each parameter was analyzed 
individually, while the other parameters were kept at their initial value. 
 
Comparison of the PBK model-based prediction of bioactivation of myristicin to the PBK 
model-based predictions for bioactivation of the structurally related compound safrole 
The predicted model outcomes for the formation of 1’-hydroxymyristicin and 1’-
sulfoxymyristicin in the liver of rat and human were compared with the predicted dose-
dependent formation of the 1’-hydroxy- and 1’-sulfoxy metabolite of the structurally related 
alkenylbenzene safrole. For this purpose, the previously defined PBK models for safrole 
described by Martati et al. (2011, 2012) for rat and human were used (Martati et al. 2011, 2012).  
For the comparison, the models describing the metabolism of myristicin and safrole were run for 
a period of 720-hr. 
 
RESULTS 
Microsomal conversion of myristicin 
To identify which organs are involved in the metabolism of myristicin in both male rat and 
human, incubations were performed using microsomal protein preparations from liver, kidney, 
lung, and small intestine of both species. Chromatographic analysis of these incubations revealed 
that for rat and human, no detectable metabolism of myristicin occurred in small intestine, lung, 
or kidney microsomes, and metabolism was only observed for liver microsomes. 
An example of a chromatogram of an incubation of myristicin with male rat liver microsomes 
and NADPH as a cofactor is shown in Figure 4. In incubations with rat liver microsomes, 2’,3’-
dihydroxymyristicin (Rt= 1.19 min), 3’-hydroxymyristicin (Rt= 2.01 min), 1’-hydroxymyristicin 
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Table 3. Parameters used in the physiologically based kinetic model for myristicin in human. 
Physiological parameters 
(Brown, 1997) 
Tissue: blood partition coefficients 
 
body weight (Kg) 60 myristicin 
percentage of body weight        liver 4.22 
        liver 2.6        fat 83.45 
       fat 21.4        rapidly perfused 4.22 
     rapidly perfused 5.0        slowly perfused 2.81 
     slowly perfused 51.7   
blood 7.9 1’-hydroxymyristicin  
         liver 0.93 
cardiac output (L/h) 310   
percentage of cardiac output   
        liver 22.7   
        fat 5.2   
        rapidly perfused 47.3   
 
Sensitivity analysis 
To determine which parameters have the greatest influence on model predictions, a sensitivity 
analysis was performed as described previously (Punt et al. 2008, 2009; van den Berg et al. 
2012; Martati et al. 2011, 2012; Al-Subeihi et al. 2011, 2012). For this purpose, normalized 
sensitivity coefficients (SCs) were determined using the following equation: 
?? ? ??? ? ?? ??? ? ?? ? ?? ?? ??  
where C is the initial value of the model output, C′ is the modified value of the model output 
resulting from an increase in parameter value, P is the initial parameter value, and P′ represents 
the modified parameter value. An increase of 5 % in parameter values was used to analyze the 
effect of a change in parameter on the formation of 1’-hydroxymyristicin and 1’-
 
 
sulfoxymyristicin (expressed as a percentage of the dose). Each parameter was analyzed 
individually, while the other parameters were kept at their initial value. 
 
Comparison of the PBK model-based prediction of bioactivation of myristicin to the PBK 
model-based predictions for bioactivation of the structurally related compound safrole 
The predicted model outcomes for the formation of 1’-hydroxymyristicin and 1’-
sulfoxymyristicin in the liver of rat and human were compared with the predicted dose-
dependent formation of the 1’-hydroxy- and 1’-sulfoxy metabolite of the structurally related 
alkenylbenzene safrole. For this purpose, the previously defined PBK models for safrole 
described by Martati et al. (2011, 2012) for rat and human were used (Martati et al. 2011, 2012).  
For the comparison, the models describing the metabolism of myristicin and safrole were run for 
a period of 720-hr. 
 
RESULTS 
Microsomal conversion of myristicin 
To identify which organs are involved in the metabolism of myristicin in both male rat and 
human, incubations were performed using microsomal protein preparations from liver, kidney, 
lung, and small intestine of both species. Chromatographic analysis of these incubations revealed 
that for rat and human, no detectable metabolism of myristicin occurred in small intestine, lung, 
or kidney microsomes, and metabolism was only observed for liver microsomes. 
An example of a chromatogram of an incubation of myristicin with male rat liver microsomes 
and NADPH as a cofactor is shown in Figure 4. In incubations with rat liver microsomes, 2’,3’-
dihydroxymyristicin (Rt= 1.19 min), 3’-hydroxymyristicin (Rt= 2.01 min), 1’-hydroxymyristicin 
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(Rt= 2.04 min), and 5-allyl-2,3-dihydroxyanisole (Rt= 2.11 min) were formed. In incubations 
with human liver microsomes, the same four metabolites were found. Identification was done 
based on the comparison of the UV spectra and retention times of the formed metabolites with 
those of the specific synthesized or commercially available reference compounds. However, 
tentative identification of 2’,3’-dihydroxymyrsticin was based on the fact that the epoxidation of 
the double bond in the allyl side chain of estragole, methyleugenol, and safrole yields the 2’,3’-
epoxide, found to be hydrolyzed by epoxide hydrolase to the 2’,3’-dihydroxy metabolite (Luo et 
al. 1992; Luo and Guenthner 1996; Guenthner and Luo 2001). The hydrolysis product of the 
epoxide, 2’,3’-dihydroxy metabolite of myristicin, safrole, or elemicin, was detected in the urine 
of rats administered high doses (100 mg/kg bw) of each substance individually or a high dose of 
nutmeg (500 mg/kg bw) (Beyer et al. 2006). Data revealed that 3’-hydroxymyristicin was formed 
directly from myristicin rather than from isomerization of 1’-hydroxymyristicin since the 
formation of 3’-hydroxymyristicin was not observed in incubations of 1’-hydroxymyristicin with 
liver microsomes and NADPH (data not shown). The kinetic constants (i.e., Vmax and Km) were 
derived from plots of the rates of formation of different microsomal metabolites in incubations 
with male rat liver microsomes, and human liver microsomes from myristicin at concentrations 
ranging from 25 to 1000 μM (for details, see Figure S1 in the supplementary materials). The 
values obtained are shown in Table 4, together with the catalytic efficiencies, calculated as 
Vmax/Km. Analysis of incubations that were performed with male rat liver microsomal 
preparations revealed that the metabolite arising from O-demethylenation of myristicin, namely 
5-allyl-2,3-dihydroxyanisole, was formed with the highest Vmax value. Moreover, the 2’,3’-
dihydroxymyristicin and 5-allyl-2,3-dihydroxyanisole were abundantly formed in incubations 
with male rat microsomal liver preparations with a high affinity. In incubations performed with 
 
 
male rat liver microsomes, 1’-hydroxymyristicin and 3’-hydroxymyristicin were the least 
important metabolites formed upon conversion of myristicin. In general, the catalytic efficiency 
for the formation of 5-allyl-2,3-dihydroxyanisole by male rat liver microsomes had the highest 
value, followed by the catalytic efficiency for the formation of 2’,3’-dihydroxymyristicin, 1’-
hydroxymyristicin, and 3’-hydroxymyristicin, respectively. The catalytic efficiency for the 
formation of 5-allyl-2,3-dihydroxyanisole was found to be approximately 7-fold higher than that 
for the formation of 3’-hydroxymyristicin. In incubations with human liver fractions, 5-allyl-2,3-
dihydroxyanisole was found to be the most abundant metabolite formed followed by 2’,3’-
dihydroxymyristicin, 1’-hydroxymyristicin, and 3’-hydroxymyristicin, respectively. Analysis of 
the catalytic efficiencies for the formation of the different microsomal metabolites of myristicin, 
obtained with pooled human liver microsomes, showed that the formations of 2’,3’-
dihydroxymyristicin, 1’-hydroxymyristicin, and 3’-hydroxymyristicin were the least important 
routes of myristicin metabolism, whereas the formation of 5-allyl-2,3-dihydroxyanisole 
represents the major pathway for the human liver microsomal conversion of myristicin. 
 
Glucuronidation of 1’-hydroxymyristicin 
Chromatographic analysis of incubations with male rat and mixed gender pooled human liver S9, 
UDPGA as cofactor and 1’-hydroxymyristicin as substrate, revealed a peak at 1.36 min 
(chromatogram not shown). Moreover, chromatographic analysis of incubations performed in the 
absence of the cofactor UDPGA did not show a peak at a retention time of 1.36 min. Together, 
these data indicate that the compound eluting at 1.36 min can be assumed to be 1’-
hydroxymyristicin glucuronide. The rate of the metabolic conversion of 1’-hydroxymyristicin to 
1’-hydroxymyristicin glucuronide in incubations with both male rat and human liver fractions 
C
ha
pt
er
 2
Chapter 2 | PBK modelling of the bioactivation of myristicin
61
 
 
(Rt= 2.04 min), and 5-allyl-2,3-dihydroxyanisole (Rt= 2.11 min) were formed. In incubations 
with human liver microsomes, the same four metabolites were found. Identification was done 
based on the comparison of the UV spectra and retention times of the formed metabolites with 
those of the specific synthesized or commercially available reference compounds. However, 
tentative identification of 2’,3’-dihydroxymyrsticin was based on the fact that the epoxidation of 
the double bond in the allyl side chain of estragole, methyleugenol, and safrole yields the 2’,3’-
epoxide, found to be hydrolyzed by epoxide hydrolase to the 2’,3’-dihydroxy metabolite (Luo et 
al. 1992; Luo and Guenthner 1996; Guenthner and Luo 2001). The hydrolysis product of the 
epoxide, 2’,3’-dihydroxy metabolite of myristicin, safrole, or elemicin, was detected in the urine 
of rats administered high doses (100 mg/kg bw) of each substance individually or a high dose of 
nutmeg (500 mg/kg bw) (Beyer et al. 2006). Data revealed that 3’-hydroxymyristicin was formed 
directly from myristicin rather than from isomerization of 1’-hydroxymyristicin since the 
formation of 3’-hydroxymyristicin was not observed in incubations of 1’-hydroxymyristicin with 
liver microsomes and NADPH (data not shown). The kinetic constants (i.e., Vmax and Km) were 
derived from plots of the rates of formation of different microsomal metabolites in incubations 
with male rat liver microsomes, and human liver microsomes from myristicin at concentrations 
ranging from 25 to 1000 μM (for details, see Figure S1 in the supplementary materials). The 
values obtained are shown in Table 4, together with the catalytic efficiencies, calculated as 
Vmax/Km. Analysis of incubations that were performed with male rat liver microsomal 
preparations revealed that the metabolite arising from O-demethylenation of myristicin, namely 
5-allyl-2,3-dihydroxyanisole, was formed with the highest Vmax value. Moreover, the 2’,3’-
dihydroxymyristicin and 5-allyl-2,3-dihydroxyanisole were abundantly formed in incubations 
with male rat microsomal liver preparations with a high affinity. In incubations performed with 
 
 
male rat liver microsomes, 1’-hydroxymyristicin and 3’-hydroxymyristicin were the least 
important metabolites formed upon conversion of myristicin. In general, the catalytic efficiency 
for the formation of 5-allyl-2,3-dihydroxyanisole by male rat liver microsomes had the highest 
value, followed by the catalytic efficiency for the formation of 2’,3’-dihydroxymyristicin, 1’-
hydroxymyristicin, and 3’-hydroxymyristicin, respectively. The catalytic efficiency for the 
formation of 5-allyl-2,3-dihydroxyanisole was found to be approximately 7-fold higher than that 
for the formation of 3’-hydroxymyristicin. In incubations with human liver fractions, 5-allyl-2,3-
dihydroxyanisole was found to be the most abundant metabolite formed followed by 2’,3’-
dihydroxymyristicin, 1’-hydroxymyristicin, and 3’-hydroxymyristicin, respectively. Analysis of 
the catalytic efficiencies for the formation of the different microsomal metabolites of myristicin, 
obtained with pooled human liver microsomes, showed that the formations of 2’,3’-
dihydroxymyristicin, 1’-hydroxymyristicin, and 3’-hydroxymyristicin were the least important 
routes of myristicin metabolism, whereas the formation of 5-allyl-2,3-dihydroxyanisole 
represents the major pathway for the human liver microsomal conversion of myristicin. 
 
Glucuronidation of 1’-hydroxymyristicin 
Chromatographic analysis of incubations with male rat and mixed gender pooled human liver S9, 
UDPGA as cofactor and 1’-hydroxymyristicin as substrate, revealed a peak at 1.36 min 
(chromatogram not shown). Moreover, chromatographic analysis of incubations performed in the 
absence of the cofactor UDPGA did not show a peak at a retention time of 1.36 min. Together, 
these data indicate that the compound eluting at 1.36 min can be assumed to be 1’-
hydroxymyristicin glucuronide. The rate of the metabolic conversion of 1’-hydroxymyristicin to 
1’-hydroxymyristicin glucuronide in incubations with both male rat and human liver fractions 
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with increasing concentrations of 1’-hydroxymyristicin is presented in Figure 5a, d, respectively. 
The kinetic constants derived from these plots are presented in Table 4. 
 
Figure 4. UPLC chromatogram of an incubation of myristicin (1000 μM) with male rat liver 
microsomes. The peak marked with an asterisk (*) was also found in the blank incubation 
without NADPH. 
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with increasing concentrations of 1’-hydroxymyristicin is presented in Figure 5a, d, respectively. 
The kinetic constants derived from these plots are presented in Table 4. 
 
Figure 4. UPLC chromatogram of an incubation of myristicin (1000 μM) with male rat liver 
microsomes. The peak marked with an asterisk (*) was also found in the blank incubation 
without NADPH. 
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Figure 5. Concentration-dependent rate of (A) glucuronidation of 1’-hydroxymyristicin in 
incubations with male rat liver S9 or (D) pooled human mixed gender liver S9, (B) oxidation of 
1’-hydroxymyristicin  in incubations with pooled male rat liver microsomes or (E) pooled human 
mixed gender liver S9, and (C) sulfonation of 1’-hydroxymyristicin in pooled male rat liver S9 or 
(F) pooled human mixed gender liver S9. Data points represent mean values +/- SD of three or 
four individual experiments. 
 
 
 
Oxidation of 1’-hydroxymyristicin 
The rate of oxidation of 1’-hydroxymyristicin with increasing concentrations of 1’-
hydroxymyristicin in incubations with male rat and pooled human liver microsomes is shown in 
Figure 5b, e, respectively, and the kinetic constants derived from these data are presented in 
Table 4. 
 
Sulfonation of 1’-hydroxymyristicin 
In the present study, GSH was used to trap the reactive 1’-sulfoxymyristicin formed upon 
sulfonation of the proximate carcinogenic metabolite of myristicin, 1’-hydroxymyristicin. The 
scavenging is based on a chemical reaction but can also be catalyzed by the GST present in the 
S9 incubations in which the sulfonation of 1’-hydroxymyristicin was measured. 
Chromatographic analysis of incubations with male rat or mixed gender pooled human liver S9, 
increasing concentration of 1’-hydroxymyristicin, PAPS, and GSH revealed a peak at 1.05 min, 
which was identified as the GSH adduct of the carbocation of 1’-sulfoxymyristicin. Identification 
was achieved based on the chromatographic analysis of incubations performed in the absence of 
GSH and the presence of PAPS and liver S9 proteins since in these incubations; no peak was 
found at 1.05 min. The identity was verified by LC–MS analysis, which revealed a deprotonated 
molecule at m/z 496 that corresponds to the expected [M–H] mass of a GSH adduct of 1’-
sulfoxymyristicin. The rate of formation of 1’-sulfoxymyristicin in incubations with male rat and 
mixed gender pooled human liver S9 is presented in Figure 5c, f, respectively. The kinetic 
constants for the conversion of 1’-hydroxymyristicin to 1’-sulfoxymyristicin in rat and human 
liver are presented in Table 4. 
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Comparison of the kinetic constants for conversion of myristicin and 1’-hydroxymyristicin by 
male rat and mixed gender pooled human tissue fractions 
To allow a comparison between the kinetic constants for metabolism of myristicin and 1’-
hydroxymyristicin by male rat and mixed gender pooled human tissue fractions, Vmax values that 
were derived in vitro expressed in nmol min−1 (mg microsomal or S9 protein)−1 were scaled to 
values representing the Vmax per μmol h−1 (g tissue)−1 using microsomal and S9 protein yields as 
described in the literature (Medinsky et al. 1994) and previously used (Martati et al. 2011, 2012; 
van den Berg et al. 2012; Punt et al. 2009; Al-Subeihi et al. 2011, 2012). Making the use of the 
in vivo Vmax values derived accordingly, a scaled catalytic efficiency (scaled ??????????? ??? ) 
for the formation of myristicin metabolites could be calculated (Table 5). For sulfonation, the 
rate constants for product formation (ml/min/mg protein) were scaled based on S9 protein yield 
of 143 mg/g liver. These values show that the catalytic efficiency for the formation of the 
proximate carcinogenic metabolite of myristicin, 1’-hydroxymyristicin, was found to be 13-fold 
higher in male rat liver as compared to human liver. This difference in catalytic efficiency for the 
formation of 1’-hydroxymyristicin is predominantly caused by the high affinity (expressed as 
Km) and high activity (expressed as Vmax) for its formation from myristicin in male rat liver, 
since the Km value in rat liver incubations was 2-fold lower than that in human liver incubations 
and Vmax in rat liver incubations was 5-fold higher than that in human liver incubations. The 
detoxification of 1’-hydroxymyristicin by formation of 1’-hydroxymyristicin glucuronide was 
found to be the main metabolic reaction with 1’-hydroxymyristicin in rat. Glucuronidation of 1’-
hydroxymyristicin occurs in male rat with higher affinity than in human (i.e., Km 836 μM), 
whereas in human the Km was 3140 μM, and analysis of the data revealed a high Vmax value for 
1’-hydroxymyristicin glucuronidation resulting in a catalytic efficiency that was 400-fold higher 
 
 
in male rats as compared to human. Oxidation of 1’-hydroxymyristicin was found to be 1.2 times 
more efficient in human liver as compared to male rat liver resulting from a 1.8-fold lower 
affinity in rat. Sulfonation was found to be the least efficient metabolic pathway for 1’-
hydroxymyristicin in both rats and human. For rat, the in vivo scaled k was 0.15 ml h−1 (g 
tissue)−1, and for human, it was 0.14 ml h−1 (g tissue)−1, indicating that sulfonation of 1’-
hydroxymyristicin is equally efficient in male rat liver and human liver. Altogether, it can be 
concluded that glucuronidation of 1’-hydroxymyristicin, representing a detoxification pathway, 
is the most important pathway in rat, and the oxidation is the most important pathway for 
conversion of 1’-hydroxymyristicin in human. Moreover, on the basis of the kinetic data 
obtained, bioactivation of 1’-hydroxymyristicin following sulfonation was found to represent 
only a minor pathway in both rat and human. 
 
Evaluation of PBK model performance 
The performance of the newly developed PBK models for myristicin could not be evaluated 
against in vivo data because quantitative data on the formation or excretion of the different 
metabolites in rat or humans exposed to myristicin are not available. However, Beyer et al. 
(2006) reported that in rats and humans, myristicin and safrole were O-demethylenated. In the 
urine of the human nutmeg abuser, who had taken 5 nutmegs, the acetylated metabolites of 5-
allyl-2,3-dihydroxyanisole and 2’,3’-dihydroxymyristicin could be identified. In the same study, 
O-demethylenation of myristicin to generate 5-allyl-2,3-dihydroxyanisole seems to result in the 
main metabolite of myristicin detected in rat urine samples collected over a 24-hr period after 
administration of a single oral dose of 100 mg/kg bw myristicin, with a percentage of 67 % of 
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urine of the human nutmeg abuser, who had taken 5 nutmegs, the acetylated metabolites of 5-
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the total dose (Beyer et al. 2006). In line with these results, the developed PBK model 
predicted 5-allyl-2,3-dihydroxyanisole to be the major metabolite formed at a dose of 100 
mg/kg bw myristicin in rat after 24-hr, with a percentage of 73 % of the total dose. This 
predicted value of 73 % of the dose matches well with the 67 % observed in the in vivo rat 
study. 
Important to note is that the PBK models for myristicin were based on the proposed 
biotransformation in Figure 2 and comparable with the PBK models for estragole, 
methyleugenol, and safrole, for which more data allowing the evaluation of the models were 
available. The performance of the rat PBK models developed for estragole, methyleugenol, 
and safrole was reported before (Punt et al. 2008; Martati et al. 2011; Al-Subeihi et al. 2011). 
Evaluation was done by comparing the predicted levels of a variety of metabolites in plasma 
or excreted in the urine of rats. Data revealed that the predicted PBK model values and the 
levels of these metabolites derived from in vivo studies adequately matched (Punt et al. 2008; 
Martati et al. 2011; Al-Subeihi et al. 2011). Furthermore, also for the developed human PBK 
models for estragole (Punt et al. 2009), methyleugenol (Al-Subeihi et al. 2012), and safrole 
(Martati et al. 2012), a comparison could be made between the model predictions and the 
reported in vivo data for blood concentrations or the urinary excretion of some of the 
metabolites, thereby further supporting the validity of the models. Considering these data, it 
was concluded that the developed PBK models for myristicin will also adequately describe 
the in vivo levels of metabolites formed in rat and human after conversion of myristicin and 
1’-hydroxymyristicin at different oral dose levels of myristicin. 
 
PBK model predictions 
PBK modeling was performed at dose levels of 0.05 and 300 mg/kg bw to allow comparison 
with the PBK model outcomes previously reported for safrole (Martati et al. 2011, 2012). 
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the total dose (Beyer et al. 2006). In line with these results, the developed PBK model 
predicted 5-allyl-2,3-dihydroxyanisole to be the major metabolite formed at a dose of 100 
mg/kg bw myristicin in rat after 24-hr, with a percentage of 73 % of the total dose. This 
predicted value of 73 % of the dose matches well with the 67 % observed in the in vivo rat 
study. 
Important to note is that the PBK models for myristicin were based on the proposed 
biotransformation in Figure 2 and comparable with the PBK models for estragole, 
methyleugenol, and safrole, for which more data allowing the evaluation of the models were 
available. The performance of the rat PBK models developed for estragole, methyleugenol, 
and safrole was reported before (Punt et al. 2008; Martati et al. 2011; Al-Subeihi et al. 2011). 
Evaluation was done by comparing the predicted levels of a variety of metabolites in plasma 
or excreted in the urine of rats. Data revealed that the predicted PBK model values and the 
levels of these metabolites derived from in vivo studies adequately matched (Punt et al. 2008; 
Martati et al. 2011; Al-Subeihi et al. 2011). Furthermore, also for the developed human PBK 
models for estragole (Punt et al. 2009), methyleugenol (Al-Subeihi et al. 2012), and safrole 
(Martati et al. 2012), a comparison could be made between the model predictions and the 
reported in vivo data for blood concentrations or the urinary excretion of some of the 
metabolites, thereby further supporting the validity of the models. Considering these data, it 
was concluded that the developed PBK models for myristicin will also adequately describe 
the in vivo levels of metabolites formed in rat and human after conversion of myristicin and 
1’-hydroxymyristicin at different oral dose levels of myristicin. 
 
PBK model predictions 
PBK modeling was performed at dose levels of 0.05 and 300 mg/kg bw to allow comparison 
with the PBK model outcomes previously reported for safrole (Martati et al. 2011, 2012). 
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Following an exposure to 0.05 mg/kg bw myristicin, both myristicin and its proximate 
carcinogenic metabolite 1’-hydroxymyristicin were predicted and observed to be almost 
completely metabolized within a 720-hr period in rat and human. At a higher oral dose level 
of 300 mg/kg bw myristicin, both myristicin and 1’-hydroxymyristicin were also predicted to 
be fully metabolized within 720-hr. Therefore, for all further modelings, values were 
calculated at 720-hr after dosing. Figure 6a shows the PBK model-based predictions for the 
dose-dependent formation of the different microsomal metabolites of myristicin in rat. The 
percentage of the dose converted to 1’-hydroxymyristicin is predicted to increase in a dose-
dependent manner. Concurrent with the increased percentage of the dose that undergoes 1’-
hydroxylation of the alkene side chain, a 1.6-fold dose-dependent decrease in the percentage 
of the dose that underwent epoxidation to give 2’,3’-dihydroxymyristicin was observed 
comparing the levels at 0.05 and 300 mg/kg bw. At the same time, a <1.6-fold increase in the 
formation of 3’-hydroxymyristicin was observed. The formation of 5-allyl-2,3-
dihydroxyanisole did not change with increasing dose levels and was equal to 48 % of the 
administered dose. Figure 6b shows the dose-dependent increase in the formation of the 
metabolites of 1’-hydroxymyristicin in rat. This reveals a 1.8-fold increase in the percentage 
of the dose ultimately converted into 1’-hydroxymyristicin glucuronide, 1’-oxomyristicin, 
and 1’-sulfoxymyristicin, going from a dose of 0.05 to 300 mg/kg bw. This dose-dependent 
increase in the formation of the different 1’-hydroxymyristicin metabolites can be explained 
by the 1.8-fold increase in the formation of 1’-hydroxymyristicin with increasing dose levels. 
Figure 7a reveals that in human, the percentage of the dose converted to 1’-hydroxymyristicin 
equal 6.5 % at a dose of 0.05 mg/kg bw and increased to 8.0 % at a dose of 300 mg/kg bw. 
Accompanying the increase in the formation of 1’-hydroxymyristicin, there were a 1.4-fold 
decrease in the formation of 2’,3’-dihydroxymyristicin and a steady formation of 5-allyl-2,3-
dihydroxyanisole. Formation of 3’-hydroxymyristicin was predicted to increase 1.8-fold with 
 
 
increasing dose from of 0.05 to 300 mg/kg bw. Figure 7b shows a 1.25-fold dose-dependent 
increase in the percentage formation of 1’-hydroxymyristicin glucuronide, 1’-
sulfoxymyristicin, and 1’-oxomyristicin, in human liver with increasing dose from of 0.05 to 
300 mg/kg bw. Comparison of the relative extent of bioactivation of myristicin by rat and 
human liver revealed that formation of 1’-hydroxymyristicin (expressed as nmol/g liver) is 
comparable in rat and human liver at the low dose of 0.05 mg/kg bw and 1.8-fold higher in 
rat liver than in human liver at a dose of 300 mg/kg bw (Figure 8a). Formation of 1’-
sulfoxymyristicin (expressed as nmol/g liver) is 4-fold higher in human liver than in rat liver 
at a low dose of 0.05 mg/kg bw and 2.8-fold lower in rat liver than in human liver at a dose of 
300 mg/kg bw (Figure 8b). 
 
 
 
 
 
 
Figure 6. PBK-predicted dose-dependent changes in overall formation of (A) microsomal 
metabolites of myristicin in rat liver and (B) metabolites of 1’-hydroxymyristicin in rat liver. 
The lines correspond to (A) 5-allyl-2,3-dihydroxyanisole (●●●●), 3’-hydroxymyristicin (▬ ● ▬), 
1’-hydroxymyristicin (▬▬), and 2',3'-dihydroxymyristicin (▬ ▬),and (B) 1’-hydroxymyristicin 
glucuronide (▬  ▬), 1'-sulfoxymyristicin (▬▬), and 1'-oxomyristicin (●●●●) 
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Following an exposure to 0.05 mg/kg bw myristicin, both myristicin and its proximate 
carcinogenic metabolite 1’-hydroxymyristicin were predicted and observed to be almost 
completely metabolized within a 720-hr period in rat and human. At a higher oral dose level 
of 300 mg/kg bw myristicin, both myristicin and 1’-hydroxymyristicin were also predicted to 
be fully metabolized within 720-hr. Therefore, for all further modelings, values were 
calculated at 720-hr after dosing. Figure 6a shows the PBK model-based predictions for the 
dose-dependent formation of the different microsomal metabolites of myristicin in rat. The 
percentage of the dose converted to 1’-hydroxymyristicin is predicted to increase in a dose-
dependent manner. Concurrent with the increased percentage of the dose that undergoes 1’-
hydroxylation of the alkene side chain, a 1.6-fold dose-dependent decrease in the percentage 
of the dose that underwent epoxidation to give 2’,3’-dihydroxymyristicin was observed 
comparing the levels at 0.05 and 300 mg/kg bw. At the same time, a <1.6-fold increase in the 
formation of 3’-hydroxymyristicin was observed. The formation of 5-allyl-2,3-
dihydroxyanisole did not change with increasing dose levels and was equal to 48 % of the 
administered dose. Figure 6b shows the dose-dependent increase in the formation of the 
metabolites of 1’-hydroxymyristicin in rat. This reveals a 1.8-fold increase in the percentage 
of the dose ultimately converted into 1’-hydroxymyristicin glucuronide, 1’-oxomyristicin, 
and 1’-sulfoxymyristicin, going from a dose of 0.05 to 300 mg/kg bw. This dose-dependent 
increase in the formation of the different 1’-hydroxymyristicin metabolites can be explained 
by the 1.8-fold increase in the formation of 1’-hydroxymyristicin with increasing dose levels. 
Figure 7a reveals that in human, the percentage of the dose converted to 1’-hydroxymyristicin 
equal 6.5 % at a dose of 0.05 mg/kg bw and increased to 8.0 % at a dose of 300 mg/kg bw. 
Accompanying the increase in the formation of 1’-hydroxymyristicin, there were a 1.4-fold 
decrease in the formation of 2’,3’-dihydroxymyristicin and a steady formation of 5-allyl-2,3-
dihydroxyanisole. Formation of 3’-hydroxymyristicin was predicted to increase 1.8-fold with 
 
 
increasing dose from of 0.05 to 300 mg/kg bw. Figure 7b shows a 1.25-fold dose-dependent 
increase in the percentage formation of 1’-hydroxymyristicin glucuronide, 1’-
sulfoxymyristicin, and 1’-oxomyristicin, in human liver with increasing dose from of 0.05 to 
300 mg/kg bw. Comparison of the relative extent of bioactivation of myristicin by rat and 
human liver revealed that formation of 1’-hydroxymyristicin (expressed as nmol/g liver) is 
comparable in rat and human liver at the low dose of 0.05 mg/kg bw and 1.8-fold higher in 
rat liver than in human liver at a dose of 300 mg/kg bw (Figure 8a). Formation of 1’-
sulfoxymyristicin (expressed as nmol/g liver) is 4-fold higher in human liver than in rat liver 
at a low dose of 0.05 mg/kg bw and 2.8-fold lower in rat liver than in human liver at a dose of 
300 mg/kg bw (Figure 8b). 
 
 
 
 
 
 
Figure 6. PBK-predicted dose-dependent changes in overall formation of (A) microsomal 
metabolites of myristicin in rat liver and (B) metabolites of 1’-hydroxymyristicin in rat liver. 
The lines correspond to (A) 5-allyl-2,3-dihydroxyanisole (●●●●), 3’-hydroxymyristicin (▬ ● ▬), 
1’-hydroxymyristicin (▬▬), and 2',3'-dihydroxymyristicin (▬ ▬),and (B) 1’-hydroxymyristicin 
glucuronide (▬  ▬), 1'-sulfoxymyristicin (▬▬), and 1'-oxomyristicin (●●●●) 
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Figure 7. PBK-predicted dose-dependent changes in overall formation of (A) microsomal 
Fig. 7  PBK-predicted dose-dependent changes in overall formation of (A) microsomal 
metabolites of myristicin in human liver and (B) metabolites of 1’-hydroxymyristicin in 
human liver. The lines correspond to (A) 5-allyl-2,3-dihydroxyanisole (●●●●), 3’-
hydroxymyristicin (▬ ● ▬ ), 1’-hydroxymyristicin (▬▬), and 2',3'-dihydroxymyristicin (▬  ▬), 
and (B) 1’-hydroxymyristicin glucuronide (▬  ▬), 1'-sulfoxymyristicin (▬▬), and 1'-
oxomyristicin (●●●●). 
 
 
Figure 8. PBK-predicted dose-dependent formation (mg/kg bw) of (A) 1’-hydroxymyristicin 
and (B) 1'-sulfoxymyristicin in rat and human liver. 
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Sensitivity analysis 
A sensitivity analysis was performed to define model parameters that are capable of 
influencing the formation of 1’-hydroxymyristicin and 1’-sulfoxymyristicin in rat and human 
liver. For this purpose, normalized sensitivity coefficients (SCs) were calculated for all 
parameters at a dose of 0.05 mg/kg bw myristicin. This sensitivity analysis reveals to what 
extent small variation in the respective parameters influences the results. The sensitivity 
analysis also reveals to which parameters the predicted outcomes are most sensitive. The 
results of this analysis are presented in Figure 9. Figure 9 especially presents the parameters 
affecting the formation of 1’-hydroxymyristicin (black) and 1’-sulfoxymyristicin (gray) that 
have a normalized SC > |0.1|. In rat liver, the formation of the ultimate carcinogenic 
metabolite 1’-sulfoxymyristicin is primarily influenced by the kinetic constants of 1’-
hydroxymyristicin formation from myristicin (Vmax HM, Km HM). The kinetic constants for the 
formation of 5-allyl-2,3-dihydroxyanisole and 2’,3’-dihydroxymyristicin (Vmax DHA, Km DHA, 
Vmax DHM, Km DHM) were also found to highly influence the formation of 1’-hydroxymyristicin 
in rat and human liver. In rat liver, the formation of the ultimate carcinogenic metabolite 1’-
sulfoxymyristicin is primarily influenced by the kinetic constants of 1’-hydroxymyristicin 
formation from myristicin (Vmax HM, Km HM), and the kinetic constants for the formation of 1’-
hydroxymyristicin glucuronide (Vmax HMG, Km HMG), k, the first-order rate constant for the 
sulfonation of 1’-hydroxymyristicin (kHMS), and the kinetic constants for the formation of 5-
allyl-2,3-dihydroxyanisole and 2’,3’-dihydroxymyristicin (Vmax DHA, Km DHA ,Vmax DHM, Km 
DHM) were also found to highly influence the formation of 1’-sulfoxymyristicin in rat liver. In 
human liver, the formation of the ultimate carcinogenic metabolite 1’-sulfoxymyristicin is 
primarily influenced by the kinetic constants of 1’-hydroxymyristicin formation from 
myristicin (Vmax HM, Km HM), the kinetic constants for the formation of 1’-oxomyristicin (Vmax 
HMO, Km HMO), k, the first-order rate constant for the sulfonation of 1’-hydroxymyristicin 
C
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Figure 7. PBK-predicted dose-dependent changes in overall formation of (A) microsomal 
Fig. 7  PBK-predicted dose-dependent changes in overall formation of (A) microsomal 
metabolites of myristicin in human liver and (B) metabolites of 1’-hydroxymyristicin in 
human liver. The lines correspond to (A) 5-allyl-2,3-dihydroxyanisole (●●●●), 3’-
hydroxymyristicin (▬ ● ▬ ), 1’-hydroxymyristicin (▬▬), and 2',3'-dihydroxymyristicin (▬  ▬), 
and (B) 1’-hydroxymyristicin glucuronide (▬  ▬), 1'-sulfoxymyristicin (▬▬), and 1'-
oxomyristicin (●●●●). 
 
 
Figure 8. PBK-predicted dose-dependent formation (mg/kg bw) of (A) 1’-hydroxymyristicin 
and (B) 1'-sulfoxymyristicin in rat and human liver. 
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Sensitivity analysis 
A sensitivity analysis was performed to define model parameters that are capable of 
influencing the formation of 1’-hydroxymyristicin and 1’-sulfoxymyristicin in rat and human 
liver. For this purpose, normalized sensitivity coefficients (SCs) were calculated for all 
parameters at a dose of 0.05 mg/kg bw myristicin. This sensitivity analysis reveals to what 
extent small variation in the respective parameters influences the results. The sensitivity 
analysis also reveals to which parameters the predicted outcomes are most sensitive. The 
results of this analysis are presented in Figure 9. Figure 9 especially presents the parameters 
affecting the formation of 1’-hydroxymyristicin (black) and 1’-sulfoxymyristicin (gray) that 
have a normalized SC > |0.1|. In rat liver, the formation of the ultimate carcinogenic 
metabolite 1’-sulfoxymyristicin is primarily influenced by the kinetic constants of 1’-
hydroxymyristicin formation from myristicin (Vmax HM, Km HM). The kinetic constants for the 
formation of 5-allyl-2,3-dihydroxyanisole and 2’,3’-dihydroxymyristicin (Vmax DHA, Km DHA, 
Vmax DHM, Km DHM) were also found to highly influence the formation of 1’-hydroxymyristicin 
in rat and human liver. In rat liver, the formation of the ultimate carcinogenic metabolite 1’-
sulfoxymyristicin is primarily influenced by the kinetic constants of 1’-hydroxymyristicin 
formation from myristicin (Vmax HM, Km HM), and the kinetic constants for the formation of 1’-
hydroxymyristicin glucuronide (Vmax HMG, Km HMG), k, the first-order rate constant for the 
sulfonation of 1’-hydroxymyristicin (kHMS), and the kinetic constants for the formation of 5-
allyl-2,3-dihydroxyanisole and 2’,3’-dihydroxymyristicin (Vmax DHA, Km DHA ,Vmax DHM, Km 
DHM) were also found to highly influence the formation of 1’-sulfoxymyristicin in rat liver. In 
human liver, the formation of the ultimate carcinogenic metabolite 1’-sulfoxymyristicin is 
primarily influenced by the kinetic constants of 1’-hydroxymyristicin formation from 
myristicin (Vmax HM, Km HM), the kinetic constants for the formation of 1’-oxomyristicin (Vmax 
HMO, Km HMO), k, the first-order rate constant for the sulfonation of 1’-hydroxymyristicin 
Chapter 2 | PBK modelling of the bioactivation of myristicin
74
 
 
(kHMS) and liver microsomal protein yield (MP), and the kinetic constants for the formation of 
5-allyl-2,3-dihydroxyanisole and 2’,3’-dihydroxymyristicin (Vmax DHA, Km DHA) were also 
found to highly influence the formation of 1’-sulfoxymyristicin in human liver. The kinetic 
constants for the formation of 1’-hydroxymyristicin glucuronide were found to highly 
influence the formation of 1’-sulfoxymyristicin in rat liver, and the kinetic constants for 
formation of 1’-oxomyristicin were predicted to affect the formation of 1’-sulfoxymyristicin 
in human liver to a high extent. These results reflect the fact that glucuronidation of 1’-
hydroxymyristicin in rat and oxidation of 1’-hydroxymyristicin in human are considered as 
the most important competitive metabolic pathways to sulfonation. 
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Comparison of the PBK model-based prediction of bioactivation of myristicin by rat and 
human to that of its structurally related compound safrole 
In a next step, the mode of action-based PBK models for myristicin metabolism in rat and 
human were used to facilitate a read-across from data on safrole (Martati et al. 2011, 2012). 
On the basis of the PBK models, a comparison was made for the dose-dependent formation of 
the proximate carcinogenic 1’-hydroxy metabolite and of the ultimate carcinogenic 1’-
sulfoxy metabolite of myristicin and safrole in the liver of rats. Figure 10 shows the dose-
dependent formation of these metabolites in rat liver as predicted by the respective PBK 
models. The PBK model-based predicted formation of the proximate carcinogenic 1’-
hydroxy metabolites shows that the formation of the 1’-hydroxy metabolites of myristicin and 
safrole was predicted to be the same at low dose 0.05 mg/kg bw and 1.4-fold higher for 
myristicin than that of safrole at dose level 100 mg/kg bw (Figure 10a). The predicted model 
outcomes for the formation of the ultimate carcinogenic 1’-sulfoxy metabolites of safrole and 
myristicin are shown in Figure 10b. The PBK models for rat predict the formation of 1’-
sulfoxymyristicin to be 1.5-fold higher for myristicin than safrole at low dose of 0.05 mg/kg 
bw and 2.2-fold higher for myristicin than for safrole at dose level of 100 mg/kg bw. Figure 
11 shows the predicted dose-dependent formation of 1’-hydroxy metabolites and 1’-sulfoxy 
metabolites of safrole and myristicin in human liver. In human liver, the predicted formation 
of 1’-hydroxymyristicin is 7-fold lower than the formation of 1’-hydroxysafrole at a dose 
level of 0.05 mg/kg bw and 4.5-fold lower for myristicin than for safrole at high dose of 100 
mg/kg bw (Figure 11a). The data also reveal that in human liver, the formation of the DNA-
reactive 1’-sulfoxy metabolite is comparable, 1.35-fold higher for safrole at low-dose level 
0.05 mg/kg bw, and 1.1-fold higher for myristicin at high-dose level 100 mg/kg bw (Figure 
11b). 
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Figure 10. PBK-predicted dose-dependent formation (nmol / g liver) of (A) 1’-
hydroxymetabolites and (B) 1'-sulfoxymetabolites of myristicin (▬▬) and safrole (▬ ▬) in 
male rat liver. 
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The margin-of-exposure (MOE) concept was applied to assess the possible risks for human 
health resulting from the daily exposure to myristicin (JECFA 2005; EFSA 2005; Barlow et 
al. 2006; O’Brien et al. 2006). The MOE is a dimensionless ratio based on a reference point 
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representing a dose causing a low but measurable cancer incidence in experimental animals 
(e.g., a BMDL10), which is divided by the estimated daily intake in humans (EFSA 2005). 
When the MOE is lower than 10000, the compound of interest is considered to be a priority 
for risk management actions and a concern for human health (EFSA 2005). To date, tumor 
data for myristicin, from which a BMDL10 can be derived, are absent in the available 
literature, hampering the application of the MOE approach in the risk assessment of 
myristicin. Nevertheless, the results of the PBK model predictions presented above indicate 
that at dose levels in the range of the BMDL10 values, the formation of 1’-sulfoxy metabolites 
of myristicin in human liver is comparable (1.1-fold higher) to that of the structurally related 
safrole. On the basis of these considerations, and the limited difference in 1’-sulfoxy 
metabolite formation for myristicin and safrole in rat and human liver, it was concluded that 
the BMDL10 values of safrole could be used to perform an initial MOE-based risk assessment 
for myristicin. Using the BMDL10 for safrole of 1.9–5.1 mg/kg bw per day (van den Berg et 
al. 2011) and an estimated daily intake of myristicin of 0.0019 mg/kg bw per day (WHO 
2009) from use of herbs and spices, the MOE for myristicin would amount to 1000–2684. 
The estimated daily intake of safrole from spice and spice oil in the USA amounts to 0.001 
mg/kg bw per day (WHO 2009). These data result in an MOE for safrole of 1900–5100, 
indicating a priority for risk management that is somewhat lower than for myristicin. 
 
DISCUSSION 
In the presented paper, the recently developed mode of action-based PBK models for 
detoxification and bioactivation of the alkenylbenzene safrole (Martati et al. 2011, 2012) in 
male rat and human were extended to the structurally related alkenylbenzene myristicin. The 
newly developed PBK models combine biochemical and physicochemical information on 
myristicin and on the physiology of the organism of interest (i.e., rat and human), enabling 
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representing a dose causing a low but measurable cancer incidence in experimental animals 
(e.g., a BMDL10), which is divided by the estimated daily intake in humans (EFSA 2005). 
When the MOE is lower than 10000, the compound of interest is considered to be a priority 
for risk management actions and a concern for human health (EFSA 2005). To date, tumor 
data for myristicin, from which a BMDL10 can be derived, are absent in the available 
literature, hampering the application of the MOE approach in the risk assessment of 
myristicin. Nevertheless, the results of the PBK model predictions presented above indicate 
that at dose levels in the range of the BMDL10 values, the formation of 1’-sulfoxy metabolites 
of myristicin in human liver is comparable (1.1-fold higher) to that of the structurally related 
safrole. On the basis of these considerations, and the limited difference in 1’-sulfoxy 
metabolite formation for myristicin and safrole in rat and human liver, it was concluded that 
the BMDL10 values of safrole could be used to perform an initial MOE-based risk assessment 
for myristicin. Using the BMDL10 for safrole of 1.9–5.1 mg/kg bw per day (van den Berg et 
al. 2011) and an estimated daily intake of myristicin of 0.0019 mg/kg bw per day (WHO 
2009) from use of herbs and spices, the MOE for myristicin would amount to 1000–2684. 
The estimated daily intake of safrole from spice and spice oil in the USA amounts to 0.001 
mg/kg bw per day (WHO 2009). These data result in an MOE for safrole of 1900–5100, 
indicating a priority for risk management that is somewhat lower than for myristicin. 
 
DISCUSSION 
In the presented paper, the recently developed mode of action-based PBK models for 
detoxification and bioactivation of the alkenylbenzene safrole (Martati et al. 2011, 2012) in 
male rat and human were extended to the structurally related alkenylbenzene myristicin. The 
newly developed PBK models combine biochemical and physicochemical information on 
myristicin and on the physiology of the organism of interest (i.e., rat and human), enabling 
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the quantification of detoxification and bioactivation in rat and human at realistic low 
exposure levels. The development of these models facilitates a risk assessment based on read-
across from data on safrole, for which in vivo chronic toxicity studies are available, to 
myristicin, a compound for which toxicity data are limited. 
The PBK models for myristicin defined in the present paper were able to predict the overall 
formation of the reactive 1’-sulfoxymyristicin metabolite in the liver of rat and human, thus 
enabling comparison to the overall formation of the 1’-sulfoxy metabolites of the 
corresponding alkenylbenzene safrole. Comparison of the rat and human PBK model 
predictions indicated an only limited species-dependent difference in the overall metabolic 
activation of myristicin. The difference observed was within the default factor of 4, which is 
generally used to describe kinetic differences between species (IPCS 2010). The newly 
developed PBK model for myristicin was also used to compare the levels of metabolic 
activation of myristicin to those predicted previously for safrole in male rat and human liver 
(Martati et al. 2011, 2012). Results reveal that the formation of the proximate and ultimate 
carcinogenic metabolites of myristicin and safrole in rat liver appears to be comparable 
varying about 1.4-fold and 2.2-fold, respectively, with rat liver bioactivation of myristicin 
predicted to be somewhat higher than that of safrole for both metabolites. In humans, the 
formation of especially the 1’-sulfoxy metabolites of the two alkenylbenzenes is predicted to 
be comparable (1.1-fold difference). The PBK model outcomes obtained for the formation of 
reactive 1’-sulfoxy metabolites of myristicin and safrole can be compared to the relative 
bioactivation of these two alkenylbenzenes observed in other studies. In an in vitro study with 
cultured human cells, the ability of myristicin to form DNA adducts upon exposure of the 
cells to myristicin appeared to be almost the same as upon exposure to safrole (Zhou et al. 
2007b) which is in line with the relative differences predicted by the PBK models. Data 
derived from another study in which mice were exposed to the alkenylbenzenes via 
 
 
intraperitoneal (i.p) injection (Table 1) suggest that the DNA adduct formation of safrole and 
myristicin is also not much different with DNA adduct formation in the liver of safrole being 
2.7 times higher than that of myristicin (Randerath et al. 1984). In a parallel study, Phillips et 
al. (Table 1) reported that in neonatal mice, both safrole and myristicin were able to form 
DNA adducts in liver, and the DNA binding levels of safrole and myristicin were 17.5 and 
7.8 pmol/mg DNA, respectively (Phillips et al. 1984). It is important to note that in these 
mice studies, DNA adduct levels were quantified by 32P post-labeling which is known to be 
less accurate than, for example, LC–MS in the quantification of DNA adduct levels 
(Randerath et al. 1984). On the basis of the results now available, it can be concluded that 
using data on safrole for a read-across to myristicin is a reasonable approach for an initial risk 
assessment on myristicin. Such a risk assessment for myristicin can be based on the MOE 
approach. Because data on tumor formation are currently not available for myristicin, risk 
assessment for myristicin was performed using the BMDL10 values for tumor formation by 
safrole, given the comparable bioactivation in human liver predicted by the newly developed 
PBK models, where the difference in the bioactivation of myristicin and safrole was predicted 
to be only 1.1-fold.  
Using the BMDL10 for safrole of 1.9–5.1 mg/kg bw per day (van den Berg et al. 2011) and an 
estimated daily intake of myristicin of 0.0019 mg/kg bw per day (WHO 2009) from use of 
herbs and spices, the MOE for myristicin would amount to 1000–2684. For comparison, the 
MOE values of safrole can be given, obtained at the estimated daily intake of safrole from 
spice and spice oil in the USA that amounts to 0.001 mg/kg bw per day (WHO 2009) and a 
BMDL10 of safrole of 1.9–5.1 mg/kg bw per day (van den Berg et al. 2011). These data result 
in an MOE for safrole of 1900–5100, indicating a priority for risk management that is lower 
than for myristicin. 
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the quantification of detoxification and bioactivation in rat and human at realistic low 
exposure levels. The development of these models facilitates a risk assessment based on read-
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myristicin, a compound for which toxicity data are limited. 
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formation of the reactive 1’-sulfoxymyristicin metabolite in the liver of rat and human, thus 
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corresponding alkenylbenzene safrole. Comparison of the rat and human PBK model 
predictions indicated an only limited species-dependent difference in the overall metabolic 
activation of myristicin. The difference observed was within the default factor of 4, which is 
generally used to describe kinetic differences between species (IPCS 2010). The newly 
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assessment on myristicin. Such a risk assessment for myristicin can be based on the MOE 
approach. Because data on tumor formation are currently not available for myristicin, risk 
assessment for myristicin was performed using the BMDL10 values for tumor formation by 
safrole, given the comparable bioactivation in human liver predicted by the newly developed 
PBK models, where the difference in the bioactivation of myristicin and safrole was predicted 
to be only 1.1-fold.  
Using the BMDL10 for safrole of 1.9–5.1 mg/kg bw per day (van den Berg et al. 2011) and an 
estimated daily intake of myristicin of 0.0019 mg/kg bw per day (WHO 2009) from use of 
herbs and spices, the MOE for myristicin would amount to 1000–2684. For comparison, the 
MOE values of safrole can be given, obtained at the estimated daily intake of safrole from 
spice and spice oil in the USA that amounts to 0.001 mg/kg bw per day (WHO 2009) and a 
BMDL10 of safrole of 1.9–5.1 mg/kg bw per day (van den Berg et al. 2011). These data result 
in an MOE for safrole of 1900–5100, indicating a priority for risk management that is lower 
than for myristicin. 
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Altogether, the results obtained indicate that PBK modeling provides an important insight 
into the limited species differences between male rat and human in the metabolic activation 
of myristicin, and that in human liver, formation of the ultimate carcinogenic 1’-sulfoxy 
metabolites is almost the same for myristicin and safrole supporting a possibility for the risk 
assessment for myristicin based on the MOE approach using the BMDL10 for tumor 
formation of safrole as a reasonable but careful approximation. The present study provides an 
example of how PBK modeling can facilitate a read-across in risk assessment from 
compounds for which in vivo toxicity studies are available to a compound for which only 
limited toxicity data have been described, thus contributing to the development of alternatives 
for animal testing. 
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Figure S1. Concentration-dependent rate of myristicin metabolite formation in incubations 
with pooled human mixed gender liver microsomes. Curves for formation of four different 
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and 5-allyl-2,3-dihydroxyanisole) are presented. 
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ABSTRACT 
The present study developed physiologically-based kinetic (PBK) models for the 
alkenylbenzene apiol in order to facilitate risk assessment based on read-across from the 
related alkenylbenzene safrole. Model predictions indicate that in rat liver the formation of 
the 1’-sulfoxy metabolite is about 3 times lower for apiol than for safrole. These data 
support that the lower confidence limit of the benchmark dose resulting in a 10% extra 
cancer incidence (BMDL10) that would be obtained in a rodent carcinogenicity study with 
apiol may be 3-fold higher for apiol than for safrole. These results enable a preliminary risk 
assessment for apiol, for which tumor data are not available, using a BMDL10 value of 3 
times the BMDL10 for safrole. Based on an estimated BMDL10 for apiol of 5.7-15.3 mg/kg 
body wt  per day and an estimated daily intake of 4×10-5 mg/kg body wt per day, the margin 
of exposure (MOE) would amount to 140000-385000. This indicates a low priority for risk 
management. The present study shows how PBK modelling can contribute to the 
development of alternatives for animal testing, facilitating read-across from compounds for 
which in vivo toxicity studies on tumor formation are available to compounds for which 
these data are unavailable.  
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sulfoxy metabolites that readily form DNA adducts that may contribute to the formation of 
hepatomas in rodent bioassays upon exposure to these alkenylbenzenes at high dose levels 
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ABSTRACT 
The present study developed physiologically-based kinetic (PBK) models for the 
alkenylbenzene apiol in order to facilitate risk assessment based on read-across from the 
related alkenylbenzene safrole. Model predictions indicate that in rat liver the formation of 
the 1’-sulfoxy metabolite is about 3 times lower for apiol than for safrole. These data 
support that the lower confidence limit of the benchmark dose resulting in a 10% extra 
cancer incidence (BMDL10) that would be obtained in a rodent carcinogenicity study with 
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body wt  per day and an estimated daily intake of 4×10-5 mg/kg body wt per day, the margin 
of exposure (MOE) would amount to 140000-385000. This indicates a low priority for risk 
management. The present study shows how PBK modelling can contribute to the 
development of alternatives for animal testing, facilitating read-across from compounds for 
which in vivo toxicity studies on tumor formation are available to compounds for which 
these data are unavailable.  
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metabolic pathways presented in Figure 2 (WHO, 2009).  Apiol however is less well studied 
than its related alkenylbenzene safrole and rodent carcinogenicity studies on apiol are not 
available hampering its risk assessment. 
 
Figure 2. Suggested metabolic pathways of apiol. 
 
The structural similarity of apiol to safrole raises a concern and provides a rationale for an 
updated risk assessment of exposure to apiol via food including food supplements. Several 
studies have reported on the DNA adduct formation by apiol in animal in vivo studies or in 
human in vitro models as compared to the related alkenylbenzenes and found apiol to be less 
potent than its structural analogues (Miller et al., 1983, Phillips et al., 1984, Randerath et al., 
1984, Zhou et al., 2007).  
 
 
 
The safety of human exposure to apiol has been assessed by the WHO in 2009 concluding 
that the structural similarities to safrole with available experimental data give evidence that 
apiol may cause toxicity and carcinogenicity in rodents exposed to high dose levels (WHO, 
2009). Because rodent bioassays characterizing the possible carcinogenicity of apiol are not 
available, the aim of the present study was to perform a risk assessment for apiol based on 
PBK-modelling based read-across from safrole for which rodent tumor data are available 
(Miller et al., 1983, Phillips et al., 1984, Randerath et al., 1984).  
 
MATERIALS AND METHODS 
Chemicals and Reagents:  
Caution: Apiol and 1’-hydroxyapiol are possible carcinogens and should be handled with 
care. 
Apiol, uridine 5’-diphosphoglucuronic acid trisodium salt (UDPGA), reduced L-glutathione 
(GSH), alamethicin (from Trichoderma viride), and 3’-phosphoadenosine-5’-phosphosulfate 
(PAPS) were obtained from Sigma Aldrich (Zwijndrecht, Netherlands). Reduced β-
nicotinamide adenine dinucleotide phosphate (NADPH) and nicotinamide adenine 
dinucleotide (NAD+) were from Roche Diagnostic (Mannheim, Germany), and dimethyl 
sulfoxide (DMSO) was obtained from Acros Organics (Geel, Belgium). Chromatographic 
grade trifluoroacetic acid (TFA) was obtained from Merck  (Darmstadt, Germany). Potassium 
dihydrogen phosphate, dipotassium hydrogen phosphate trihydrate, acetic acid, and 
magnesium chloride were provided by VWR International (Darmstadt, Germany). 
Acetonitrile (ACN) (ULC/MS grade) was purchased from Biosolve BV (Valkenswaard, The 
Netherlands).  
Pooled male rat liver microsomes and S9 from Sprague−Dawley and mixed gender pooled 
human liver microsomes and S9 were from BD Gentest (Woburn, United States). Pooled 
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male Sprague−Dawley rat lung, kidney, and small intestinal microsomes and pooled gender 
human lung, kidney, and intestinal microsomes were purchased from BioPredic International 
(Rennes, France).  
 
 Synthesis of 1’-hydroxyapiol and 1’-oxoapiol 
The synthesis of 1’-hydroxyapiol from apiol was done as described previously for the 
synthesis of 1’-hydroxysafrole from safrole by Jeurissen et al. (Jeurissen et al., 2004) and 1’-
oxoapiol was synthesized from 1’-hydroxyapiol according to the method used for synthesis of 
1’-oxoestragole from 1’-hydroxyestragole (Wislocki et al., 1976). 
 
In vitro incubations 
Microsomal metabolism of apiol by rat and human microsomes 
Liver, kidney, lung and small intestine microsomes from male Sprague Dawley rat and from 
human were used to determine tissue-specificity of the microsomal biotransformation of apiol 
in rat and human. Incubations were performed by adding 1 mg/ml of the microsomal protein 
preparation to an incubation mixture containing (final concentrations) 3 mM NADPH in 0.2 
M Tris-HCl (pH 7.4). After a 1 minute pre-incubation at 37°C, apiol (final concentration 1000 
μM) was added from a 100 times concentrated stock solution in DMSO so that the final 
DMSO content was 1 % (v/v). After 120 minutes incubation at 37°C for rat and human 
microsomes the reactions were terminated by adding 25 μl ice-cold acetonitrile. All samples 
were centrifuged for 5 minutes at 16000×g and the supernatant was stored at -20°C until Ultra 
Performance Liquid Chromatography (UPLC) analysis.  
For both male rat and human, metabolism of apiol was only observed in incubations with 
liver microsomes (See the results section) and hence kinetic constants for the formation of 
microsomal metabolites were determined only for liver microsomes. To determine the kinetic 
 
 
constants incubations following the conditions described above were done using final 
concentrations of apiol from 25 to 1000 μM for rat and human liver while keeping the DMSO 
content at 1 % (v/v). Blank incubations were performed in the absence of the cofactor 
NADPH. All incubations were performed in triplicate.  
 
Glucuronidation of 1’-hydroxyapiol to 1’-hydroxyapiol glucuronide by rat and human liver 
S9 
The kinetic constants for the metabolic conversion of 1’-hydroxyapiol to 1’-hydroxyapiol 
glucuronide in incubations with both male rat and human liver fractions were determined as 
described previously for related 1’-hydroxyalkenylbenzenes (Al-Subeihi et al., 2012, Al-
Subeihi et al., 2011, Martati et al., 2011b, Martati et al., 2012b, Punt et al., 2008, Punt et al., 
2009, Van den Berg et al., 2012). In short, incubations were performed using (final 
concentrations) 10 mM UDPGA and 0.5 mg/mL male Sprague−Dawley rat or pooled gender 
human S9 protein in 0.2 M Tris-HCl (pH 7.4) containing 10 mM MgCl2. First the incubations 
were pre-treated on ice for 15 minutes with 0.025 mg/mL alamethicin added from a 200 times 
concentrated stock solution in methanol to overcome enzyme latency and to obtain maximal 
glucuronidation activity. After the pre-treatment on ice and pre-incubation at 37°C for 1 
minute, the reactions were subsequently started by adding 1’-hydroxyapiol in final 
concentrations of 10 to 2000 μM. 1’-Hydroxyapiol was added from 100 times concentrated 
stock solutions dissolved in DMSO. The reaction was incubated for 30 and 120 minutes for 
rat and human S9, respectively, and terminated by adding 25 μL of ice-cold acetonitrile. 
Blank incubations were carried out in the absence of the cofactor UDPGA. Experiments were 
performed in triplicate.  All samples were centrifuged for 5 minutes at 16000×g, and the 
supernatant was stored at −20°C until UPLC analysis.  
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Oxidation of 1’-hydroxyapiol to 1’-oxoapiol by rat and human liver microsomes 
The kinetic constants for the enzymatic conversion of 1’-hydroxyapiol to 1’-oxoapiol were 
determined using incubation mixtures containing (final concentrations) 3 mM NAD+, 2 mM 
GSH, and 1 mg/mL rat or human liver microsomes in 0.2 M Tris-HCl (pH 7.4). GSH was 
added to the incubation mixtures to trap the reactive 1’-oxometabolite formed after oxidation 
of 1’-hydroxyapiol.  To determine the kinetic constants incubations following the conditions 
described above were done using final concentrations of 1’-hydroxyapiol from 50 to 2000 
μM added to the incubation mixture from 100 times concentrated stock solutions in DMSO. 
After pre-incubation for 1 minute at 37°C the reactions were started by adding the 1’-
hydroxyapiol and were terminated after 60 minutes of incubation at 37°C by adding 25 μL of 
ice-cold acetonitrile. The formation of the GSH conjugate of 1’-oxoapiol, GS-1’-oxoapiol, 
was linear with time and microsomal protein under the experimental conditions used. Blank 
incubations were performed without the cofactor NAD+. Incubations were performed in 
triplicate. All samples were centrifuged for 5 minutes at 16000×g, and the supernatant was 
stored at −20°C until UPLC analysis.  
 
Sulfonation of 1’-hydroxyapiol to 1’-sulfoxyapiol by rat and human liver S9 
The kinetic constants for the enzymatic conversion of 1’-hydroxyapiol to 1’-sulfoxyapiol 
were determined using incubation mixtures containing (final concentrations) 10 mM GSH, 
0.2 mM PAPS, and 3 mg/mL Sprague−Dawley rat or mixed gender pooled human liver S9 
proteins in 0.1 M potassium phosphate buffer (pH 8.0). GSH was used as a scavenger of the 
reactive carbocation formed due to the unstable nature of the 1’-sulfoxymetabolite in an 
aqueous environment. After pre-incubation for 1 minute at 37°C 1’-hydroxyapiol dissolved in 
DMSO was added in final concentrations ranging between 50 and 2000 μM, while keeping 
the final DMSO content at 1 % (v/v). The reaction was terminated after 360 minutes by 
 
 
adding 25 μL of ice-cold acetonitrile. The formation of the GSH conjugate of 1’-sulfoxyapiol 
was linear with time and S9 protein concentration under the experimental conditions used. 
The scavenging may either be chemically or catalysed by the glutathione S-transferases 
present in the S9 incubations in which the sulfonation of 1’-hydroxyapiol was measured. 
Blank incubations were performed in the absence of PAPS. Incubations were performed in 
triplicate. All samples were centrifuged for 5 minutes at 16000×g, and the supernatant was 
stored at −20°C until UPLC analysis. 
 
 Identification and quantification of apiol metabolites 
Apiol metabolites formed in microsomal incubations were identified using a photodiode array 
detection (UPLC-PDA) composed of a Waters (Waters, Milford, MA) Acquity solvent 
manager, sample manager, and diode array detector, equipped with a Water Acquity UPLC 
BEH C18 column. The gradient was made with a mixture of ACN and ultrapure water 
containing 0.1 % (v/v) TFA. The flow rate was 0.6 ml/min. After equilibrating the column at 
the starting condition of 10 % ACN, ACN increased to 50 % over 4 min, was further 
increased to 80 % over 0.5 min, decreased to 10 % over 0.5 min and was finally kept at 10 % 
for 1 min. Metabolites were identified as described in the Result section. Quantification of 
microsomal apiol metabolites was done by comparison of the peak areas obtained at a 
wavelength of 208 nm to the calibration curve of synthesized 1’-hydroxyapiol because UV 
spectra of all metabolites were similar.  
The concentration of 1’-hydroxyapiol glucuronide was determined using the same UPLC-
PDA system as described above. The gradient was made with acetonitrile and ultrapure water 
containing 0.1 % (v/v) TFA. The flow rate was 0.6 ml/min. In a mixture of ACN and 
ultrapure water containing 0.1 % (v/v) TFA, the gradient started at 10 % ACN, increased to 
60% ACN over 3.5 minutes, further increased to 80% over 0.5 min, kept at 80% ACN for 0.5 
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Apiol metabolites formed in microsomal incubations were identified using a photodiode array 
detection (UPLC-PDA) composed of a Waters (Waters, Milford, MA) Acquity solvent 
manager, sample manager, and diode array detector, equipped with a Water Acquity UPLC 
BEH C18 column. The gradient was made with a mixture of ACN and ultrapure water 
containing 0.1 % (v/v) TFA. The flow rate was 0.6 ml/min. After equilibrating the column at 
the starting condition of 10 % ACN, ACN increased to 50 % over 4 min, was further 
increased to 80 % over 0.5 min, decreased to 10 % over 0.5 min and was finally kept at 10 % 
for 1 min. Metabolites were identified as described in the Result section. Quantification of 
microsomal apiol metabolites was done by comparison of the peak areas obtained at a 
wavelength of 208 nm to the calibration curve of synthesized 1’-hydroxyapiol because UV 
spectra of all metabolites were similar.  
The concentration of 1’-hydroxyapiol glucuronide was determined using the same UPLC-
PDA system as described above. The gradient was made with acetonitrile and ultrapure water 
containing 0.1 % (v/v) TFA. The flow rate was 0.6 ml/min. In a mixture of ACN and 
ultrapure water containing 0.1 % (v/v) TFA, the gradient started at 10 % ACN, increased to 
60% ACN over 3.5 minutes, further increased to 80% over 0.5 min, kept at 80% ACN for 0.5 
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min and then decreased to 10 % ACN over 0.5 min. 1’-hydroxyapiol glucuronide was 
identified as described in the results section. Quantification of 1’-hydroxyapiol glucuronide 
was done by comparison of the peak areas obtained at a wavelength of 208 nm to the 
calibration curve of synthesized 1’-hydroxyapiol.  
The concentration of the glutathione conjugate of 1’-oxoapiol was determined using the same 
UPLC-PDA system as described above. The gradient was made with acetonitrile and 
ultrapure water containing 0.1 % (v/v) TFA. The flow rate was 0.6 ml/min. In a mixture of 
ACN and ultrapure water containing 0.1 % (v/v) TFA, the gradient started at 10% ACN, 
increased to 30 % ACN over 2.5 minutes, was further increased  to 80 % ACN over 0.5 min, 
kept at 80 % ACN for 0.5 min and finally decreased to 10 % ACN over 0.5 min, and kept at 
10 % ACN for 0.5 min. Quantification of the GSH adduct of the metabolite was done by 
comparison of the peak areas obtained at a wavelength of 280 nm to the calibration curve of 
the GSH adduct of the synthesized 1’-oxoapiol.  
The concentration of the glutathione conjugate of 1’-sulfoxyapiol was determined using the 
same UPLC-PDA system described above. The flow rate was 0.6 ml/min. In a mixture of 
ACN and ultrapure water containing 0.1 % (v/v) TFA, the gradient started at 0 % ACN, 
increased to 20 % ACN over 0.2 minutes, further increased to 30 % ACN over 4.3 min, and 
again increased to 100 % ACN over 0.3 min, kept at 100 % ACN for 0.2 min, and finally 
decreased to 0 % ACN over 0.2 min and kept at 0 % ACN for 0.8 min. The GSH adduct of 
1’-sulfoxyapiol formed was identified by LC-MS using a microTOF MS (Bruker) coupled to 
an Agilent LC (1200 Series) equipped with an Altima C18 column (150 x 4.6 mm, 3 μm). 
The mobile phase used consisted of nanopure water with 0.1 % formic acid and ACN with 
0.1 % formic acid. Elution was at a flow rate of 0.8 ml/min, starting at 22 % ACN with a 
linear increase to 100 % ACN in 30 min. Subsequently, the gradient returned linearly to the 
initial condition in 2 min and remained 13 min at this condition prior to the next injection. 
 
 
Quantification of the GSH adduct of 1’-sulfoxyapiol was done by comparison of the peak 
areas obtained at a wavelength of 280 nm to the calibration curve of the GSH adduct of 
synthesized 1’-oxoapiol since their UV spectra are comparable. Mass spectrometric analysis 
was in the negative electrospray mode using a spray capillary voltage of 4500 V, a capillary 
temperature of 200°C and nitrogen as nebulizer gas at 8.0 L/min. 
 
Determination of kinetic constants of apiol and 1’-hydroxyapiol metabolic conversions 
Kinetic constants for the metabolic conversions of apiol and 1’-hydroxyapiol were calculated 
by two equations depending on the dose-dependency of the kinetics of the conversion. If the 
reaction reached saturation with increasing substrate concentration, the kinetic constants were 
derived by fitting the data to the standard Michaelis-Menten equation; v = Vmax × [S]/(Km + 
[S]), in which [S] represents the substrate concentration, Vmax the maximum velocity and Km 
the Michaelis-Menten constant for the formation of the different metabolites of apiol or 1’-
hydroxyapiol. Data analysis was accomplished using GraphPad Prism, version 5.04 
(GraphPad Software, San Diego, California, USA). When the reaction did not reach  
saturation and rather displayed a linear increase in the rate of conversion with increasing 
substrate concentration, the kinetic rate constant for a first order reaction was derived by 
using the following equation; v =  k·[S], with k being the first order rate constant and [S] 
representing the substrate concentration.  
 
Apiol PBK models in rat and human 
PBK models were developed describing the dose-dependent bioactivation and detoxification 
of apiol in respectively rat and human. The apiol models were based on the PBK models 
previously defined for the metabolism of estragole, methyleugenol, elemicin and safrole in rat 
and human (Al-Subeihi et al., 2011, Al-Subeihi et al., 2012, Martati et al., 2011, Martati et 
C
ha
pt
er
 3
Chapter 3 | PBK modelling of the bioactivation of apiol
99
 
 
min and then decreased to 10 % ACN over 0.5 min. 1’-hydroxyapiol glucuronide was 
identified as described in the results section. Quantification of 1’-hydroxyapiol glucuronide 
was done by comparison of the peak areas obtained at a wavelength of 208 nm to the 
calibration curve of synthesized 1’-hydroxyapiol.  
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0.1 % formic acid. Elution was at a flow rate of 0.8 ml/min, starting at 22 % ACN with a 
linear increase to 100 % ACN in 30 min. Subsequently, the gradient returned linearly to the 
initial condition in 2 min and remained 13 min at this condition prior to the next injection. 
 
 
Quantification of the GSH adduct of 1’-sulfoxyapiol was done by comparison of the peak 
areas obtained at a wavelength of 280 nm to the calibration curve of the GSH adduct of 
synthesized 1’-oxoapiol since their UV spectra are comparable. Mass spectrometric analysis 
was in the negative electrospray mode using a spray capillary voltage of 4500 V, a capillary 
temperature of 200°C and nitrogen as nebulizer gas at 8.0 L/min. 
 
Determination of kinetic constants of apiol and 1’-hydroxyapiol metabolic conversions 
Kinetic constants for the metabolic conversions of apiol and 1’-hydroxyapiol were calculated 
by two equations depending on the dose-dependency of the kinetics of the conversion. If the 
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hydroxyapiol. Data analysis was accomplished using GraphPad Prism, version 5.04 
(GraphPad Software, San Diego, California, USA). When the reaction did not reach  
saturation and rather displayed a linear increase in the rate of conversion with increasing 
substrate concentration, the kinetic rate constant for a first order reaction was derived by 
using the following equation; v =  k·[S], with k being the first order rate constant and [S] 
representing the substrate concentration.  
 
Apiol PBK models in rat and human 
PBK models were developed describing the dose-dependent bioactivation and detoxification 
of apiol in respectively rat and human. The apiol models were based on the PBK models 
previously defined for the metabolism of estragole, methyleugenol, elemicin and safrole in rat 
and human (Al-Subeihi et al., 2011, Al-Subeihi et al., 2012, Martati et al., 2011, Martati et 
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al., 2012, Punt et al., 2008, Punt et al., 2009). Figure 3 presents an overview of the developed 
PBK models for apiol metabolism in rat and human. 
 
 
Figure 3. Overview of the PBK model for apiol. 
 
The models consist of several compartments representing different organs and tissues (i.e. 
liver, fat tissue, rapidly perfused tissues and slowly perfused tissues) which are connected 
through the systemic circulation. First order kinetics was used to describe the uptake of apiol 
from the gastrointestinal tract assuming a direct and complete uptake by the liver with an 
absorption rate constant (ka) of 1.0 h-1 which is based on the fast and complete absorption of 
the structurally related alkenylbenzene estragole from the gastrointestinal tract (WHO, 2009).  
For both rat and human, only the liver microsomes were able to convert apiol to different 
microsomal metabolites (see results section) and this is why no other tissue compartments 
were described as separate compartments in the model. In liver microsomal incubations 2’,3’-
dihydroxyapiol (DHA), 1’-hydroxyapiol (HA), and 4-allyl-3,6-dimethoxybenzene-1,2-diol 
(ADD) were formed and their formation was included. Since 2’,3’-dihydroxyapiol is formed 
after hydrolysis of apiol-2’,3’-oxide, data for both metabolites that result from epoxidation of 
 
 
apiol were combined and referred to as 2’,3’-dihydroxyapiol. Accordingly, a mass balance 
equation for apiol in rat and human liver is as follows:  
???? ?? ? ???????? ?? ? ?? ? ???? ? ??? ???? ???  
?????? ? ? ??? ???? ?????? ? ??? ???? ???  
??????? ?? ? ??? ???? ????? ?? ? ??? ???? ???  
?????? ?? ? ??? ???? ??????? ? ??? ???? ???  
??????? ?? ? ?????? ?? ? ?? ? ???????  
??????? ? ????????? 
??? ? ??? ???  
  
Where uptakeA (μmol) is the amount of apiol taken up from the gastrointestinal tract, AGIA 
(μmol) is the amount of apiol remaining in the gastrointestinal tract, ALA (μmol) is the 
amount of apiol in liver. CLA is the apiol concentration in the liver (μmol/L). CAA is the apiol 
concentrations in the arterial blood (in μmol/L), QL is the blood flow rate to liver (L/h), VL is 
the volume of the liver (L), PLA is the liver/blood partition coefficient of apiol, and Vmax, and 
Km, are the values representing the maximum rate of formation and Michaelis-Menten 
constant, respectively, for the formation of 1’-hydroxyapiol (HA), 2’,3’-dihydroxyapiol 
(DHA), and 4-allyl-3,6-dimethoxybenzene-1,2-diol (ADD).  
In both models, the conversion of apiol to 2’,3’-dihydroxyapiol and 4-allyl-3,6-
dimethoxybenzene-1,2-diol are described, but further reactions with these metabolites were 
not included in the model. It was assumed that these metabolites and/or their possible 
conjugates were completely excreted into the urine. Since the liver is the major target organ 
for alkenylbenzene-induced carcinogenicity in rats and mice, the present study focused 
primarily on metabolic conversion of 1’-hydroxyapiol by glucuronidation, oxidation and 
sulfonation in the liver only. The mass balance equation for 1’-hydroxyapiol in rat and human 
liver is as follows:  
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(μmol) is the amount of apiol remaining in the gastrointestinal tract, ALA (μmol) is the 
amount of apiol in liver. CLA is the apiol concentration in the liver (μmol/L). CAA is the apiol 
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the volume of the liver (L), PLA is the liver/blood partition coefficient of apiol, and Vmax, and 
Km, are the values representing the maximum rate of formation and Michaelis-Menten 
constant, respectively, for the formation of 1’-hydroxyapiol (HA), 2’,3’-dihydroxyapiol 
(DHA), and 4-allyl-3,6-dimethoxybenzene-1,2-diol (ADD).  
In both models, the conversion of apiol to 2’,3’-dihydroxyapiol and 4-allyl-3,6-
dimethoxybenzene-1,2-diol are described, but further reactions with these metabolites were 
not included in the model. It was assumed that these metabolites and/or their possible 
conjugates were completely excreted into the urine. Since the liver is the major target organ 
for alkenylbenzene-induced carcinogenicity in rats and mice, the present study focused 
primarily on metabolic conversion of 1’-hydroxyapiol by glucuronidation, oxidation and 
sulfonation in the liver only. The mass balance equation for 1’-hydroxyapiol in rat and human 
liver is as follows:  
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Rat: 
????? ?? ? ?????? ? ? ??? ???? ????? ? ? ??? ???? ????  
??????? ?? ? ???? ????? ????? ?? ? ???? ????? ???  
????? ? ???? ?????  
????? ? ???? ?????  
???? ? ???? ???  
Human: 
????? ?? ? ?????? ? ? ??? ???? ????? ? ? ??? ???? ????  
??????? ?? ? ???? ????? ????? ?? ? ???? ????? ???  
??????? ?? ? ???? ????? ????? ?? ? ???? ????? ???  
????? ? ???? ?????  
???? ? ???? ???  
 
where ALHA is the amount of 1’-hydroxyapiol in the liver (μmol), CLHA is the 1’-
hydroxyapiol  concentration in the liver (μmol/L), PLHA is the liver/blood partition coefficient 
of 1’-hydroxyapiol, Vmax, and Km, are the maximum rate of formation and Michaelis-Menten 
constant, respectively, for the formation of the different apiol  metabolites, including 1’-
hydroxyapiol glucuronide (HAG) in the rat and human liver and  1’-oxoapiol (HAO) in 
human, and k is the first order rate constant for formation of 1’-oxoapiol in rat, and 1’-
sulfoxyapiol (HAS) in rat and human liver.  
Vmax and Km values and first order rate constants k in case of absence of saturation (for 
oxidation in rat and sulfonation of 1’-hydroxyapiol) for the different metabolic pathways of 
apiol and 1’-hydroxyapiol were derived in vitro in the present study. Vmax values that were 
derived in vitro expressed as nmol min-1 (mg liver microsomal or S9 protein)-1 were scaled to 
values representing the Vmax per μmol h-1 (g liver)-1 using microsomal yields of 35 mg/g liver 
in rat and 32 mg/g liver in human and S9 protein yields of  143 mg/g liver as defined by Punt 
 
 
et al. (Punt et al., 2008, Punt et al., 2009) based on Medinsky et al. (Medinsky et al., 1994). 
First order rate constants k expressed in ml min-1 (mg liver microsomal or S9 protein)-1 were 
scaled to values expressed in ml h-1 per g liver using the same conversion factor for 
microsomal and S9 protein yield. 
Tables 1 and 2 summarize the physiological parameters (i.e. tissue volumes, cardiac output 
and tissue blood flows) for rat and human respectively which were derived from literature 
(Brown et al., 1997). Partition coefficients were derived in silico based on a method 
described by DeJongh et al.(DeJongh et al., 1997) using the log Kow. Log Kow values for 
apiol (ClogP 3.12) and 1’-hydroxyapiol (ClogP 1.56) were estimated using ChemBio3D 2010 
(CambrigeSoft, USA). Mass balance equations were coded and numerically integrated in 
Berkeley Madonna 8.3.18 (Macey and Oster, UC Berkeley, CA, USA) using the 
Rosenbrockʹs algorithm for stiff systems. The PBK models were run during 720-hr after the 
dosing to allow full conversion of the parent compound. 
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????? ? ???? ?????  
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First order rate constants k expressed in ml min-1 (mg liver microsomal or S9 protein)-1 were 
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and tissue blood flows) for rat and human respectively which were derived from literature 
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described by DeJongh et al.(DeJongh et al., 1997) using the log Kow. Log Kow values for 
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Rosenbrockʹs algorithm for stiff systems. The PBK models were run during 720-hr after the 
dosing to allow full conversion of the parent compound. 
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Table 1. Parameters used in the physiologically based biokinetic model for apiol in male rat. 
Physiological parameters 
Tissue: blood partition coefficients 
 Body wt (kg)  0.25 
 Percentage of body wt apiol 
liver  3.4 liver 2.40 
fat  7.0 fat 75.93 
rapidly perfused  5.1 rapidly perfused 2.40 
slowly perfused  60.2 slowly perfused 0.80 
arterial blood 1.85   
venous blood 5.55   
 Cardiac output (L/h) 5.4 1’-hydroxyapiol 
 Percentage of cardiac output liver 1.10 
liver  25.0   
fat 7.0   
rapidly perfused 51.0   
slowly perfused 17.0   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Parameters used in the physiologically based biokinetic model for apiol in human. 
Physiological parameters 
Tissue: blood partition coefficients 
 Body wt (kg)  60 
 Percentage of body wt apiol 
liver  2.6 liver 6.45 
fat  21.4 fat 104.74 
rapidly perfused  5.0 rapidly perfused 6.45 
slowly perfused  51.7 slowly perfused 4.08 
blood 7.9   
  1’-hydroxyapiol 
 Cardiac output (L/h) 310 liver 1.55 
 Percentage of cardiac output   
liver  22.7   
fat 5.2   
rapidly perfused 47.3   
slowly perfused 24.8   
 
Model sensitivity analysis using normalized sensitivity coefficients 
A sensitivity analysis was used to determine which parameters have the greatest influence on 
model predictions, and performed as described previously(Al-Subeihi et al., 2012, Al-Subeihi 
et al., 2011, Martati et al., 2011, Martati et al., 2012, Punt et al., 2008, Punt et al., 2009, Van 
den Berg et al., 2012). For this purpose normalized sensitivity coefficients (SC) were 
determined using the following equation: SC = (Cʹ – C)/(Pʹ – P)·(P/C), with C being the 
initial value of model output, Cʹ the modified value of the model output resulting from an 
increase in parameter value, P being the initial parameter value and Pʹ representing the 
modified parameter value. An increase of 5 % in parameter values was used to analyse the 
effect of a change in parameter on the formation of 1’-hydroxyapiol and 1’-sulfoxyapiol 
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(expressed as a percentage of the dose over 720-hr). Each parameter was analysed 
individually while the other parameters were kept at their initial value.  
 
Comparison of the newly developed apiol PBK models based predictions with PBK 
model predictions for the structurally related compound safrole 
The PBK model-based predictions for the formation of 1’-hydroxyapiol and 1’-sulfoxyapiol 
were compared to the PBK model-based predictions for the dose-dependent formation of the 
1’-hydroxy and 1’-sulfoxymetabolites of the structurally related alkenylbenzene safrole. For 
this purpose the previously defined PBK models for safrole in rat and human described by 
Martati et al. (Martati et al., 2011, Martati et al., 2012) were used. For comparison with apiol, 
the models describing the metabolism of safrole were also run for 720-hr.  
 
RESULTS 
To identify the organs involved in the metabolism of apiol in both male rat and human, 
incubations were performed using microsomal protein preparations from liver, kidney, lung 
and small intestine. UPLC analysis of these incubations revealed that for both rat and human 
conversion of apiol was detected only in incubations with liver microsomes. An example of a 
chromatogram of an incubation of apiol with male rat liver microsomes and NADPH as the 
cofactor was shown in Figure 4.  
The metabolites formed in incubations with both rat and human liver microsomes were 2’,3’-
dihydroxyapiol (RT 1.5 minutes), 1’-hydroxyapiol  (RT 2.4 minutes), and 4-allyl-3,6-
dimethoxybenzene-1,2-diol (RT 2.2 minutes). Identification of 1’-hydroxyapiol was done 
based on comparison of the UV-spectrum and retention time of the formed 1’-hydroxyapiol 
with those of the specific synthesized reference compound. 
 
 
 
Figure 4. Chromatogram showing the different metabolites of apiol formed in incubations 
with male rat liver microsomes.  
 
Tentative identification of 4-allyl-3,6-dimethoxybenzene-1,2-diol, resulting from the O-
demethylenation of apiol (Benedetti et al., 1977, Beyer et al., 2006, Lee et al., 1998), and 
2’,3’-dihydroxyapiol was based on analogy to UPLC chromatograms of metabolic 
conversions of safrole and the fact that apiol-2’,3’-oxide, formed following incubation of 
apiol with liver microsomes and NADPH, would be hydrolysed by epoxide hydrolase to 
2’,3’-dihydroxyapiol as was previously demonstrated for the structurally related 
alkenylbenzenes (Al-Subeihi et al., 2011, Martati et al., 2011, Punt et al., 2008, Luo et al., 
1992, Luo and Guenthner, 1996, Guenthner and Luo, 2001). Furthermore the formation of 
these three major metabolites is in line with the overview presented by JECFA of the three 
primary biotransformation pathways for methylenedioxy-substituted alkenylbenzenes 
including safrole, myristicin and apiol (WHO, 2009). Safrole, myristicin and apiol were 
reported to be converted primarily by 1,2 ring-O-demethenylation yielding diphenolic 
derivatives (Benedetti et al., 1977, Beyer et al., 2006, Lee et al., 1998),  by epoxidation of the 
double bond in the allyl side-chain yielding the 2’,3’-epoxide (Luo and Guenthner, 1996, Luo 
et al., 1992), and by hydroxylation  of the alkene side-chain to yield the 1’-hydroxy 
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metabolite (Benedetti et al., 1977, Miller et al., 1983, Zangouras et al., 1981). Apiol 
concentration-dependent formation of the various microsomal metabolites was also 
characterised and the kinetic constants derived from these data on the concentration-
dependent microsomal metabolite formation of apiol in incubations with both male rat and 
human liver samples are presented in Table 3.  
 
Glucuronidation of 1’-hydroxyapiol to 1’-hydroxyapiol glucuronide by rat and human 
liver S9 
UPLC analysis of incubations with male rat liver S9 or mixed gender pooled human liver S9, 
UDPGA as cofactor and 1’-hydroxyapiol as substrate revealed a peak at 1.5 minutes, 
representing 1’-hydroxyapiol glucuronide since this peak was increased with increasing apiol 
concentration. Chromatographic analysis of blank incubations performed in the absence of 
the cofactor UDPGA did not show this peak at a retention time of 1.50 minutes, and the 
formation and elution behaviour of the metabolite was in analogous to results from similar 
incubations with safrole (Martati et al., 2011, Martati et al., 2012).  
The 1’-hydroxyapiol concentration-dependent increase in glucuronidation of 1’-hydroxyapiol 
to 1’-hydroxyapiol glucuronide in incubations with both male rat and human liver fractions is 
presented in figures 5A and 5D respectively. The kinetic constants derived from these data 
are presented in Table 3.  
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metabolite (Benedetti et al., 1977, Miller et al., 1983, Zangouras et al., 1981). Apiol 
concentration-dependent formation of the various microsomal metabolites was also 
characterised and the kinetic constants derived from these data on the concentration-
dependent microsomal metabolite formation of apiol in incubations with both male rat and 
human liver samples are presented in Table 3.  
 
Glucuronidation of 1’-hydroxyapiol to 1’-hydroxyapiol glucuronide by rat and human 
liver S9 
UPLC analysis of incubations with male rat liver S9 or mixed gender pooled human liver S9, 
UDPGA as cofactor and 1’-hydroxyapiol as substrate revealed a peak at 1.5 minutes, 
representing 1’-hydroxyapiol glucuronide since this peak was increased with increasing apiol 
concentration. Chromatographic analysis of blank incubations performed in the absence of 
the cofactor UDPGA did not show this peak at a retention time of 1.50 minutes, and the 
formation and elution behaviour of the metabolite was in analogous to results from similar 
incubations with safrole (Martati et al., 2011, Martati et al., 2012).  
The 1’-hydroxyapiol concentration-dependent increase in glucuronidation of 1’-hydroxyapiol 
to 1’-hydroxyapiol glucuronide in incubations with both male rat and human liver fractions is 
presented in figures 5A and 5D respectively. The kinetic constants derived from these data 
are presented in Table 3.  
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Figure 5. Concentration-dependent rate of (A) glucuronidation of 1’-hydroxyapiol in 
incubations with pooled male rat liver S9 or (D) pooled human mixed gender liver S9, (B) 
oxidation of 1’-hydroxyapiol  in incubations with pooled male rat liver microsomes or (E) 
pooled human mixed gender liver S9, and (C) sulfonation of 1’-hydroxyapiol in pooled male 
rat liver S9 or (F) pooled human mixed gender liver S9. Data points represent mean values 
+/- SD of three or four individual experiments. 
 
 
 
 
Oxidation of 1’-hydroxyapiol to 1’-oxoapiol   by rat and human liver microsomes 
UPLC analysis of incubations with male rat liver microsomes or mixed gender pooled human 
liver microsomes, NAD+ as cofactor and 1’-hydroxyapiol as substrate revealed a peak at 2.0 
minutes. In this incubation GSH was also added to trap the reactive oxidation metabolite 1’-
oxoapiol. The peak at 2.0 minutes was identified as the GSH conjugate of 1’-oxoapiol, GS-
1’-oxoapiol. Identification of GS-1’-oxoapiol was done based on comparison of the UV-
spectrum and retention time of the formed GS-1’-oxoapiol with those of the synthesized 
reference compound.   
The rate of oxidation of 1’-hydroxyapiol in male rat liver microsomes and pooled human 
liver microsomes with increasing concentrations of 1’-hydroxyapiol is presented in figures 
5B and 5E respectively. Table 3 presents the kinetic constants derived from these data.  
 
Sulfonation of 1’-hydroxyapiol to 1’-sulfoxyapiol by rat and human liver S9 
The reactive 1’-sulfoxyapiol formed upon sulfonation of the proximate carcinogenic 
metabolite 1’-hydroxyapiol was trapped by using GSH. The scavenging may be either 
chemically or catalysed by the glutathione S-transferases present in the S9 incubations in 
which the sulfonation of 1’-hydroxyapiol was measured.  
UPLC analysis of incubations with male rat liver S9 or mixed gender pooled human liver S9, 
1’-hydroxyapiol, PAPS and GSH revealed a peak at 1.3 minutes. The LC-MS analysis 
showed increased signal of m/z 526 with negative ion mode. The ion at m/z 526 corresponds 
to the theoretically expected [M-H]- mass of a GSH adduct of 1’-sulfoxyapiol. Figures 5C 
and 5F present the 1’-hydroxyapiol concentration dependent rate of formation of 1’-
sulfoxyapiol in incubations with male rat liver S9 or mixed gender pooled human liver S9. 
The kinetic constants for the conversion of 1’-hydroxyapiol to 1’-sulfoxyapiol in rat and 
human liver derived from these data are presented in Table 3. 
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liver microsomes with increasing concentrations of 1’-hydroxyapiol is presented in figures 
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metabolite 1’-hydroxyapiol was trapped by using GSH. The scavenging may be either 
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which the sulfonation of 1’-hydroxyapiol was measured.  
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1’-hydroxyapiol, PAPS and GSH revealed a peak at 1.3 minutes. The LC-MS analysis 
showed increased signal of m/z 526 with negative ion mode. The ion at m/z 526 corresponds 
to the theoretically expected [M-H]- mass of a GSH adduct of 1’-sulfoxyapiol. Figures 5C 
and 5F present the 1’-hydroxyapiol concentration dependent rate of formation of 1’-
sulfoxyapiol in incubations with male rat liver S9 or mixed gender pooled human liver S9. 
The kinetic constants for the conversion of 1’-hydroxyapiol to 1’-sulfoxyapiol in rat and 
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Comparison of the kinetic constants for conversion of apiol and 1’-hydroxyapiol by 
male rat and mixed gender pooled human tissue fractions 
In order to allow a comparison between the kinetic constants for metabolism of apiol and 1’-
hydroxyapiol  by male rat and mixed gender pooled human tissue fractions, Vmax values that 
were derived in vitro expressed as nmol min-1 (mg microsomal or S9 protein)-1 were scaled to 
values representing the Vmax per μmol h-1 (g tissue)-1 using microsomal and S9 protein yields 
as described in literature (Medinsky et al., 1994) and previously used by Punt et al., (Punt et 
al., 2009, Punt et al., 2008), Al-Subeihi et al. (Al-Subeihi et al., 2012, Al-Subeihi et al., 2011) 
and Martati et al. (Martati et al., 2012, Martati et al., 2011). The in vivo Vmax values derived 
accordingly, were used to calculate a scaled catalytic efficiency (scaled Vmax in vivo/ Km) for 
the formation of apiol metabolites (Table 4). These values revealed that the catalytic 
efficiency for formation of the proximate carcinogenic metabolite of apiol, 1’-hydroxyapiol, 
is 3.3 times higher in male rat liver than in human liver. The difference in the formation rate 
is mainly due to the 3-fold difference in the maximum velocity (Vmax) for the conversion of 
apiol to 1’-hydroxyapiol (see Table 3). 
The formation of 1’-hydroxyapiol glucuronide was found to represent the main metabolic 
reaction for detoxification of 1’-hydroxyapiol in rat and human liver while in rat liver the 
catalytic efficiency for this conjugation was found to be 11.2-fold higher than in human.  
For 1’-hydroxyapiol oxidation, the scaled k for rat liver was found to be 3.1 times lower than 
the scaled in vivo catalytic efficiency for human liver. While for sulfonation the scaled k was 
1.3-fold higher in rat liver than in human liver.  
Altogether, the results revealed that glucuronidation of 1’-hydroxyapiol, representing a 
detoxification pathway, is the most important pathway in rat and in human for conversion of 
1’-hydroxyapiol, and bioactivation of 1’-hydroxyapiol by sulfonation was found to represent 
only a minor pathway in both rat and human.  
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Comparison of the kinetic constants for conversion of apiol and 1’-hydroxyapiol by 
male rat and mixed gender pooled human tissue fractions 
In order to allow a comparison between the kinetic constants for metabolism of apiol and 1’-
hydroxyapiol  by male rat and mixed gender pooled human tissue fractions, Vmax values that 
were derived in vitro expressed as nmol min-1 (mg microsomal or S9 protein)-1 were scaled to 
values representing the Vmax per μmol h-1 (g tissue)-1 using microsomal and S9 protein yields 
as described in literature (Medinsky et al., 1994) and previously used by Punt et al., (Punt et 
al., 2009, Punt et al., 2008), Al-Subeihi et al. (Al-Subeihi et al., 2012, Al-Subeihi et al., 2011) 
and Martati et al. (Martati et al., 2012, Martati et al., 2011). The in vivo Vmax values derived 
accordingly, were used to calculate a scaled catalytic efficiency (scaled Vmax in vivo/ Km) for 
the formation of apiol metabolites (Table 4). These values revealed that the catalytic 
efficiency for formation of the proximate carcinogenic metabolite of apiol, 1’-hydroxyapiol, 
is 3.3 times higher in male rat liver than in human liver. The difference in the formation rate 
is mainly due to the 3-fold difference in the maximum velocity (Vmax) for the conversion of 
apiol to 1’-hydroxyapiol (see Table 3). 
The formation of 1’-hydroxyapiol glucuronide was found to represent the main metabolic 
reaction for detoxification of 1’-hydroxyapiol in rat and human liver while in rat liver the 
catalytic efficiency for this conjugation was found to be 11.2-fold higher than in human.  
For 1’-hydroxyapiol oxidation, the scaled k for rat liver was found to be 3.1 times lower than 
the scaled in vivo catalytic efficiency for human liver. While for sulfonation the scaled k was 
1.3-fold higher in rat liver than in human liver.  
Altogether, the results revealed that glucuronidation of 1’-hydroxyapiol, representing a 
detoxification pathway, is the most important pathway in rat and in human for conversion of 
1’-hydroxyapiol, and bioactivation of 1’-hydroxyapiol by sulfonation was found to represent 
only a minor pathway in both rat and human.  
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Evaluation of apiol PBK model performance 
Since there are no available quantitative experimental data on the excretion of the apiol 
metabolites formed after metabolism in both rat and human exposed to apiol, the performance 
of the newly developed PBK models for apiol could not be evaluated against in vivo data. 
Therefore the evaluation of the PBK models for apiol was based on the evaluation of the 
similar PBK models for safrole and the other alkenylbenzenes, for which more in vivo data 
allowing evaluation of the models were available. The performance of the rat PBK model 
developed for safrole was evaluated by Martati et al. (Martati et al., 2011b) where the 
predicted and observed levels of a variety of safrole metabolites in plasma or the urine of rats 
were compared. The predicted and observed safrole metabolite levels were found to be 
similar(Martati et al., 2011). Besides that, a comparison could be made between the 
predictions of the developed human PBK model for safrole (Martati et al., 2012) and the 
known in vivo data for human plasma concentrations or the urinary excretion of selected 
safrole metabolites. Furthermore a comparison of the predictions of the developed PBK 
models for other alkenylbenzenes (estragole and methyleugenol) (Al-Subeihi et al., 2012, Al-
Subeihi et al., 2011, Punt et al., 2008, Punt et al., 2009) and the reported plasma and urine 
levels of their metabolites could be done to support the validity of developed PBK models for 
the alkenylbenzenes, thus indirectly supporting the validity of the apiol models. Based on the 
above considerations showing the validity of developed PBK models for all other 
alkenylbenzenes, it was concluded that it is a reasonable assumption that these models also 
adequately describe the metabolite levels formed in vivo in both rat and human after ingestion 
of different oral doses of apiol.  
 
 
 
 
 
Apiol PBK model predictions for rat and human 
Figure 6A shows the PBK model-based predictions for the dose-dependent formation of the 
different microsomal metabolites of apiol in rat liver. 4-Allyl-3,6-dimethoxybenzene-1,2-diol 
appears to be the major metabolite formed amounting to 91.5-85 % of the dose with the 
percentage somewhat decreasing with increasing dose. The percentage of the dose converted 
to 1’-hydroxyapiol was predicted to increase in a dose-dependent manner from 4 % to about 7 
% of the dose at low and high dose levels respectively. Concurrent with the increase in the 
percentage of the dose that undergoes 1’-hydroxylation of the alkene side chain, a dose-
dependent increase from about 4 % to 8 % of the dose converted by epoxidation was 
observed.  Figure 6B shows the PBK model-based predictions for the dose-dependent 
increase in the formation of the metabolites of 1’-hydroxyapiol in rat liver. The percentage of 
the dose of apiol converted to 1’-sulfoxyapiol varies with the dose amounting to 0.0032 % at 
a low dose of 0.05 mg/kg bw to 0.0050 % of the dose at a relatively high dose of 300 mg/kg 
bw, while these percentages amount to 0.017 % at low dose and 0.026 % at high dose for 1’-
oxoapiol. Glucuronidation appears to be the major metabolic route for 1’-hydroxyapiol at all 
dose levels as 1’-hydroxyapiol glucuronide amounts to about 4.38 % of the dose at low dose 
levels and to 6.80 % of the dose at high dose levels. 
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Figure 6. PBK-predicted dose-dependent changes in overall formation of (A) microsomal 
metabolites of apiol in rat liver and (B) metabolites of 1’-hydoxyapiol in rat liver. The lines 
correspond to (A)  4-allyl-3,6-dimethoxybenzene-1,2-diol (●●●●), 1’-hydroxyapiol (▬▬), and 
2’,3’-dihydroxyapiol (▬  ▬), and (B) 1’-hydroxyapiol glucuronide (▬  ▬), 1’-sulfoxyapiol 
(▬▬), and 1’-oxoapiol (●●●●). 
 
Figure 7A shows the PBK model-based predictions for the dose-dependent formation of the 
different microsomal metabolites of apiol in human liver. In human liver 4-allyl-3,6-
dimethoxybenzene-1,2-diol was predicted to be the major microsomal metabolite amounting 
to about 82.6-83.5% of the dose. In human liver the percentage of the dose converted to 1’-
hydroxyapiol was only slightly decreased with the dose amounting to 6.7-6.3 % of the dose. 
The decrease in the formation of 1’-hydroxyapiol with increasing dose, is predicted to be 
accompanied by a decrease in the formation of apiol-2’,3’-oxide. Figure 7B shows the dose-
dependent decrease in the relative formation of 1’-hydroxyapiol glucuronide and 1’-oxoapiol 
and the dose-dependent decrease of the relative formation of 1’-sulfoxyapiol in human liver. 
There were only limited changes in the relative percentage of the different metabolites with 
the dose. 1’-Hydroxyapiol glucuronide appears to be the major 1’-hydroxyapiol metabolite 
amounting to about 5.9-5.5% of the dose, while 1’-oxoapiol amounts to about 0.75% of the 
dose and 1ʹsulfoxyapiol to 0.035% of the dose. 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. PBK-predicted dose-dependent changes in overall formation of (A) microsomal 
metabolites of apiol in human liver and (B) metabolites of 1’-hydoxyapiol in human liver. 
The lines correspond to (A) 4-allyl-3,6-dimethoxybenzene-1,2diol (●●●●), 1’-hydroxyapiol 
(▬▬), and 2’,3’-dihydroxyapiol (▬  ▬), and (B) 1’-hydroxyapiol glucoronide (▬  ▬), 1’-
sulfoxyapiol (▬▬), and 1’-oxoapiol  (●●●●).  
 
 Figure 8 shows a comparison of the relative extent of bioactivation of apiol by rat and human 
liver. There are species differences in the formation of 1’-hydroxyapiol (Figure 8A) and 1’-
sulfoxyapiol (Figure 8B) (expressed as nmol/g liver). In rat liver the formation of 1’-
hydroxyapiol at low dose was almost 2 times lower than in human liver and gradually 
increased with increasing the dose to reach almost the same relative level as in human at high 
dose. Human liver was predicted to be more efficient in formation of 1’-sulfoxyapiol being 
15-fold higher at low dose and 8-fold higher at high dose than 1’-sulfoxyapiol formation by 
rat liver (Figure 8B). This higher relative formation of 1’-sulfoxyapiol in human than rat liver 
in spite of the almost equal rate of formation of its metabolic precursor 1’-hydroxyapiol in rat 
and human liver is due to the fact that the glucuronidation of 1’-hydroxyapiol in rat liver is 
around 10 times more efficient than that in human liver providing increased opportunity for 
the competing sulfonation. The difference in overall formation of the 1’-sulfoxyapiol 
formation between rat and human is not due to a marked difference in the kinetics for 
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sulfonation of the 1’-hydroxyapiol since this difference appeared limited with an only 1.35-
fold higher first order rate constant for sulfonation in rat than human liver (see Table 3).  
 
 
 
 
 
 
 
 
Figure 8. PBK-predicted dose-dependent formation of (A) 1’-hydroxyapiol and (B) 1’-
sulfoxyapiol in rat and human liver. 
 
Sensitivity analysis 
In order to know the model parameters that have the highest impact on the formation of 1’-
hydroxyapiol and 1’-sulfoxyapiol in rat and human liver, a sensitivity analysis was performed. 
The analysis was done at an apiol dose of 0.05 mg/kg body wt per day to calculate the 
normalized sensitivity coefficients for all model parameters. Normalized sensitivity 
coefficient values higher than 0.1, affecting the formation of 1’-hydroxyapiol and 1’-
sulfoxyapiol in rat and human liver, are shown in figures 9A and 9B. Figure 9 shows that in 
both rat and human the parameters that influence the formation of both metabolites to the 
highest extent are the same. 1’-Hydroxyapiol formation is mainly influenced by the kinetic 
constants for formation of 1’-hydroxyapiol (Vmax,HA, km,HA) and the kinetic constants for 
formation of 4-allyl-3,6-dimethoxybenzene-1,2-diol (Vmax,ADD, km,ADD). Besides the above 
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parameters, 1’-sulfoxyapiol formation was influenced by kinetic constants for formation of 
1’-hydroxyapiol glucuronide (Vmax,HAG, km,HAG) and of 1’-sulfoxyapiol (k,HAS).  
 
Figure 9. Normalized  sensitivity coefficients for the formation of 1’-hydroxy apiol (black) 
and 1’-sulfoxyapiol (grey ) in the liver of rat and human. S9PL = S9 protein yield of the liver, 
MPL = microsomal protein yield of the liver, Vmax the maximum velocity and Km the 
Michaelis-Menten constant for the formation of the different metabolites, k = the kinetic rate 
constant for a first order reaction,  ADD = 4-allyl-3,6-dimethoxybenzene-1,2-diol,  DHA = 
2’,3’-di hydroxyapiol ,  HA = 1'-hydroxyapiol,  HAG  = 1’-hydroxyapiol glucuronide,  HAO 
= 1'-oxoapiol, HES = 1'-sulfoxyapiol 
 
Comparison of the PBK model-based prediction of bioactivation of apiol by rat and 
human to the PBK model predictions for bioactivation of the structurally related 
compound safrole.  
The PBK model-based predictions for bioactivation of apiol in rat and human, were compared 
to the PBK model-based predictions for bioactivation of safrole to facilitate a read-across-
based risk assessment. Figure 10 shows the dose-dependent formation of the 1’-hydroxy and 
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sulfonation of the 1’-hydroxyapiol since this difference appeared limited with an only 1.35-
fold higher first order rate constant for sulfonation in rat than human liver (see Table 3).  
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Comparison of the PBK model-based prediction of bioactivation of apiol by rat and 
human to the PBK model predictions for bioactivation of the structurally related 
compound safrole.  
The PBK model-based predictions for bioactivation of apiol in rat and human, were compared 
to the PBK model-based predictions for bioactivation of safrole to facilitate a read-across-
based risk assessment. Figure 10 shows the dose-dependent formation of the 1’-hydroxy and 
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1’-sulfoxy metabolites in rat liver as predicted by the respective PBK models from dose levels 
representing estimated human daily intakes up to dose levels causing liver tumors in rodent 
bioassays with safrole. In rat liver the PBK model-based predicted formation of the proximate 
carcinogenic 1’-hydroxy metabolite was found to be 2.8-fold lower for apiol than for safrole 
at low dose and 2.0-fold lower at the highest dose (Figure 10A). Figure 10B shows the 
predicted model outcomes for the formation of the ultimate carcinogenic 1ʹsulfooxy 
metabolites of apiol and safrole. In rat liver the formation of the 1’-sulfoxymetabolite is 
predicted to be about 3-fold lower for apiol than for safrole. For both alkenylbenzenes the 
formation of their 1’-sulfoxymetabolite increases linearly with increase of the dose.  
 
 
 
 
 
 
 
 
Figure 10. PBK-predicted dose-dependent formation (nmol/g liver) of (A) 1’-
hydroxymetabolites and (B) 1’-sulfoxymetabolites of apiol (▬▬) and safrole (▬ ▬) in male rat 
liver. 
 
Figure 11 shows the predicted dose-dependent formation of the 1’-hydroxymetabolites and 
1’-sulfoxymetabolites of apiol and safrole in human liver. The predicted formation of the 1’-
hydroxy metabolite is predicted to be about 8-fold lower for apiol than for safrole at low dose 
and about 6-fold lower at high dose levels. In human liver the formation of the 1’-
sulfoxymetabolites of apiol is predicted to be 2 times lower for apiol than for safrole.  
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Figure 11. PBK-predicted dose-dependent formation (nmol/g liver) of (A) 1’-
hydroxymetabolites and (B) 1’-sulfoxymetabolites of apiol (▬▬) and safrole (▬ ▬) in human 
liver.  
 
Implications for risk assessment 
In order to evaluate the possible human health hazards due to daily consumption of apiol, the 
margin of exposure (MOE) approach can be used. The MOE is the preferred approach to 
assess the safety of a compound that is carcinogenic and genotoxic(EFSA, 2005).  
Carcinogenicity data for apiol from which a BMDL10 can be derived are absent, hampering 
the application of the MOE approach in the risk assessment of apiol. On the other hand, the 
results of the PBK model predictions presented above indicate that at dose levels in the range 
at which safrole exposed rodents develop tumors (10-100 mg/kg body wt per day)(Long et al., 
1963), the formation of 1’-sulfoxymetabolites of apiol in rat liver is about 3-fold lower than 
that of safrole.  Based on this result it can be assumed that the PBK modelling supports use of 
the BMDL10 for tumor formation by safrole for risk assessment of the related compound apiol 
making a correction for the expected 3-fold lower formation of the ultimate carcinogenic 1’-
sulfoxymetabolite assuming the same mode of action for these two analogues.  Depending on 
the differences of formation of ultimate carcinogen of apiol and safrole in rat liver at dose 
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1’-sulfoxy metabolites in rat liver as predicted by the respective PBK models from dose levels 
representing estimated human daily intakes up to dose levels causing liver tumors in rodent 
bioassays with safrole. In rat liver the PBK model-based predicted formation of the proximate 
carcinogenic 1’-hydroxy metabolite was found to be 2.8-fold lower for apiol than for safrole 
at low dose and 2.0-fold lower at the highest dose (Figure 10A). Figure 10B shows the 
predicted model outcomes for the formation of the ultimate carcinogenic 1ʹsulfooxy 
metabolites of apiol and safrole. In rat liver the formation of the 1’-sulfoxymetabolite is 
predicted to be about 3-fold lower for apiol than for safrole. For both alkenylbenzenes the 
formation of their 1’-sulfoxymetabolite increases linearly with increase of the dose.  
 
 
 
 
 
 
 
 
Figure 10. PBK-predicted dose-dependent formation (nmol/g liver) of (A) 1’-
hydroxymetabolites and (B) 1’-sulfoxymetabolites of apiol (▬▬) and safrole (▬ ▬) in male rat 
liver. 
 
Figure 11 shows the predicted dose-dependent formation of the 1’-hydroxymetabolites and 
1’-sulfoxymetabolites of apiol and safrole in human liver. The predicted formation of the 1’-
hydroxy metabolite is predicted to be about 8-fold lower for apiol than for safrole at low dose 
and about 6-fold lower at high dose levels. In human liver the formation of the 1’-
sulfoxymetabolites of apiol is predicted to be 2 times lower for apiol than for safrole.  
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Figure 11. PBK-predicted dose-dependent formation (nmol/g liver) of (A) 1’-
hydroxymetabolites and (B) 1’-sulfoxymetabolites of apiol (▬▬) and safrole (▬ ▬) in human 
liver.  
 
Implications for risk assessment 
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1963), the formation of 1’-sulfoxymetabolites of apiol in rat liver is about 3-fold lower than 
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levels that induce liver tumor formation in rodents exposed to safrole, the BMDL10 of safrole 
which amounts to 1.9-5.1 mg/kg body wt per day (van den Berg et al., 2011) was multiplied 
by factor of 3 resulting in a BMDL10 of 5.7-15.3 mg/kg body wt per day. The estimated mean 
daily intake of apiol from spice and spice oil in the USA was reported to amount to 4×10-5 
mg/kg body wt per day(WHO, 2009).  Using a BMDL10 of 5.7-15.3 mg/kg body wt per day 
and an estimated daily intake of apiol of 4×10-5mg/kg body wt per day the MOE for apiol 
would amount to 140000 -385000. This indicates that there would be a low concern and a low 
priority for risk management of the current levels of exposure to apiol. For comparison the 
MOE values of safrole can be given, obtained at the estimated daily intake of safrole from 
spice and spice oil in USA that amounts to 1×10-3mg/kg body wt per day (WHO, 2009), and 
using a BMDL10 of safrole of 1.9-5.1 mg/kg body wt per day. These data result in an MOE 
for safrole of 1900-5100 indicating a priority for risk management that is higher than for 
apiol. 
 
DISCUSSION 
The present paper describes the definition of mode of action-based PBK models for 
detoxification and bioactivation of the alkenylbenzene apiol in rat and human and the use of 
predictions made by these models to facilitate a read-across-based risk assessment to the 
structurally related alkenylbenzene safrole (Martati et al., 2011, Martati et al., 2012), for 
which in vivo carcinogenicity data are available. Previously, using a similar approach and 
read-across to estragole and methyleugenol, the risks of exposure to elemicin for which also 
no in vivo rodent tumor data were available could be evaluated (Van den Berg et al., 2012). 
The approach enables a preliminary risk assessment of apiol for which in vivo toxicity data 
are limited without the need for additional animal studies. The physiological parameters for 
rat and human and the biochemical and physiochemical parameters for apiol were defined to 
 
 
develop the apiol PBK models.  The newly developed PBK models for apiol provide insight 
into the species-differences in the relative extent of bioactivation and detoxification, and 
could also be used to compare the level of metabolic activation of apiol to that of safrole in 
male rat and human liver(Martati et al., 2011b, Martati et al., 2012b). Comparing the apiol 
and safrole model-based predictions showed that the formation of the proximate and ultimate 
carcinogenic metabolites of the two alkenylbenzenes in rat is predicted to be comparable 
within an order of magnitude. The PBK models predict the formation of the ultimate 
carcinogenic 1’-sulfoxymetabolite at a dose level of 100 mg/kg body wt, at which safrole is 
causing liver tumors in rodent animal(Long et al., 1963, WHO, 2009), to be 3-fold lower for 
apiol than for safrole in rat liver.  In line with these differences, Randerath et al. (Randerath 
et al., 1984), using 32P-postlabeling reported that the number of DNA adducts formed by 
apiol in adult mouse liver was lower than for safrole. In a parallel study, Phillips et al. 
(Phillips et al., 1984) reported that in preweaning male mice the level of DNA adducts 
formed after neonatal apiol exposure was about 12-fold lower than after neonatal safrole 
exposure (Phillips et al., 1984).  In addition, the ability of apiol to form DNA adducts in 
cultured human (HepG2) cells was reported to be 3-5 times lower than that of safrole (Zhou 
et al., 2007).  
It is important to note that the PBK model-based predictions quantify the amount of the 
ultimate carcinogenic metabolite formed and not the ability of these compounds to bind to 
DNA or other macromolecules. One could argue that this reactivity may differ between the 
different alkenylbenzene compounds and that an increasing number of methoxy groups may 
reduce the electrophilicity of the 1’-sulfoxymetabolite or its carbocation decreasing its ability 
to bind to DNA (Miller et al., 1983, Randerath et al., 1984). However, given that the PBK 
model-based predicted differences are in line with the currently available data from in vivo 
and cellular in vitro studies on DNA adduct formation by apiol and safrole it is concluded that 
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levels that induce liver tumor formation in rodents exposed to safrole, the BMDL10 of safrole 
which amounts to 1.9-5.1 mg/kg body wt per day (van den Berg et al., 2011) was multiplied 
by factor of 3 resulting in a BMDL10 of 5.7-15.3 mg/kg body wt per day. The estimated mean 
daily intake of apiol from spice and spice oil in the USA was reported to amount to 4×10-5 
mg/kg body wt per day(WHO, 2009).  Using a BMDL10 of 5.7-15.3 mg/kg body wt per day 
and an estimated daily intake of apiol of 4×10-5mg/kg body wt per day the MOE for apiol 
would amount to 140000 -385000. This indicates that there would be a low concern and a low 
priority for risk management of the current levels of exposure to apiol. For comparison the 
MOE values of safrole can be given, obtained at the estimated daily intake of safrole from 
spice and spice oil in USA that amounts to 1×10-3mg/kg body wt per day (WHO, 2009), and 
using a BMDL10 of safrole of 1.9-5.1 mg/kg body wt per day. These data result in an MOE 
for safrole of 1900-5100 indicating a priority for risk management that is higher than for 
apiol. 
 
DISCUSSION 
The present paper describes the definition of mode of action-based PBK models for 
detoxification and bioactivation of the alkenylbenzene apiol in rat and human and the use of 
predictions made by these models to facilitate a read-across-based risk assessment to the 
structurally related alkenylbenzene safrole (Martati et al., 2011, Martati et al., 2012), for 
which in vivo carcinogenicity data are available. Previously, using a similar approach and 
read-across to estragole and methyleugenol, the risks of exposure to elemicin for which also 
no in vivo rodent tumor data were available could be evaluated (Van den Berg et al., 2012). 
The approach enables a preliminary risk assessment of apiol for which in vivo toxicity data 
are limited without the need for additional animal studies. The physiological parameters for 
rat and human and the biochemical and physiochemical parameters for apiol were defined to 
 
 
develop the apiol PBK models.  The newly developed PBK models for apiol provide insight 
into the species-differences in the relative extent of bioactivation and detoxification, and 
could also be used to compare the level of metabolic activation of apiol to that of safrole in 
male rat and human liver(Martati et al., 2011b, Martati et al., 2012b). Comparing the apiol 
and safrole model-based predictions showed that the formation of the proximate and ultimate 
carcinogenic metabolites of the two alkenylbenzenes in rat is predicted to be comparable 
within an order of magnitude. The PBK models predict the formation of the ultimate 
carcinogenic 1’-sulfoxymetabolite at a dose level of 100 mg/kg body wt, at which safrole is 
causing liver tumors in rodent animal(Long et al., 1963, WHO, 2009), to be 3-fold lower for 
apiol than for safrole in rat liver.  In line with these differences, Randerath et al. (Randerath 
et al., 1984), using 32P-postlabeling reported that the number of DNA adducts formed by 
apiol in adult mouse liver was lower than for safrole. In a parallel study, Phillips et al. 
(Phillips et al., 1984) reported that in preweaning male mice the level of DNA adducts 
formed after neonatal apiol exposure was about 12-fold lower than after neonatal safrole 
exposure (Phillips et al., 1984).  In addition, the ability of apiol to form DNA adducts in 
cultured human (HepG2) cells was reported to be 3-5 times lower than that of safrole (Zhou 
et al., 2007).  
It is important to note that the PBK model-based predictions quantify the amount of the 
ultimate carcinogenic metabolite formed and not the ability of these compounds to bind to 
DNA or other macromolecules. One could argue that this reactivity may differ between the 
different alkenylbenzene compounds and that an increasing number of methoxy groups may 
reduce the electrophilicity of the 1’-sulfoxymetabolite or its carbocation decreasing its ability 
to bind to DNA (Miller et al., 1983, Randerath et al., 1984). However, given that the PBK 
model-based predicted differences are in line with the currently available data from in vivo 
and cellular in vitro studies on DNA adduct formation by apiol and safrole it is concluded that 
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these possible differences in electrophilicity of the two 1’-sulfoxymetabolites does not affect 
the predictions to an extent that it would modify the conclusions of the current MOE based 
preliminary risk assessment.  
Based on the rat PBK model predictions for formation of the related 1’-sulfoxymetabolite, 
being 3-fold lower for apiol than for safrole at dose levels that are known to induce tumors in 
safrole-exposed rodent models, it was concluded that the BMDL10 that would be expected in a 
rodent animal bioassay for apiol could be 3-fold higher than that of safrole. Based on these 
considerations a preliminary risk assessment was performed for apiol using the MOE 
approach and an estimated BMDL10 for apiol, of 3 times the BMDL10 for safrole (1.9-5.1 
mg/kg body wt per day) (Suzanne J. P. L. van den Berg et al., 2011) and the MOE for apiol 
was calculated to amount to 140000 -385000. It is of interest to note that the PBK model of 
the present study predicted that the formation of the ultimate carcinogenic 1’-
sulfoxymetabolite of apiol in human liver would be about 10 times higher than its formation 
in rat liver. This difference is included in the MOE of 10000 which was defined to include a 
factor of 10 for interspecies differences (EFSA, 2005). Given that the MOE values actually 
obtained for apiole are 14-38-fold higher than 10000 they could accommodate an even larger 
species difference than the 10-fold difference now included in the MOE of 10000 without 
leading to a different conclusion. Furthermore, comparison of the MOE values obtained in the 
present study for apiol and safrole, indicate a priority for risk management of safrole that is 
higher than for apiol, due to its 3 times lower BMDL10 and its 25-fold higher estimated daily 
intake. 
In conclusion, the present study reports the development of apiol PBK models for rat and 
human providing insight into the occurrence of species differences in the metabolic activation 
of this food-borne compound that is genotoxic and carcinogenic. In addition the PBK model 
predictions were applied to support read-across from safrole for which tumor data are 
 
 
available facilitating a preliminary risk assessment for apiol for which limited in vivo data are 
available. This example illustrates how PBK modelling can be used to contribute to risk 
assessment eliminating the need for animal bioassays thereby contributing to the 3Rs of 
animal testing in human safety assessments. 
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ABSTRACT 
A risk assessment of basil-based pesto sauces containing methyleugenol and related 
alkenylbenzenes was performed based on their levels detected in a series of pesto sauces 
available on the Dutch market. The estimated daily intake (EDI) values of alkenylbenzenes as 
a result of consumption of the different pesto sauces amounted to 1.2–44.3 μg/kg bw for 
individual alkenylbenzenes, 14.3–43.5 μg/kg bw when adding up the alkenylbenzene levels 
assuming equal potency, and 17.3–62.9 μg/kg bw when expressed in methyleugenol 
equivalents using alkenylbenzenes defined toxic equivalency factors (TEF). The margin of 
exposure approach (MOE), used to evaluate the potential risks, resulted in MOE values that 
were generally lower than 10000 indicating a priority for risk management when assuming 
daily consumption. The levels of methyleugenol detected in the pesto sauces would allow 
consumption of 1.1–29.8, 7.5–208, 15.1–416.5, and 32.4–892.5 g of pesto sauce on a daily 
basis, once a week, once every two weeks, and once a month, respectively, to achieve MOE 
values above the 10000 limit indicating low priority for risk management. It is concluded that 
consumption of pesto sauces would only be of concern if consumed on a daily basis over 
longer periods of time. 
 
Abbreviations 
EDI, estimated daily intake; BMDL10, lower confidence limit of the benchmark dose resulting 
in a 10% extra cancer incidence; EFSA, European Food Safety Authority; ESCO, scientific 
cooperation projects between EFSA and its counterparts in the Member States; MOE, margin 
of exposure; UPLC, Ultra Performance Liquid Chromatography; TEF, toxic equivalency 
factor; TEQ, toxic equivalency 
 
Keywords 
Margin Of Exposure (MOE); Basil-based pesto; combined risk assessment; Toxic 
Equivalency Factors (TEFs) 
 
 
 
INTRODUCTION 
The genus ocimum, collectively called basil, belongs to the Lamiaceae family (the mint 
family), a family that contains 236 genera (Harley et al. 2004) and 7534 species (Kew). The 
plants are aromatic and cultivated for culinary purposes. Basil adds a distinctive flavor to 
many foods, and is consumed fresh, dried, as essential oil, or processed. In its processed form, 
basil, especially Ocimum basilicum cv. Genovese gigante cultivar, is employed in the 
production of pesto, a typical Italian sauce. The worldwide consumption of pesto has 
increased due to recent interest in Mediterranean cuisine, which is considered to be healthy 
and valuable. The complex matrix of pesto (e.g. cheese, extra-virgin olive oil, pine nuts 
and/or walnuts, and garlic) significantly affects its taste and flavor (Salvadeo et al. 2007). 
Previously, the aromatic composition of basil was determined from different areas of north 
western Italy and showed methyleugenol (1,2-dimethoxy-4-prop-2-en-1-yl-benzene) and 
eugenol as main components (Miele et al. 2001), while estragole was shown to be present in 
pesto sauces made of basil cultivars different from the Genovese gigante cultivar (Marotti et 
al. 1996; Siano et al. 2003). In 1999, the Committee of Experts on Flavoring Substances of 
the Council of Europe concluded that methyleugenol is a naturally-occurring genotoxic 
carcinogenic compound with a DNA-binding potency similar to that of safrole (EC 2001). In 
2001, the Scientific Committee on Food (SCF) of the European Union concluded that 
methyleugenol, and its structural analogues estragole and safrole (Figure 1) are genotoxic and 
carcinogenic and that reductions in exposure and restrictions in use levels are indicated (SCF 
2001a; SCF 2001b; SCF 2002). Rodent studies performed at high dose levels provided 
sufficient evidence of the hepatocarcinogenicity of methyleugenol, estragole and safrole, 
displaying similar characteristics regarding mode of action and tumor formation (Phillips et 
al. 1981; Miller et al. 1983; Randerath et al. 1984; NTP 2000; Zhou et al. 2007; Kobets et al. 
2016). EC Regulation 1334/2008, which became effective in January 2011, prohibits the 
C
ha
pt
er
 4
Chapter 4 | Risk assessment of alkenylbenzenes in basil-containing sauce of pesto
133
 
 
ABSTRACT 
A risk assessment of basil-based pesto sauces containing methyleugenol and related 
alkenylbenzenes was performed based on their levels detected in a series of pesto sauces 
available on the Dutch market. The estimated daily intake (EDI) values of alkenylbenzenes as 
a result of consumption of the different pesto sauces amounted to 1.2–44.3 μg/kg bw for 
individual alkenylbenzenes, 14.3–43.5 μg/kg bw when adding up the alkenylbenzene levels 
assuming equal potency, and 17.3–62.9 μg/kg bw when expressed in methyleugenol 
equivalents using alkenylbenzenes defined toxic equivalency factors (TEF). The margin of 
exposure approach (MOE), used to evaluate the potential risks, resulted in MOE values that 
were generally lower than 10000 indicating a priority for risk management when assuming 
daily consumption. The levels of methyleugenol detected in the pesto sauces would allow 
consumption of 1.1–29.8, 7.5–208, 15.1–416.5, and 32.4–892.5 g of pesto sauce on a daily 
basis, once a week, once every two weeks, and once a month, respectively, to achieve MOE 
values above the 10000 limit indicating low priority for risk management. It is concluded that 
consumption of pesto sauces would only be of concern if consumed on a daily basis over 
longer periods of time. 
 
Abbreviations 
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of exposure; UPLC, Ultra Performance Liquid Chromatography; TEF, toxic equivalency 
factor; TEQ, toxic equivalency 
 
Keywords 
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INTRODUCTION 
The genus ocimum, collectively called basil, belongs to the Lamiaceae family (the mint 
family), a family that contains 236 genera (Harley et al. 2004) and 7534 species (Kew). The 
plants are aromatic and cultivated for culinary purposes. Basil adds a distinctive flavor to 
many foods, and is consumed fresh, dried, as essential oil, or processed. In its processed form, 
basil, especially Ocimum basilicum cv. Genovese gigante cultivar, is employed in the 
production of pesto, a typical Italian sauce. The worldwide consumption of pesto has 
increased due to recent interest in Mediterranean cuisine, which is considered to be healthy 
and valuable. The complex matrix of pesto (e.g. cheese, extra-virgin olive oil, pine nuts 
and/or walnuts, and garlic) significantly affects its taste and flavor (Salvadeo et al. 2007). 
Previously, the aromatic composition of basil was determined from different areas of north 
western Italy and showed methyleugenol (1,2-dimethoxy-4-prop-2-en-1-yl-benzene) and 
eugenol as main components (Miele et al. 2001), while estragole was shown to be present in 
pesto sauces made of basil cultivars different from the Genovese gigante cultivar (Marotti et 
al. 1996; Siano et al. 2003). In 1999, the Committee of Experts on Flavoring Substances of 
the Council of Europe concluded that methyleugenol is a naturally-occurring genotoxic 
carcinogenic compound with a DNA-binding potency similar to that of safrole (EC 2001). In 
2001, the Scientific Committee on Food (SCF) of the European Union concluded that 
methyleugenol, and its structural analogues estragole and safrole (Figure 1) are genotoxic and 
carcinogenic and that reductions in exposure and restrictions in use levels are indicated (SCF 
2001a; SCF 2001b; SCF 2002). Rodent studies performed at high dose levels provided 
sufficient evidence of the hepatocarcinogenicity of methyleugenol, estragole and safrole, 
displaying similar characteristics regarding mode of action and tumor formation (Phillips et 
al. 1981; Miller et al. 1983; Randerath et al. 1984; NTP 2000; Zhou et al. 2007; Kobets et al. 
2016). EC Regulation 1334/2008, which became effective in January 2011, prohibits the 
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addition of methyleugenol, estragole and safrole to foods and restricts their concentration in 
compound foods of dairy products, meat preparations and meat products (including poultry 
and game), fish preparations and fish products, ready to eat savouries, non-alcoholic 
beverages, processed fruit and vegetables, and soups and sauces including pesto. For soups 
and sauces including pesto that have been prepared with flavorings or food ingredients with 
flavoring properties maximum allowed limits of 60 mg/kg for methyleugenol and 25 mg/kg 
for safrole have been defined while a limit for estragole has not been presented (EC 2008). 
However, if the only food ingredients with flavoring properties that have been added are only 
the fresh, dried or frozen herbs, the maximum limit for methyleugenol does not apply. This 
implies that pesto sauce made with basil is permitted in food preparations, regardless of its 
genotoxic carcinogenic compounds content. 
 
 
 
Figure 1. Structural formula of methyleugenol and its structural analogues. 
 
A major issue in the safety assessment of alkenylbenzene-containing food items is how to 
provide guidance on the potential risks for human health resulting from the exposure to low 
levels of these genotoxic and carcinogenic compounds (EFSA 2005). The European Food 
Safety Authority (EFSA) recommended the Margin of Exposure (MOE) approach (EFSA 
2005) to evaluate the priority for risk management actions for compounds that are both 
genotoxic and carcinogenic and present in a botanical or botanical preparation of 
interest (EFSA 2009a; EFSA 2009b). The MOE compares the exposure levels causing 
 
 
malignant tumors in experimental animals with dietary intake estimates in humans (EDI), 
taking into account differences in consumption patterns. The Scientific Committee of the 
European Food Safety Authority recommends the use of the benchmark dose (the BMDL10; 
the lower confidence limit of the benchmark dose resulting in a 10% extra cancer incidence) 
to obtain the MOE (EFSA 2005). The benchmark dose is a standardized reference point 
derived from the animal data by mathematical modelling within the observed range of 
experimental data (EFSA 2009b). Pesto eaters could be exposed to some of the highest levels 
of methyleugenol, because fresh pesto is prepared from a large quantity of fresh basil, 
reflected by basil amounts in pesto sauce products on the market that amounted on average to 
36% (an average from different products in the market). It has been estimated that the 
theoretical dietary exposure to methyleugenol could reach ?250 μg/kg bw per meal for adults 
and 500 μg/kg bw per meal for children, based on the assumptions that the percentage of 
methyleugenol in the essential oil is generally >40 %, the amount of essential oil in O. 
basilicum cv. Genovese gigante corresponds 0.5 % and that one portion of pesto contains 
?10 g of basil (Miele et al. 2001). The French food control administration analysed 
methyleugenol in a limited number of well-defined food products and reported that the 
methyleugenol concentration for one sample of pesto sauce was 6.02 μg/g and for one sample 
of pasta with pesto was 1.53 μg/g (Smith et al. 2010). Ávila et al. reported methyleugenol 
concentrations in a pesto sample amounting to 48 μg/g (Avila et al. 2009), and Siano et al. 
reported methyleugenol concentrations of 0.01–0.52 μg/g and estragole concentrations that 
amounted to 0.05–19.30 μg/g (Siano et al. 2003). It appears that the current values reported on 
levels of the alkenylbenzenes in sauces of pesto are limited with values that vary orders of 
magnitude. The aim of the present study was to make a more detailed analysis of the presence 
of methyleugenol and possible other alkenylbenzenes in basil-containing sauce of pesto and 
perform an associated risk assessment based on the MOE approach, taking into consideration 
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addition of methyleugenol, estragole and safrole to foods and restricts their concentration in 
compound foods of dairy products, meat preparations and meat products (including poultry 
and game), fish preparations and fish products, ready to eat savouries, non-alcoholic 
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the fresh, dried or frozen herbs, the maximum limit for methyleugenol does not apply. This 
implies that pesto sauce made with basil is permitted in food preparations, regardless of its 
genotoxic carcinogenic compounds content. 
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taking into account differences in consumption patterns. The Scientific Committee of the 
European Food Safety Authority recommends the use of the benchmark dose (the BMDL10; 
the lower confidence limit of the benchmark dose resulting in a 10% extra cancer incidence) 
to obtain the MOE (EFSA 2005). The benchmark dose is a standardized reference point 
derived from the animal data by mathematical modelling within the observed range of 
experimental data (EFSA 2009b). Pesto eaters could be exposed to some of the highest levels 
of methyleugenol, because fresh pesto is prepared from a large quantity of fresh basil, 
reflected by basil amounts in pesto sauce products on the market that amounted on average to 
36% (an average from different products in the market). It has been estimated that the 
theoretical dietary exposure to methyleugenol could reach ?250 μg/kg bw per meal for adults 
and 500 μg/kg bw per meal for children, based on the assumptions that the percentage of 
methyleugenol in the essential oil is generally >40 %, the amount of essential oil in O. 
basilicum cv. Genovese gigante corresponds 0.5 % and that one portion of pesto contains 
?10 g of basil (Miele et al. 2001). The French food control administration analysed 
methyleugenol in a limited number of well-defined food products and reported that the 
methyleugenol concentration for one sample of pesto sauce was 6.02 μg/g and for one sample 
of pasta with pesto was 1.53 μg/g (Smith et al. 2010). Ávila et al. reported methyleugenol 
concentrations in a pesto sample amounting to 48 μg/g (Avila et al. 2009), and Siano et al. 
reported methyleugenol concentrations of 0.01–0.52 μg/g and estragole concentrations that 
amounted to 0.05–19.30 μg/g (Siano et al. 2003). It appears that the current values reported on 
levels of the alkenylbenzenes in sauces of pesto are limited with values that vary orders of 
magnitude. The aim of the present study was to make a more detailed analysis of the presence 
of methyleugenol and possible other alkenylbenzenes in basil-containing sauce of pesto and 
perform an associated risk assessment based on the MOE approach, taking into consideration 
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the possible combined exposure to different alkenylbenzenes. Given that the alkenylbenzenes 
are known to act by a similar mode of action, at a similar target organ causing the same 
adverse effect, being liver carcinogenicity caused by a genotoxic mode of action, combined 
exposure can be evaluated by dose addition. This implies that the response to the mixture can 
be predicted by summing the doses of the components if needed after adjusting for the 
differences in potencies. Dose addition is considered most appropriate for mixtures with 
components that affect the same endpoint by the same mode of action (EPA 1986a; EPA 
1988; EPA 2000). Dose addition is the underlying assumption of the toxic equivalency factor 
(TEF) approach (ATSDR 2004). 
 
MATERIALS AND METHODS 
Pesto sauce samples and chemicals 
Basil containing pesto sauce samples were purchased from local Dutch markets. Table 
1 presents an overview of the collected samples and their major characteristics as indicated on 
the label of each product. Methyleugenol, myristicin, estragole and apiol (purity, >97%), 
methanol (HPLC gradient) and acetonitrile (LC/MS gradient) were supplied by Sigma 
Aldrich (Steinheim, Germany). Nano pure water was obtained from a Barnstead Nanopure 
Type I ultrapure water system. Dimethyl sulfoxide (DMSO) was obtained from Acros 
organics (Geel, Belgium). Acetonitrile (ACN) (LC/MS grade) was purchased from Biosolve 
BV (Valkenswaard, The Netherlands). Trifluoroacetic acid TFA was obtained from Merck 
(Darmstadt, Germany). 
 
 
 
 
 
Table1. Basil-containing pesto sauce samples used in the present study and their major 
characteristics. Information provided was derived from the product labels unless stated 
otherwise. 
Sample no. Description Ingredients 
1 Pesto, Italian basil sauce, 85 g Cold-pressed olive oil, fresh basil, fresh garlic, pine nuts, sea salt 
2 
Genovese pesto, biological, totally 
vegetarian, cheese free, gluten free, 
130 g 
Extra virgin olive oil 36%, Genovese basil in extra virgin olive oil 
27.6%, salt, cashew nuts, walnuts, pine kernels, apple fibre, garlic, 
acidity 
3 
Combined with dried tomatoes and 
a hint of spice routes, biological, 
135 g 
Sunflower oil, breadcrumbs, cashew, basil, honey, garlic, olive oil, dried 
tomatoes (22.5%), vinegar, sea salt, natural flavour, pepper, thyme, 
paprika powder, cumin, chili pepper 
4 Traditional terrasa pesto, bio, organic, 180 g 
Extra virgin olive oil, fresh basil (35%), pecorino sheep cheese (6%), 
pine kernels (5%), garlic (3%), sea salt 
5 Genovese pesto, costa ligure, 135 g 
Sunflower oil, fresh basil 73%, salt, cashew, pine nuts, parmesan 
cheese, garlic, wine vinegar, starch, acidity regulators of critic acid, 
lactic acid  
6 Green pesto, 190 g Sunflower oil, basil 36%, cashew nut, whey powder, cheese, salt, potato, sugar, acid regulator, dried garlic 
7 Italian Genovese pesto, 90 g  Sunflower oil, basil 35%, glucose, potato flake, cashew nut, milk, salt, rennet, preservatives 
8 Excellent Genovese pesto, 135 g Extra virgin olive oil, sunflower oil, fresh basil 69%, pine nut 13%, parmesan. 
9 Tartufo pesto, costa ligure, 135 g 
Sunflower oil, basil 42%, salt, cashew, pine nuts, parmesan cheese, 
garlic, wine vinegar, starch, acidity regulators of critic acid, lactic acid, 
1% truffle 
10 Limon pesto, 135 g 
Oiled sunflower, fresh basil 59%, salt, cashew, pine nuts, parmesan 
cheese,  garlic, wine vinegar, starch, acidity regulators of critic acid, 
lactic acid, 1.5 citron 
11 Genovese pesto, 185 g 
Sunflower oil (34%), basil 29%, potatoes, corn syrup, cashew nuts, 
grana padano cheese (4.5%), pecorino cheese (4.5%), salt, extra virgin 
olive oil, pine nuts (1%), natural flavours, garlic, concentrated lemon 
juice 
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the possible combined exposure to different alkenylbenzenes. Given that the alkenylbenzenes 
are known to act by a similar mode of action, at a similar target organ causing the same 
adverse effect, being liver carcinogenicity caused by a genotoxic mode of action, combined 
exposure can be evaluated by dose addition. This implies that the response to the mixture can 
be predicted by summing the doses of the components if needed after adjusting for the 
differences in potencies. Dose addition is considered most appropriate for mixtures with 
components that affect the same endpoint by the same mode of action (EPA 1986a; EPA 
1988; EPA 2000). Dose addition is the underlying assumption of the toxic equivalency factor 
(TEF) approach (ATSDR 2004). 
 
MATERIALS AND METHODS 
Pesto sauce samples and chemicals 
Basil containing pesto sauce samples were purchased from local Dutch markets. Table 
1 presents an overview of the collected samples and their major characteristics as indicated on 
the label of each product. Methyleugenol, myristicin, estragole and apiol (purity, >97%), 
methanol (HPLC gradient) and acetonitrile (LC/MS gradient) were supplied by Sigma 
Aldrich (Steinheim, Germany). Nano pure water was obtained from a Barnstead Nanopure 
Type I ultrapure water system. Dimethyl sulfoxide (DMSO) was obtained from Acros 
organics (Geel, Belgium). Acetonitrile (ACN) (LC/MS grade) was purchased from Biosolve 
BV (Valkenswaard, The Netherlands). Trifluoroacetic acid TFA was obtained from Merck 
(Darmstadt, Germany). 
 
 
 
 
 
Table1. Basil-containing pesto sauce samples used in the present study and their major 
characteristics. Information provided was derived from the product labels unless stated 
otherwise. 
Sample no. Description Ingredients 
1 Pesto, Italian basil sauce, 85 g Cold-pressed olive oil, fresh basil, fresh garlic, pine nuts, sea salt 
2 
Genovese pesto, biological, totally 
vegetarian, cheese free, gluten free, 
130 g 
Extra virgin olive oil 36%, Genovese basil in extra virgin olive oil 
27.6%, salt, cashew nuts, walnuts, pine kernels, apple fibre, garlic, 
acidity 
3 
Combined with dried tomatoes and 
a hint of spice routes, biological, 
135 g 
Sunflower oil, breadcrumbs, cashew, basil, honey, garlic, olive oil, dried 
tomatoes (22.5%), vinegar, sea salt, natural flavour, pepper, thyme, 
paprika powder, cumin, chili pepper 
4 Traditional terrasa pesto, bio, organic, 180 g 
Extra virgin olive oil, fresh basil (35%), pecorino sheep cheese (6%), 
pine kernels (5%), garlic (3%), sea salt 
5 Genovese pesto, costa ligure, 135 g 
Sunflower oil, fresh basil 73%, salt, cashew, pine nuts, parmesan 
cheese, garlic, wine vinegar, starch, acidity regulators of critic acid, 
lactic acid  
6 Green pesto, 190 g Sunflower oil, basil 36%, cashew nut, whey powder, cheese, salt, potato, sugar, acid regulator, dried garlic 
7 Italian Genovese pesto, 90 g  Sunflower oil, basil 35%, glucose, potato flake, cashew nut, milk, salt, rennet, preservatives 
8 Excellent Genovese pesto, 135 g Extra virgin olive oil, sunflower oil, fresh basil 69%, pine nut 13%, parmesan. 
9 Tartufo pesto, costa ligure, 135 g 
Sunflower oil, basil 42%, salt, cashew, pine nuts, parmesan cheese, 
garlic, wine vinegar, starch, acidity regulators of critic acid, lactic acid, 
1% truffle 
10 Limon pesto, 135 g 
Oiled sunflower, fresh basil 59%, salt, cashew, pine nuts, parmesan 
cheese,  garlic, wine vinegar, starch, acidity regulators of critic acid, 
lactic acid, 1.5 citron 
11 Genovese pesto, 185 g 
Sunflower oil (34%), basil 29%, potatoes, corn syrup, cashew nuts, 
grana padano cheese (4.5%), pecorino cheese (4.5%), salt, extra virgin 
olive oil, pine nuts (1%), natural flavours, garlic, concentrated lemon 
juice 
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Table1. (Continued) Basil-containing pesto sauce samples used in the present study and their 
major characteristics. Information provided was derived from the product labels unless stated 
otherwise. 
Sample no. Description Ingredients 
12 Italian arugula pesto, 190 g 
Sunflower oil, arugula 30%, basil 8%, pecorino romano cheese, sea 
salt, garlic, vegetable fibres, pine nuts, extra virgin olive oil, acidity 
regulator: lactic acid 
13 
Biological green pesto, 135g Sunflower oil, fresh basil 79%, salt 1%, pine nuts, garlic, white wine 
vinegar, acid regulator (lactic acid, citric acid) 
14 
The real Italian seasoning, green 
pesto, 190 g 
Basil 42%, sunflower oil, cashew nut 6.5%, water, parmigiano reggiano 
cheese 2.5%, salt, garlic, yogurt powder, olive oil 0.5%, pine 0.5%, 
acidity regulator: lactic acid, natural basil flavor, natural white pepper 
flavor, whey protein, antioxidant: E300 
15 
Green pesto, classic basil pesto, 
garlic and parmesan cheese, 125 g 
Basil 42%, sunflower oil 32.2%, cashew nuts, parmesan 4% (milk, salt, 
rennet), salt, pecorino cheese 2%, garlic 1.5%, glucose syrup, milk 
protein, acidity regulator: lactic acid, extra virgin olive oil, pine 0.5%, 
natural flavor 
16 Green pesto, with more basil, 185 g 
Basil 46%, sunflower oil, Italian cheese 7% (grana padano, pecorino 
romano), cashews, salt, extra virgin olive oil with virgin olive oil 2%, 
glucose syrup, sugar, potato flakes, flavor, garlic 0.5%, pine nut 0.5%, 
lactic acid 
17 Green vegan pesto with extra virgin oil, bio, organic, 180 g Extra virgin oil, basil 30%, walnuts, cashew nuts, pine kernels, sea salt 
18 Italian green pesto, 90g 
Basil 39%, 27% sunflower oil, water, lactose, 4% cashews, 4% 
parmigiano reggiano, 2.8% olive oil, 2% pine nuts, salt, spices extract, 
1% pecorino cheese, garlic, acid: E270, natural flavoring 
19 Fresh green pesto, in-house made (supermarket), 100 g 
Sunflower oil, basil 23.7%, 9.5% cheese powder, walnuts, parsley, salt, 
vinegar, garlic 2%, 1.9%, pine nuts, sugar water, white pepper, food 
acids: lactic acid and citric acid, thickening agent, E415 and E415, 
preservative E202 
20 Artisan and full of flavor green pesto, 100 g 
Sunflower oil, basil 30%, 8.5% grana padano cheese, cashews, olive 
oil, salt, pecorino cheese, fructose, pine, bamboo fiber, garlic, 
antioxidant E300 
21 Creamy green pesto with basil, cheese and pine nuts, 125 g 
Vegetable oil (27% olive, rapeseed), basil 22%, 11% cheese powder, 
7% pine nuts, parsley, 2.5% garlic puree, white wine vinegar, salt, sugar, 
vinegar, natural flavoring, preservative (E200, E210), black pepper, 
thickening agent (guar gum, xanthan gum) 
 
 
 
 
 
 
 
Table1. (Continued) Basil-containing pesto sauce samples used in the present study and their 
major characteristics. Information provided was derived from the product labels unless stated 
otherwise. 
Sample no. Description Ingredients 
22 Creamy red pesto with tomato, cheese and pine nuts, 125 g 
Vegetable oil (13% olive, rapeseed), 16 tomatoes, basil 14%, 12% cheese 
powder, 8% pine nuts, parsley, 3% garlic puree, white wine vinegar, salt, 
sugar, vinegar, natural flavoring, preservative (E200, E210), thickener (guar 
gum, xanthan gum), 1.5% sundried tomatoes, red peppers 
23 Pesto with Sicilian pistachio nuts, 130 g Olive oil, Genovese basil 22%, pistachio nut (18%), cashew nuts, sea salt 
24 Pesto with lemon zest, 135g 
Olive oil, fresh basil 59%, cashew nuts, salt, cheese mix (2%), limon rinds 
(1.5%), fructose, pine nuts, wine vinegar, garlic, natural lemon flavoring, 
acidity regulator citric acid, lactic acid 
25 Pesto with basil & truffle, 130g Olive oil, Genovese basil 22%, cashew nuts, sea salt, pine nuts, white truffle 
26 Rosso pesto with sun dried tomato and basil, 130g 
Olive oil, sun dried tomato 25%, Genovese basil 25%, cashew nuts, sea 
salt, pine nuts,  acidity regulator citric acid, lactic acid 
27 Freshly made pesto, from Italian food products shop Private recipe 
28 Freshly made pesto, from cheese shop Private recipe 
29 Pesto spread, 90g 
Sunflower oil, 15% pine nuts, low-fat cream cheese, basil 9%, spinach, 
white wine vinegar, 2.5 pecorino, garlic, salt, emulsifier (E472), bovine 
gelatin, preservative (E202, E224) 
30 Special basil pesto, 100g Sunflower oil, pine nut 15%, 12% old cheese, basil 11%, 10% spinach, white wine vinegar, dried garlic, sea salt, preservative (E202, E224) 
31 Bio basil pesto,100g Basil 32%, sunflower oil, cheese, olive oil 55, 4% pine nuts, vinegar, garlic, lemon juice, sea salt, spices, coconut blossom sugar 
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Table1. (Continued) Basil-containing pesto sauce samples used in the present study and their 
major characteristics. Information provided was derived from the product labels unless stated 
otherwise. 
Sample no. Description Ingredients 
12 Italian arugula pesto, 190 g 
Sunflower oil, arugula 30%, basil 8%, pecorino romano cheese, sea 
salt, garlic, vegetable fibres, pine nuts, extra virgin olive oil, acidity 
regulator: lactic acid 
13 
Biological green pesto, 135g Sunflower oil, fresh basil 79%, salt 1%, pine nuts, garlic, white wine 
vinegar, acid regulator (lactic acid, citric acid) 
14 
The real Italian seasoning, green 
pesto, 190 g 
Basil 42%, sunflower oil, cashew nut 6.5%, water, parmigiano reggiano 
cheese 2.5%, salt, garlic, yogurt powder, olive oil 0.5%, pine 0.5%, 
acidity regulator: lactic acid, natural basil flavor, natural white pepper 
flavor, whey protein, antioxidant: E300 
15 
Green pesto, classic basil pesto, 
garlic and parmesan cheese, 125 g 
Basil 42%, sunflower oil 32.2%, cashew nuts, parmesan 4% (milk, salt, 
rennet), salt, pecorino cheese 2%, garlic 1.5%, glucose syrup, milk 
protein, acidity regulator: lactic acid, extra virgin olive oil, pine 0.5%, 
natural flavor 
16 Green pesto, with more basil, 185 g 
Basil 46%, sunflower oil, Italian cheese 7% (grana padano, pecorino 
romano), cashews, salt, extra virgin olive oil with virgin olive oil 2%, 
glucose syrup, sugar, potato flakes, flavor, garlic 0.5%, pine nut 0.5%, 
lactic acid 
17 Green vegan pesto with extra virgin oil, bio, organic, 180 g Extra virgin oil, basil 30%, walnuts, cashew nuts, pine kernels, sea salt 
18 Italian green pesto, 90g 
Basil 39%, 27% sunflower oil, water, lactose, 4% cashews, 4% 
parmigiano reggiano, 2.8% olive oil, 2% pine nuts, salt, spices extract, 
1% pecorino cheese, garlic, acid: E270, natural flavoring 
19 Fresh green pesto, in-house made (supermarket), 100 g 
Sunflower oil, basil 23.7%, 9.5% cheese powder, walnuts, parsley, salt, 
vinegar, garlic 2%, 1.9%, pine nuts, sugar water, white pepper, food 
acids: lactic acid and citric acid, thickening agent, E415 and E415, 
preservative E202 
20 Artisan and full of flavor green pesto, 100 g 
Sunflower oil, basil 30%, 8.5% grana padano cheese, cashews, olive 
oil, salt, pecorino cheese, fructose, pine, bamboo fiber, garlic, 
antioxidant E300 
21 Creamy green pesto with basil, cheese and pine nuts, 125 g 
Vegetable oil (27% olive, rapeseed), basil 22%, 11% cheese powder, 
7% pine nuts, parsley, 2.5% garlic puree, white wine vinegar, salt, sugar, 
vinegar, natural flavoring, preservative (E200, E210), black pepper, 
thickening agent (guar gum, xanthan gum) 
 
 
 
 
 
 
 
Table1. (Continued) Basil-containing pesto sauce samples used in the present study and their 
major characteristics. Information provided was derived from the product labels unless stated 
otherwise. 
Sample no. Description Ingredients 
22 Creamy red pesto with tomato, cheese and pine nuts, 125 g 
Vegetable oil (13% olive, rapeseed), 16 tomatoes, basil 14%, 12% cheese 
powder, 8% pine nuts, parsley, 3% garlic puree, white wine vinegar, salt, 
sugar, vinegar, natural flavoring, preservative (E200, E210), thickener (guar 
gum, xanthan gum), 1.5% sundried tomatoes, red peppers 
23 Pesto with Sicilian pistachio nuts, 130 g Olive oil, Genovese basil 22%, pistachio nut (18%), cashew nuts, sea salt 
24 Pesto with lemon zest, 135g 
Olive oil, fresh basil 59%, cashew nuts, salt, cheese mix (2%), limon rinds 
(1.5%), fructose, pine nuts, wine vinegar, garlic, natural lemon flavoring, 
acidity regulator citric acid, lactic acid 
25 Pesto with basil & truffle, 130g Olive oil, Genovese basil 22%, cashew nuts, sea salt, pine nuts, white truffle 
26 Rosso pesto with sun dried tomato and basil, 130g 
Olive oil, sun dried tomato 25%, Genovese basil 25%, cashew nuts, sea 
salt, pine nuts,  acidity regulator citric acid, lactic acid 
27 Freshly made pesto, from Italian food products shop Private recipe 
28 Freshly made pesto, from cheese shop Private recipe 
29 Pesto spread, 90g 
Sunflower oil, 15% pine nuts, low-fat cream cheese, basil 9%, spinach, 
white wine vinegar, 2.5 pecorino, garlic, salt, emulsifier (E472), bovine 
gelatin, preservative (E202, E224) 
30 Special basil pesto, 100g Sunflower oil, pine nut 15%, 12% old cheese, basil 11%, 10% spinach, white wine vinegar, dried garlic, sea salt, preservative (E202, E224) 
31 Bio basil pesto,100g Basil 32%, sunflower oil, cheese, olive oil 55, 4% pine nuts, vinegar, garlic, lemon juice, sea salt, spices, coconut blossom sugar 
 
 
 
 
 
 
 
Chapter 4 | Risk assessment of alkenylbenzenes in basil-containing sauce of pesto
140
 
 
Methanol extracts 
All basil-containing pesto sauces were extracted using methanol based on the method 
described by Ávila et al. (Avila et al. 2009), with minor modifications. In short, 5 g of each 
sauce sample were sonicated in an ultrasonic bath for 10 min and macerated for 12-hr at 50°C 
with 80 ml of methanol in a closed glass vessel. Finally, an aliquot of the extract solution was 
centrifuged at 13000×g for 5 min, and stored at −20°C until Ultra Performance Liquid 
Chromatography (UPLC) analysis. Samples were extracted and then analyzed on UPLC in 
triplicate. The accuracy of the developed method was assessed by means of a recovery study 
and standard deviations of the replicates. For recovery, pure standards of commercially 
available alkenylbenzenes were added in two different quantities (final concentration of 5 and 
10 μM) to 5 g of two pesto sauce samples (sample 16 and 21) which covers the whole range 
of analysis in a final volume of methanol of 80 ml. Samples were prepared and analyzed as 
described above to quantify the alkenylbenzene levels enabling determination of the recovery. 
The extraction capacity linearity was demonstrated to applying a range of weight of sample to 
final volume of the solution ratio of 1.5 % up to 10 %. 
 
UPLC analysis 
For quantification of alkenylbenzenes in the extracts, 3.5 μl of each sample was subjected to 
UPLC analysis. The UPLC system consisted of a Waters (Waters, Milford, MA) Acquity 
solvent manager, sample manager, and photodiode array detector. Chromatographic 
separation was achieved using an ACQUITY UPLC BEH C18 1.7 μm column, 2.1 × 50 mm. 
The column was thermostated at 35 °C and the sample manager was set at 10 °C. An isocratic 
gradient was made for the separation using a mixture of acetonitrile (ACN) and ultrapure 
water containing 0.1 % (v/v) trifluoroacetic acid (TFA). The mobile phase consisted of 40% 
acetonitrile for 4 min, which was the time needed to separate alkenylbenzenes of interest. 
 
 
During the whole run, the flow rate was 0.6 ml/min. Under these conditions, the retention 
times for methyleugenol, estragole, myristicin, and apiol were 1.5, 2.2, 2.4, and 2.8 min, 
respectively. Identification of the alkenylbenzenes was achieved by comparing the UV 
spectrum and retention time of the peak to the UV spectrum and retention time of the peaks of 
commercially available reference compounds. Quantification was done by comparing the area 
of the alkenylbenzene peak to that of the calibration curve of the reference compounds 
determined using UPLC with photodiode array detection (UPLC/PDA) at a wavelength 201 
nm for methyleugenol and estragole, and a wavelength 210 nm for myristicin and apiol. 
 
 Determination of estimated daily intake (EDI) of alkenylbenzenes resulting from the use 
of pesto sauce 
The estimate daily intake (EDI) of alkenylbenzenes resulting from the use of pesto sauce was 
determined based on the alkenylbenzene content in the pesto sauce as determined in the 
present study (see results) and a body weight of 70 kg, the default value for adult body weight 
proposed by EFSA (EFSA 2012b). Daily consumption of pesto sauce was based on the 
reported use of about 10 g basil for a meal (Miele et al. 2001), and on the basil content of the 
samples as mentioned on the label (Table 1). If there was no information on the basil content 
in the pesto sauce on the label the average content of basil in pesto sauce of 36.0 ± 19.6 % 
(n = 27) (Table 1) was used. Firstly, the EDI was calculated for individual compounds for all 
of the samples. And since several alkenylbenzenes were found in some of the pesto samples, 
and the different alkenylbenzenes show similarity in structure, target organ, type of adverse 
effects and mode of action through formation of a DNA reactive 1’-sulfoxymetabolite 
contributing to formation of liver tumors, a combined exposure assessment and subsequent 
risk assessment were also performed for those samples. To this end two approaches were 
used; summing up the EDIs of the alkenylbenzenes assuming equal potency, and a so-called 
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Methanol extracts 
All basil-containing pesto sauces were extracted using methanol based on the method 
described by Ávila et al. (Avila et al. 2009), with minor modifications. In short, 5 g of each 
sauce sample were sonicated in an ultrasonic bath for 10 min and macerated for 12-hr at 50°C 
with 80 ml of methanol in a closed glass vessel. Finally, an aliquot of the extract solution was 
centrifuged at 13000×g for 5 min, and stored at −20°C until Ultra Performance Liquid 
Chromatography (UPLC) analysis. Samples were extracted and then analyzed on UPLC in 
triplicate. The accuracy of the developed method was assessed by means of a recovery study 
and standard deviations of the replicates. For recovery, pure standards of commercially 
available alkenylbenzenes were added in two different quantities (final concentration of 5 and 
10 μM) to 5 g of two pesto sauce samples (sample 16 and 21) which covers the whole range 
of analysis in a final volume of methanol of 80 ml. Samples were prepared and analyzed as 
described above to quantify the alkenylbenzene levels enabling determination of the recovery. 
The extraction capacity linearity was demonstrated to applying a range of weight of sample to 
final volume of the solution ratio of 1.5 % up to 10 %. 
 
UPLC analysis 
For quantification of alkenylbenzenes in the extracts, 3.5 μl of each sample was subjected to 
UPLC analysis. The UPLC system consisted of a Waters (Waters, Milford, MA) Acquity 
solvent manager, sample manager, and photodiode array detector. Chromatographic 
separation was achieved using an ACQUITY UPLC BEH C18 1.7 μm column, 2.1 × 50 mm. 
The column was thermostated at 35 °C and the sample manager was set at 10 °C. An isocratic 
gradient was made for the separation using a mixture of acetonitrile (ACN) and ultrapure 
water containing 0.1 % (v/v) trifluoroacetic acid (TFA). The mobile phase consisted of 40% 
acetonitrile for 4 min, which was the time needed to separate alkenylbenzenes of interest. 
 
 
During the whole run, the flow rate was 0.6 ml/min. Under these conditions, the retention 
times for methyleugenol, estragole, myristicin, and apiol were 1.5, 2.2, 2.4, and 2.8 min, 
respectively. Identification of the alkenylbenzenes was achieved by comparing the UV 
spectrum and retention time of the peak to the UV spectrum and retention time of the peaks of 
commercially available reference compounds. Quantification was done by comparing the area 
of the alkenylbenzene peak to that of the calibration curve of the reference compounds 
determined using UPLC with photodiode array detection (UPLC/PDA) at a wavelength 201 
nm for methyleugenol and estragole, and a wavelength 210 nm for myristicin and apiol. 
 
 Determination of estimated daily intake (EDI) of alkenylbenzenes resulting from the use 
of pesto sauce 
The estimate daily intake (EDI) of alkenylbenzenes resulting from the use of pesto sauce was 
determined based on the alkenylbenzene content in the pesto sauce as determined in the 
present study (see results) and a body weight of 70 kg, the default value for adult body weight 
proposed by EFSA (EFSA 2012b). Daily consumption of pesto sauce was based on the 
reported use of about 10 g basil for a meal (Miele et al. 2001), and on the basil content of the 
samples as mentioned on the label (Table 1). If there was no information on the basil content 
in the pesto sauce on the label the average content of basil in pesto sauce of 36.0 ± 19.6 % 
(n = 27) (Table 1) was used. Firstly, the EDI was calculated for individual compounds for all 
of the samples. And since several alkenylbenzenes were found in some of the pesto samples, 
and the different alkenylbenzenes show similarity in structure, target organ, type of adverse 
effects and mode of action through formation of a DNA reactive 1’-sulfoxymetabolite 
contributing to formation of liver tumors, a combined exposure assessment and subsequent 
risk assessment were also performed for those samples. To this end two approaches were 
used; summing up the EDIs of the alkenylbenzenes assuming equal potency, and a so-called 
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toxic equivalency (TEQ) approach calculating the estimated daily intake (EDI) values of the 
alkenylbenzenes using their toxic equivalency factor (TEF) relative to methyleugenol. 
Methyleugenol was taken as the reference compound (TEF = 1.0), expressing the 
concentrations of the other alkenylbenzenes in methyleugenol equivalents. TEF values for the 
different alkenylbenzenes for the TEQ approach need to be defined, which was done by 
calculating an average of three endpoints. The first one was the slope of the dose-response 
curve for DNA-adduct formation in female CD-1 mice liver upon exposure to different 
alkenylbenzenes (Randerath et al. 1984). The second one, was the in vivo level of formation 
of the hepatocarcinogenic 1’-sulfoxymetabolites of the different alkenylbenzenes predicted 
using human physiologically based kinetic (PBK) models at a dose level of 
0.01 mg/kg bw (Punt et al. 2009; Al-Subeihi et al. 2012; Alajlouni et al. 2016a; Al-Malahmeh 
et al. 2017). And finally, the BMDL10 values derived from in vivo tumor data for safrole, 
estragole, and methyleugenol (Miller et al. 1983), or by read-across from safrole for 
myristicin and apiol (Alajlouni et al. 2016a; Al-Malahmeh et al. 2017) (Table 2). The TEF 
values for the different alkenylbenzenes defined by the three approaches relative to 
methyleugenol were subsequently averaged to define the final TEF values. Using these TEF 
values the EDI of alkenylbenzenes in the pesto sauces expressed in (μg methyleugenol 
equivalents/kg bw per day) was calculated using the formula: 
???????? ????????????????????????????????????? ? ????? ? ?????,  
i; differnt alkenybenzenes 
 
 
 
 
 
 
 
Table 2. Data used for estimation of the TEF values for the different alkenylbenzenes as 
derived from data reported for i) the dose-dependent level of DNA adduct formation in the 
liver of alkenylbenzene exposed female CD-1 mice (Randerath et al. 1984) ii) the formation 
of the proximate carcinogenic 1’-sulfoxy metabolites in liver in μmol/kg bw as predicted by  
available PBK models at a dose level of 0.01 mg/kg bw (Punt et al. 2009; Al-Subeihi et al. 
2012; Alajlouni et al. 2016a; Al-Malahmeh et al. 2017), and iii) BMDL10 values reported in 
the literature (van den Berg et al. 2011; Alajlouni et al. 2016a; Al-Malahmeh et al. 2017). The 
TEF values were calculated relative to methyleugenol as the reference compound, expressing 
the concentrations of the other alkenylbenzenes in methyleugenol equivalents. 
Compound 
  
Formation of  DNA 
adduct in 107  
nucleotides versus 
dose in mg/kg bw 
  
Formation of the 
proximate carcinogenic 
1’-sulfoxy metabolite  
  
In vivo tumor data 
  
Average 
TEF value 
± SD  
slope of 
the curve TEF 
formation level 
(μmol/kg bw) at 
0.01 mg/kg bw 
dose 
TEF 
BMDL10        
(mg/kg bw per 
day)  
TEF 
Safrole 1.68 1.05 3.28E-05 1.08 1.9 8.05 3.39±4.04 
myristicin 0.39 0.24 2.44E-05 0.8 1.9 8.05 3.03±4.36 
apiol 0.11 0.07 1.62E-05 0.53 5.7 2.68 1.09±1.40 
estragole 2.48 1.55 14.1E-05 4.62 3.3 4.64 3.60±1.78 
methyleugenol 1.60 1.00 3.05E-05 1.00 15.3 1.00 1.00 
 
Calculation of the margin of exposure 
Risk assessment of consumption of the pesto sauce samples was performed using the Margin 
of Exposure (MOE) approach (EFSA 2005). For the individual alkenylbenzene approach, the 
BMDL10 values of each compound were used (van den Berg et al. 2011; Alajlouni et al. 
2016a; Al-Malahmeh et al. 2017) and then compared with the EDIs of the alkenylbenzenes 
resulting from the use of pesto sauce. For the equal potency assumption approach, the 
BMDL10 value of the predominating alkenylbenzene in the samples was used and compared 
to the sum of the EDIs. And finally, for the TEQ approach, the BMDL10 of the reference 
compound methyleugenol was compared to the EDI expressed in methyleugenol equivalents. 
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toxic equivalency (TEQ) approach calculating the estimated daily intake (EDI) values of the 
alkenylbenzenes using their toxic equivalency factor (TEF) relative to methyleugenol. 
Methyleugenol was taken as the reference compound (TEF = 1.0), expressing the 
concentrations of the other alkenylbenzenes in methyleugenol equivalents. TEF values for the 
different alkenylbenzenes for the TEQ approach need to be defined, which was done by 
calculating an average of three endpoints. The first one was the slope of the dose-response 
curve for DNA-adduct formation in female CD-1 mice liver upon exposure to different 
alkenylbenzenes (Randerath et al. 1984). The second one, was the in vivo level of formation 
of the hepatocarcinogenic 1’-sulfoxymetabolites of the different alkenylbenzenes predicted 
using human physiologically based kinetic (PBK) models at a dose level of 
0.01 mg/kg bw (Punt et al. 2009; Al-Subeihi et al. 2012; Alajlouni et al. 2016a; Al-Malahmeh 
et al. 2017). And finally, the BMDL10 values derived from in vivo tumor data for safrole, 
estragole, and methyleugenol (Miller et al. 1983), or by read-across from safrole for 
myristicin and apiol (Alajlouni et al. 2016a; Al-Malahmeh et al. 2017) (Table 2). The TEF 
values for the different alkenylbenzenes defined by the three approaches relative to 
methyleugenol were subsequently averaged to define the final TEF values. Using these TEF 
values the EDI of alkenylbenzenes in the pesto sauces expressed in (μg methyleugenol 
equivalents/kg bw per day) was calculated using the formula: 
???????? ????????????????????????????????????? ? ????? ? ?????,  
i; differnt alkenybenzenes 
 
 
 
 
 
 
 
Table 2. Data used for estimation of the TEF values for the different alkenylbenzenes as 
derived from data reported for i) the dose-dependent level of DNA adduct formation in the 
liver of alkenylbenzene exposed female CD-1 mice (Randerath et al. 1984) ii) the formation 
of the proximate carcinogenic 1’-sulfoxy metabolites in liver in μmol/kg bw as predicted by  
available PBK models at a dose level of 0.01 mg/kg bw (Punt et al. 2009; Al-Subeihi et al. 
2012; Alajlouni et al. 2016a; Al-Malahmeh et al. 2017), and iii) BMDL10 values reported in 
the literature (van den Berg et al. 2011; Alajlouni et al. 2016a; Al-Malahmeh et al. 2017). The 
TEF values were calculated relative to methyleugenol as the reference compound, expressing 
the concentrations of the other alkenylbenzenes in methyleugenol equivalents. 
Compound 
  
Formation of  DNA 
adduct in 107  
nucleotides versus 
dose in mg/kg bw 
  
Formation of the 
proximate carcinogenic 
1’-sulfoxy metabolite  
  
In vivo tumor data 
  
Average 
TEF value 
± SD  
slope of 
the curve TEF 
formation level 
(μmol/kg bw) at 
0.01 mg/kg bw 
dose 
TEF 
BMDL10        
(mg/kg bw per 
day)  
TEF 
Safrole 1.68 1.05 3.28E-05 1.08 1.9 8.05 3.39±4.04 
myristicin 0.39 0.24 2.44E-05 0.8 1.9 8.05 3.03±4.36 
apiol 0.11 0.07 1.62E-05 0.53 5.7 2.68 1.09±1.40 
estragole 2.48 1.55 14.1E-05 4.62 3.3 4.64 3.60±1.78 
methyleugenol 1.60 1.00 3.05E-05 1.00 15.3 1.00 1.00 
 
Calculation of the margin of exposure 
Risk assessment of consumption of the pesto sauce samples was performed using the Margin 
of Exposure (MOE) approach (EFSA 2005). For the individual alkenylbenzene approach, the 
BMDL10 values of each compound were used (van den Berg et al. 2011; Alajlouni et al. 
2016a; Al-Malahmeh et al. 2017) and then compared with the EDIs of the alkenylbenzenes 
resulting from the use of pesto sauce. For the equal potency assumption approach, the 
BMDL10 value of the predominating alkenylbenzene in the samples was used and compared 
to the sum of the EDIs. And finally, for the TEQ approach, the BMDL10 of the reference 
compound methyleugenol was compared to the EDI expressed in methyleugenol equivalents. 
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RESULTS 
Determination of methyleugenol content in the basil-containing pesto sauce samples, 
EDI, and resulting MOEs 
Table 3 presents the levels of methyleugenol detected in the various pesto sauces. The results 
obtained revealed that methyleugenol was detected in all the samples analyzed. The level of 
methyleugenol in the different samples varied about 28-fold ranging between 3.6 and 
99.3 μg/g pesto sauce. Estimated daily intakes (EDIs) of methyleugenol from basil containing 
pesto sauce were calculated using the methyleugenol content in the samples, a daily 
consumption of pesto calculated based on the reported use of about 10 g basil for a 
meal (Miele et al. 2001), and the basil content of the samples as mentioned on the label (Table 
1) or the assumption that the basil content in pesto sauce was on average 36.0 ± 19.6 % 
(n = 27) (Table 1) in case this % of basil in the pesto sauce was not mentioned on the label, 
and an adult body weight of 70 kg. The EDI values thus obtained for methyleugenol vary in 
the range of 3.2–44.3 μg/kg bw per day. The MOE values were calculated using the 
BMDL10 value reported in the literature for methyleugenol of 15.3 mg/kg bw per day (van 
den Berg et al. 2011) (Table 3). The MOE values obtained vary from 345 to 4781 and were all 
lower than 10000, the value suggested by EFSA to judge if there is a priority for risk 
management (EFSA 2005). 
 
 
 
 
 
 
 
 
 
Table 3. Level of methyleugenol detected in the pesto sauce samples, EDI for methyleugenol 
upon consumption of these pesto samples, and the resulting MOE. 
Sample no. 
Methyleugenol 
concentration in the pesto 
sample Average ± SD (μg/g) 
EDI  
(μg/kg bw per 
day) 
MOE 
1 17.9 ± 2.4 7.1 2154 
2 11.4 ± 1.5 5.9 2593 
3 11.1 ±1.5 4.4 3474 
4 35.6 ± 4.8 14.5 1053 
5 32.3 ± 4.3 6.3 2421 
6 41.2 ± 5.5 16.4 936 
7 29.6 ± 4 12.1 1266 
8 27.6 ± 3.7 5.0 3066 
9 25.3 ± 3.4 8.6 1778 
10 38.1 ± 5.1 9.2 1659 
11 20.5 ± 2.7 10.1 1515 
12 3.8 ± 0.5 6.8 2255 
13 34.1 ± 4.6 6.2 2481 
14 60.5 ± 8.1 20.6 744 
15 21.8 ± 2.9 7.4 2063 
16 39.0 ± 5.2 12.1 1263 
17 12.4 ± 1.7 5.9 2591 
18 35.8 ± 4.8 13.1 1167 
19 56.4 ± 7.5 34.0 450 
20 15.2 ± 2.0 7.2 2114 
21 22.9 ± 3.1 6.4 2404 
22 15.1 ± 2.0 14.9 1029 
23 8.4 ± 1.1 15.4 993 
24 33.0 ± 4.4 5.5 2805 
25 9.8 ± 1.3 8.0 1915 
26 5.6 ± 0.7 3.2 4781 
27 14.3 ± 1.9 5.7 2696 
28 13.4 ± 1.8 5.3 2877 
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RESULTS 
Determination of methyleugenol content in the basil-containing pesto sauce samples, 
EDI, and resulting MOEs 
Table 3 presents the levels of methyleugenol detected in the various pesto sauces. The results 
obtained revealed that methyleugenol was detected in all the samples analyzed. The level of 
methyleugenol in the different samples varied about 28-fold ranging between 3.6 and 
99.3 μg/g pesto sauce. Estimated daily intakes (EDIs) of methyleugenol from basil containing 
pesto sauce were calculated using the methyleugenol content in the samples, a daily 
consumption of pesto calculated based on the reported use of about 10 g basil for a 
meal (Miele et al. 2001), and the basil content of the samples as mentioned on the label (Table 
1) or the assumption that the basil content in pesto sauce was on average 36.0 ± 19.6 % 
(n = 27) (Table 1) in case this % of basil in the pesto sauce was not mentioned on the label, 
and an adult body weight of 70 kg. The EDI values thus obtained for methyleugenol vary in 
the range of 3.2–44.3 μg/kg bw per day. The MOE values were calculated using the 
BMDL10 value reported in the literature for methyleugenol of 15.3 mg/kg bw per day (van 
den Berg et al. 2011) (Table 3). The MOE values obtained vary from 345 to 4781 and were all 
lower than 10000, the value suggested by EFSA to judge if there is a priority for risk 
management (EFSA 2005). 
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upon consumption of these pesto samples, and the resulting MOE. 
Sample no. 
Methyleugenol 
concentration in the pesto 
sample Average ± SD (μg/g) 
EDI  
(μg/kg bw per 
day) 
MOE 
1 17.9 ± 2.4 7.1 2154 
2 11.4 ± 1.5 5.9 2593 
3 11.1 ±1.5 4.4 3474 
4 35.6 ± 4.8 14.5 1053 
5 32.3 ± 4.3 6.3 2421 
6 41.2 ± 5.5 16.4 936 
7 29.6 ± 4 12.1 1266 
8 27.6 ± 3.7 5.0 3066 
9 25.3 ± 3.4 8.6 1778 
10 38.1 ± 5.1 9.2 1659 
11 20.5 ± 2.7 10.1 1515 
12 3.8 ± 0.5 6.8 2255 
13 34.1 ± 4.6 6.2 2481 
14 60.5 ± 8.1 20.6 744 
15 21.8 ± 2.9 7.4 2063 
16 39.0 ± 5.2 12.1 1263 
17 12.4 ± 1.7 5.9 2591 
18 35.8 ± 4.8 13.1 1167 
19 56.4 ± 7.5 34.0 450 
20 15.2 ± 2.0 7.2 2114 
21 22.9 ± 3.1 6.4 2404 
22 15.1 ± 2.0 14.9 1029 
23 8.4 ± 1.1 15.4 993 
24 33.0 ± 4.4 5.5 2805 
25 9.8 ± 1.3 8.0 1915 
26 5.6 ± 0.7 3.2 4781 
27 14.3 ± 1.9 5.7 2696 
28 13.4 ± 1.8 5.3 2877 
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Table 3. (Continued) level of methyleugenol detected in the pesto sauce samples, EDI for 
methyleugenol upon consumption of these pesto samples, and the resulting MOE 
Sample no. 
Methyleugenol 
concentration in the pesto 
sample Average ± SD 
(μg/g) 
EDI  
(μg/kg bw per day) MOE 
29 3.6 ± 0.5 5.7 2678 
30 3.8 ± 0.5 4.9 3100 
31 99.3 ± 13.3 44.3 345 
 
Determination of other alkenylbenzenes in the pesto sauce samples, EDI for the 
combined exposure, and resulting MOEs 
In four samples (16, 18, 19, and 21) other alkenylbenzenes were detected in addition to 
methyleugenol, including estragole, myristicin, and/or apiol (Table 4). The levels of 
methyleugenol, detected in these samples, were already presented in Table 3. Estragole that is 
known to be present in some basil cultivars in addition to methyleugenol, was detected in two 
samples (16,18), with one of these samples indeed containing another cultivar than the 
Genovese cultivar as mentioned on the label (Table 1). The estragole level varied 10-fold 
between the two samples in which it was detected. Myristicin and apiol were detected in two 
samples of green pesto (Table 4), which may be due to the fact that these samples contain 
other herbs in addition to basil (e.g. parsley) (Table 1). For samples 16, 18, 19 and 21 the EDI 
for the individual alkenylbenzenes varied between 6.4–34.0 μg/kg bw per day for 
methyleugenol, 1.2–10.6 μg/kg bw per day for estragole, 8.6–9.6 μg/kg bw per day for 
myristicin, and 2.2 μg/kg bw per day for apiol the latter being detected in only one sample 
(Table 4). 
 
 
 
 
Table 4. Level of alkenylbenzenes methyleugenol, estragole, myristicin, and apiol in the four 
pesto sauce samples that contained other alkenylbenzenes in addition to methyleugenol and 
EDI values for the individual alkenylbenzenes, as well as combined EDI values calculated 
either by assuming equal potency, or in methyleugenol equivalents using the TEF values 
presented in Table 2.  
Sample 
no. 
Alkenylbenzenes level in the pesto 
sample average ± SD (μg/g) 
EDI (μg/kg bw per day) 
individual combined exposure 
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  based on 
TEF           
methyleugenol 
equivalents 
16 39.0 ± 5.2 34.1 ± 2.8     12.1 10.6     22.7 50.3 
18 35.8 ± 4.8 3.2 ± 1.5     13.1 1.2     14.3 17.3 
19 56.4 ± 7.5   15.8 ± 0.01   34   9.6   43.5 62.9 
21 22.9 ± 3.1   13.2 ± 1.2 
3.4 
± 
0.2 
6.4   8.6 2.2 17.2 
34.8 
 
Since several alkenylbenzenes were found in some pesto samples, and because these 
alkenylbenzenes are known to display similarity in structure, target organ, type of adverse 
effects and mode of action through formation of a DNA reactive 1’-sulfoxymetabolite 
contributing to formation of liver tumors, a combined exposure and risk assessment was also 
performed. To this end the combined exposure was estimated in two ways, assuming either 
equal potency or using a so-called toxic equivalency (TEQ) approach. When assuming equal 
potency of the different alkenylbenzenes the combined EDI can be calculated by adding up 
the EDIs of the different alkenylbenzenes. Table 4 presents the combined EDI values obtained 
for the four pesto sauce samples in which more than one alkenylbenzene were detected. The 
values obtained varied from 14.3 to 43.5 mg/kg bw per day with methyleugenol being the 
major alkenylbenzene making up 53.3–91.6% of these values except for sample 22 where 
methyleugenol makes up 37.2% of the alkenylbenzenes and myristicin appeared to be the 
major one at 50.0%. In a second approach the combined exposure was calculated in 
methyleugenol equivalents taking the relative potency of the different alkenylbenzenes into 
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Table 3. (Continued) level of methyleugenol detected in the pesto sauce samples, EDI for 
methyleugenol upon consumption of these pesto samples, and the resulting MOE 
Sample no. 
Methyleugenol 
concentration in the pesto 
sample Average ± SD 
(μg/g) 
EDI  
(μg/kg bw per day) MOE 
29 3.6 ± 0.5 5.7 2678 
30 3.8 ± 0.5 4.9 3100 
31 99.3 ± 13.3 44.3 345 
 
Determination of other alkenylbenzenes in the pesto sauce samples, EDI for the 
combined exposure, and resulting MOEs 
In four samples (16, 18, 19, and 21) other alkenylbenzenes were detected in addition to 
methyleugenol, including estragole, myristicin, and/or apiol (Table 4). The levels of 
methyleugenol, detected in these samples, were already presented in Table 3. Estragole that is 
known to be present in some basil cultivars in addition to methyleugenol, was detected in two 
samples (16,18), with one of these samples indeed containing another cultivar than the 
Genovese cultivar as mentioned on the label (Table 1). The estragole level varied 10-fold 
between the two samples in which it was detected. Myristicin and apiol were detected in two 
samples of green pesto (Table 4), which may be due to the fact that these samples contain 
other herbs in addition to basil (e.g. parsley) (Table 1). For samples 16, 18, 19 and 21 the EDI 
for the individual alkenylbenzenes varied between 6.4–34.0 μg/kg bw per day for 
methyleugenol, 1.2–10.6 μg/kg bw per day for estragole, 8.6–9.6 μg/kg bw per day for 
myristicin, and 2.2 μg/kg bw per day for apiol the latter being detected in only one sample 
(Table 4). 
 
 
 
 
Table 4. Level of alkenylbenzenes methyleugenol, estragole, myristicin, and apiol in the four 
pesto sauce samples that contained other alkenylbenzenes in addition to methyleugenol and 
EDI values for the individual alkenylbenzenes, as well as combined EDI values calculated 
either by assuming equal potency, or in methyleugenol equivalents using the TEF values 
presented in Table 2.  
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16 39.0 ± 5.2 34.1 ± 2.8     12.1 10.6     22.7 50.3 
18 35.8 ± 4.8 3.2 ± 1.5     13.1 1.2     14.3 17.3 
19 56.4 ± 7.5   15.8 ± 0.01   34   9.6   43.5 62.9 
21 22.9 ± 3.1   13.2 ± 1.2 
3.4 
± 
0.2 
6.4   8.6 2.2 17.2 
34.8 
 
Since several alkenylbenzenes were found in some pesto samples, and because these 
alkenylbenzenes are known to display similarity in structure, target organ, type of adverse 
effects and mode of action through formation of a DNA reactive 1’-sulfoxymetabolite 
contributing to formation of liver tumors, a combined exposure and risk assessment was also 
performed. To this end the combined exposure was estimated in two ways, assuming either 
equal potency or using a so-called toxic equivalency (TEQ) approach. When assuming equal 
potency of the different alkenylbenzenes the combined EDI can be calculated by adding up 
the EDIs of the different alkenylbenzenes. Table 4 presents the combined EDI values obtained 
for the four pesto sauce samples in which more than one alkenylbenzene were detected. The 
values obtained varied from 14.3 to 43.5 mg/kg bw per day with methyleugenol being the 
major alkenylbenzene making up 53.3–91.6% of these values except for sample 22 where 
methyleugenol makes up 37.2% of the alkenylbenzenes and myristicin appeared to be the 
major one at 50.0%. In a second approach the combined exposure was calculated in 
methyleugenol equivalents taking the relative potency of the different alkenylbenzenes into 
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account. For this TEQ approach the required toxic equivalency factor (TEF) relative to 
methyleugenol were estimated as summarized in Table 2. TEF values for the different 
alkenylbenzenes were defined by calculating the average of the relative potency as available 
for three end points, including (i) the slope of the dose-response curve for DNA-adduct 
formation in female CD-1 mice liver upon exposure to different alkenylbenzenes (Randerath 
et al. 1984), (ii) the in vivo level of formation of the hepatocarcinogenic 1’-sulfoxymetabolites 
of the different alkenylbenzenes predicted using human physiologically based kinetic models 
at a dose level of 0.01 mg/kg bw (Punt et al. 2009; Al-Subeihi et al. 2012; Alajlouni et al. 
2016a; Al-Malahmeh et al. 2017), and (iii) the BMDL10 values derived from in vivo tumor 
data for safrole, estragole, and methyleugenol (Miller et al. 1983), or by read-across from 
safrole for myristicin and apiol (Alajlouni et al. 2016a; Al-Malahmeh et al. 2017). 
Methyleugenol was taken as the reference compound (TEF = 1.0), expressing the 
concentrations of the other alkenylbenzenes in methyleugenol equivalents (Table 2). 
Using these TEF values and the toxic equivalency approach (TEQ) the combined EDI values 
obtained vary in the range of 17.3–62.9 μg methyleugenol equivalents/kg bw per day (Table 
4). 
Using the EDI values thus obtained MOE values were calculated. To this end different 
BMDL10 values were used for different approaches to obtain the MOE values. The 
BMDL10 values for the individual alkenylbenzenes were taken from literature (van den Berg 
et al. 2011; Alajlouni et al. 2016a; Al-Malahmeh et al. 2017), and were used to calculate 
MOE values for intakes of each individual alkenylbenzene (Table 5). MOE values thus 
obtained were all below 10000. Assuming equal potency, the BMDL10 of methyleugenol of 
15.3 mg/kg bw per day (van den Berg et al. 2011), being a dominant alkenylbenzenes in the 
samples was compared with the combined EDI. The MOE values thus obtained varies 
between 351 and 1071 (Table 5). For the TEQ approach, the BMDL10 of methyleugenol of 
 
 
15.3 mg/kg bw per day (van den Berg et al. 2011) was compared to the EDI expressed in 
methyleugenol equivalents to calculate the MOE. When using the TEQ approach, MOE 
values ranged from 243 to 883. 
 
Table 5. The MOE values obtained for samples containing several alkenylbezenes. MOE 
values were calculated for each individual alkenylbenzenes, and based on combined exposure 
estimates either assuming equal potency, or based on a TEQ approach.  
Sample 
no. 
MOE individual alkenylbenzenes MOE based on equal 
potency and BMDL10 
of the highest level 
alkenylbenzene in the 
sample 
MOE based on 
TEF methyleugenol estragole myristicin apiol 
16 1263 3209   674 304 
18 1166 355   1071 883 
19 450  199  351 243 
21 1028  221 2582 892 353 
 
From the data thus obtained it is clear that the estimated daily consumption of the pesto 
sauces at 10 g basil per meal per day (based on wet weight) would result in MOE values that 
indicate a priority for risk management for all pesto sauces. It is of interest to evaluate what 
level of methyleugenol, amount of pesto sauce consumed and/or what exposure frequency 
would result in an MOE of 10000. To evaluate how these parameters could be modified to 
result in MOE values that would be of low priority for risk management, Figure 2 shows the 
relation between the level of methyleugenol detected in a pesto sauce sample and the amount 
of pesto sauce consumed that would result in MOE values of 10000 at a certain frequency of 
intake. For these calculations, it was assumed that Haber’s rule would apply so the daily dose 
would be linearly dependent on the frequency of intake. The results presented indicate that 
daily intake of for example 30 g pesto sauce would be of low priority for risk management at 
a methyleugenol level of 3.6 μg/g, while weekly intake of 30 g would be of low concern at a 
methyleugenol value of 25.0 μg/g. The curves can also be used to derive that for the pesto 
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account. For this TEQ approach the required toxic equivalency factor (TEF) relative to 
methyleugenol were estimated as summarized in Table 2. TEF values for the different 
alkenylbenzenes were defined by calculating the average of the relative potency as available 
for three end points, including (i) the slope of the dose-response curve for DNA-adduct 
formation in female CD-1 mice liver upon exposure to different alkenylbenzenes (Randerath 
et al. 1984), (ii) the in vivo level of formation of the hepatocarcinogenic 1’-sulfoxymetabolites 
of the different alkenylbenzenes predicted using human physiologically based kinetic models 
at a dose level of 0.01 mg/kg bw (Punt et al. 2009; Al-Subeihi et al. 2012; Alajlouni et al. 
2016a; Al-Malahmeh et al. 2017), and (iii) the BMDL10 values derived from in vivo tumor 
data for safrole, estragole, and methyleugenol (Miller et al. 1983), or by read-across from 
safrole for myristicin and apiol (Alajlouni et al. 2016a; Al-Malahmeh et al. 2017). 
Methyleugenol was taken as the reference compound (TEF = 1.0), expressing the 
concentrations of the other alkenylbenzenes in methyleugenol equivalents (Table 2). 
Using these TEF values and the toxic equivalency approach (TEQ) the combined EDI values 
obtained vary in the range of 17.3–62.9 μg methyleugenol equivalents/kg bw per day (Table 
4). 
Using the EDI values thus obtained MOE values were calculated. To this end different 
BMDL10 values were used for different approaches to obtain the MOE values. The 
BMDL10 values for the individual alkenylbenzenes were taken from literature (van den Berg 
et al. 2011; Alajlouni et al. 2016a; Al-Malahmeh et al. 2017), and were used to calculate 
MOE values for intakes of each individual alkenylbenzene (Table 5). MOE values thus 
obtained were all below 10000. Assuming equal potency, the BMDL10 of methyleugenol of 
15.3 mg/kg bw per day (van den Berg et al. 2011), being a dominant alkenylbenzenes in the 
samples was compared with the combined EDI. The MOE values thus obtained varies 
between 351 and 1071 (Table 5). For the TEQ approach, the BMDL10 of methyleugenol of 
 
 
15.3 mg/kg bw per day (van den Berg et al. 2011) was compared to the EDI expressed in 
methyleugenol equivalents to calculate the MOE. When using the TEQ approach, MOE 
values ranged from 243 to 883. 
 
Table 5. The MOE values obtained for samples containing several alkenylbezenes. MOE 
values were calculated for each individual alkenylbenzenes, and based on combined exposure 
estimates either assuming equal potency, or based on a TEQ approach.  
Sample 
no. 
MOE individual alkenylbenzenes MOE based on equal 
potency and BMDL10 
of the highest level 
alkenylbenzene in the 
sample 
MOE based on 
TEF methyleugenol estragole myristicin apiol 
16 1263 3209   674 304 
18 1166 355   1071 883 
19 450  199  351 243 
21 1028  221 2582 892 353 
 
From the data thus obtained it is clear that the estimated daily consumption of the pesto 
sauces at 10 g basil per meal per day (based on wet weight) would result in MOE values that 
indicate a priority for risk management for all pesto sauces. It is of interest to evaluate what 
level of methyleugenol, amount of pesto sauce consumed and/or what exposure frequency 
would result in an MOE of 10000. To evaluate how these parameters could be modified to 
result in MOE values that would be of low priority for risk management, Figure 2 shows the 
relation between the level of methyleugenol detected in a pesto sauce sample and the amount 
of pesto sauce consumed that would result in MOE values of 10000 at a certain frequency of 
intake. For these calculations, it was assumed that Haber’s rule would apply so the daily dose 
would be linearly dependent on the frequency of intake. The results presented indicate that 
daily intake of for example 30 g pesto sauce would be of low priority for risk management at 
a methyleugenol level of 3.6 μg/g, while weekly intake of 30 g would be of low concern at a 
methyleugenol value of 25.0 μg/g. The curves can also be used to derive that for the pesto 
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sauce samples of the present study with methyleugenol levels that vary from 99.3 to 3.6 μg/g 
pesto sauce, the consumption of 1.1–29.8, 7.5–208, 15.1–416.5, and 32.4–892.5 g of pesto 
sauce on a daily basis, once a week, once every two weeks, and once a month, respectively, 
could be considered of low concern. 
 
 
Figure 2. Relation between the methyleugenol content (μg/g) and daily pesto sauce 
consumption that would result in an MOE of 10000 upon daily (▬▬), weekly (▬  ▬), two 
weekly (▬ ● ▬ ), or monthly (●●●●) consumption. Combinations of methyleugenol levels and 
pesto sauce intake that result in values below the respective curves result in MOE values 
above 10000 and would be of low priority for risk management.  
 
DISCUSSION 
The aim of the present study was to make a more detailed analysis of the presence of 
methyleugenol and possible other alkenylbenzenes in basil-containing sauce of pesto and 
perform an associated risk assessment based on the MOE approach, taking into consideration 
the combined exposure to different alkenylbenzenes. 
It is important to consider the variance in aromatic composition of basil at different growth 
stages from different areas. The methyleugenol content of the volatile oil from commercial 
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samples of sweet basil, and in the leaf, flower and stem for the same cultivar of sweet basil 
were in the range of 0–2.4 % (Tsai and Sheen 1987; Sheen et al. 1991; Lawrence et al. 1993). 
It was also reported that the content of methyleugenol in the essential oil of basil plants 
decreases from 100 % to 10 % as plant height and maturity increase (Miele et al. 2001). 
Different studies revealed different levels of estragole and methyleugenol in basil for different 
genotypes and as a function of region and harvesting. The concentrations in fresh basil 
amount 10.2–2029 μg/g for estragole and 0.07–560 μg/g for methyleugenol (Siano et al. 2003; 
Lee et al. 2005; Avila et al. 2009). For pesto sauce, studies showed different concentrations of 
estragole that varied between 0.05 and 19.3 μg/g, and of methyleugenol at values that varied 
between 0.01 and 52 μg/g (Siano et al. 2003; Avila et al. 2009). The levels of methyleugenol 
determined in the pesto sauces of the present study amounted to 3.6–99.3 μg/g pesto sauce, 
and of estragole, being present in only two out of the 32 pesto sauce samples analyzed, to 3.2 
and 34.1 μg/g pesto sauces. Based on these levels and taking the basil content (%) as 
indicated on the label of the pesto sauces into account, the level of methyleugenol in basil 
used to prepare the pesto sauce was estimated to vary between 22.4–310.3 μg/g. The 
determination of the levels of alkenylbenzenes in basil-containing sauce of pesto revealed that 
all the samples analyzed contained methyleugenol. In addition to methyleugenol, two of the 
samples contained estragole, while two other samples contained myristicin, and one sample 
contained both myristicin and apiol in addition to methyleugenol. Based on chemical analysis 
the EDI values could be determined assuming a body weight of 70 kg and intake of 10 g of 
basil (based on wet weight) per meal (Miele et al. 2001), provided by an amount of pesto 
sauce that could be calculated taking into account the basil content (%) in the pesto sauce as 
indicated on the label (Table 1). For samples containing only methyleugenol, the EDI values 
ranged from 3.2–44.3 μg/kg bw per day. These EDI values resulted in MOE values of 345–
4781. Since several alkenylbenzenes were found in four of the pesto samples, and these 
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sauce samples of the present study with methyleugenol levels that vary from 99.3 to 3.6 μg/g 
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above 10000 and would be of low priority for risk management.  
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samples of sweet basil, and in the leaf, flower and stem for the same cultivar of sweet basil 
were in the range of 0–2.4 % (Tsai and Sheen 1987; Sheen et al. 1991; Lawrence et al. 1993). 
It was also reported that the content of methyleugenol in the essential oil of basil plants 
decreases from 100 % to 10 % as plant height and maturity increase (Miele et al. 2001). 
Different studies revealed different levels of estragole and methyleugenol in basil for different 
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Lee et al. 2005; Avila et al. 2009). For pesto sauce, studies showed different concentrations of 
estragole that varied between 0.05 and 19.3 μg/g, and of methyleugenol at values that varied 
between 0.01 and 52 μg/g (Siano et al. 2003; Avila et al. 2009). The levels of methyleugenol 
determined in the pesto sauces of the present study amounted to 3.6–99.3 μg/g pesto sauce, 
and of estragole, being present in only two out of the 32 pesto sauce samples analyzed, to 3.2 
and 34.1 μg/g pesto sauces. Based on these levels and taking the basil content (%) as 
indicated on the label of the pesto sauces into account, the level of methyleugenol in basil 
used to prepare the pesto sauce was estimated to vary between 22.4–310.3 μg/g. The 
determination of the levels of alkenylbenzenes in basil-containing sauce of pesto revealed that 
all the samples analyzed contained methyleugenol. In addition to methyleugenol, two of the 
samples contained estragole, while two other samples contained myristicin, and one sample 
contained both myristicin and apiol in addition to methyleugenol. Based on chemical analysis 
the EDI values could be determined assuming a body weight of 70 kg and intake of 10 g of 
basil (based on wet weight) per meal (Miele et al. 2001), provided by an amount of pesto 
sauce that could be calculated taking into account the basil content (%) in the pesto sauce as 
indicated on the label (Table 1). For samples containing only methyleugenol, the EDI values 
ranged from 3.2–44.3 μg/kg bw per day. These EDI values resulted in MOE values of 345–
4781. Since several alkenylbenzenes were found in four of the pesto samples, and these 
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alkenylbenzenes show high similarity in structure, target organ, type of adverse effects and 
mode of action through formation of a DNA reactive 1’-sulfoxymetabolite contributing to 
formation of liver tumors, for these four samples a combined exposure assessment and 
subsequent risk assessment were performed. EDI values based on individual compounds 
amounted to 1.2–34.0 μg/kg bw per day. These EDI values resulted in MOE values of 199–
3209 for the individual levels of estragole, myristicin and apiole, indicating that these 
alkenylbenzenes add to the possible health risks. Assuming equal potency of the 
alkenylbenzenes, combined EDI values obtained ranged from 14.3–43.5 μg/kg bw per day 
resulting in MOE values ranging from 351 to 1071. Estimation of the TEF values used in this 
study was based on in vitro and in vivo data. It is of interest to note that in an ideal situation 
TEF values would be derived from in vivo data. However in practice in vitro endpoints are 
also frequently used, for example in the case of TEF values derived for dioxins (Van den Berg 
et al. 2006 ) and, more recently, in the case of interim TEF values defined for pyrrolizidine 
alkaloids (Merz and Schrenk 2016). Using a TEF concept combined EDI values ranged from 
17.5–59.7 μg methyleugenol equivalents/kg bw leading to MOE values ranging from 243 to 
883. MOE values resulting from this combined exposure assessment were 1.5–5-fold lower 
than the MOE values obtained when considering the presence of only methyleugenol in these 
four samples, and are all below 10000. Combined risk assessment based on equal potency did 
not vary much from results obtained using the TEQ approach. This can be ascribed to the 
minor variation in potencies of the different alkenylbenzenes detected in the pesto samples. 
It is of interest to note that these MOE values refer to regular daily consumption of pesto 
which may be an overestimation of realistic human consumption. Levels of methyleugenol in 
pesto sauce samples and consumption frequency of pesto sauce directly impact the EDI and 
the resulting MOE values. The levels of methyleugenol detected in the pesto sauces of the 
present study vary between 99.3 and 3.6 μg/g and would allow consumption of 1.1–29.8, 7.5–
 
 
208, 15.1–416.5, and 32.4–892.5 g of pesto sauce on a daily basis, once a week, once every 
two weeks, and once a month, respectively, to achieve MOE values above the 10000 safety 
limit for low priority for risk management. It is concluded that consumption of pesto sauces 
would only be of concern if consumed on a daily basis over longer periods of time. The 
results of the present paper reveal that pesto consumption does not always represent a cancer 
risk and provide insight into when this might be the case and under which level and frequency 
of consumption pesto consumption would not raise a concern. 
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subsequent risk assessment were performed. EDI values based on individual compounds 
amounted to 1.2–34.0 μg/kg bw per day. These EDI values resulted in MOE values of 199–
3209 for the individual levels of estragole, myristicin and apiole, indicating that these 
alkenylbenzenes add to the possible health risks. Assuming equal potency of the 
alkenylbenzenes, combined EDI values obtained ranged from 14.3–43.5 μg/kg bw per day 
resulting in MOE values ranging from 351 to 1071. Estimation of the TEF values used in this 
study was based on in vitro and in vivo data. It is of interest to note that in an ideal situation 
TEF values would be derived from in vivo data. However in practice in vitro endpoints are 
also frequently used, for example in the case of TEF values derived for dioxins (Van den Berg 
et al. 2006 ) and, more recently, in the case of interim TEF values defined for pyrrolizidine 
alkaloids (Merz and Schrenk 2016). Using a TEF concept combined EDI values ranged from 
17.5–59.7 μg methyleugenol equivalents/kg bw leading to MOE values ranging from 243 to 
883. MOE values resulting from this combined exposure assessment were 1.5–5-fold lower 
than the MOE values obtained when considering the presence of only methyleugenol in these 
four samples, and are all below 10000. Combined risk assessment based on equal potency did 
not vary much from results obtained using the TEQ approach. This can be ascribed to the 
minor variation in potencies of the different alkenylbenzenes detected in the pesto samples. 
It is of interest to note that these MOE values refer to regular daily consumption of pesto 
which may be an overestimation of realistic human consumption. Levels of methyleugenol in 
pesto sauce samples and consumption frequency of pesto sauce directly impact the EDI and 
the resulting MOE values. The levels of methyleugenol detected in the pesto sauces of the 
present study vary between 99.3 and 3.6 μg/g and would allow consumption of 1.1–29.8, 7.5–
 
 
208, 15.1–416.5, and 32.4–892.5 g of pesto sauce on a daily basis, once a week, once every 
two weeks, and once a month, respectively, to achieve MOE values above the 10000 safety 
limit for low priority for risk management. It is concluded that consumption of pesto sauces 
would only be of concern if consumed on a daily basis over longer periods of time. The 
results of the present paper reveal that pesto consumption does not always represent a cancer 
risk and provide insight into when this might be the case and under which level and frequency 
of consumption pesto consumption would not raise a concern. 
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ABSTRACT 
A risk assessment of nutmeg-based plant food supplements (PFS) containing different 
alkenylbenzenes was performed based on the alkenylbenzene levels quantified in a series of PFS 
collected via the online market. The estimated daily intake (EDI) of the alkenylbenzenes 
amounted to 0.3 to 312 μg kg-1 body weight (bw) for individual alkenylbenzenes, to 1.5 to 631 
μg kg-1 bw when adding up the alkenylbenzene levels assuming equal potency, and to 0.4 to 295 
μg kg-1 bw when expressed in safrole equivalents using toxic equivalency factors (TEFs). The 
margin of exposure approach (MOE) was used to evaluate the potential risks. Independent of the 
method used for the intake estimate, the MOE values obtained were generally lower than 10000 
indicating a priority for risk management. When taking into account that PFS may be used for 
shorter periods of time and using Haber’s rule to correct for shorter than lifetime exposure it was 
shown that limiting exposure to only 1 or 2 weeks would result in MOE values that would be, 
with the presently determined levels of alkenylbenzenes and proposed uses of the PFS, of low 
priority for risk management (MOE > 10000). It is concluded that the results of the present paper 
reveal that nutmeg-based PFS consumption following recommendations for daily intake 
especially for longer periods of time raise a concern.  
 
 
Keywords: margin of exposure (MOE); plant food supplement (PFS); nutmeg-based PFS; 
alkenylbenzenes; combined risk assessment; toxic equivalency factors (TEFs) 
 
 
 
 
 
 
INTRODUCTION 
Plant food supplements (PFS) are concentrated sources of dietary ingredients derived from 
various plants and herbal extracts. PFS are usually marketed in the form of capsules or powder 
and are supposed to supplement the normal diet. Regional regulations, consumer awareness, 
product availability and acceptance all affect the market for herbal supplements. The global 
herbal supplement market witnessed fast growth over the last decade and is expected to reach 
US$112 billion by the end of the year 2020 (Strategyr, 2015), with Europe accounting for the 
largest share of the world market (Vargas-Murga et al., 2011). In the US, the supplement 
industry is approximately $36.7 billion (Bradley, 2015). Online marketing of PFS has been 
increasing, and the sale online is expected to be of growing interest (Vargas-Murga et al., 2011). 
The need for stricter control and safety testing of PFS products is becoming more vital to protect 
consumers against adverse health effects. Some PFS may consist (in part) of botanicals and/or 
botanical preparations that contain compounds that are of concern for human health. Previously, 
some general concerns related to the quality and safety of botanical preparations such as PFS 
were expressed by the European Food Safety Authority (EFSA), and a compendium listing 
botanicals known to contain naturally occurring substances of possible concern for human health 
when used in food and food supplements was published (EFSA, 2012a). Specific concerns were 
expressed over the presence of naturally occurring toxic compounds (EFSA, 2004). The group of 
alkenylbenzenes, for example, contains compounds such as estragole, methyleugenol, 
safrole, elemicin, myristicin and apiol (Figure 1), that are genotoxic and carcinogenic, and may 
be present in botanicals like basil, nutmeg, tarragon and fennel (SCF, 2001a, b, 2002; Rietjens 
et al., 2008). Nutmeg is derived from several species of trees in the genus Myristica, mostly from 
Myristica fragrans, and known to contain, in addition to methyleugenol and safrole, especially 
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ABSTRACT 
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another alkenylbenzene, namely myristicin (van den Berg et al., 2011; Britannica, 2016). In 
2001, The Scientific Committee on Food (SCF) concluded that the structural analogues, 
methyleugenol, estragole, and safrole are genotoxic and carcinogenic and indicated the need for 
a reduction in exposure and restrictions in the levels of use (SCF, 2001a, b, 2002). Rodent 
studies performed at high dose levels provided sufficient evidence of the hepatocarcinogenicity 
of methyleugenol, estragole and safrole, displaying similar characteristics regarding mode of 
action and tumor formation (Phillips et al., 1981; Miller et al., 1983; Randerath et al., 1984; 
Wiseman et al., 1985; NTP, 2000; Zhou et al., 2007; Kobets et al., 2016). EC Regulation 
1334/2008, which became effective in January 2011, prohibits the addition of methyleugenol, 
estragole and safrole to foods and restricts their concentration in certain compound food as 
consumed to which flavorings and/or food ingredients with flavoring properties have been added 
(European Commission, 2008). 
 
 
Figure 1. The structural formulas of the alkenylbenzenes estragole, methyleugenol, elemicin, 
safrole, myristicin and apiol 
 
 
 
A major issue in the assessment of the potential risks of human exposure to these genotoxic and 
carcinogenic compounds via the use of alkenylbenzene-containing PFS is how to perform this 
assessment (EFSA, 2005). For compounds that are both genotoxic and carcinogenic, the EFSA 
recommended the Margin of Exposure (MOE) approach to evaluate the priority for risk 
management actions (EFSA, 2005, 2009a). The MOE compares the exposure levels causing 
malignant tumors in experimental animals with dietary intake estimates (EDI) in humans, 
considering differences in consumption patterns. To obtain the MOE, EFSA recommends the use 
of the BMDL10 (the lower confidence limit of the benchmark dose resulting in 10% extra cancer 
incidence) (EFSA, 2009b). The BMDL10 is a standardized reference point derived, by 
mathematical modelling, from the animal data within the observed range of experimental data 
(EFSA, 2009a). Using the MOE approach, van den Berg et al. (2011) revealed that 25 out of 28 
PFS samples containing botanicals including basil, fennel, sassafras, nutmeg, cinnamon, and 
calamus had alkenylbenzenes at levels that would result in estimated daily intakes that would 
give rise to MOE values below 10000, indicating a priority for risk management. The aim of the 
present study was to make a more detailed and extended analysis of the presence of different 
alkenylbenzenes in nutmeg-based PFS and perform an associated risk assessment based on the 
MOE approach, taking into consideration the possible combined exposure to different 
alkenylbenzenes. To this end, the level of alkenylbenzenes in various nutmeg-containing PFS 
was quantified providing the basis for the risk assessment. In this risk assessment, combined 
exposure to different alkenylbenzenes was also taken into account. For this group of botanical 
ingredients combined exposure can be evaluated by dose addition, which is considered 
appropriate for mixtures with components acting by a similar mode of action, at a similar target 
organ, i.e. causing liver carcinogenicity (EPA, 1986a, 1988, 2000). This implies that the response 
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to the mixture can be predicted by summing the doses of the components, if needed, after 
adjusting for the differences in potencies using toxic equivalency factors (TEFs) (ATSDR, 
2004). 
 
MATERIALS AND METHODS 
Nutmeg-based PFS samples and chemicals 
Nutmeg-based PFS samples were purchased online. Table 1 presents an overview of the 
collected samples and their major characteristics as indicated on the label of each product. 
Methyleugenol, myristicin, and safrole (purity, > 97%), methanol (HPLC grade) and acetonitrile 
(LC/MS grade) were supplied by Sigma-Aldrich (Zwijndrecht, Netherland). Elemicin was 
obtained from Synchem OHG (Felsberg, Germany). Nano pure water was obtained from a 
Barnstead Nanopure Type I ultrapure water system. Dimethyl sulfoxide (DMSO) was obtained 
from Acros Organics (Geel, Belgium). Acetonitrile (ACN) (LC/MS grade) was purchased from 
Biosolve BV (Valkenswaard, The Netherlands). Trifluoroacetic acid (TFA) was obtained from 
Merck (Darmstadt, Germany).  
 
Methanol extracts  
All nutmeg-based PFS samples were extracted using methanol based on the method described by 
Gursale et al. (2010) with minor modifications. In short, 0.5 g of each PFS sample was sonicated 
in an ultrasonic bath for 10 min followed by maceration for 12-hr at 50°C with 80 ml of 
methanol in a closed glass vessel. Finally, an aliquot of the extract solution was centrifuged at 
13000×g for 5min, and stored at 20°C until Ultra Performance Liquid Chromatography (UPLC) 
analysis. Samples were extracted and analysed on UPLC in three independent experiments. The 
 
 
accuracy of the developed method was assessed using a recovery study and standard deviations 
of the replicates. For recovery studies, pure standards of commercially available alkenylbenzenes 
were added in two different quantities (final concentration of 5 and 10 μM) to 0.5 g of two PFS 
samples (sample 5 and 8) which covers the whole range of analyses. Samples were prepared and 
analyzed as described above to quantify the alkenylbenzene levels enabling determination of the 
recovery. The extraction capacity linearity was demonstrated by analysing a range of weight of 
the sample to a final volume of the solution ratio of 0.3 % up to 1 % (w/v). 
 
UPLC analysis 
For the determination of the alkenylbenzene level in the extracts, 3.5 μl of each sample was 
subjected to UPLC analysis. The UPLC system consisted of a Waters (Milford, MA, USA) 
Acquity solvent manager, sample manager and photodiode array detector. Chromatographic 
conditions for compound separation were achieved using an ACQUITY UPLC BEH C18 
1.7 μm column, 2.1 × 50 mm. The column oven was set at 35°C and the sample compartment 
was set at 10°C. An isocratic gradient was maintained for the separation using a mixture of 
acetonitrile (ACN) and ultrapure water containing 0.1 % (v/v) trifluoroacetic acid (TFA). The 
mobile phase consisted of 40 % acetonitrile for 4min, which was the time needed to separate the 
alkenylbenzenes of interest.  During the whole run, the flow rate was 0.6 ml min-1. Under these 
conditions, the retention times for elemicin, methyleugenol, safrole, and myristicin were 1.4, 2.1, 
2.2 and 2.4 min, respectively. Identification of the alkenylbenzenes was achieved by comparing 
the UV spectrum and retention time of the peak to the UV spectrum and the peak retention time 
of commercially available reference compounds. Quantification was done by comparison of the 
area of the alkenylbenzene peak to that of the calibration curve of the reference compound  
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Table 1. Nutmeg-based PFS samples used in the present study and their major characteristics. 
Information provided was derived from the product labels unless stated otherwise 
PFS sample Description Ingredients Recommendation for daily intake 
1 
Ayurvedic nutmeg herbal 
supplement "complementary 
or alternative medicine" 
Nutmeg powder (Myristica fragrans). Capsule 
content: 330 mg  2 capsules  (660 mg) 
2 Dietary  supplement Nutmeg powder (Myristica fragrans). Capsule content: 750 mg 1-5 capsules (3750 mg) 
3 Dietary supplement Nutmeg powder (Myristica fragrans). Capsule content: 600 mg 
 2 capsules, (1200 mg) with water 
at meal time 
4 
Nutmeg herbal supplement 
"complementary or alternative 
medicine" 
Nutmeg powder (Myristica fragrans). Capsule 
content: 360 mg 1-3 capsules (360 mg) 
5 
100% pure nutmeg 
Therapeutic grade essential oil 
supplement 
Essential oil of nutmeg. Every drop is around 
72 mg 
Dilute 1 drop with 1 drop of V-6™ 
or olive oil. Put in a capsule and 
takes up to three times daily or as 
needed (216 mg) 
6 
Ayurvedic invigorates male 
sexual vitality herbal 
supplement 
Blend of cinnamon camphora, nutmeg 
(Myristica fragrans), hygrophila auriculata, 
tribulus terrestris, withania somnifera, asparagus 
recemosus, cardamom, dioscorea sativa, shilajit, 
processed silica. Capsule content: 350 mg 
4 capsules, 15-30 minutes after 
meals, daily over a period of at 
least 2-3 months (1400 mg) 
7 
Weight loss formula and clean 
sensory experience, dietry 
supplement. 
Super xtreme supergenic complex of: green 
coffee bean extract (52.6%), caffeine anhydrous 
(17.8%), nutmeg seed extract (Myristica 
fragrans) (13.2%), sage leaf powder (salvia 
officinalis) (6.5%), alpha lipoic acid (3.3%), 
cocoa seed extract (theobroma cacao) (3.3%), 
green tea leaf and shoot extract (camellia 
sinensis) (3.3%). Capsule content: 760 mg 
3 capsules (2280 mg) 
8 Nutmeg herbal supplement Nutmeg powder (Myristica fragrans). Capsule content: 100 mg 6 capsules (600 mg) 
9 Nutmeg herbal supplement Nutmeg powder (Myristica fragrans). Capsule content: 900 mg 2 capsules (1800 mg) 
10 Organic nutmeg herbal supplement seed capsules 
Nutmeg powder (Myristica fragrans). Capsule 
content: 465 mg 2 capsules (930 mg) 
11 
Herbal supplement, Vigor care 
for woman, for female libido 
support, help maintain normal 
sexual desire 
Mix of: ashwagandha (root), nutmeg (aril), 
lodh tree (bark), cyperus (tuber), spanish 
pellitory (root), ginger (rhizome). Capsule 
content: 820 mg 
2 capsules (1640 mg) 
12 Organic nutmeg seed capsules, herbal dietry supplement 
Organic nutmeg seed, pure herb (Myristica 
fragrans). Capsule content: 470 mg 1-2 capsules, 2-3 times (940 mg) 
13 Nutmeg herbal supplement Nutmeg powder (Myristica fragrans). Capsule content: 400mg 1-2 capsules (400 mg) 
 
 
determined using UPLC with photodiode array detection (UPLC/PDA) at a wavelength 201nm 
for elemicin and methyleugenol, and a wavelength 210 nm for myristicin and safrole. 
 
Determination of EDI of alkenylbenzenes resulting from the use of nutmeg-based PFS 
The EDI of alkenylbenzenes resulting from the use of the nutmeg based PFS was determined 
based on the alkenylbenzene content as determined in the present study (see Results) and a body 
weight of 70 kg, the default value for adult body weight proposed by EFSA (EFSA, 2012b). 
Daily consumption of nutmeg-based PFS was also based on the recommendation for daily intake 
provided by the manufacturer and the amount of the material stated on the label to be present 
in each capsule or drop (Table 1). First, the EDI was calculated for individual compounds for all 
the samples. As several samples were found to contain more than one alkenylbenzene, and the 
different alkenylbenzenes show similarity in structure, target organ, type of adverse effects and 
mode of action through formation of a DNA reactive 1’-sulfoxymetabolite contributing to 
formation of liver tumors, a combined exposure assessment and subsequent risk assessment were 
also performed for those samples. To this end two approaches were used; summing up the EDIs 
of the alkenylbenzenes assuming equal potency, and a so-called toxic equivalency (TEQ) 
approach calculating the EDI values of the alkenylbenzenes using their TEF relative to safrole 
(Alajlouni et al., 2016b). In this study, safrole was taken as the reference compound (TEF = 1.0), 
enabling expression of the overall alkenylbenzene concentration and EDI in safrole equivalents. 
TEF values for the different alkenylbenzenes for the TEQ approach need to be defined, which 
was done by calculating an average of three endpoints. The first one was the slope of the dose– 
response curve for DNA-adduct formation in female CD-1 mice liver upon exposure to different 
alkenylbenzenes (Randerath et al., 1984). The second one, was the in vivo level of formation of 
C
ha
pt
er
 5
Chapter 5 | Risk assessment of alkenylbenzenes in nutmeg-based plant food supplements
169
 
 
Table 1. Nutmeg-based PFS samples used in the present study and their major characteristics. 
Information provided was derived from the product labels unless stated otherwise 
PFS sample Description Ingredients Recommendation for daily intake 
1 
Ayurvedic nutmeg herbal 
supplement "complementary 
or alternative medicine" 
Nutmeg powder (Myristica fragrans). Capsule 
content: 330 mg  2 capsules  (660 mg) 
2 Dietary  supplement Nutmeg powder (Myristica fragrans). Capsule content: 750 mg 1-5 capsules (3750 mg) 
3 Dietary supplement Nutmeg powder (Myristica fragrans). Capsule content: 600 mg 
 2 capsules, (1200 mg) with water 
at meal time 
4 
Nutmeg herbal supplement 
"complementary or alternative 
medicine" 
Nutmeg powder (Myristica fragrans). Capsule 
content: 360 mg 1-3 capsules (360 mg) 
5 
100% pure nutmeg 
Therapeutic grade essential oil 
supplement 
Essential oil of nutmeg. Every drop is around 
72 mg 
Dilute 1 drop with 1 drop of V-6™ 
or olive oil. Put in a capsule and 
takes up to three times daily or as 
needed (216 mg) 
6 
Ayurvedic invigorates male 
sexual vitality herbal 
supplement 
Blend of cinnamon camphora, nutmeg 
(Myristica fragrans), hygrophila auriculata, 
tribulus terrestris, withania somnifera, asparagus 
recemosus, cardamom, dioscorea sativa, shilajit, 
processed silica. Capsule content: 350 mg 
4 capsules, 15-30 minutes after 
meals, daily over a period of at 
least 2-3 months (1400 mg) 
7 
Weight loss formula and clean 
sensory experience, dietry 
supplement. 
Super xtreme supergenic complex of: green 
coffee bean extract (52.6%), caffeine anhydrous 
(17.8%), nutmeg seed extract (Myristica 
fragrans) (13.2%), sage leaf powder (salvia 
officinalis) (6.5%), alpha lipoic acid (3.3%), 
cocoa seed extract (theobroma cacao) (3.3%), 
green tea leaf and shoot extract (camellia 
sinensis) (3.3%). Capsule content: 760 mg 
3 capsules (2280 mg) 
8 Nutmeg herbal supplement Nutmeg powder (Myristica fragrans). Capsule content: 100 mg 6 capsules (600 mg) 
9 Nutmeg herbal supplement Nutmeg powder (Myristica fragrans). Capsule content: 900 mg 2 capsules (1800 mg) 
10 Organic nutmeg herbal supplement seed capsules 
Nutmeg powder (Myristica fragrans). Capsule 
content: 465 mg 2 capsules (930 mg) 
11 
Herbal supplement, Vigor care 
for woman, for female libido 
support, help maintain normal 
sexual desire 
Mix of: ashwagandha (root), nutmeg (aril), 
lodh tree (bark), cyperus (tuber), spanish 
pellitory (root), ginger (rhizome). Capsule 
content: 820 mg 
2 capsules (1640 mg) 
12 Organic nutmeg seed capsules, herbal dietry supplement 
Organic nutmeg seed, pure herb (Myristica 
fragrans). Capsule content: 470 mg 1-2 capsules, 2-3 times (940 mg) 
13 Nutmeg herbal supplement Nutmeg powder (Myristica fragrans). Capsule content: 400mg 1-2 capsules (400 mg) 
 
 
determined using UPLC with photodiode array detection (UPLC/PDA) at a wavelength 201nm 
for elemicin and methyleugenol, and a wavelength 210 nm for myristicin and safrole. 
 
Determination of EDI of alkenylbenzenes resulting from the use of nutmeg-based PFS 
The EDI of alkenylbenzenes resulting from the use of the nutmeg based PFS was determined 
based on the alkenylbenzene content as determined in the present study (see Results) and a body 
weight of 70 kg, the default value for adult body weight proposed by EFSA (EFSA, 2012b). 
Daily consumption of nutmeg-based PFS was also based on the recommendation for daily intake 
provided by the manufacturer and the amount of the material stated on the label to be present 
in each capsule or drop (Table 1). First, the EDI was calculated for individual compounds for all 
the samples. As several samples were found to contain more than one alkenylbenzene, and the 
different alkenylbenzenes show similarity in structure, target organ, type of adverse effects and 
mode of action through formation of a DNA reactive 1’-sulfoxymetabolite contributing to 
formation of liver tumors, a combined exposure assessment and subsequent risk assessment were 
also performed for those samples. To this end two approaches were used; summing up the EDIs 
of the alkenylbenzenes assuming equal potency, and a so-called toxic equivalency (TEQ) 
approach calculating the EDI values of the alkenylbenzenes using their TEF relative to safrole 
(Alajlouni et al., 2016b). In this study, safrole was taken as the reference compound (TEF = 1.0), 
enabling expression of the overall alkenylbenzene concentration and EDI in safrole equivalents. 
TEF values for the different alkenylbenzenes for the TEQ approach need to be defined, which 
was done by calculating an average of three endpoints. The first one was the slope of the dose– 
response curve for DNA-adduct formation in female CD-1 mice liver upon exposure to different 
alkenylbenzenes (Randerath et al., 1984). The second one, was the in vivo level of formation of 
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the hepatocarcinogenic 1’-sulfoxymetabolite of the different alkenylbenzenes predicted using 
human physiologically based kinetic (PBK) models at a dose level of 0.01mg kg-1 bw (Punt 
et al., 2009; Al-Subeihi et al., 2012;Martati et al., 2012; van den Berg et al., 2012; Alajlouni et 
al., 2016a; Al-Malahmeh et al., 2017). A third value was defined based on the BMDL10 values 
derived from in vivo tumor data for safrole, estragole and methyleugenol (Miller et al., 1983), 
and by read-across from safrole for myristicin and apiol (Alajlouni et al., 2016a; Al-Malahmeh et 
al., 2017), or by read-across from methyleugenol and estragole for elemicin (van den Berg et al., 
2012). The TEF values for the different alkenylbenzenes defined by the three approaches relative 
to safrole were subsequently averaged to define the final TEF values (Alajlouni et al., 2016b). 
Using these TEF values, the EDI of alkenylbenzenes in the nutmeg-based PFS were expressed in 
μg safrole equivalents kg-1 bw per day.  
 
Calculation of the margin of exposure  
Risk assessment of consumption of the nutmeg-based PFS samples was performed using the 
MOE approach (EFSA, 2005). For the individual alkenylbenzene approach, the BMDL10 values 
of the individual compounds were used (van den Berg et al., 2012; Alajlouni et al., 2016a; Al-
Malahmeh et al., 2017), and then compared with the EDIs of the alkenylbenzenes resulting from 
the use of nutmeg-based PFS. For the equal potency assumption approach, the BMDL10 value of 
myristicin, the major alkenylbenzene in most of the samples, was used and compared to the sum 
of the EDIs. And finally, for the TEQ approach, the BMDL10 of the reference compound safrole 
was compared to the EDI expressed in safrole equivalents. 
 
 
 
 
RESULTS 
Table 2 presents the level of the different alkenylbenzenes found in the PFS samples. In eight 
PFS samples, four different alkenylbenzenes were detected including elemicin, methyleugenol, 
myristicin and safrole. In PFS 6, elemicin and myristicin were detected. Elemicin, myristicin, 
and safrole were detected in PFS 10, and elemicin, methyleugenol, and safrole in PFS 12. PFS 7 
and PFS 11 did not contain a detectable level of any of the alkenylbenzenes. Table 2 also 
presents the EDI of the individual alkenylbenzenes obtained for these samples when considering 
the recommended dose regimen. The values obtained varied from 0.3 to 312 μg kg-1 bw per day 
with myristicin being the major alkenylbenzene. Figure 2 presents the relative contribution of the 
different alkenylbenzenes to the total alkenylbenzene content of the different PFS and shows that 
myristicin makes up 18.5 to 85.1 % of the sum of all alkenylbenzenes, followed by elemicin 
making up 3.7 to 81.5%, then safrole making up 8.8 to 25.1%, and finally methyleugenol being 
the minor alkenylbenzene making up 2.4 to 21.0%. As several alkenylbenzenes were found in 
the samples, and because these alkenylbenzenes are known to display similarity in structure, 
target organ, type of adverse effects and mode of action through the formation of a DNA reactive 
10-sulfoxymetabolite contributing to the formation of liver tumors, a combined exposure and 
risk assessment were also performed. To this end, the combined exposure was estimated in two 
ways, assuming either equal potency or using a so-called TEQ approach. When assuming equal 
potency of the different alkenylbenzenes the combined EDI can be calculated by adding up the 
EDIs of the different alkenylbenzenes. In a second approach, the combined exposure was 
calculated in safrole equivalents taking the relative potency of the different alkenylbenzenes into 
account. Using the equal potency approach, the combined EDI values obtained vary in the range 
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the hepatocarcinogenic 1’-sulfoxymetabolite of the different alkenylbenzenes predicted using 
human physiologically based kinetic (PBK) models at a dose level of 0.01mg kg-1 bw (Punt 
et al., 2009; Al-Subeihi et al., 2012;Martati et al., 2012; van den Berg et al., 2012; Alajlouni et 
al., 2016a; Al-Malahmeh et al., 2017). A third value was defined based on the BMDL10 values 
derived from in vivo tumor data for safrole, estragole and methyleugenol (Miller et al., 1983), 
and by read-across from safrole for myristicin and apiol (Alajlouni et al., 2016a; Al-Malahmeh et 
al., 2017), or by read-across from methyleugenol and estragole for elemicin (van den Berg et al., 
2012). The TEF values for the different alkenylbenzenes defined by the three approaches relative 
to safrole were subsequently averaged to define the final TEF values (Alajlouni et al., 2016b). 
Using these TEF values, the EDI of alkenylbenzenes in the nutmeg-based PFS were expressed in 
μg safrole equivalents kg-1 bw per day.  
 
Calculation of the margin of exposure  
Risk assessment of consumption of the nutmeg-based PFS samples was performed using the 
MOE approach (EFSA, 2005). For the individual alkenylbenzene approach, the BMDL10 values 
of the individual compounds were used (van den Berg et al., 2012; Alajlouni et al., 2016a; Al-
Malahmeh et al., 2017), and then compared with the EDIs of the alkenylbenzenes resulting from 
the use of nutmeg-based PFS. For the equal potency assumption approach, the BMDL10 value of 
myristicin, the major alkenylbenzene in most of the samples, was used and compared to the sum 
of the EDIs. And finally, for the TEQ approach, the BMDL10 of the reference compound safrole 
was compared to the EDI expressed in safrole equivalents. 
 
 
 
 
RESULTS 
Table 2 presents the level of the different alkenylbenzenes found in the PFS samples. In eight 
PFS samples, four different alkenylbenzenes were detected including elemicin, methyleugenol, 
myristicin and safrole. In PFS 6, elemicin and myristicin were detected. Elemicin, myristicin, 
and safrole were detected in PFS 10, and elemicin, methyleugenol, and safrole in PFS 12. PFS 7 
and PFS 11 did not contain a detectable level of any of the alkenylbenzenes. Table 2 also 
presents the EDI of the individual alkenylbenzenes obtained for these samples when considering 
the recommended dose regimen. The values obtained varied from 0.3 to 312 μg kg-1 bw per day 
with myristicin being the major alkenylbenzene. Figure 2 presents the relative contribution of the 
different alkenylbenzenes to the total alkenylbenzene content of the different PFS and shows that 
myristicin makes up 18.5 to 85.1 % of the sum of all alkenylbenzenes, followed by elemicin 
making up 3.7 to 81.5%, then safrole making up 8.8 to 25.1%, and finally methyleugenol being 
the minor alkenylbenzene making up 2.4 to 21.0%. As several alkenylbenzenes were found in 
the samples, and because these alkenylbenzenes are known to display similarity in structure, 
target organ, type of adverse effects and mode of action through the formation of a DNA reactive 
10-sulfoxymetabolite contributing to the formation of liver tumors, a combined exposure and 
risk assessment were also performed. To this end, the combined exposure was estimated in two 
ways, assuming either equal potency or using a so-called TEQ approach. When assuming equal 
potency of the different alkenylbenzenes the combined EDI can be calculated by adding up the 
EDIs of the different alkenylbenzenes. In a second approach, the combined exposure was 
calculated in safrole equivalents taking the relative potency of the different alkenylbenzenes into 
account. Using the equal potency approach, the combined EDI values obtained vary in the range 
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of 1.5 to 631 μg kg-1 bw per day. Using TEF values and the TEQ the combined EDI values 
obtained vary in the range of 0.4 to 295 μg safrole equivalents kg-1 bw per day (Table 3).  
Using the EDI values thus obtained MOE values were calculated. To this end, different BMDL10 
values were used for different approaches to obtain the MOE values. The BMDL10 values for the 
individual alkenylbenzenes were taken from literature (van den Berg et al., 2012; Alajlouni et al., 
2016a; Al-Malahmeh et al., 2017) and were used to calculate MOE values for intakes of each 
alkenylbenzene (Table 4). MOE values thus obtained were all below 10000 except for elemicin 
in samples 4 and 6, with MOE values amounting to 10729 and 25877, respectively. Assuming 
equal potency, the BMDL10 of myristicin of 1.9 mg kg-1 bw per day (Al-Malahmeh et al., 2017), 
was compared with the combined EDI, because in most cases myristicin was the major 
alkenylbenzene detected in the samples. The MOE values thus obtained vary between 3 and 
1309 (Table 4). For the TEQ approach, the BMDL10 of safrole of 1.9mg kg-1 bw per day (van 
den Berg et al., 2012) was compared with the EDI expressed in safrole equivalents to calculate 
the MOE. When using the TEQ approach, MOE values ranged from 6 to 5020 (Table 4). 
Comparison of the MOE values obtained when using the combined exposure reveals that the 
values tend to increase when using the TEF concept. This is because the TEF for myristicin, the 
major alkenylbenzene detected in the samples, is lower than 1.0 resulting in lower EDI and 
higher MOE values. In spite of these differences, the priority for risk management for the PFS 
does not vary because the MOE remains below 10000 (in most cases even below 1000). From 
the data thus obtained it is clear that the EDI resulting from the daily use of the nutmeg-based 
PFS would generally result in MOE values that indicate a priority for risk management, 
independent of the way in which the EDI and the MOE were calculated. 
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of 1.5 to 631 μg kg-1 bw per day. Using TEF values and the TEQ the combined EDI values 
obtained vary in the range of 0.4 to 295 μg safrole equivalents kg-1 bw per day (Table 3).  
Using the EDI values thus obtained MOE values were calculated. To this end, different BMDL10 
values were used for different approaches to obtain the MOE values. The BMDL10 values for the 
individual alkenylbenzenes were taken from literature (van den Berg et al., 2012; Alajlouni et al., 
2016a; Al-Malahmeh et al., 2017) and were used to calculate MOE values for intakes of each 
alkenylbenzene (Table 4). MOE values thus obtained were all below 10000 except for elemicin 
in samples 4 and 6, with MOE values amounting to 10729 and 25877, respectively. Assuming 
equal potency, the BMDL10 of myristicin of 1.9 mg kg-1 bw per day (Al-Malahmeh et al., 2017), 
was compared with the combined EDI, because in most cases myristicin was the major 
alkenylbenzene detected in the samples. The MOE values thus obtained vary between 3 and 
1309 (Table 4). For the TEQ approach, the BMDL10 of safrole of 1.9mg kg-1 bw per day (van 
den Berg et al., 2012) was compared with the EDI expressed in safrole equivalents to calculate 
the MOE. When using the TEQ approach, MOE values ranged from 6 to 5020 (Table 4). 
Comparison of the MOE values obtained when using the combined exposure reveals that the 
values tend to increase when using the TEF concept. This is because the TEF for myristicin, the 
major alkenylbenzene detected in the samples, is lower than 1.0 resulting in lower EDI and 
higher MOE values. In spite of these differences, the priority for risk management for the PFS 
does not vary because the MOE remains below 10000 (in most cases even below 1000). From 
the data thus obtained it is clear that the EDI resulting from the daily use of the nutmeg-based 
PFS would generally result in MOE values that indicate a priority for risk management, 
independent of the way in which the EDI and the MOE were calculated. 
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Figure 2. Level of the different alkenylbenzenes in the nutmeg-based plant food supplements 
(PFS) samples expressed as percentage of the total amount of alkenylbenzenes. 
 
It is of importance; however, to consider that often use of PFS will not be for a lifetime but for 
shorter periods of time and how this may affect the risk assessment. There is no generally 
established method for taking a shorter than lifetime exposure into account, but one could 
consider using Haber’s rule. Assuming that Haber’s rule would apply, the toxic effect would 
vary linearly with the time of exposure and the concentration (i.e. C × T = k, where C is 
concentration or dose, T is time of exposure, and k is a constant toxic response for the specific 
substance) (Doull and Rozman, 2000). It is of interest to evaluate, using Haber’s rule, what level 
of alkenylbenzenes, what amount of nutmeg-based PFS consumed and/or what exposure 
frequency would result in an MOE of 10000 and be of low priority for risk management. To this 
end, Figure 3 shows the relation between the total recommended daily intake of nutmeg-based 
PFS and the total level of alkenylbenzene in nutmeg-based PFS samples that would result in 
 
 
MOE values of 10000 assuming equal potency but different periods of use, including life time 
(estimated life expectancy of 75 years) (Felter et al., 2011), 4, 2, or 1week in a life time. The 
results presented indicate that the daily recommended consumption range of samples that contain 
216 to 3750 mg nutmeg-based PFS, the range of recommended daily intake (Table 1) would be 
of low priority for risk management at a total alkenylbenzene level of 61.6 to 3.6 μg g-1 for life-
time exposure. Intake of the recommended daily consumption of the nutmeg-based PFS, for 
limited periods of time, for example, 4, 2 and 1week, would be of low priority for risk 
management when the PFS would contain total alkenylbenzene levels of 60032 to 3458, 120069 
to 6916, and 240139 to 13832 μg g-1, respectively.  
 
Table 3. Combined EDI values for PFS samples, tested positive for the presence of 
alkenylbenzenes, assuming equal potency and using a TEQ approach 
PFS sample 
EDI      
Equal potency a   (μg/kg bw day)  TEQ b (μg safrole equivalents/kg bw) 
1 58.8 39.3 
2 631 295 
3 19.1 12.3 
4 61.1 41.8 
5 367 246 
6 1.5 0.4 
8 86.0 49.9 
9 45.0 18.5 
10 250 112 
12 102 36.0 
13 76.6 46.0 
 
a Calculated using the formula;  
 
b Calculated using the formula;                                                                                                                        
i; different alkenylbenzene  
Average TEF values ±SD (Alajlouni et al. 2016b) 
Safrole  1.00 (the reference compound) 
Myristicin 0.66 ± 0.39 
Methyleugenol 0.67 ± 0.46 
Elemicin 0.17 ± 0.16 
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The curves can also be used to derive that for the nutmeg-based PFS of the present study with 
total alkenylbenzene levels that vary from 73 to 118878 μg g-1 nutmeg-based PFS, daily 
consumption for a lifetime should be limited to 182 to 0.1 mg of the nutmegbased PFS to be of 
low concern. For shorter periods of time for example 4, 2, and 1 week, the maximum allowance 
of consumption of the nutmeg-based PFS for the levels of alkenylbenzenes quantified in this 
study would be of low priority for risk management when the PFS would contain 177630 to 109, 
355274 to 218, and 710548 to 436 mg nutmeg-based material. This result also indicates that at 
the current levels of alkenylbenzenes in nutmeg-based PFS, their proposed uses would be of 
concern especially for people who use these PFS frequently during longer periods of time.  
 
Table 4. MOE values for PFS, tested positive for presence of alkenylbenzenes, based on EDI 
values for individual alkenylbenzenes, and on combined EDI values calculated assuming equal 
potency and using a TEQ approach 
PFS 
Sample 
MOE 
 Individual  Equal potency a TEQ b 
Elemicin Methyleugenol Myristicin Safrole 
1 6386 2604 48 225 32 48 
2 104 581 8 28 3 6 
3 7870 7425 228 396 100 154 
4 10729 4349 41 222 31 45 
5 2229 1764 6 59 5 8 
6 25877 NA 7072 NA 1309 5020 
8 1445 1239 45 186 22 38 
9 1169 7062 159 406 42 103 
10 239 NA 20 68 8 17 
12 401 2272 NA 103 19 53 
13 2050 952 51 238 25 41 
a Calculated using the BMDL10 of myristicin, the major alkenylbenzene in most of the samples 
b Calculated using the BMDL10 of safrole, (the reference compound) 
 
 
 
 
 
To further illustrate how short-term exposure would affect F4 the MOE values, Figure 4 presents 
a comparison between MOE values obtained for combined exposure during lifetime and 4weeks. 
Figure 5 shows the number of weeks of daily consumption of nutmeg-based PFS samples 
analysed in this study that would result in a MOE of 10000 indicating a low priority for risk 
management.  
 
Figure 3. Relation between the total alkenylbenzene content (μg g-1) in a nutmeg-based PFS and 
the recommended daily intake of the PFS (mg), that would result in an MOE of 10000 upon daily 
consumption for a lifetime (insert), 1 (▬ ●), 2 (▬ ▬), and 4 weeks (▬). The calculations assumed 
combined exposure and equal potency of the different alkenylbenzenes and uses the BMDL10 of 
myristicin, the major alkenylbenzene detected in most PFS. Combinations of total 
alkenylbenzene levels and nutmeg-based PFS intake that result in values below the respective 
curves result in MOE values above 10000 and would be of low priority for risk management. W; 
week.  
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Assuming both approaches, the equal potency and the TEQ, the longest time of daily combined 
exposure that would make the risk of low priority for risk management was for PFS 6 (the 
sample with the lowest EDI; 1.5 μg kg-1 bw day) and amounted to 511 and 1958 weeks, and the 
shortest time of daily combined exposure to make the risk of low priority was for PFS 2 (the 
sample with the highest EDI; 631 μg kg-1 bw day) amounting to 1 and 3 weeks, respectively. 
 
 
 
Figure 4. MOE values for the  combined exposure assuming equal potency of the 
alkenylbenzenes and using the BMDL10 value of myristicin (black bars), and combined exposure 
using the TEQ approach based on safrole equivalents and using the BMDL10 value of safrole 
(grey bars), assuming life time intake (A), and 4 weeks intake (B). The black horizontal line in 
Figure B presents the MOE of 10000. Note the difference in the Y axis of Figure A and B. The 
values for PFS 6 are presented in the insert at the right top of the graph. 
 
 
 
Figure 5. The number of weeks needed that would result in an MOE of 10000 upon daily 
consumption of nutmeg-based PFS samples analysed in the present study. The calculations 
assumed combined exposure and equal potency of the different alkenylbenzenes using the 
BMDL10 of myristicin, the major alkenylbenzene detected in most PFS (black bars), and 
combined exposure using the TEQ approach based on safrole equivalents and using the BMDL10 
value of safrole (grey bars), also taking into account the total alkenylbenzene content (μg g-1) of 
the nutmeg-based PFS obtained in the present study and the recommended daily intake of the 
PFS (mg) for the analysed samples. The values for PFS 6 are presented in the insert at the right 
top of the graph. 
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Assuming both approaches, the equal potency and the TEQ, the longest time of daily combined 
exposure that would make the risk of low priority for risk management was for PFS 6 (the 
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PFS (mg) for the analysed samples. The values for PFS 6 are presented in the insert at the right 
top of the graph. 
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DISCUSSION 
The aim of the present study was to make a more detailed and extended analysis of the presence 
of different alkenylbenzenes in nutmeg-based PFS and perform an associated risk assessment 
based on the MOE approach, taking into consideration the possible combined exposure to 
different alkenylbenzenes. Given that the different alkenylbenzenes act by a similar mode of 
action, at a similar target organ causing liver carcinogenicity (EPA, 1986a, 1988, 2000), 
combined exposure can be evaluated by dose addition; predicting the response to the mixture by 
adding up the doses of the components considering equal potency, and/or after adjusting for the 
differences in potencies, using the TEQ approach (ATSDR, 2004). PFS samples analyzed were 
made of nutmeg powder alone or from nutmeg combined with material from other botanicals 
(Table 1). Nutmeg is obtained from the nutmeg tree, Myristica frangans Houtt (Myristicaceae). 
The nutmeg seeds contain 5–15 % essential volatile oil and 24–40 % nutmeg butter (Forrest and 
Heacock, 1972). The relative percentages of the different components and the alkenylbenzenes 
vary depending on the geographical origin of the nutmeg and length of storage. The compounds 
that have been isolated and identified in the essential volatile oil were terpenes, monoterpene 
alcohol, a sesquiterpene, terpinic esters, acids, aromatic hydrocarbons, and our focus in this 
study; the aromatic ethers (myristicin, safrole, methyleugenol, and elemicin) (FAO, 1994). 
Levels of myristicin, elemicin, safrole, and  methyleugenol detected in the nutmeg-based PFS 
samples analysed in the present study varied from 13 to 101124, from 59 to 9655, from 279 to 
10494, and from 84 to 2813 μg g-1 nutmeg-based PFS, respectively, with levels of these 
alkenylbenzenes making up 26.5 to 85.1 %, 3.7 to 81.5 %, 8.8 to 25.1 %, 2.4 to 21.0 % of the 
total alkenylbenzene content (Figure 2), with myristicin often being the major one detected, 
followed by elemicin and safrole, and methyleugenol. Literature data indicate that myristicin, 
 
 
safrole and elemicin may account for 3.86 to 12.7 %, 0.53 to 3.42 % and 0.02 to 2.36 %, 
respectively of the nutmeg oil samples (IPCS, 1997). The wide variation in the alkenylbenzenes 
content of the different PFS may be caused by the variability  between the quality (differences in 
composition) and quantity of nutmeg oil present in the various plants, depending on plant 
species, culture conditions, harvesting conditions and processing methods (Smith et al., 2002). 
Based on the alkenylbenzenes contents detected in the present study and the use levels of the 
respective PFS recommended on the labels, EDI values calculated for individual 
alkenylbenzenes ranged from 0.3 to 312 μg kg-1 bw per day. Using the respective BMDL10 
values these EDI values resulted in MOE values mostly below 10000 ranging from 6 to 7870, 
except for sample 4 and 6 for which the MOE value for elemicin of 10729 and 25877, 
respectively, exceeded the 10000 safety limit. A combined exposure assessment and subsequent 
risk assessment were performed for those PFS in which more than one alkenylbenzene was 
detected. Assuming equal potency of the alkenylbenzenes, combined EDI values obtained ranged 
from 1.5 to 631 μg kg-1 bw per day resulting in MOE values ranging from 3 to 1309 for the 
samples in which more than one alkenylbenzenes was detected. Using a TEQ concept with TEF 
values based on in vitro and in vivo data (Miller et al., 1983; Randerath et al., 1984; Punt et al., 
2009; Al-Subeihi et al., 2012; Martati et al., 2012; van den Berg et al., 2012; Alajlouni et al., 
2016a; Al-Malahmeh et al., 2017), combined EDI values ranged from 0.4 to 295 μg safrole 
equivalents kg-1 bw leading to MOE values ranging from 6 to 5020. MOE values resulting from 
both these combined exposure assessments were up to 5-fold lower than the MOE values 
obtained when considering individual exposure to alkenylbenzenes. The MOE values obtained 
for the combined risk assessment based on the TEQ concept were higher than the ones obtained 
when assuming equal potency. This can be ascribed to the fact that the TEF values of the 
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DISCUSSION 
The aim of the present study was to make a more detailed and extended analysis of the presence 
of different alkenylbenzenes in nutmeg-based PFS and perform an associated risk assessment 
based on the MOE approach, taking into consideration the possible combined exposure to 
different alkenylbenzenes. Given that the different alkenylbenzenes act by a similar mode of 
action, at a similar target organ causing liver carcinogenicity (EPA, 1986a, 1988, 2000), 
combined exposure can be evaluated by dose addition; predicting the response to the mixture by 
adding up the doses of the components considering equal potency, and/or after adjusting for the 
differences in potencies, using the TEQ approach (ATSDR, 2004). PFS samples analyzed were 
made of nutmeg powder alone or from nutmeg combined with material from other botanicals 
(Table 1). Nutmeg is obtained from the nutmeg tree, Myristica frangans Houtt (Myristicaceae). 
The nutmeg seeds contain 5–15 % essential volatile oil and 24–40 % nutmeg butter (Forrest and 
Heacock, 1972). The relative percentages of the different components and the alkenylbenzenes 
vary depending on the geographical origin of the nutmeg and length of storage. The compounds 
that have been isolated and identified in the essential volatile oil were terpenes, monoterpene 
alcohol, a sesquiterpene, terpinic esters, acids, aromatic hydrocarbons, and our focus in this 
study; the aromatic ethers (myristicin, safrole, methyleugenol, and elemicin) (FAO, 1994). 
Levels of myristicin, elemicin, safrole, and  methyleugenol detected in the nutmeg-based PFS 
samples analysed in the present study varied from 13 to 101124, from 59 to 9655, from 279 to 
10494, and from 84 to 2813 μg g-1 nutmeg-based PFS, respectively, with levels of these 
alkenylbenzenes making up 26.5 to 85.1 %, 3.7 to 81.5 %, 8.8 to 25.1 %, 2.4 to 21.0 % of the 
total alkenylbenzene content (Figure 2), with myristicin often being the major one detected, 
followed by elemicin and safrole, and methyleugenol. Literature data indicate that myristicin, 
 
 
safrole and elemicin may account for 3.86 to 12.7 %, 0.53 to 3.42 % and 0.02 to 2.36 %, 
respectively of the nutmeg oil samples (IPCS, 1997). The wide variation in the alkenylbenzenes 
content of the different PFS may be caused by the variability  between the quality (differences in 
composition) and quantity of nutmeg oil present in the various plants, depending on plant 
species, culture conditions, harvesting conditions and processing methods (Smith et al., 2002). 
Based on the alkenylbenzenes contents detected in the present study and the use levels of the 
respective PFS recommended on the labels, EDI values calculated for individual 
alkenylbenzenes ranged from 0.3 to 312 μg kg-1 bw per day. Using the respective BMDL10 
values these EDI values resulted in MOE values mostly below 10000 ranging from 6 to 7870, 
except for sample 4 and 6 for which the MOE value for elemicin of 10729 and 25877, 
respectively, exceeded the 10000 safety limit. A combined exposure assessment and subsequent 
risk assessment were performed for those PFS in which more than one alkenylbenzene was 
detected. Assuming equal potency of the alkenylbenzenes, combined EDI values obtained ranged 
from 1.5 to 631 μg kg-1 bw per day resulting in MOE values ranging from 3 to 1309 for the 
samples in which more than one alkenylbenzenes was detected. Using a TEQ concept with TEF 
values based on in vitro and in vivo data (Miller et al., 1983; Randerath et al., 1984; Punt et al., 
2009; Al-Subeihi et al., 2012; Martati et al., 2012; van den Berg et al., 2012; Alajlouni et al., 
2016a; Al-Malahmeh et al., 2017), combined EDI values ranged from 0.4 to 295 μg safrole 
equivalents kg-1 bw leading to MOE values ranging from 6 to 5020. MOE values resulting from 
both these combined exposure assessments were up to 5-fold lower than the MOE values 
obtained when considering individual exposure to alkenylbenzenes. The MOE values obtained 
for the combined risk assessment based on the TEQ concept were higher than the ones obtained 
when assuming equal potency. This can be ascribed to the fact that the TEF values of the 
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alkenylbenzenes present in the PFS, including myristicin, elemicin, and methyleugenol, are 
lower than that of safrole leading to lower EDI values when expressed in safrole equivalents and 
higher MOE values. 
It is of interest to note that these MOE values refer to regular daily consumption of nutmeg-based 
PFS during a whole lifetime which may be an overestimation of realistic human consumption. 
Levels of alkenylbenzenes in nutmeg-based PFS samples and consumption frequency directly 
impact the EDI and the resulting MOE values. Using Haber’s rule to correct for shorter than 
lifetime exposure it was also shown that limiting exposure to only one or two weeks could result 
in MOE values that would be, with the presently detected levels of alkenylbenzenes and 
proposed uses of the PFS, higher than 10000 and thus of low priority for risk management. 
Use of Haber’s Rule for products consumed for shorter periods of time may prevent 
overestimation of the actual risk to human health that may occur if MOE values are calculated 
assuming lifetime exposure. Applying Haber’s Rule, however, is not a generally accepted 
approach when using the MOE for risk assessment of exposure to genotoxic carcinogens. Felter 
et al. (2011) was the first to propose use of Haber’s Rule for assessing the risk from less-than 
lifetime exposure to carcinogens. It is important to acknowledge the assumptions underlying this 
methodology, which include the fact that chemical-specific carcinogenicity data should be 
available and that the data support a linear dose–response relationship (Felter et al., 2011). 
Whether such a linear dose–response relationship would apply to the dose-dependent induction 
of liver tumors by the alkenylbenzenes remains to be established and may depend on the mode of 
action underlying the carcinogenicity. This mode of action proceeds by cytochrome P450-
catalyzed hydroxylation to a 1’-hydroxymetabolite, followed by sulfotransferase (SULT)- 
 
 
mediated conversion to a 1’- sulfoxymetabolite (Phillips et al., 1981). This metabolite is unstable 
and reacts with DNA. Studies using PBK modelling revealed that the bioactivation of 
alkenylbenzenes to their ultimate carcinogenic 1’-sulfoxy metabolites is linear with the dose, 
from dose levels as low as levels of realistic human dietary intake up to dose levels as high 
as the BMD10 inducing liver tumors in rodent bioassays (Punt et al., 2009; Rietjens et al., 2010; 
Al-Subeihi et al., 2012; Martati et al., 2012). The mutagenic potential of alkenylbenzenes DNA 
adducts has not been extensively quantified so far. Herrmann et al. (2012) investigated the 
mutagenic potential of sulfate conjugates of 1’-hydroxymethyleugenol and showed that different 
isomeric hydroxylated metabolites of methyleugenol are mutagenic in an Ames test using 
Salmonella typhimurium TA100 strains expressing different sulfotransferase enzymes. This 
suggests that the formation of the 1’-sulfoxymetabolite and subsequently formed DNA adducts 
play an important role in the alkenylbenzene-induced carcinogenicity, and that knowledge of the 
levels of DNA adduct formation in human livers at relevant dietary intake levels would be of use 
to facilitate risk assessment for low-dose alkenylbenzenes intake. In this respect it is of interest 
to note that Herrmann et al. (2013) reported detection of  methyleugenol DNA adducts in liver 
samples obtained from human subjects. Methyleugenol DNA adducts in the livers of these 
human subjects likely results from dietary intakes. The results of the present study imply that it 
would be of interest to look for also other alkenylbenzene DNA adducts in human liver samples. 
It would also be of use to extend the already-developed PBK models in humans to 
physiologically based dynamic (PBD) models that enable prediction of DNA adduct formation in 
human liver upon exposure to selected alkenylbenzenes. In a previous study by Paini et al. 
(2012) such a PBD model for liver DNA adduct formation was developed and validated in an in 
vivo study for estragole DNA adduct formation in the liver of rats. This study also revealed that 
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alkenylbenzenes present in the PFS, including myristicin, elemicin, and methyleugenol, are 
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Use of Haber’s Rule for products consumed for shorter periods of time may prevent 
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et al. (2011) was the first to propose use of Haber’s Rule for assessing the risk from less-than 
lifetime exposure to carcinogens. It is important to acknowledge the assumptions underlying this 
methodology, which include the fact that chemical-specific carcinogenicity data should be 
available and that the data support a linear dose–response relationship (Felter et al., 2011). 
Whether such a linear dose–response relationship would apply to the dose-dependent induction 
of liver tumors by the alkenylbenzenes remains to be established and may depend on the mode of 
action underlying the carcinogenicity. This mode of action proceeds by cytochrome P450-
catalyzed hydroxylation to a 1’-hydroxymetabolite, followed by sulfotransferase (SULT)- 
 
 
mediated conversion to a 1’- sulfoxymetabolite (Phillips et al., 1981). This metabolite is unstable 
and reacts with DNA. Studies using PBK modelling revealed that the bioactivation of 
alkenylbenzenes to their ultimate carcinogenic 1’-sulfoxy metabolites is linear with the dose, 
from dose levels as low as levels of realistic human dietary intake up to dose levels as high 
as the BMD10 inducing liver tumors in rodent bioassays (Punt et al., 2009; Rietjens et al., 2010; 
Al-Subeihi et al., 2012; Martati et al., 2012). The mutagenic potential of alkenylbenzenes DNA 
adducts has not been extensively quantified so far. Herrmann et al. (2012) investigated the 
mutagenic potential of sulfate conjugates of 1’-hydroxymethyleugenol and showed that different 
isomeric hydroxylated metabolites of methyleugenol are mutagenic in an Ames test using 
Salmonella typhimurium TA100 strains expressing different sulfotransferase enzymes. This 
suggests that the formation of the 1’-sulfoxymetabolite and subsequently formed DNA adducts 
play an important role in the alkenylbenzene-induced carcinogenicity, and that knowledge of the 
levels of DNA adduct formation in human livers at relevant dietary intake levels would be of use 
to facilitate risk assessment for low-dose alkenylbenzenes intake. In this respect it is of interest 
to note that Herrmann et al. (2013) reported detection of  methyleugenol DNA adducts in liver 
samples obtained from human subjects. Methyleugenol DNA adducts in the livers of these 
human subjects likely results from dietary intakes. The results of the present study imply that it 
would be of interest to look for also other alkenylbenzene DNA adducts in human liver samples. 
It would also be of use to extend the already-developed PBK models in humans to 
physiologically based dynamic (PBD) models that enable prediction of DNA adduct formation in 
human liver upon exposure to selected alkenylbenzenes. In a previous study by Paini et al. 
(2012) such a PBD model for liver DNA adduct formation was developed and validated in an in 
vivo study for estragole DNA adduct formation in the liver of rats. This study also revealed that 
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not only bioactivatoin to the reactive 1’-sulfoxymetabolite but also DNA adduct formation in rat 
liver was linear with the dose of estragole (Paini et al., 2010, 2012). Development of such PBD 
models for liver DNA adduct formation in human could be achieved by combining the existing 
human PBK models with data on alkenylbenzene concentration-dependent DNA adduct 
formation in isolated human hepatocytes as done for rat hepatocytes exposed to estragole 
previously (Paini et al., 2010, Paini et al., 2012). Such studies in primary hepatocytes are likely 
to also account for possible repair and stability of the alkenylbenzene adducts and would thus 
provide insight in whether formation of adducts, even during a short period, could have 
irreversible effects and thus be deleterious, or whether they are likely to be repaired, thereby 
decreasing risk. Another issue to consider in this respect is whether it would be realistic that 
intake is not prolonged over time, especially in individuals who regard PFS as healthy and 
natural. A cross-sectional, 12 month retrospective survey that has been conducted in 24 cities in 
six European countries, by the PlantLIBRA consumer survey (2014), revealed that PFS product 
usage patterns are most often taken ‘periodically’ (37.3 %), when experiencing a ‘worsening of a 
condition’ (22.2 %), ‘whenever/sporadically’ (19.8 %), and on ‘other non-specified occasions’ 
(17.8 %). Periodically meaning ‘once daily for at least 2 consecutive or non-consecutive weeks, 
more doses per week for at least 3 consecutive weeks, more doses per week for at least 4 
consecutive or non-consecutive weeks, or 2 or more different PFS, in an appropriate dose form, 
at a minimum frequency of 1 or more doses per week, with the sum of the usage period of the 2 
or more products being equal to at least 4 weeks (Garcia-Alvarez et al., 2014). This result 
indicates that some parts of the population may tend to use such products indeed for longer 
periods of time, whereas others may show more restricted periods of use. It is concluded that the 
 
 
results of the present paper reveal that daily nutmeg-based PFS consumption according to 
recommendations for daily intake for especially longer periods of time raise a concern. 
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GENERAL DISCUSSION 
The present thesis focusses on the alkenylbenzenes myristicin, apiol, safrole, estragole, elemicin 
and methyleugenol. These alkenylbenzenes are naturally occurring in a variety of botanicals 
including anise, star anise, fennel, sweet fennel and parsley, belonging to the plant family 
Umbelliferae, nutmeg and mace, belonging to the plant family Myristicaceae, sweet and exotic 
basil, belonging to the family Labiatae, and tarragon, belonging to the plant family Compositeae. 
Exposure to myristicin, safrole, estragole, and methyleugenol via food occurs mostly from basil, 
nutmeg, and parsley. The range of estimated daily intakes (EDIs) of these alkenylbenzenes from 
the use of spices and spice oils ranges from 0.9 to 166 μg/kg bw per day, with the EDI of safrole 
being the lowest and that for estragole the highest (JECFA 2009). The EDIs of elemicin and 
apiol from all sources make a minor contribution to overall intake (Gavin et al. 2007). With 
respect to alkenylbenzene exposure, pesto paste eaters are considered the highest exposed group, 
with 20 mg methyleugenol on average in each meal, making the EDI amount to 250 μg/kg bw 
per day of methyleugenol for a 70 kg person (Miele et al. 2001).  
The alkenylbenzenes safrole, myristicin, apiol, estragole, methyleugenol, and elemicin are 
structurally related, and they may share similar metabolism, mode of action and biological 
effects (JECFA 2009; van den Berg et al. 2012). Botanicals and botanical preparation containing 
alkenylbenzenes may be of concern because these compounds may be genotoxic and 
carcinogenic displaying similar characteristics regarding tumor formation (Phillips et al. 1981; 
Miller et al. 1983; Randerath et al. 1984; Wiseman et al. 1985; NTP 2000; Zhou et al. 2007; 
Kobets et al. 2016). For myristicin and apiol, studies that show the ability to induce liver cancer 
are not available. The similarity of myristicin and apiol to safrole provides the basis for a mode 
 
 
of action based risk assessment using physiologically based kinetic (PBK) modelling based read-
across from safrole for which adequate rodent tumor data are available.  
PBK models, in general, are developed in order to study effects related to interspecies 
differences, intra-species differences, high to low dose extrapolations, route to route 
extrapolations, and exposure scenario extrapolations. PBK models integrate diverse sets of 
kinetic data, and can predict tissue dosimetry for situations relevant to human dietary intake of 
chemicals of interest.  
For the assessment of the potential risks of human exposure to compounds that are both 
genotoxic and carcinogenic, the European Food Safety Authority (EFSA) recommended the 
Margin of Exposure (MOE) approach to evaluate the priority for risk management actions (EFSA 
2005; EFSA 2009a). The MOE compares the exposure levels causing malignant tumors in 
experimental animals with dietary intake estimates (EDIs) in humans, considering differences in 
consumption patterns. To obtain the MOE, EFSA recommends the use of the BMDL10  (the 
lower confidence limit of the benchmark dose resulting in 10% extra cancer incidence) (EFSA 
2009b). The BMDL10 is a standardized reference point derived, by mathematical modelling, 
from the animal data, and falls within the observed range of experimental data (EFSA 2009a). In 
previous studies, the BMDL10 values for safrole, estragole, and methyleugenol could be derived 
from in vivo tumor data (van den Berg et al. 2011). However, not for all alkenylbenzenes tumor 
data enabling definition of a BMDL10 for risk assessment are available. Such data are not 
available for elemicin, myristicin and apiol. Previously, a BMDL10 value for elemicin was 
derived by read-across from methyleugenol and estragole (van den Berg et al. 2012).  
The aim of the present study was to develop a MOA and PBK modeling based approach for 
read-across in risk assessment from safrole for which in vivo toxicity studies are available to the  
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PBK models, in general, are developed in order to study effects related to interspecies 
differences, intra-species differences, high to low dose extrapolations, route to route 
extrapolations, and exposure scenario extrapolations. PBK models integrate diverse sets of 
kinetic data, and can predict tissue dosimetry for situations relevant to human dietary intake of 
chemicals of interest.  
For the assessment of the potential risks of human exposure to compounds that are both 
genotoxic and carcinogenic, the European Food Safety Authority (EFSA) recommended the 
Margin of Exposure (MOE) approach to evaluate the priority for risk management actions (EFSA 
2005; EFSA 2009a). The MOE compares the exposure levels causing malignant tumors in 
experimental animals with dietary intake estimates (EDIs) in humans, considering differences in 
consumption patterns. To obtain the MOE, EFSA recommends the use of the BMDL10  (the 
lower confidence limit of the benchmark dose resulting in 10% extra cancer incidence) (EFSA 
2009b). The BMDL10 is a standardized reference point derived, by mathematical modelling, 
from the animal data, and falls within the observed range of experimental data (EFSA 2009a). In 
previous studies, the BMDL10 values for safrole, estragole, and methyleugenol could be derived 
from in vivo tumor data (van den Berg et al. 2011). However, not for all alkenylbenzenes tumor 
data enabling definition of a BMDL10 for risk assessment are available. Such data are not 
available for elemicin, myristicin and apiol. Previously, a BMDL10 value for elemicin was 
derived by read-across from methyleugenol and estragole (van den Berg et al. 2012).  
The aim of the present study was to develop a MOA and PBK modeling based approach for 
read-across in risk assessment from safrole for which in vivo toxicity studies are available to the  
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related compounds myristicin and apiol for which tumor data are not reported, thus contributing 
to alternatives in animal testing, and to use the outcomes for risk assessment for the consumption 
of PFS and other botanical products containing myristicin and structurally related 
alkenylbenzenes considering individual and combined exposure. 
In chapter 2 of this thesis, physiologically based kinetic (PBK) models were developed for 
myristicin by extension of the PBK models for the structurally related alkenylbenzene safrole in 
rat and human. The newly defined models provide a quantitative insight into the consequences of 
dose- and species- dependent effects on bioactivation of myristicin. The models were based on in 
vitro metabolic parameters determined using relevant tissue fractions, in silico derived partition 
coefficients, and physiological parameters derived from the literature. The models consist of six 
compartments including liver as metabolizing compartment, and separate compartments for fat, 
arterial blood, venous blood, richly perfused, and slowly perfused tissues. Following an exposure 
to dose levels of 0.05 mg/kg bw to 300 mg/kg bw myristicin, plasma and liver levels of 
myristicin and its proximate carcinogenic metabolite 1’-hydroxymyristicin were predicted 
showing myristicin to be almost completely metabolized within a 720-hr period in rat and 
human. Comparing the predicted metabolite formation at 0.05 and 300 mg/kg bw, the percentage 
of the dose converted to the proximate carcinogenic metabolite 1’-hydroxymyristicin was 
predicted to increase in a dose-dependent manner. Comparison of the relative extent of 
bioactivation of myristicin by rat and human liver revealed that formation of 1’-
hydroxymyristicin (expressed as nmol/g liver) is comparable in rat and human liver at the low 
dose of 0.05 mg/kg bw and 1.8-fold higher in rat liver than in human liver at a dose of 300 mg/kg 
bw. Formation of the ultimate carcinogenic metabolite 1’-sulfoxymyristicin was predicted to be 
 
 
4-fold higher in human liver than in rat liver at a low dose of 0.05 mg/kg bw and 2.8-fold higher 
in human liver than in rat liver at a dose of 300 mg/kg bw.  
It was also shown that glucuronidation of 1’-hydroxymyristicin, representing a detoxification 
pathway, is the most important pathway in rat, while its oxidation is the most important pathway 
for conversion of 1’-hydroxymyristicin in human. Moreover, on the basis of the kinetic data 
obtained, bioactivation of 1’-hydroxymyristicin following sulfonation was found to represent 
only a minor pathway in both rat and human. 
The PBK models for myristicin were comparable to the PBK models for estragole, 
methyleugenol, and safrole, for which more data allowing the evaluation of the models were 
available. The performance of the rat and human PBK models developed for estragole, 
methyleugenol, and safrole was reported before (Punt et al. 2008; Punt et al. 2009; Al-Subeihi et 
al. 2011; Martati et al. 2011; Al-Subeihi et al. 2012; Martati et al. 2012). Evaluation was done by 
comparing the predicted levels of a variety of metabolites in plasma or excreted in the urine of 
rats and the predicted blood concentrations in human to comparable data reported in the 
literature. These comparisons revealed that the predicted PBK model values and the levels of 
these metabolites derived from in vivo studies adequately matched. The performance of the 
newly developed PBK models for myristicin could not be evaluated against in vivo data because 
quantitative data on the formation or excretion of the different metabolites in rat or humans 
exposed to this compound are not available. The only data reported that were of use were the 
data by Beyer et al. (2006) reporting that for both rats and humans exposed to nutmeg, the 
corresponding O-demethylenation metabolite of myristicin was the predominant metabolite, 
exceeding other metabolites by at least a factor of 10. In rat urine samples collected over a 24-hr 
period after administration of a single oral dose of 100 mg/kg bw myristicin, urinary metabolites 
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related compounds myristicin and apiol for which tumor data are not reported, thus contributing 
to alternatives in animal testing, and to use the outcomes for risk assessment for the consumption 
of PFS and other botanical products containing myristicin and structurally related 
alkenylbenzenes considering individual and combined exposure. 
In chapter 2 of this thesis, physiologically based kinetic (PBK) models were developed for 
myristicin by extension of the PBK models for the structurally related alkenylbenzene safrole in 
rat and human. The newly defined models provide a quantitative insight into the consequences of 
dose- and species- dependent effects on bioactivation of myristicin. The models were based on in 
vitro metabolic parameters determined using relevant tissue fractions, in silico derived partition 
coefficients, and physiological parameters derived from the literature. The models consist of six 
compartments including liver as metabolizing compartment, and separate compartments for fat, 
arterial blood, venous blood, richly perfused, and slowly perfused tissues. Following an exposure 
to dose levels of 0.05 mg/kg bw to 300 mg/kg bw myristicin, plasma and liver levels of 
myristicin and its proximate carcinogenic metabolite 1’-hydroxymyristicin were predicted 
showing myristicin to be almost completely metabolized within a 720-hr period in rat and 
human. Comparing the predicted metabolite formation at 0.05 and 300 mg/kg bw, the percentage 
of the dose converted to the proximate carcinogenic metabolite 1’-hydroxymyristicin was 
predicted to increase in a dose-dependent manner. Comparison of the relative extent of 
bioactivation of myristicin by rat and human liver revealed that formation of 1’-
hydroxymyristicin (expressed as nmol/g liver) is comparable in rat and human liver at the low 
dose of 0.05 mg/kg bw and 1.8-fold higher in rat liver than in human liver at a dose of 300 mg/kg 
bw. Formation of the ultimate carcinogenic metabolite 1’-sulfoxymyristicin was predicted to be 
 
 
4-fold higher in human liver than in rat liver at a low dose of 0.05 mg/kg bw and 2.8-fold higher 
in human liver than in rat liver at a dose of 300 mg/kg bw.  
It was also shown that glucuronidation of 1’-hydroxymyristicin, representing a detoxification 
pathway, is the most important pathway in rat, while its oxidation is the most important pathway 
for conversion of 1’-hydroxymyristicin in human. Moreover, on the basis of the kinetic data 
obtained, bioactivation of 1’-hydroxymyristicin following sulfonation was found to represent 
only a minor pathway in both rat and human. 
The PBK models for myristicin were comparable to the PBK models for estragole, 
methyleugenol, and safrole, for which more data allowing the evaluation of the models were 
available. The performance of the rat and human PBK models developed for estragole, 
methyleugenol, and safrole was reported before (Punt et al. 2008; Punt et al. 2009; Al-Subeihi et 
al. 2011; Martati et al. 2011; Al-Subeihi et al. 2012; Martati et al. 2012). Evaluation was done by 
comparing the predicted levels of a variety of metabolites in plasma or excreted in the urine of 
rats and the predicted blood concentrations in human to comparable data reported in the 
literature. These comparisons revealed that the predicted PBK model values and the levels of 
these metabolites derived from in vivo studies adequately matched. The performance of the 
newly developed PBK models for myristicin could not be evaluated against in vivo data because 
quantitative data on the formation or excretion of the different metabolites in rat or humans 
exposed to this compound are not available. The only data reported that were of use were the 
data by Beyer et al. (2006) reporting that for both rats and humans exposed to nutmeg, the 
corresponding O-demethylenation metabolite of myristicin was the predominant metabolite, 
exceeding other metabolites by at least a factor of 10. In rat urine samples collected over a 24-hr 
period after administration of a single oral dose of 100 mg/kg bw myristicin, urinary metabolites 
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resulting from O-demethylenation amounted to 67 % of the total dose (Beyer et al. 2006). In line 
with these results, the developed rat PBK model predicted the O-demethylenated myristicin 
metabolite 5-allyl-2,3-dihydroxyanisole to be the major metabolite formed at a dose of 100 
mg/kg bw myristicin in rat after 24-hr, with a percentage of 73 % of the total dose. This 
predicted value of 73 % of the dose matches well with the 67 % observed in the in vivo rat study 
and it was concluded that the developed PBK models for myristicin will also adequately describe 
the in vivo levels of metabolites formed in rat and human after conversion of myristicin and 1’-
hydroxymyristicin at different oral dose levels of myristicin. Comparison of the PBK model-
based predictions of the bioactivation of myristicin by rat and human to that of its structurally 
related compound safrole, reveals that the formation of the DNA-reactive 1’-sulfoxy metabolite 
is comparable; in human formation of the 1’-sulfoxy metabolite is predicted to be 1.35-fold 
higher for safrole than for myristicin at a low dose level 0.05 mg/kg bw, and 1.1-fold higher for 
myristicin at high dose level 100 mg/kg bw, in rat formation of the 1’-sulfoxy metabolite is 
predicted to be 1.5-fold higher for myristicin than for safrole at low dose level 0.05 mg/kg bw, 
and 2.2-fold higher for myristicin at high dose level 100 mg/kg bw. This shows that the dose-
response function for myristicin is steeper (higher curve slope), and that the formation of the 1’-
sulfoxymetabolite is higher for safrole at lower doses, but that the order changes to have the 
formation of the 1’-sulfoxymetaboilte of myristicin being higher than that of safrole at higher 
doses. The PBK model outcomes obtained for the formation of reactive 1’-sulfoxy metabolites of 
myristicin and safrole can be compared to the relative bioactivation of these two alkenylbenzenes 
observed in other studies (Phillips et al. 1984; Randerath et al. 1984; Zhou et al. 2007). 32P-
postlabeling indicated that safrole and myristicin have the ability to produce DNA adducts in 
adult mouse liver upon intraperitoneal injections, amounting to levels of 17.5 and 7.8 pmol/mg 
 
 
DNA, respectively (Phillips et al. 1984). In another study the covalent binding to adult female 
mice CD-1 liver of safrole was 2.7 times higher than that of myristicin at low dose (2 mg/mouse) 
and 4.0 times higher at higher dose (10 mg/mouse) (Randerath et al. 1984). Using human HepG2 
cells exposed in vitro, the level of DNA adduct formation by safrole was 1.6-fold higher than 
that for myristicin at low concentration (50 μmol/l), while at higher concentration (450 μmol/l), 
the level of adduct formation for myristicin was 1.6-fold higher than for safrole (Zhou et al. 
2007). 
Altogether, the results obtained support the possibility to perform the risk assessment for 
myristicin based on the MOE approach using the BMDL10 of safrole for tumor formation. Thus, 
risk assessment of myristicin may be based on the BMDL10 derived for safrole of 1.9–5.1 mg/kg 
bw per day (van den Berg et al. 2011). Using an estimated daily intake of myristicin of 0.0019 
mg/kg bw per day (Gavin et al. 2007) resulting from the use of herbs and spices, this results in 
MOE values for myristicin that amount to 1000–2700, indicating a priority for risk management.  
In chapter 3, a similar study was undertaken for apiol. To this end PBK models for apiol were 
developed in order to facilitate risk assessment based on read-across from the related 
alkenylbenzene safrole. The formation of the different microsomal metabolites of apiol in rat 
liver by the PBK model-based predictions was dose dependent with a relative increase in 
bioactivation of apiol at higher doses. 
With the model obtained the relative extent of bioactivation and detoxification of apiol at 
different oral doses was examined. At low doses, formation of 4-allyl-3,6-dimethoxy benzene-
1,2-diol (ADD) and 2',3'-dihydroxyapiol (DHA) leading to detoxification appeared to represent 
the major metabolic pathways, occurring in the liver. At high doses, the rat model revealed a 
relative increase in the percentage of formation of the proximate carcinogenic metabolite 1’- 
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resulting from O-demethylenation amounted to 67 % of the total dose (Beyer et al. 2006). In line 
with these results, the developed rat PBK model predicted the O-demethylenated myristicin 
metabolite 5-allyl-2,3-dihydroxyanisole to be the major metabolite formed at a dose of 100 
mg/kg bw myristicin in rat after 24-hr, with a percentage of 73 % of the total dose. This 
predicted value of 73 % of the dose matches well with the 67 % observed in the in vivo rat study 
and it was concluded that the developed PBK models for myristicin will also adequately describe 
the in vivo levels of metabolites formed in rat and human after conversion of myristicin and 1’-
hydroxymyristicin at different oral dose levels of myristicin. Comparison of the PBK model-
based predictions of the bioactivation of myristicin by rat and human to that of its structurally 
related compound safrole, reveals that the formation of the DNA-reactive 1’-sulfoxy metabolite 
is comparable; in human formation of the 1’-sulfoxy metabolite is predicted to be 1.35-fold 
higher for safrole than for myristicin at a low dose level 0.05 mg/kg bw, and 1.1-fold higher for 
myristicin at high dose level 100 mg/kg bw, in rat formation of the 1’-sulfoxy metabolite is 
predicted to be 1.5-fold higher for myristicin than for safrole at low dose level 0.05 mg/kg bw, 
and 2.2-fold higher for myristicin at high dose level 100 mg/kg bw. This shows that the dose-
response function for myristicin is steeper (higher curve slope), and that the formation of the 1’-
sulfoxymetabolite is higher for safrole at lower doses, but that the order changes to have the 
formation of the 1’-sulfoxymetaboilte of myristicin being higher than that of safrole at higher 
doses. The PBK model outcomes obtained for the formation of reactive 1’-sulfoxy metabolites of 
myristicin and safrole can be compared to the relative bioactivation of these two alkenylbenzenes 
observed in other studies (Phillips et al. 1984; Randerath et al. 1984; Zhou et al. 2007). 32P-
postlabeling indicated that safrole and myristicin have the ability to produce DNA adducts in 
adult mouse liver upon intraperitoneal injections, amounting to levels of 17.5 and 7.8 pmol/mg 
 
 
DNA, respectively (Phillips et al. 1984). In another study the covalent binding to adult female 
mice CD-1 liver of safrole was 2.7 times higher than that of myristicin at low dose (2 mg/mouse) 
and 4.0 times higher at higher dose (10 mg/mouse) (Randerath et al. 1984). Using human HepG2 
cells exposed in vitro, the level of DNA adduct formation by safrole was 1.6-fold higher than 
that for myristicin at low concentration (50 μmol/l), while at higher concentration (450 μmol/l), 
the level of adduct formation for myristicin was 1.6-fold higher than for safrole (Zhou et al. 
2007). 
Altogether, the results obtained support the possibility to perform the risk assessment for 
myristicin based on the MOE approach using the BMDL10 of safrole for tumor formation. Thus, 
risk assessment of myristicin may be based on the BMDL10 derived for safrole of 1.9–5.1 mg/kg 
bw per day (van den Berg et al. 2011). Using an estimated daily intake of myristicin of 0.0019 
mg/kg bw per day (Gavin et al. 2007) resulting from the use of herbs and spices, this results in 
MOE values for myristicin that amount to 1000–2700, indicating a priority for risk management.  
In chapter 3, a similar study was undertaken for apiol. To this end PBK models for apiol were 
developed in order to facilitate risk assessment based on read-across from the related 
alkenylbenzene safrole. The formation of the different microsomal metabolites of apiol in rat 
liver by the PBK model-based predictions was dose dependent with a relative increase in 
bioactivation of apiol at higher doses. 
With the model obtained the relative extent of bioactivation and detoxification of apiol at 
different oral doses was examined. At low doses, formation of 4-allyl-3,6-dimethoxy benzene-
1,2-diol (ADD) and 2',3'-dihydroxyapiol (DHA) leading to detoxification appeared to represent 
the major metabolic pathways, occurring in the liver. At high doses, the rat model revealed a 
relative increase in the percentage of formation of the proximate carcinogenic metabolite 1’- 
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hydroxyapiol; from 4% to about 7% of the dose at low and high dose levels respectively, 
occurring in the liver. By comparing the PBK model based predicted 1’-sulfoxy metabolite 
formation of apiol with that for safrole, it appeared that at similar dose levels the formation of the 
1’-sulfoxymetabolite for apiol is predicted to be about 3-fold lower than for safrole in rat liver 
and 2-fold lower in human liver. Based on these PBK modeling results, making a correction for 
the expected 3-fold lower formation of the ultimate carcinogenic 1’-sulfoxymetabolite at similar 
dose levels, the apiol BMDL10 value would be 3 times the BMDL10 for safrole. Based on an 
estimated BMDL10 for apiol of 5.7 to15.3 mg/kg bw per day and an estimated daily intake of 
4×10-5 mg/kg bw per day, the margin of exposure (MOE) would amount to 140000 to 385000, 
and this indicates a low priority for risk management. 
In Chapter 4, a more detailed analysis of the risks of the presence of alkenylbenzenes in basil-
containing sauce of pesto was made using the MOE approach and taking into consideration the 
possible combined exposure to different alkenylbenzenes. The determination of the levels of 
alkenylbenzenes in basil-containing sauce of pesto revealed that all the samples analysed 
contained methyleugenol. In addition to methyleugenol, some samples contained estragole, 
myristicin, and/or apiol. Based on chemical analysis the EDI values could be determined 
assuming a body weight of 70 kg and intake of 10 g of basil (based on wet weight) per meal 
(Miele et al. 2001), provided by an amount of pesto sauce that could be calculated taking into 
account the basil content (%) in the pesto sauce as indicated on the label. For samples containing 
only methyleugenol, the EDI values for methyleugenol ranged from 3.2–44.3 μg/kg bw per day. 
These EDI values resulted in MOE values of 345–4781. Since several alkenylbenzenes were 
found in some of the pesto samples, and these alkenylbenzenes show high similarity in structure, 
target organ, type of adverse effects and mode of action through formation of a DNA reactive 1’-
 
 
sulfoxymetabolite contributing to formation of liver tumors, a combined exposure assessment 
and subsequent risk assessment were also performed. For this combined risk assessment, the 
EDIs were calculated assuming equal potency of the alkenylbenzenes and also based on use of 
the so-called Toxic Equivalency (TEQ) approach. The Toxic Equivalency Factors (TEFs) for the 
different alkenylbenzenes were defined using methyleugenol as the reference compound 
(TEF=1). The TEF values for the other compounds were defined using different sets of literature 
data, including data for in vivo DNA adduct formation in the liver (Randerath et al. 1984) and 
also  the PBK model based predictions for formation of the ultimate carcinogenic 1'-sulfoxy 
metabolites and the BMDL10 values obtained by read-across from safrole as defined for 
myristicin and apiol in Chapter 2 and Chapter 3 of the thesis, as well as the previously derived 
BMDL10 values for methyleugenol and safrole (van den Berg et al. 2011). In samples containing 
multiple alkenylbenzenes, the MOE values resulting from combined exposure assessment were 
1.5–5-fold lower than the MOE values obtained when considering the presence of only 
methyleugenol, and are all below 10000. Combined risk assessment based on equal potency did 
not vary much from results obtained using the TEQ approach. This can be ascribed to the minor 
variation in potencies of the different alkenylbenzenes detected in the pesto samples.  
It is of interest to note that these MOE values refer to regular daily consumption of pesto which 
may be an overestimation of realistic human consumption. Levels of methyleugenol in pesto 
sauce samples and consumption frequency of pesto sauce directly impact the EDI and the 
resulting MOE values. There is no generally established method for taking a shorter than life 
time exposure into account but one could consider using Haber’s rule. Assuming that Haber’s 
rule would apply, the toxic effect would vary linearly with the time of exposure and the 
concentration (i.e. C × T = k, where C is concentration or dose, T is time of exposure, and k is a 
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hydroxyapiol; from 4% to about 7% of the dose at low and high dose levels respectively, 
occurring in the liver. By comparing the PBK model based predicted 1’-sulfoxy metabolite 
formation of apiol with that for safrole, it appeared that at similar dose levels the formation of the 
1’-sulfoxymetabolite for apiol is predicted to be about 3-fold lower than for safrole in rat liver 
and 2-fold lower in human liver. Based on these PBK modeling results, making a correction for 
the expected 3-fold lower formation of the ultimate carcinogenic 1’-sulfoxymetabolite at similar 
dose levels, the apiol BMDL10 value would be 3 times the BMDL10 for safrole. Based on an 
estimated BMDL10 for apiol of 5.7 to15.3 mg/kg bw per day and an estimated daily intake of 
4×10-5 mg/kg bw per day, the margin of exposure (MOE) would amount to 140000 to 385000, 
and this indicates a low priority for risk management. 
In Chapter 4, a more detailed analysis of the risks of the presence of alkenylbenzenes in basil-
containing sauce of pesto was made using the MOE approach and taking into consideration the 
possible combined exposure to different alkenylbenzenes. The determination of the levels of 
alkenylbenzenes in basil-containing sauce of pesto revealed that all the samples analysed 
contained methyleugenol. In addition to methyleugenol, some samples contained estragole, 
myristicin, and/or apiol. Based on chemical analysis the EDI values could be determined 
assuming a body weight of 70 kg and intake of 10 g of basil (based on wet weight) per meal 
(Miele et al. 2001), provided by an amount of pesto sauce that could be calculated taking into 
account the basil content (%) in the pesto sauce as indicated on the label. For samples containing 
only methyleugenol, the EDI values for methyleugenol ranged from 3.2–44.3 μg/kg bw per day. 
These EDI values resulted in MOE values of 345–4781. Since several alkenylbenzenes were 
found in some of the pesto samples, and these alkenylbenzenes show high similarity in structure, 
target organ, type of adverse effects and mode of action through formation of a DNA reactive 1’-
 
 
sulfoxymetabolite contributing to formation of liver tumors, a combined exposure assessment 
and subsequent risk assessment were also performed. For this combined risk assessment, the 
EDIs were calculated assuming equal potency of the alkenylbenzenes and also based on use of 
the so-called Toxic Equivalency (TEQ) approach. The Toxic Equivalency Factors (TEFs) for the 
different alkenylbenzenes were defined using methyleugenol as the reference compound 
(TEF=1). The TEF values for the other compounds were defined using different sets of literature 
data, including data for in vivo DNA adduct formation in the liver (Randerath et al. 1984) and 
also  the PBK model based predictions for formation of the ultimate carcinogenic 1'-sulfoxy 
metabolites and the BMDL10 values obtained by read-across from safrole as defined for 
myristicin and apiol in Chapter 2 and Chapter 3 of the thesis, as well as the previously derived 
BMDL10 values for methyleugenol and safrole (van den Berg et al. 2011). In samples containing 
multiple alkenylbenzenes, the MOE values resulting from combined exposure assessment were 
1.5–5-fold lower than the MOE values obtained when considering the presence of only 
methyleugenol, and are all below 10000. Combined risk assessment based on equal potency did 
not vary much from results obtained using the TEQ approach. This can be ascribed to the minor 
variation in potencies of the different alkenylbenzenes detected in the pesto samples.  
It is of interest to note that these MOE values refer to regular daily consumption of pesto which 
may be an overestimation of realistic human consumption. Levels of methyleugenol in pesto 
sauce samples and consumption frequency of pesto sauce directly impact the EDI and the 
resulting MOE values. There is no generally established method for taking a shorter than life 
time exposure into account but one could consider using Haber’s rule. Assuming that Haber’s 
rule would apply, the toxic effect would vary linearly with the time of exposure and the 
concentration (i.e. C × T = k, where C is concentration or dose, T is time of exposure, and k is a 
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constant toxic response for the specific substance) (Doull and Rozman 2000). In Chapter 4 it was 
evaluated, using Haber’s rule, what level of alkenylbenzenes, what amount of basil-based pesto 
sauce consumed and/or what exposure frequency would result in an MOE of 10000 or higher and 
be of low priority for risk management. Based on that analysis it was concluded that 
consumption of pesto sauces would especially be of concern if consumed on a daily basis over 
longer periods of time. The results of chapter 4 reveal that pesto consumption does not always 
represent a cancer risk and provide insight into when this might be the case and under which 
level and frequency of consumption pesto consumption would not raise a concern. 
In Chapter 5, a risk assessment of nutmeg-based plant food supplements (PFS) containing 
different alkenylbenzenes was performed based on the alkenylbenzene levels quantified in a 
series of PFS collected via the online market. Based on the alkenylbenzene contents detected and 
the use levels of the respective PFS recommended on the labels, EDI values calculated for 
individual alkenylbenzenes ranged from 0.3 to 312 μg/kg bw per day. Using the respective 
BMDL10 values these EDI values resulted in MOE values that were generally below 10000 
ranging from 6 to 7870. A combined exposure assessment and subsequent risk assessment were 
performed for those PFS in which more than one alkenylbenzene was detected. Assuming equal 
potency of the alkenylbenzenes, combined EDI values obtained ranged from 1.5 to 631 μg/kg bw 
per day resulting in MOE values ranging from 3 to 1309 for the samples in which more than one 
alkenylbenzene was detected. Using a TEQ concept and the Toxic Equivalency Factors (TEFs) 
for the different alkenylbenzenes defined as described in Abdul et al. (2016) using safrole as the 
reference compound (TEF=1) (Alajlouni et al. 2016b). Combined EDI values ranged from 0.4 to 
295 μg safrole equivalents/kg bw leading to MOE values ranging from 6 to 5020. MOE values 
resulting from both these combined exposure assessments were up to 5-fold lower than the MOE 
 
 
values obtained when considering individual exposure to alkenylbenzenes. The MOE values 
obtained for the combined risk assessment based on the TEQ concept were higher than the ones 
obtained when assuming equal potency. This can be ascribed to the fact that the TEF values of 
the alkenylbenzenes present in the PFS, including myristicin, elemicin, and methyleugenol, are 
lower than that of safrole leading to lower EDI values when expressed in safrole equivalents and 
higher MOE values.  
It is of interest to note that these MOE values refer to regular daily consumption of nutmeg-based 
PFS during a whole lifetime which may be an overestimation of realistic human consumption. 
Levels of alkenylbenzenes in nutmeg-based PFS samples and consumption frequency directly 
impact the EDI and the resulting MOE values. Using Haber’s rule to correct for shorter than life 
time exposure it was shown that limiting exposure to only one or two weeks could result in MOE 
values that would be, with the levels of alkenylbenzenes detected in the PFS in the study and the 
proposed uses of these PFS, higher than 10000 and thus of low priority for risk management. It is 
concluded that the results of the study reveal that daily nutmeg-based PFS consumption 
following recommendations for daily intake for especially longer periods of time raises a 
concern. 
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constant toxic response for the specific substance) (Doull and Rozman 2000). In Chapter 4 it was 
evaluated, using Haber’s rule, what level of alkenylbenzenes, what amount of basil-based pesto 
sauce consumed and/or what exposure frequency would result in an MOE of 10000 or higher and 
be of low priority for risk management. Based on that analysis it was concluded that 
consumption of pesto sauces would especially be of concern if consumed on a daily basis over 
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values obtained when considering individual exposure to alkenylbenzenes. The MOE values 
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FUTURE PERSPECTIVES 
This thesis presents the use of physiologically based kinetic (PBK) modeling to facilitate read-
across in risk assessment from a compound for which in vivo toxicity studies are available to a 
related compound for which tumor data are not reported, and risk assessment of individual and 
combined exposure to alkenylbenzenes present in basil-containing pesto and nutmeg-based plant 
food supplements (PFS). In the next sections some suggestions are given for steps to be taken in 
the near future for further improvement of risk and safety assessment of individual and combined 
exposure to alkenylbenzenes from botanical preparations. Such steps include (1) Further 
development of the PBK models and the read-across approach to predict toxicological reference 
points for risk assessment of genotoxic carcinogens, (2) incorporation of the dynamic 
characteristics of the active chemical substance(s) in the in silico models, (3) additional 
considerations for the MOE based risk assessment including the incorporation of Chemical 
Specific Adjustment Factors (CSAFs) for interspecies and interindividual variation in kinetics 
within the human population, (4) long to short-term exposure adjustment, (5) further 
improvement of the TEF approach, (6) banding of the MOE values and related conclusions for 
risk management, and (7) quality assurance of food supplements and botanical preparations.  
 
Further development of the PBK models and the read-across approach to predict 
toxicological reference points for risk assessment of genotoxic carcinogens 
The MOE approach needs carcinogenicity data to define the BMDL10. However, not for all 
alkenylbenzenes tumor data enabling definition of a BMDL10 for risk assessment are available. 
Such data are missing for myristicin and apiol. So, a mode of action based PBK model approach 
was developed in chapter 2 and chapter 3 to perform a read-across from a compound for which 
 
 
rodent tumor data are available (safrole) to these compounds for which such data are not 
available (myristicin and apiol). The read-across was based on the similarity in structure, 
metabolism, mechanism of toxicity, and ultimate adverse effect of the alkenylbenzenes. 
Previously, a BMDL10 value for elemicin was derived by PBK model based read-across from 
methyleugenol and estragole (Van den Berg et al. 2012). The PBK models quantify the dose-
dependent formation of the ultimate carcinogenic 1’-sulfoxymetabolite thereby facilitating the 
read-across based on predictions of relative bioactivation. It is important to realise that the PBK 
models as developed for the read-across in the present thesis required a large number of 
parameters many of which needed to be defined for each individual compound. This makes the 
development of these models time and effort consuming. For that reason, for efficient future 
development of this PBK model based read-across approach priority should be given to the 
development of generic PBK models for groups of related compounds to facilitate an efficient 
and time-and-cost-saving risk assessment on genotoxic carcinogens for which rodent tumor data 
are not available (Bessems et al. 2014). The models developed for the alkenylbenzenes, and 
especially the results of the sensitivity analyses, could be of use since they define and evaluate 
the influence of the various input parameters on the output. This could be of great use in the 
development of generic models for other botanical-borne naturally occurring group of 
compounds, focusing on those aspects in the model that affect the predictions most. Another 
category of botanical ingredients of concern for which limited tumor data for their risk 
assessment are available and for which PBK model based read-across would facilitate risk 
assessment are the pyrrolizidine alkaloids (Chen et al. 2017).  
Some efforts in development of generic PBK models have already been reported. Brightman et 
al. (2007) introduced a generic model PBK model that was parameterized for human physiology 
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predicting the in vivo pharmacokinetics of compounds for which plasma levels in human have 
been determined following an intravenous dose, concluding that the generic PBK model can be a 
powerful, efficient, and cost-effective tool for toxicokinetic predictions and reduction of in vivo 
animal experimentation. Chemical-specific data required by the model are generated from in 
silico (QSAR) and/or in vitro procedures. For oral exposure; generic PBK models likely will 
require quantitative values for intestinal barrier permeability, a measure of lipophilicity, an 
estimate of the fraction of the compound bound to plasma proteins, and an estimate of intrinsic 
hepatic clearance (Brightman et al. 2005; Brightman et al. 2006; d’Yvoire et al. 2007). 
Depending on the group of chemicals under study a few compound specific parameters may have 
to be added but the PBK model development could start from the generic basic model and its 
evaluation before adding additional parameters. Focusing on a limited set of parameters and 
definition of validated generic models will facilitate future applications of the PBK model based 
read-across presented in the present thesis for the alkenylbenzenes. 
 
Incorporation of the dynamic characteristics of the active chemical substance(s) in the in 
silico models 
For refinement of the read-across process in risk assessment of genotoxic carcinogens, dynamic 
processes including DNA-adduct formation, DNA repair, mutation modulation, gene and protein 
expression and tumor formation occurring at low realistic intake levels should be considered in 
addition to already predicted kinetics (bioactivation and detoxification) of myristicin and apiol 
(Chapter 2 and 3). The dynamic process could be described using Physiologically Based 
Dynamic (PBD) models. 
 
 
Extending the PBK models to model the possible levels of DNA adduct formation upon exposure 
to the alkenylbenzenes has been done before for estragole (Paini et al. 2010). To this end, the 
PBK model describing the formation of the proximate carcinogenic 1’-hydroxymetabolite, was 
extended by linking the area under the curve for 1’-hydroxyestragole formation predicted by the 
PBK model to the area under the curve for 1’-hydroxyestragole in the in vitro experiments on 
DNA adduct formation in rat primary hepatocytes exposed to 1’-hydroxyestragole.  
In this model formation of 1’-sulfoxyestragole as well as DNA repair were implicitly included, 
since these reactions occur in the isolated hepatocytes and thus affect the ultimate levels of DNA 
adduct formation detected. The PBD model for liver DNA adduct formation thus developed for 
rats predicted the formation of E-3’-N2-dGuo in the liver of rat at 400 mg/ kg bw per day, 
quantified by LC-ESI-MS/MS, at a level amounting to 4 adducts in 10000 nucleotides. This 
value was within the same order of magnitude as DNA adduct formation in the liver of mice 
exposed to estragole determined using 32P-postlabeling detecting 1 adduct in 10000 nucleotides 
(Randerath et al. 1984). 
The results obtained revealed that DNA adduct formation was adequately predicted and also that 
not only bioactivation to the reactive 1’-sulfoxymetabolite but also DNA adduct formation in rat 
liver was linear with the dose of estragole (Paini et al. 2010). Such studies also account for 
possible repair and stability of the alkenylbenzene adducts and would thus provide insight in 
whether formation of adducts, even during a short period, could have irreversible effects and thus 
be deleterious, or whether they are likely to be efficiently repaired, thereby decreasing risk. Also 
prediction of DNA adduct formation is one step closer to the ultimate mutagenicity and 
carcinogenicity than the predicted 1’-sulfooxyestragole formation, thus providing an even better 
basis for read-across. 
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Additional considerations for the MOE based risk assessment including the incorporation 
of Chemical Specific Adjustment Factors (CSAFs) for interspecies and interindividual 
variation in kinetics within the human population 
Many qualitative and quantitative approaches can be used to assess the risk of genotoxic 
carcinogenic compounds. Data used in these approaches are mainly obtained from rodent 
bioassays performed at high dose levels. This implies that extrapolation to lower exposure levels 
is required in order to judge the risks at realistic human daily exposure levels. Such an 
extrapolation may be far outside the experimental data range and up to five orders of magnitude 
below the observable response in the animal bioassay. EFSA questioned if such an extrapolation 
is justified, and denies quantitative risk assessment based on high to low dose extrapolation as a 
scientifically acceptable approach (Barlow et al. 2006; O'Brien et al. 2006; Benford et al. 2010). 
EFSA considered, amongst other reasons, that this extrapolation depends too much on the model 
applied, that evidence for the frequently used linear extrapolation model is not available, and that 
this extrapolation of rodent tumor data to human risk levels does not take into account species 
differences. As an alternative EFSA proposed the Margin of Exposure (MOE), defined as the 
ratio between the BMDL10 and the estimated daily intake (EDI), that was also applied in the 
present thesis. The EFSA Scientific Committee considered that an MOE of 10000 or more, based 
on animal cancer bioassay data, “would be of low concern from a public health point of view and 
might reasonably be considered as a low priority for risk management actions” (EFSA 2005). 
The value of 10000 was considered to include all possible uncertainties that may be involved and 
affect the risk assessment. It includes a factor of 100 for kinetic and dynamic differences 
between species and within humans, a factor of 10 that presents the variability in cell cycle 
control and DNA repair within humans, and a factor of 10 that takes into account that the 
 
 
BMDL10 represents a 10% BMR (EFSA 2005; O'Brien et al. 2006). Subdivision of the 
interspecies uncertainty factor of 10 into toxicokinetics and toxicodynamic components would 
allow part of the default value to be replaced by chemical-specific data consistent with the 
weight of evidence for mode of action when they are available. The proposed default value of 10 
for interspecies differences for example can be considered to consist of a factor of 4 and 2.5 for 
the toxicokinetics and toxicodynamic components, respectively. This implies that when relevant 
chemical-specific toxicokinetics and toxicodynamic data on species differences would be 
available, the default values could be replaced with CSAFs for interspecies differences in 
toxicokinetics and toxicodynamic (HealthCanada 1994; Renwick 1999; Gundert-Remy and 
Sonich-Mullin 2002; Meek et al. 2003; IPCS 2005). The default uncertainty factor for 
interspecies differences in toxicokinetics can be informed through the use of PBK models 
(Rowland 1985; Andersen et al. 1995; Jarabek 1995). The PBK model based predictions for the 
formation of the ultimate carcinogenic 1’-sulfoxymetabolite for myristicin and apiol in rat and 
human defined in the present thesis showed that at low dose in human the formation of the 
ultimate carcinogenic metabolite is 4 times higher than in rat, while for apiol the difference was 
15-fold. These results of the present thesis suggest that a factor of 4 to take into account species 
differences in toxicokinetics may be sufficient for myristicin but not for apiol.  For apiol, the 
default MOE value of 10000 may increase accordingly which would result in more samples to 
result in MOE values that might be of concern. 
In future, Monte Carlo simulation on the variability in the formation of the 1’-sulfoxymetabolite 
can potentially be used to derive the CSAFs, which can be used to evaluate the appropriateness 
of the default factor of 3.16 generally assumed to reflect interindividual variation in kinetics 
within the human population (Barton et al. 1996; Dourson et al. 1996; Clewell et al. 1999; Price 
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et al. 1999; Haber et al. 2002; Lipscomb and Ohanian 2007). The results of this thesis illustrate 
how these PBK models may assist the development of CASFs in risk assessment.  
 
Long to short-term exposure adjustment  
The risk assessments presented in this thesis were based on the MOE approach which defines an 
MOE based on BMDL10 values from chronic carcinogenicity data as well as EDI values 
assuming daily exposure over a life time. Use of the PFS and of sauce of pesto however, may be 
less than daily and not over a whole life time. This raises the question how to accommodate these 
different exposure scenario’s in the MOE based risk assessment. One way to extrapolate from 
longer durations to shorter durations of exposure is through the use of Haber’s Law: ? ? ? ? , 
where c is the dose, t the exposure time and k a constant. This implies a linear relationship 
between the dose and the exposure time. The use of linear time-to-dose extrapolation to assess 
the risk from less-than-life-time exposure to genotoxic substances has been discussed by various 
authors, i.e. if linearity is assumed, then it is important to determine if Haber’s Rule (C×T) is 
appropriate for the exposure scenario of concern, Haber’s rule supports distributing the lifetime 
dose over the total number of exposure days during less-than-lifetime exposure, thereby allowing 
for a higher daily intake than would be the case for lifetime exposure. If the response is 
nonlinear, it should be critically evaluated whether application of Haber’s law is appropriate in 
estimating a toxicological reference point, taking into account the MOA and TK/TD based 
considerations.  If Haber’s law applies, several approaches could be considered, i.e. using 
Haber’s law strictly without adjustment, adjusted by application of a Dose-Response Correction 
Factor (DRCF), the magnitude of which could vary according to the exposure scenario and/or 
what is known about the MOA, or according to predefined exposure scenarios (acute for14 days 
 
 
or fewer, short-term ≥14 days to 1 year, intermediate ≥1 year to 7 years, chronic ≥7 years to 70 
years), and assign “default” adjustment factors (Bos et al. 2004; Callis et al. 2010; Felter et al. 
2011). 
Felter et al. (2011) indicated that it is important to acknowledge the assumptions underlying this 
methodology of linear time-to-dose extrapolation, which include the fact that chemical-specific 
carcinogenicity data should be available and that the data support a linear dose-response 
relationship (Felter et al. 2011). Whether such a linear dose-response relationship would apply to 
the dose dependent induction of liver tumors by the alkenylbenzenes remains to be established 
and may depend on the MOA underlying the carcinogenicity. This mode of action proceeds by 
cytochrome P450-catalyzed hydroxylation to a 1’-hydroxymetabolite, followed by 
sulfotransferase (SULT)-mediated conversion to a 1’- sulfoxymetabolite (Phillips et al. 1981). 
This metabolite is unstable and reacts with DNA. Studies using PBK modelling revealed that the 
bioactivation of alkenylbenzenes to their ultimate carcinogenic 1’-sulfoxy metabolites is linear 
with the dose, from dose levels as low as levels of realistic human dietary intake up to dose 
levels as high as the BMDL10 and BMD10 inducing liver tumors in rodent bioassays (Punt et al. 
2009; Rietjens et al. 2010; Al-Subeihi et al. 2012; Martati et al. 2012). The mutagenic potential 
of the 1’-sulfoxy alkenylbenzene DNA adducts has not been extensively quantified so far. 
Herrmann et al. (2012) investigated the mutagenic potential of sulfate conjugates of 1’-
hydroxymethyleugenol and showed that different isomeric hydroxylated metabolites of 
methyleugenol are mutagenic in an Ames test using Salmonella typhimurium TA100 strains 
expressing different sulfotransferase enzymes (Herrmann et al. 2012). This suggests that the 1’-
sulfoxymetabolite and the subsequently formed DNA adducts play an important role in the 
alkenylbenzene-induced carcinogenicity, and that knowledge of the levels of DNA adduct 
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hydroxymethyleugenol and showed that different isomeric hydroxylated metabolites of 
methyleugenol are mutagenic in an Ames test using Salmonella typhimurium TA100 strains 
expressing different sulfotransferase enzymes (Herrmann et al. 2012). This suggests that the 1’-
sulfoxymetabolite and the subsequently formed DNA adducts play an important role in the 
alkenylbenzene-induced carcinogenicity, and that knowledge of the levels of DNA adduct 
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formation in human livers at relevant dietary intake levels would be of use to facilitate risk 
assessment for low-dose alkenylbenzenes intake. In this respect it is of interest to note that 
Herrmann et al. (2013) reported detection of methyleugenol DNA adducts in liver samples 
obtained from human subjects (Herrmann et al. 2013). Methyleugenol DNA adducts in the livers 
of these human subjects likely results from dietary intakes. The results of the present study imply 
that it would be of interest to look for also other alkenylbenzene DNA adducts in human liver 
samples. It would also be of use to extend the already-developed PBK models in humans to 
physiologically based dynamic (PBD) models that enable prediction of DNA adduct formation in 
human liver upon exposure to selected alkenylbenzenes. As already outline above in a previous 
study by Paini et al. (2012) such a PBD model for liver DNA adduct formation was developed 
and validated in an in vivo study for estragole DNA adduct formation in the liver of rats. This 
study also revealed that not only bioactivatoin to the reactive 1’-sulfoxymetabolite but also DNA 
adduct formation in rat liver was linear with the dose of estragole (Paini et al. 2010; Paini et al. 
2012). Development of such PBD models for liver DNA adduct formation in human could be 
achieved by combining the existing human PBK models with data on 1’-hydroxyalkenylbenzene 
concentration-dependent DNA adduct formation in isolated human hepatocytes as done for rat 
hepatocytes exposed to 1’-hydroxyestragole previously (Paini et al. 2010; Paini et al. 2012). 
Thus the available data on bioactivation and DNA adduct formation of alkenylbenzenes show 
linearity and thereby provide kinetic and some dynamic data to support use of Haber’s rule.   
Another issue to consider when evaluating short term exposure scenarios is whether it would be 
realistic that intake is not prolonged over time, especially in individuals who regard PFS as 
healthy and natural. A cross-sectional, 12-month retrospective survey that has been conducted in 
24 cities in six European countries, by the PlantLIBRA consumer survey (2014), revealed that 
 
 
PFS product usage patterns are most often taken “periodically” (37.3%), when experiencing a 
“worsening of a condition” (22.2%), “whenever/sporadically” (19.8%), and on “other non-
specified occasions” (17.8%). Periodically meaning “once daily for at least 2 consecutive or non-
consecutive weeks, more doses per week for at least 3 consecutive weeks, more doses per week 
for at least 4 consecutive or non-consecutive weeks, or 2 or more different PFS, in an appropriate 
dose form, at a minimum frequency of 1 or more doses per week, with the sum of the usage 
period of the 2 or more products being equal to at least 4 weeks” (Garcia-Alvarez et al. 2014). 
This result indicates that some parts of the population may tend to use such products indeed for 
longer periods of time, while others may show more restricted periods of use. The results of the 
present thesis illustrated how, using Haber’s rule, the risks of different exposure scenario’s, 
including scenario’s with restricted periods of intake, could be evaluated.  The results of the 
present thesis reveal that based on the MOE approach without a correction from long to short 
term exposure, daily consumption of PFS following recommendations for daily intake raises a 
concern. 
 
Further improvement of the TEF approach  
When analysing alkenylbenzene containing foods including the sauce of pesto and nutmeg-based 
PFS it appeared that many preparations contain more than one alkenylbenene, pointing at 
combined exposure (Alajlouni et al. 2016b; Al-Malahmeh et al. 2017a). This was also reported 
before by other authors (Meek et al. 2011; EFSA 2013; Pose-Juan et al. 2016; Alajlouni et al. 
2016b; Al-Malahmeh et al. 2017b). For this reason risk assessment of combined exposure to 
alkenylbenzenes was performed for nutmeg-based PFS and basil-based pesto sauce.  
C
ha
pt
er
 6
Chapter 6 | General discussion and future perspective
215
 
 
formation in human livers at relevant dietary intake levels would be of use to facilitate risk 
assessment for low-dose alkenylbenzenes intake. In this respect it is of interest to note that 
Herrmann et al. (2013) reported detection of methyleugenol DNA adducts in liver samples 
obtained from human subjects (Herrmann et al. 2013). Methyleugenol DNA adducts in the livers 
of these human subjects likely results from dietary intakes. The results of the present study imply 
that it would be of interest to look for also other alkenylbenzene DNA adducts in human liver 
samples. It would also be of use to extend the already-developed PBK models in humans to 
physiologically based dynamic (PBD) models that enable prediction of DNA adduct formation in 
human liver upon exposure to selected alkenylbenzenes. As already outline above in a previous 
study by Paini et al. (2012) such a PBD model for liver DNA adduct formation was developed 
and validated in an in vivo study for estragole DNA adduct formation in the liver of rats. This 
study also revealed that not only bioactivatoin to the reactive 1’-sulfoxymetabolite but also DNA 
adduct formation in rat liver was linear with the dose of estragole (Paini et al. 2010; Paini et al. 
2012). Development of such PBD models for liver DNA adduct formation in human could be 
achieved by combining the existing human PBK models with data on 1’-hydroxyalkenylbenzene 
concentration-dependent DNA adduct formation in isolated human hepatocytes as done for rat 
hepatocytes exposed to 1’-hydroxyestragole previously (Paini et al. 2010; Paini et al. 2012). 
Thus the available data on bioactivation and DNA adduct formation of alkenylbenzenes show 
linearity and thereby provide kinetic and some dynamic data to support use of Haber’s rule.   
Another issue to consider when evaluating short term exposure scenarios is whether it would be 
realistic that intake is not prolonged over time, especially in individuals who regard PFS as 
healthy and natural. A cross-sectional, 12-month retrospective survey that has been conducted in 
24 cities in six European countries, by the PlantLIBRA consumer survey (2014), revealed that 
 
 
PFS product usage patterns are most often taken “periodically” (37.3%), when experiencing a 
“worsening of a condition” (22.2%), “whenever/sporadically” (19.8%), and on “other non-
specified occasions” (17.8%). Periodically meaning “once daily for at least 2 consecutive or non-
consecutive weeks, more doses per week for at least 3 consecutive weeks, more doses per week 
for at least 4 consecutive or non-consecutive weeks, or 2 or more different PFS, in an appropriate 
dose form, at a minimum frequency of 1 or more doses per week, with the sum of the usage 
period of the 2 or more products being equal to at least 4 weeks” (Garcia-Alvarez et al. 2014). 
This result indicates that some parts of the population may tend to use such products indeed for 
longer periods of time, while others may show more restricted periods of use. The results of the 
present thesis illustrated how, using Haber’s rule, the risks of different exposure scenario’s, 
including scenario’s with restricted periods of intake, could be evaluated.  The results of the 
present thesis reveal that based on the MOE approach without a correction from long to short 
term exposure, daily consumption of PFS following recommendations for daily intake raises a 
concern. 
 
Further improvement of the TEF approach  
When analysing alkenylbenzene containing foods including the sauce of pesto and nutmeg-based 
PFS it appeared that many preparations contain more than one alkenylbenene, pointing at 
combined exposure (Alajlouni et al. 2016b; Al-Malahmeh et al. 2017a). This was also reported 
before by other authors (Meek et al. 2011; EFSA 2013; Pose-Juan et al. 2016; Alajlouni et al. 
2016b; Al-Malahmeh et al. 2017b). For this reason risk assessment of combined exposure to 
alkenylbenzenes was performed for nutmeg-based PFS and basil-based pesto sauce.  
Chapter 6 | General discussion and future perspective
216
 
 
For alkenylbenzenes, known to have similar chemical structures, metabolic pathways and a 
similar MOA underlying induction of a similar adverse effect, and for which it can be assumed 
that they will display similarly shaped dose-response curves, the combined toxicity of the 
individual components can be estimated by so-called dose-addition using the sum of their doses, 
equally or scaled for potency relative to that of another component of the mixture for which 
adequate dose-response information is available. Based on the dose addition concept, the TEF 
methodology applies. Application of this methodology in human health risk assessment has been 
described and reaffirmed for use by for example the guidance of the Environmental Protection 
Agency (EPA) entitled: “Supplementary Guidance for Conducting Health Risk Assessment of 
Chemical Mixtures’’ (EPA 2000). In practice, the scaling factor for each chemical in the group is 
typically based on a comparison of its toxic potency to that of a designated index chemical. The 
index chemical is well-studied toxicologically and must have a dose-response function to apply 
the methodology to a mixture. Toxicological data considered for these comparisons of toxic 
potency can be derived from both in vitro and in vivo studies as well as from structure-activity 
relationships. The relative potencies can also be defined based on biochemical changes, toxicity, 
and/or carcinogenicity.  
Application of the TEF approach to the human health risk assessment of chemicals carries with it 
some uncertainties, i.e. the assumption of parallel dose-response curves, which is difficult to 
show particularly in the low response region of interest, and the assumption that the estimate of 
relative potency (REP) from animal studies are predictive of REPs in humans. In the process and 
data used to derive TEF (or REP) values, even more uncertainties evolve i.e. variability in the 
kind of information available in many types of in vivo and in vitro studies for comparing the 
responses. Safrole and methyleugenol were both used as index compound in this thesis, 
 
 
depending on their presence in the mixture of the botanical preparation studied. Both, safrole and 
methyleugenol are well-studied toxicologically and have a well-defined dose-response function 
for various endpoints on which the TEF values could be based including data from  
carcinogenicity studies, data on in vivo DNA adduct formation and data on formation of the 
reactive 1’-sulfoxy meytabolites. 
A number of different methods are employed to calculate REP (or TEF) values (Haws et al. 
2006), with the uncertainty in Toxic Equivalence (TEQ) estimates and in the TEF methodology 
being highly dependent on the exposure estimates used in the TEQ calculations. The BMD 
approach is suitable for the definition of TEF as it enables the estimation of equipotent doses by 
interpolation between applied doses, and it has been used to provide relative potency estimates 
for different organophosphates (Bosgra et al. 2009), for estimating equipotent doses in in vivo 
and in vitro genotoxicity tests (Bemis et al. 2015; Wills et al. 2015; Soeteman-Hernandez et al. 
2015a; Soeteman-Hernandez et al. 2015b), and for testing if dose addition applies in chemical 
mixtures (Kienhuis et al. 2015). In this thesis combined risk assessment, based on either equal 
potencies and also based on relative potency of the different alkenylbenzenes was considered, the 
latter using TEF values. In an ideal situation such TEF values should be based on the endpoint 
under consideration, i.e. tumor formation. The carcinogenic potency of alkenylbenzenes was 
shown in previous studies (Miller et al. 1983; Phillips et al. 1984; Randerath et al. 1984; Zhou et 
al. 2007), but these studies focused on only a few of the alkenylbenzenes under study and did not 
provide data for myristicin and apiol that could be compared to those of safrole, estragole and 
myristicin to set TEF values. Therefore in the present thesis TEF values were determined using 
BMDL10 values obtained via read-across from safrole, but also surrogate endpoints including 
relative formation of the ultimate carcinogenic 1’-sulfoxy metabolite and DNA adduct formation 
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upon in vivo exposure. The MOE values obtained for the combined risk assessment based on the 
TEQ concept did not vary much from the ones obtained when assuming equal potency. This can 
be ascribed to the fact that the TEF values of the alkenylbenzenes present in botanical 
preparations analysed vary by less than 2-fold. Therefore it can be concluded that for a first Tier 
risk assessment on combined exposure to mixtures of alkenylbenzens dose addition without 
correction of differences in relative potencies is adequate and that only in cases where the 
outcome indicates the need for a refined estimate, i.e. when MOE values are around the threshold 
value of 10000, a TEF based approach might be needed. 
 
Banding of the MOE values and related conclusions for risk management 
MOE values obtained in the present thesis showed wide variation with values above and values 
below 10000 and some values even being lower than 1000. Even though the MOE approach was 
introduced to avoid the misleading use of apparently precise risk numbers, the threshold value of 
10000 proposed to be used in discriminating whether there is a concern or not introduces a sharp 
cutoff value. This implies that an MOE of 10, or one of 9000, values that are both < 10000 are 
both  of concern, and one of 11000 or 100000 (both > 10000) are both of no concern, although 
they may indicate different levels of concern. When using an MOE approach based on the 
BMDL10 from an animal study, some banding systems have been proposed to aid risk 
communication. The Committee on Carcinogenicity of Chemicals in Food, Consumer Products 
and the Environment (COC) has proposed a banding system (i.e. <10000, may be a concern; 
10000-1000000, unlikely to be a concern; and >1000000, highly unlikely to be a concern). This 
suggests some banding of the MOE, but it does not yet proposes how to interpret different values 
<10000. 
 
 
One could consider further banding of MOE cut-off values that are < 10000 as follows: MOE < 
1000: Very high concern: MOE = 1000-5000: High concern : MOE = 5000 – 10000: Moderate 
concern. 
Banding was also proposed for the so-called exposure potency index (EPI) approach, an 
alternative to the MOE approach proposed by Health Canada, in their Human Health Risk 
Assessment for Priority Substances under the Canadian Environmental Protection Act 
(HealthCanada 1994). The EPI is calculated as the average exposure in the population divided by 
the dose in experimental animals that produces a 5% incidence of tumors. The EPI can be 
regarded as a reciprocal of the MOE and the reciprocals of the EPI values correspond to MOE 
values of <5000 (high priority), 5000–500000 (moderate priority) and >500000 (low priority) 
(HealthCanada 1994). The biological basis and derivation of the different banding systems were 
not explained.  
In addition to banding the value of the MOE outcome, one could also consider a new approach 
for banding based on the frequency of consumption, the amount consumed, and/or the content of 
the chemical of interest. In such a system the considerations discussed above for time-dose 
extrapolations could be taken into account, to correct the critical MOE value used to make the 
risk management decision for deviating time or dose regimens. 
All together it is concluded that an internationally scientific framework to assess and refine the 
MOE approach, taking into account shorter than life time exposure, and models for banding of 
MOE values would be of use, and would improve the potential of the MOE approach for risk 
assessment.  
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Quality assurance of food supplements and botanical preparations  
Results of the present thesis revealed that food supplements and botanical preparations 
containing alkenylbenzenes at levels that do raise a safety concern are still freely available on the 
Dutch market and via the internet. This raises the issue of quality control. The guidelines for 
Good Agricultural and Wild Collection Practice of Medicinal and Aromatic (Culinary) plants 
are suggested to be applied to the growing and primary processing practices of plants and their 
derivatives traded and used in the European Union. Hence they apply to the production of all 
plant materials utilized either in a direct or processed form. They also apply to all methods of 
production including organic production in accordance with the European regulations. Plant raw 
material should meet the demands of the consumer and the standards of the highest quality. The 
presence and concentration of physiologically active substances in a botanical species can vary 
considerably depending on growth, development and chemical profile, influenced by a number 
of external factors such as soil quality and water properties, temperature, sunlight, the season of 
cultivation and time of harvesting. It is equally important that the batches of the botanical raw 
material undergo appropriate testing before acceptance for further processing to ensure that the 
concentrations of substances with known physiological effects fall within predetermined limits 
and allow for the natural variability of the botanical material. Accurate identification of all 
botanical source material selected for further processing is crucial as well. Care should be taken 
with the identification to avoid renaming or reclassification or switching of varieties. All 
participants of the production process, primary producers to traders, are required to keep the 
traceability of the production process. The most important information about the batch should 
always follow the material by a batch documentation, and Integrity of botanical material 
(EUROPAM 2006; FoodSupplementsEurope 2016). 
 
 
Establishment, applying and assuring a good quality system during botanical product 
preparation, and practicing in-house, internationally harmonized, and/or transferred valid 
analytical methods to characterize and to identify the bioactive compounds within these products 
will facilitate risk assessment and help to guarantee the quality of the final product. Integrated 
plans and continuous improvement through auditing, correcting and preventing non-conformities 
should be applied from farming to marketing.  
 
CONCLUSION 
This thesis assessed the risks of nutmeg-based PFS and basil-containing pesto sauce products 
that contain alkenylbenzenes using read-across through building of PBK models for two 
alkenylbenzenes (myristicin and apiol). This facilitated the estimation of a BMDL10 for 
myristicin and apiol without the need for a rodent bioassay. These BMDL10 values and the ones 
derived for structurally related alkenylbenzenes directly from bioassays or via read-across were 
subsequently used in the risk assessment of exposure to these alkenylbenzenes via nutmeg-based 
PFS and basil-containing pesto sauce. The overall conclusion of the risk assessment of 
consumption of basil-based pesto sauce and nutmeg-based PFS revealed that daily lifetime 
consumption of most of these products would be a priority for risk management. On the other 
hand, exposure to those products for shorter periods of time will increase the MOE values to 
levels > 10000 indicating a low priority for risk management. Thus, it can be concluded that the 
risks associated with the use of these products would be limited, provided intake is for only a few 
weeks during a lifetime. The thesis also provided new proofs of principle of how PBK model 
based approaches can facilitate novel non-animal based strategies in risk assessment contributing 
to the development of alternatives for animal testing. 
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to the development of alternatives for animal testing. 
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Botanicals and botanical preparations have become widely available on the market in the form of 
food supplements and other food preparations. In Europe the safety of botanicals and derived 
food products placed on the market has to comply with the general requirements set out 
in regulation (EC) No 178/2002. In spite of this regulation, the risks of botanicals and botanical 
preparations are generally not assessed before they enter the market. 
The present thesis aimed to perform a risk assessment of some selected botanicals and derived 
preparations focusing on samples containing the so-called alkenylbenzenes, including myristicin, 
apiol, safrole, methyleugenol, elemicin, and estragole.  Samples containing alkenylbenzenes may 
be of concern because these compounds may be genotoxic and carcinogenic displaying similar 
characteristics regarding mode of action (MOA) and tumor formation. The aim of the present study 
was to develop a MOA based approach for read-across in risk assessment from safrole, for which in vivo 
toxicity studies are available to myristicin and apiol for which tumor data are not reported, thus 
contributing to alternatives in animal testing. This was done using physiologically based kinetic 
(PBK) modelling. Botanical preparations included in the risk assessments performed in the 
present thesis were basil-containing pesto and nutmeg-based plant food supplements (PFS). 
Given that several of the preparations analyzed contained several alkenylbenzenes a risk 
assessment of combined exposure to these alkenylbenzenes was included as well, to give a better 
understanding of when risk management actions would be needed for botanicals and derived 
preparations containing these ingredients.  
The introduction chapter starts with a short background and definition of the aim of the thesis, 
followed by a description of the physicochemical properties, natural occurrence and estimated 
daily intake (EDI) of the alkenylbenzenes, as well as of their ADME (absorption, distribution, 
metabolism and excretion) characteristics, carcinogenicity and MOA, the relevant risk 
assessment approach, and finally PBK modelling. 
 
 
Chapter 2 and 3 of the thesis describe the development of PBK models for myristicin and apiol 
in male rat and human, enabling the prediction of dose-dependent effects in bioactivation and 
detoxification of these alkenylbenzenes. This allows comparison of the PBK model-based 
prediction of bioactivation of myristicin or apiol to the PBK model-based predictions for 
bioactivation of the structurally related compound safrole, enabling estimation of a BMDL10 for 
myristicin and apiol from read-across to the BMDL10 available for safrole, thereby facilitating 
risk assessment of current dietary exposure to myristicin or apiol. The results from PBK analysis 
support that risk assessment of myristicin may be based on the BMDL10 derived for safrole, and 
that risk assessment of apiol may be performed using a BMDL10 value of 3 times the BMDL10 
for safrole. These results enabled a preliminary risk assessment of current exposure to these 
alkenylbenzenes showing that the current exposure to myristicin results in MOE values 
indicating a priority for risk management (Chapter 2), while current exposure to apiol does not 
raise a concern (Chapter 3). The results obtained illustrate that PBK modeling can facilitate a 
read-across in risk assessment from a compound for which in vivo toxicity studies are available 
to a related compound for which tumor data are not reported, thus contributing to alternatives in 
animal testing. 
Subsequently, in Chapter 4 the BMDL10 values obtained were used to perform a risk assessment  
for alkenylbenzenes in basil-based pesto sauce. To this end the levels of methyleugenol and other 
alkenylbenzenes in basil-containing sauce of pesto were quantified enabling an associated risk 
assessment based on the MOE approach, taking into consideration the possible combined 
exposure to different alkenylbenzenes and the BMDL10 values as defined in literature and in 
chapter 2 and 3 of the thesis. The MOE values obtained generally indicated a priority for risk 
management when assuming daily consumption of basil-based pesto sauce. It was concluded that 
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for safrole. These results enabled a preliminary risk assessment of current exposure to these 
alkenylbenzenes showing that the current exposure to myristicin results in MOE values 
indicating a priority for risk management (Chapter 2), while current exposure to apiol does not 
raise a concern (Chapter 3). The results obtained illustrate that PBK modeling can facilitate a 
read-across in risk assessment from a compound for which in vivo toxicity studies are available 
to a related compound for which tumor data are not reported, thus contributing to alternatives in 
animal testing. 
Subsequently, in Chapter 4 the BMDL10 values obtained were used to perform a risk assessment  
for alkenylbenzenes in basil-based pesto sauce. To this end the levels of methyleugenol and other 
alkenylbenzenes in basil-containing sauce of pesto were quantified enabling an associated risk 
assessment based on the MOE approach, taking into consideration the possible combined 
exposure to different alkenylbenzenes and the BMDL10 values as defined in literature and in 
chapter 2 and 3 of the thesis. The MOE values obtained generally indicated a priority for risk 
management when assuming daily consumption of basil-based pesto sauce. It was concluded that 
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consumption of pesto sauces would be of concern if consumed on a daily basis over longer 
periods of time. 
Chapter 5 evaluates the risk of exposure to myristicin and related alkenylbenzenes through 
human exposure to nutmeg-based PFS based on the MOE approach. Chemical analysis of 
various PFS samples was performed and the amount of alkenylbenzenes that would be consumed 
through consumption of these nutmeg-based PFS where quantified. MOE values where 
calculated for the individual alkenylbenzenes as well as taking into account the presence of more 
than one alkenylbenzenes within selected PFS samples. It was concluded that the results reveal 
that daily nutmeg-based PFS consumption following recommendations for daily intake for 
especially longer periods of time would raise a concern. 
Chapter 6 summarizes the results obtained in the thesis, compiles the overall discussion and 
presents the future perspectives that follow from the results obtained.  
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